OMNIBUS SOLICITATION OF THE
NATIONAL INSTITUTES OF HEALTH,
CENTERS FOR DISEASE CONTROL AND PREVENTION, AND
FOOD AND DRUG ADMINISTRATION FOR

SMALL BUSINESS INNOVATION
RESEARCH (SBIR)

AND

SMALL BUSINESS TECHNOLOGY
TRANSFER (STTR)

GRANT APPLICATIONS

NIH, CDC, and FDA Program Descriptions and
Research Topics

SUBMISSION DATES

APRIL 5, 2018, SEPTEMBER 5, 2018, JANUARY
7, 2019, AND APRIL 5, 2019

National Institutes of Health (SBIR and STTR)
Centers for Disease Control and Prevention (SBIR)
Food and Drug Administration (SBIR)
# TABLE OF CONTENTS

## NIH, CDC, AND FDA PROGRAM DESCRIPTIONS AND RESEARCH TOPICS

### NATIONAL INSTITUTES OF HEALTH (NIH)

- **Trans-NIH Research Programs**
- Phase IIB Competing Renewal Awards
- Research Supplements to Promote Diversity in Health-Related Research

### Technical Assistance Programs (Subject to Change)

- Niche Assessment Program
- Commercialization Accelerator Program (CAP)

### National Institute on Aging (NIA)

- Phase IIB Competing Renewal Awards
- Research Topics of Interest to NIA
- NIA Non-Clinical Trials Topics
- Division of Behavioral and Social Research (DBSR)
- Division of Aging Biology (DAB)
- Division of Neuroscience (DN)
- Division of Geriatrics and Clinical Gerontology (DGCG)
- NIA Clinical Trials Topics
- Division of Behavioral and Social Research (DBSR)
- Division of Aging Biology (DAB)
- Division of Neuroscience (DN)
- Division of Geriatrics and Clinical Gerontology (DGCG)

### National Institute on Alcohol Abuse and Alcoholism (NIAAA)

- Limited Amount of Award
- Phase IIB Competing Renewal Awards
- Commercialization Assistance Programs
- Research Topics of Interest to NIAAA
- NIAAA Non-Clinical Trials Topics
- Medications Development
- Technological Methods for the Treatment of Hazardous Drinking and Alcohol Use Disorders
- Prevention
- Improving the Delivery of Alcohol Treatment Services
- Fetal Alcohol Spectrum Disorder (FASD) and Alcohol-Related Birth Defects
- Development of Clinical Biomarkers of Alcohol Exposure and Alcohol-Induced Organ Damage
- Alcohol Biosensors
- Alcohol Use and HIV Infection, and HIV Co-infection with HCV, HBV, or TB
- Electronic Diagnostic Clinical Assessment of Frailty among HIV+ Individuals with Past and/or Current Alcohol Use Disorders: Severity and Patterns
- Monitoring Alcohol Use among HIV+ Patients
- Stem Cell Research for Alcohol-induced Disorders
- Role of Non-coding RNAs in the Neuroadaptation to Alcoholism
- In vivo Detection of Neuromodulators in Behaving Animals
- Ex vivo Efficacy Screens to Identify Pharmacotherapies for Alcohol Dependence
- Develop Network Pharmacology Strategy for Preclinical Medication Development
- Novel Tools and Technologies to Detect the Effects of Alcohol on the CNS Structure and Activities
- Research Tools
- Roadside Driver Tests to Detect Marijuana or Other Drug Use Immediately Before Driving
NIAAA Clinical Trials Topics: ................................................................. 38
Medications Development ............................................................... 38
Innovative Technologies to Measure and Increase Medication Adherence in Clinical Trials 39
Technological Methods for the Treatment of Hazardous Drinking and Alcohol Use
   Disorders .......................................................................................... 40
   Prevention ......................................................................................... 40
Improving the Delivery of Alcohol Treatment Services ................................................. 41
Development of Clinical Biomarkers of Alcohol Exposure and Alcohol-Induced Organ 
   Damage ........................................................................................... 43
   Alcohol Biosensors ........................................................................ 44
Alcohol Use and HIV Infection, and HIV Co-infection with HCV, HBV, or TB ............ 44
Electronic Diagnostic Clinical Assessment of Frailty among HIV+ Individuals with Past and/or 
   Current Alcohol Use Disorders: Severity and Patterns ........................................... 45
   Monitoring Alcohol Use among HIV+ Patients .............................................. 46
Roadside Driver Tests to Detect Marijuana or Other Drug Use Immediately Before Driving 46

NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES (NIAID) ............... 47
   Limited Total Amounts for Phase I and Phase II Awards ........................................ 47
   Phase IIB Competing Renewal Awards ................................................................ 47
   Research Topics of Interest to NIAID .................................................................. 47
   NIAID Non-Clinical Trials Topics: ....................................................................... 49
   Division of AIDS ......................................................................................... 49
   Basic Sciences Program ................................................................................. 49
   Vaccine Research Program ............................................................................. 50
   Therapeutics Research Program ...................................................................... 51
   Prevention Science Program ......................................................................... 51
   Division of Allergy, Immunology, and Transplantation .................................... 52
   Division of Microbiology and Infectious Diseases ........................................... 54
   NIAID Clinical Trials Topics: ......................................................................... 57

NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES (NIAMS) ... 58
   Limited Amount of Award ........................................................................... 58
   Research Topics of Interest to NIAMS ......................................................... 58
   NIAMS Non-Clinical Trials Topics: ............................................................. 59
   Arthritis and Musculoskeletal and Skin Diseases ........................................... 59
   Special Emphasis Areas of Interest to Small Businesses: ................................. 60
   NIAMS Clinical Trials Topics: ....................................................................... 60

NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERING (NIBIB) ............ 61
   Research Topics of Interest to NIBIB ........................................................... 61
   NIBIB Non-Clinical Trials Topics: ............................................................... 62
   NIBIB Clinical Trials Topics: ....................................................................... 65

NATIONAL CANCER INSTITUTE (NCI) ................................................................... 66
   Major NCI SBIR/STTR Portfolio Areas: ......................................................... 66
   Limited Amount of Award ........................................................................... 66
   Phase IIB Competing Renewal Awards .......................................................... 67
   Research Topics of Interest to NCI ............................................................... 67
   NCI Non-Clinical Trials Topics: ................................................................. 68
   NCI Clinical Trials Topics: ........................................................................ 68

EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH AND HUMAN DEVELOPMENT (NICHD) .......................................................... 71
   Phase IIB Competing Renewal Awards .......................................................... 72
   NICHD Supported Funding Opportunity Announcements (FOAs) ......................... 72
   Research Topics of Interest to NICHD .......................................................... 73
   NICHD Non-Clinical Trials Topics: ............................................................... 74
   NICHD Clinical Trials Topics: ..................................................................... 83
NATIONAL INSTITUTE ON DRUG ABUSE (NIDA) ................................................................. 93
  Limited Amount of Award .................................................................................................. 93
  Fast-Track Applications ..................................................................................................... 94
  Phase IIB Competing Renewal Awards ............................................................................ 95
  Research Topics of Interest to NIDA .................................................................................. 96
  NIDA Non-Clinical Trials Topics: ....................................................................................... 97
  High Programmatic Priority Research Topics ................................................................. 97
  NIDA Clinical Trials Topics: ............................................................................................. 98
  High Programmatic Priority Research Topics ..................................................................... 98
  Division of Neuroscience and Behavior ............................................................................ 98
  Division of Therapeutics and Medical Consequences ...................................................... 99
  Division of Epidemiology, Services and Prevention Research ......................................... 101
  Special Research Topics ..................................................................................................... 102

NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS (NIDCD) ..... 103
  Limited Amount of Award ............................................................................................... 103
  Phase IIB Competing Renewal Awards ............................................................................ 103
  Research Topics of Interest to NIDCD .............................................................................. 103
  NIDCD Non-Clinical Trials Topics: ..................................................................................... 104
  Hearing and Balance Program .......................................................................................... 104
  Voice, Speech, and Language Programs ........................................................................... 105
  Taste and Smell Program .................................................................................................. 106
  NIDCD Clinical Trials Topics: .......................................................................................... 106

NATIONAL INSTITUTE OF DENTAL AND CRANIOFACIAL RESEARCH (NIDCR) ....................... 107
  Research Topics of Interest to NIDCR .............................................................................. 107
  NIDCR Non-Clinical Trials Topics: ..................................................................................... 108
  Developmental Biology and Mammalian Genetics ......................................................... 108
  Infectious Diseases and Immunity .................................................................................... 108
  Oral, Oropharyngeal and Salivary Gland Cancers .......................................................... 109
  Temporomandibular Disorders and Orofacial Pain ......................................................... 109
  Saliva, Salivary Diagnostics, and Salivary Gland Diseases .............................................. 110
  Biotechnology, Biomaterials, and Applications for Regeneration and Restoration of Oral, Dental and Craniofacial Tissues ............................................................... 110
  Preclinical Research ......................................................................................................... 112
  NIDCR Clinical Trials Topics: .......................................................................................... 112
  Biomedical Clinical Research .......................................................................................... 112
  Behavioral Clinical Research ............................................................................................ 113

NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES (NIDDK) .......... 115
  Limited Amount of Award ............................................................................................... 115
  Phase IIB Competing Renewal Awards ............................................................................ 115
  Final Progress Reports ...................................................................................................... 116
  Additional Programs and Services for NIDDK SBIR/STTR Awardees ................................. 116
  Research Topics of Interest to NIDDK .............................................................................. 116
  NIDDK Non-Clinical Trials Topics: ..................................................................................... 118
  Diabetes, Endocrinology and Metabolic Diseases ............................................................ 118
  Digestive Diseases and Nutrition ....................................................................................... 120
  Kidney, Urologic and Hematologic Diseases ................................................................. 121
  NIDDK Clinical Trials Topics: .......................................................................................... 125

NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES (NIEHS) ................................. 127
  Research Topics of Interest to NIEHS .............................................................................. 127
  NIEHS Non-Clinical Trials Topics: ..................................................................................... 128
  Exposure Assessment Tools .............................................................................................. 128
  Nano Environmental Health and Safety ............................................................................ 129
  Toxicity Screening, Testing, and Modeling ........................................................................ 129
Biomarkers of Exposure and Response ................................................................. 130
Intervention Technologies .................................................................................... 131
Education/Outreach .............................................................................................. 131
Hazardous Substances Remediation and Site Characterization SBIR Program .... 131
Worker Training Program ..................................................................................... 133
NIEHS Clinical Trials Topics: ................................................................................ 133

NATIONAL EYE INSTITUTE (NEI) ................................................................................. 135
Limited Amount of Award ...................................................................................... 135
Phase IIB Competing Renewal Awards ................................................................. 135
Research Topics of Interest to NEI ....................................................................... 135
NEI Non-Clinical Trials Topics: ............................................................................. 136
NEI Clinical Trials Topics: .................................................................................... 137
Additional Information .......................................................................................... 138

NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES (NIGMS) .................... 139
Limited Amount of Award ...................................................................................... 139
Phase IIB Competing Renewal Awards ................................................................. 139
Research Topics of Interest to NIGMS ................................................................. 140
NIGMS Non-Clinical Trials Topics: ...................................................................... 141
Division of Cell Biology and Biophysics ............................................................... 141
Division of Genetics and Developmental Biology .............................................. 142
Division of Pharmacology, Physiology, and Biological Chemistry ................. 143
Division of Biomedical Technology, Bioinformatics, and Computational Biology 144
Division of Training, Workforce Development, and Diversity ......................... 145
Center for Research Capacity Building ............................................................... 146
NIGMS Clinical Trials Topics: ............................................................................. 146

NATIONAL HEART, LUNG, AND BLOOD INSTITUTE (NHLBI) ............................... 149
Phase II Applications ............................................................................................. 149
NHLBI-Supported Funding Opportunity Announcements (FOAs) .................... 149
Phase IIB Competing Renewal Awards ................................................................. 149
Limited Amount of Award .................................................................................... 150
Final Progress Reports ......................................................................................... 151
Programs and Services for NHLBI Small Business Awardees ......................... 151
Research Topics of Interest to NHLBI ............................................................... 151
NHLBI Non-Clinical Trials Topics: ...................................................................... 152
Cardiovascular Sciences ...................................................................................... 152
Lung Diseases ....................................................................................................... 153
Blood Diseases and Resources ........................................................................... 153
Center for Translation Research and Implementation Science ....................... 153
NHLBI Clinical Trials Topics: ............................................................................. 154
Cardiovascular Sciences ...................................................................................... 154
Lung Diseases ....................................................................................................... 154
Blood Diseases and Resources ........................................................................... 154
Center for Translation Research and Implementation Science ....................... 154

NATIONAL HUMAN GENOME RESEARCH INSTITUTE (NHGRI) ......................... 156
Research Topics of Interest to NHGRI ............................................................... 156
NHGRI Non-Clinical Trials Topics: ...................................................................... 157
NHGRI Clinical Trials Topics: ............................................................................. 159

NATIONAL INSTITUTE OF MENTAL HEALTH (NIMH) ............................................... 160
Phase IIB Competing Renewal Awards ................................................................. 160
Research Topics of Interest to NIMH ................................................................. 162
NIMH Non-Clinical Trials Topics: ...................................................................... 164
Division of Neuroscience and Basic Behavioral Science (DNBBS) ................. 164
Division of Translational Research (DTR) .......................................................... 165
Division of AIDS Research (DAR) ................................................................. 166
Division of Services and Intervention Research (DSIR) .............................. 166
NIMH Clinical Trials Topics: ........................................................................ 168
Division of Neuroscience and Basic Behavioral Science (DNBBS).............. 168
Division of Translational Research (DTR) .................................................... 169
Division of AIDS Research (DAR) ................................................................. 170
Division of Services and Intervention Research (DSIR) .............................. 171

NATIONAL INSTITUTE ON MINORITY HEALTH AND HEALTH DISPARITIES (NIMHD) ........................ 174
  Research Topics of Interest to NIMHD .......................................................... 174
  NIMHD Non-Clinical Trials Topics: ............................................................... 175
  NIMHD Clinical Trials Topics: ................................................................. 176

NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE (NINDS) ......................... 177
  Limited Amount of Award and Budget Waivers ........................................... 177
  Phase IIB Competing Renewal Awards ......................................................... 177
  Research Topics of Interest to NINDS .......................................................... 177
  NINDS Non-Clinical Trials Topics: ............................................................... 178
  General Areas of Interest ........................................................................... 178
  NINDS Priorities ....................................................................................... 179
  Translational Research .............................................................................. 179
  Brain Research through Advancing Innovative Neurotechnologies (BRAIN) Initiative .................. 180
  NINDS Clinical Trials Topics: .................................................................... 180

NATIONAL INSTITUTE OF NURSING RESEARCH (NINR) ......................................................... 181
  Limited Amount of Award ........................................................................... 181
  Research Topics of Interest to NINR .......................................................... 181
  NINR Non-Clinical Trials Topics: ............................................................... 182
  NINR Clinical Trials Topics: ...................................................................... 183

NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES (NCATS) ......................... 185
  Limited Amount of Award ........................................................................... 185
  Phase IIB Competing Renewal Awards ......................................................... 185
  Research Topics of Interest to NCATS ......................................................... 185
  NCATS Non-Clinical Trials Topics: ............................................................... 186
  Drug Discovery and Development ............................................................... 186
  Biomedical, Clinical, & Health Research Informatics ................................... 187
  Clinical, Dissemination and Implementation Research ............................... 187
  NCATS Clinical Trials Topics: .................................................................... 188

NATIONAL CENTER FOR COMPLEMENTARY AND INTEGRATIVE HEALTH (NCCIH) .................. 189
  Research Topics of Interest to NCCIH .......................................................... 189
  NCCIH Non-Clinical Trials Topics: ............................................................... 190
  NCCIH Clinical Trials Topics: .................................................................... 192

NATIONAL LIBRARY OF MEDICINE (NL M) ......................................................... 194
  Research Topics of Interest to NLM ............................................................ 194
  NLM Non-Clinical Trials Topics: ............................................................... 195
  NLM Clinical Trials Topics: ...................................................................... 195

DIVISION OF PROGRAM COORDINATION, PLANNING, AND STRATEGIC INITIATIVES (DPCPSI),
OFFICE OF RESEARCH INFRASTRUCTURE PROGRAMS (ORIP) .............................................. 197
  Phase IIB Competing Renewal Awards ......................................................... 197
  Research Topics of Interest to ORIP ........................................................... 197
  ORIP Non-Clinical Trials Topics: ............................................................... 198
  Division of Comparative Medicine ............................................................. 198
  Division of Construction and Instruments .................................................. 200
  ORIP Clinical Trials Topics: ...................................................................... 200
CENTERS FOR DISEASE CONTROL AND PREVENTION (CDC) ........................................... 202

Research Topics of Interest to CDC ................................................................. 202
CDC Non-Clinical Trials Topics ....................................................................... 204

CENTER FOR GLOBAL HEALTH (CGH) ............................................................... 204
(1) Portable Multi-function System for Assessing NTD Program Impact ........... 204
(2) Development of Immersive Virtual or Augmented Reality Laboratory (AR/VR) Training Modules ................................................................. 205

NATIONAL CENTER ON BIRTH DEFECTS AND DEVELOPMENTAL DISABILITIES (NCBDDD) ........ 207
(3) Computer-assisted diagnostic assessment to improve identification of childhood mental disorders ............................................................... 207
(4) Improving Newborn Screening of Coarctation of the Aorta ...................... 208
(5) Innovation in Measurement of Head Circumference at Birth .................... 209
(6) Technology-Assisted In-Office Screening for Mental, Emotional and Behavioral Disorders in Pediatric Practices ............................................. 210

NATIONAL CENTER FOR CHRONIC DISEASE PREVENTION AND HEALTH PROMOTION (NCCDPHP) ................................................................. 212
(7) Clinical Decision Support for Contraception Practice Guidelines .............. 212
(8) Electronic transmission of assisted reproductive technology pregnancy outcome data ................................................................. 213
(9) Food Service Guidelines Algorithmic Database Processing and ID Tool ...... 215
(10) Innovative Approaches for Maternal and Infant Safety in Maternity Hospitals ................................................................. 217
(11) Population Health Data Using Blockchain Technology ............................. 218

NATIONAL CENTER FOR EMERGING AND ZOONOTIC INFECTIOUS DISEASES (NCEZID) ........ 220
(12) Antibiotic Resistant Healthcare-Associate Infections ............................... 220
(14) Rapid Diagnostic Test for Candida species Identification and Multidrug Resistance Profiling ................................................................. 221
(15) Vector Borne Diseases: Detection, Prevention, Diagnosis and Response .... 222

NATIONAL CENTER FOR HIV/AIDS, VIRAL HEPATITIS, STD, AND TB PREVENTION (NCHHSTP) ................................................................. 224
(16) Improved Diagnostic Tests for HIV, STDs, Hepatitis and TB ..................... 224

NATIONAL CENTER FOR IMMUNIZATION AND RESPIRATORY DISEASES (NCIRD) ................................................................. 226
(17) Prevention and Diagnosis of Acute Respiratory Infections in the US and Globally ................................................................. 226

NATIONAL CENTER FOR INJURY PREVENTION AND CONTROL (NCIPC) ................................................................. 227
(18) Improving Platforms for Data Linkage in Drug Overdose Prevention .......... 227
(19) Innovations to Reduce Motor Vehicle-Related Deaths and Injuries ............ 228
(20) Innovative Technology or Media to Prevent Violence ................................ 229
(21) Technological Tools for Monitoring Children’s Symptoms after Traumatic Brain Injury ................................................................. 230

NATIONAL INSTITUTE FOR OCCUPATIONAL SAFETY AND HEALTH (NIOSH) ................................................................. 231
(22) Control Technology and Personal Protective Equipment for High Risk Occupations ................................................................. 231
(23) Exposure Assessment Methods for High Risk Occupations ..................... 233
(24) Work-related Injuries from Motor Vehicle Crashes ................................... 234

FOOD AND DRUG ADMINISTRATION (FDA) ........................................................ 236

Research Topics of Interest to FDA ................................................................. 236
FDA Non-Clinical Trials Topics ....................................................................... 237

CENTER FOR BIOLOGICS EVALUATION AND RESEARCH (CBER) ................. 237

CENTER FOR DRUG EVALUATION AND RESEARCH (CDER) ................. 237
<table>
<thead>
<tr>
<th>Center for Food Safety and Applied Nutrition (CFSAN)</th>
<th>238</th>
</tr>
</thead>
<tbody>
<tr>
<td>Center for Devices and Radiological Health (CDRH)</td>
<td>239</td>
</tr>
<tr>
<td>Center for Veterinary Medicine (CVM)</td>
<td>240</td>
</tr>
<tr>
<td>Office of Critical Path Programs</td>
<td>240</td>
</tr>
<tr>
<td>Office of Orphan Products Development</td>
<td>241</td>
</tr>
</tbody>
</table>

**APPENDIX A: NATIONAL INSTITUTES OF HEALTH SBA-APPROVED SBIR/STTR TOPICS FOR AWARDS OVER STATUTORY BUDGET LIMITATIONS** ....................................................... 242

<table>
<thead>
<tr>
<th>National Cancer Institute (NCI)</th>
<th>244</th>
</tr>
</thead>
<tbody>
<tr>
<td>National Center for Advancing Translational Sciences (NCATS)</td>
<td>245</td>
</tr>
<tr>
<td>National Center for Complementary and Integrative Health (NCCIH)</td>
<td>246</td>
</tr>
<tr>
<td>National Eye Institute (NEI)</td>
<td>247</td>
</tr>
<tr>
<td>National Heart, Lung, and Blood Institute (NHLBI)</td>
<td>248</td>
</tr>
<tr>
<td>National Human Genome Research Institute (NHGRI)</td>
<td>249</td>
</tr>
<tr>
<td>National Institute on Aging (NIA)</td>
<td>250</td>
</tr>
<tr>
<td>National Institute on Alcohol Abuse and Alcoholism (NIAAA)</td>
<td>257</td>
</tr>
<tr>
<td>National Institute of Allergy and Infectious Diseases (NIAID)</td>
<td>258</td>
</tr>
<tr>
<td>National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)</td>
<td>261</td>
</tr>
<tr>
<td>National Institute of Biomedical Imaging and Bioengineering (NIBIB)</td>
<td>262</td>
</tr>
<tr>
<td>Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)</td>
<td>264</td>
</tr>
<tr>
<td>National Institute on Deafness and Other Communication Disorders (NIDCD)</td>
<td>266</td>
</tr>
<tr>
<td>National Institute of Dental and Craniofacial Research (NIDCR)</td>
<td>267</td>
</tr>
<tr>
<td>National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)</td>
<td>269</td>
</tr>
<tr>
<td>National Institute on Drug Abuse (NIDA)</td>
<td>270</td>
</tr>
<tr>
<td>National Institute of Environmental Health Sciences (NIEHS)</td>
<td>271</td>
</tr>
<tr>
<td>National Institute of General Medical Sciences (NIGMS)</td>
<td>272</td>
</tr>
<tr>
<td>National Institute of Mental Health (NIMH)</td>
<td>274</td>
</tr>
<tr>
<td>National Institute on Minority Health and Health Disparities (NIMHD)</td>
<td>278</td>
</tr>
<tr>
<td>National Institute of Neurological Disorders and Stroke (NINDS)</td>
<td>279</td>
</tr>
<tr>
<td>National Institute of Nursing Research (NINR)</td>
<td>281</td>
</tr>
<tr>
<td>National Library of Medicine (NLM)</td>
<td>282</td>
</tr>
</tbody>
</table>

**DIVISION OF PROGRAM COORDINATION, PLANNING, AND STRATEGIC INITIATIVES (DPCPSI), OFFICE OF RESEARCH INFRASTRUCTURE PROGRAMS (ORIP)** .................................................. 283
Funding Opportunity Announcements, Application Instructions, and Appendices are contained in separate files. Follow the links below to view these documents.

### FUNDING OPPORTUNITY ANNOUNCEMENTS

**REMINDER: ALL APPLICATIONS MUST BE SUBMITTED IN RESPONSE TO A FUNDING OPPORTUNITY ANNOUNCEMENT THROUGH GRANTS.GOV**

**PHS 2018-02 OMNIBUS SOLICITATION OF THE NIH, CDC, AND FDA FOR SMALL BUSINESS INNOVATION RESEARCH GRANT APPLICATIONS (PARENT SBIR [R43/R44] CLINICAL TRIAL NOT ALLOWED)**

HTTP://GRANTS.NIH.GOV/GRANTS/GUIDE/PA-FILES/PA-18-574.HTML

**PHS 2018-02 OMNIBUS SOLICITATION OF THE NIH FOR SMALL BUSINESS TECHNOLOGY TRANSFER GRANT APPLICATIONS (PARENT STTR [R41/R42] CLINICAL TRIAL NOT ALLOWED)**

HTTP://GRANTS.NIH.GOV/GRANTS/GUIDE/PA-FILES/PA-18-575.HTML

**PHS 2018-02 OMNIBUS SOLICITATION OF THE NIH FOR SMALL BUSINESS INNOVATION RESEARCH GRANT APPLICATIONS (PARENT SBIR [R43/R44] CLINICAL TRIAL REQUIRED)**

HTTP://GRANTS.NIH.GOV/GRANTS/GUIDE/PA-FILES/PA-18-573.HTML

**PHS 2018-02 OMNIBUS SOLICITATION OF THE NIH FOR SMALL BUSINESS TECHNOLOGY TRANSFER GRANT APPLICATIONS (PARENT STTR [R41/R42] CLINICAL TRIAL REQUIRED)**

HTTP://GRANTS.NIH.GOV/GRANTS/GUIDE/PA-FILES/PA-18-576.HTML

**ADDITIONAL SPECIAL ANNOUNCEMENTS FOR SMALL BUSINESS RESEARCH OPPORTUNITIES**

HTTPS://SBIR.NIH.GOV/FUNDING/INDIVIDUAL-ANNOUNCEMENTS

### APPLICATION INSTRUCTIONS

**SF424 (R&R) APPLICATION INSTRUCTIONS AND ELECTRONIC SUBMISSION INFORMATION**

HTTPS://GRANTS.NIH.GOV/GRANTS/HOW-TO-APPLY-APPLICATION-GUIDE.HTML

### APPENDICES

**STTR MODEL AGREEMENT**

MS WORD

**EXTRAMURAL INVENTION REPORTING COMPLIANCE RESPONSIBILITIES**

HTTPS://S-EDISON.INFO.NIH.GOV/IEDISON/TIMELINE.JSP
PROGRAM DESCRIPTIONS AND RESEARCH GRANT TOPICS

The research topics shown in this solicitation represent program areas that may be of interest to applicant small business concerns in the development of projects that have potential for commercialization. Small business concerns are encouraged to submit SBIR/STTR grant applications in these areas.

APPLICABLE TO NIH ONLY: SBIR and STTR grant applications will be accepted and considered in any area within the mission of the awarding components (i.e., Institutes and Centers (ICs)) identified in this solicitation.

Applicants are strongly encouraged to subscribe to the NIH Guide for Grants and Contracts LISTSERV (http://grants.nih.gov/grants/guide/listserv.htm) or query program administrators periodically via email to learn of new or emerging scientific interests of the NIH, CDC, and FDA awarding components.

You may also subscribe to the SBIR-STTR LISTSERV list to get timely information about the NIH SBIR/STTR Programs (https://sbir.nih.gov/engage/listserv).

Additional information on each of the awarding components (ICs) and their research interests is available electronically on the home pages shown throughout the "Research Topics" section of the solicitation.

The Fogarty International Center, which provides support only for conferences, postdoctoral fellowships for research in the United States and abroad, and senior scientist exchanges between the United States and other countries, does not participate in the SBIR/STTR program.

NATIONAL INSTITUTES OF HEALTH (NIH)

NIH is the steward of medical and behavioral research for the Nation. Its mission is science in pursuit of fundamental knowledge about the nature and behavior of living systems and the application of that knowledge to enhance health, lengthen life, and reduce the burdens of illness and disability.

The goals of the agency are as follows:

1. to foster fundamental creative discoveries, innovative research strategies, and their applications as a basis for ultimately protecting and improving health;
2. to develop, maintain, and renew scientific human and physical resources that will assure the Nation's capability to prevent disease;
3. to expand the knowledge base in medical and associated sciences in order to enhance the Nation's economic well-being and ensure a continued high return on the public investment in research; and
4. to exemplify and promote the highest level of scientific integrity, public accountability, and social responsibility in the conduct of science.

In realizing these goals, the NIH provides leadership and direction to programs designed to improve the health of the Nation by conducting and supporting research:

- in the causes, diagnosis, prevention, and cure of human diseases;
- in the processes of human growth and development;
- in the biological effects of environmental contaminants;
- in the understanding of mental, addictive and physical disorders; and
- in directing programs for the collection, dissemination, and exchange of information in medicine and health, including the development and support of medical libraries and the training of medical librarians and other health information specialists.
In addition, the NIH sponsors training of research personnel; career development of new and established scientists; construction and renovation of research facilities and provision of other research resources.

To carry out these responsibilities, the NIH is organized into awarding components (Institutes/Centers). Those components that have an extramural element, that is, those that provide funds for research and research training activities in organizations external to the NIH, are shown below. The NIH makes every effort to finance worthy applications, including the co-funding of such applications by one or more awarding components having relevance in the projects.

Funding levels for projects are determined through the combined interaction among peer review, grants management, program, budget, and other Institute and/or Centers (IC) staff. These levels are based on allowable costs that are consistent with the principles of sound cost management and in consideration of IC priorities, constraints on the growth of average grant costs, and the availability of funds.

Before considering and/or preparing an application to the SBIR & STTR programs, all applicants are strongly encouraged to review the agencies’ and NIH Institutes’ and Centers’ websites and to contact the SBIR-STTR program coordinators listed in the Omnibus Solicitation.

**TRANS-NIH RESEARCH PROGRAMS**

**Phase IIB Competing Renewal Awards**

Some NIH Institutes/Centers (ICs) offer Phase II SBIR/STTR awardees the opportunity to apply for Phase IIB Competing Renewal awards. These are available for those projects that require extraordinary time and effort in the R&D phase and may or may not require FDA approval for the development of such projects, including drugs, devices, vaccines, therapeutics, and medical implants related to the mission of the IC. Some ICs have announced this opportunity through the NIH Guide for Grants and Contracts (see link below), and some are using this Omnibus SBIR/STTR Grant Solicitation. Only those small business concerns who have been awarded a Phase II are eligible to apply for a Phase IIB Competing Renewal award. Prospective applicants are strongly encouraged to contact NIH staff prior to submission. Additional requirements and instructions (e.g., submission of a letter of intent) are available in the specific IC research topics section and in the specific IC Program Funding Opportunity Announcements. The following NIH ICs will accept applications for Phase IIB Competing Renewal awards: NIA, NIAAA, NIAID (SBIR only), NICHD (SBIR only and only Competing Renewals of NICHD-supported Phase II awards), NIDA (SBIR only), NIDCD, NIDDK (only Competing Renewals of NIDDK-supported Phase II awards), NEI (SBIR only), NIGMS (SBIR only), NIMH (SBIR only), NCATS (SBIR only and only Competing Renewals of NCATS-supported Phase II awards), and ORIP (SBIR only and only Competing Renewals of ORIP-supported Phase II awards). NCI offers Phase IIB opportunities that focus on the commercialization of SBIR-developed technologies. Contact the NCI SBIR Development Center at 301-594-7709, NCISBIR@mail.nih.gov for additional information. NHLBI offers Phase IIB Competing Renewals that focus on the commercialization of technologies requiring regulatory approval through the NHLBI Phase IIB Bridge Awards and the Phase IIB Small Market Awards: https://www.nhlbi.nih.gov/grants-and-training/funding-opportunities-and-contacts/small-business-program. Contact Gary Robinson, Ph.D., at gary.robinson@nih.gov for additional information. NINDS accepts Phase IIB SBIR/STTR Competing Renewal applications through specific opportunities that focus on the commercialization of SBIR and STTR developed technologies. These opportunities can be found on the NINDS Funding Opportunities webpage: https://www.ninds.nih.gov/Funding/Find-Funding-Opportunities. Contact Stephanie Fertig, M.B.A., at fertigs@ninds.nih.gov for additional information.

**Research Supplements to Promote Diversity in Health-Related Research**

Every facet of the United States scientific research enterprise—from basic laboratory research to clinical and translational research to policy formation—requires superior intellect, creativity, and a wide range of skill sets and viewpoints. NIH’s ability to help ensure that the nation remains a global leader in scientific discovery and innovation is dependent upon a pool of highly talented scientists from diverse backgrounds who will help to further NIH’s mission. Research shows that diverse teams working together and capitalizing on innovative ideas and distinct perspectives outperform homogenous teams. Scientists and trainees from diverse backgrounds and life experiences bring different Perspectives, creativity, and individual enterprise to address complex scientific problems. There are many benefits that flow from a diverse NIH-supported scientific workforce, including: fostering scientific innovation, enhancing global competitiveness, contributing to robust learning environments, improving the quality of the researchers, advancing the likelihood that underserved or health disparate populations participate in, and benefit from, health research, and enhancing public trust. In spite of tremendous advancements in scientific research, information, educational and research opportunities are not equally available to all. The NIH seeks to diversify the scientific workforce by enhancing the participation of individuals from groups identified as nationally underrepresented in the biomedical, clinical, behavioral and social sciences.

The NIH notifies Principal Investigators holding specific types of NIH research grants (including SBIR and STTR awards) that funds are available for administrative supplements to improve diversity by supporting and recruiting students, postdoctorates, and eligible investigators from groups that have been shown to be nationally underrepresented in the biomedical, behavioral, clinical, and social sciences research workforce. Although the administrative supplements supported under this program provide funding for less than one percent of all individuals involved in NIH supported research, the NIH has found these awards to be an effective means of encouraging institutions to recruit from currently underrepresented groups. Further information on the NIH diversity policy and the groups that have been identified as underrepresented in biomedical research can be found at [https://grants.nih.gov/grants/guide/notice-files/NOT-OD-18-122.html](https://grants.nih.gov/grants/guide/notice-files/NOT-OD-18-122.html). Administrative supplements must support work within the scope of the original project.

All NIH awarding components and the National Institute for Occupational Safety and Health at the CDC participate in this program. Candidates eligible for support under this supplement program include individuals at various career levels who come from groups that have been shown to be nationally underrepresented in science. Such candidates include individuals from underrepresented racial and ethnic groups, individuals with disabilities, and individuals from disadvantaged backgrounds. Detailed eligibility criteria are described in the full announcement.

An application for a supplement may be submitted at any time. Administrative supplements normally end with the competitive cycle of the parent grant.

**Technical Assistance Programs (Subject to Change)**

Available to HHS SBIR/STTR Awardees

One of the goals of the SBIR and STTR programs is to "increase private sector commercialization of innovations developed through Federal Research and Development." To help HHS SBIR/STTR awardees move their products into the marketplace, NIH has developed assistance programs that provide technical and/or commercialization assistance specific to the individual needs of HHS SBIR/STTR awardees. In accordance with the SBIR/STTR Reauthorization Act of 2011, applicants can also identify and utilize their own technical assistance vendor, however they are required to include this as a consultant in the budget section with a detailed budget justification. See SF424 (R&R) SBIR/STTR Application Guide for instructions. Please note, if funds are requested to utilize your own technical assistance vendor and an award is made, the awardee cannot apply for the NIH-provided technical assistance program for the phase of their award.
Additional information about these programs is available at https://sbir.nih.gov/tap. Questions may be addressed to the NIH SBIR/STTR Office at sbir@od.nih.gov.

**Niche Assessment Program**

*(FOR HHS SBIR/STTR PHASE I Awardees)*

The Niche Assessment Program focuses on providing strategic information about the technology’s market and customer opportunities. Often, a research scientist does not have the entrepreneurial skills to assess whether there are other applications or market niches for their SBIR/STTR-developed technology. As a result, they may underestimate its true market value. This program assesses the market opportunities, needs and concerns of end-users and helps to discover new markets for possible entry for the SBIR/STTR-developed technology. With the assistance of the participant, a contractor helps identify niches and potential partners. The contractor performs the due diligence and provides an in-depth report that assesses such items as the potential end-users needs, the competing technologies and products, the competitive advantage, the market size and share that the participant might expect, etc. Targets (end users) are contacted to ensure they are viable leads and their contact information is included in the report for possible follow-up. Participants may find this report helpful in preparing the requisite Commercialization Plan required for a Phase II application. For detailed information about the Niche Assessment Program, see https://sbir.nih.gov/nap.

Participation in this program is open to active HHS SBIR and STTR Phase I awardees (grants, cooperative agreements, and contracts) and participants need only commit a few hours to inform and make the contractor fully conversant on their technology and the niche they would like to have investigated. There is no cost to the HHS awardee to participate in this program.

**Commercialization Accelerator Program (CAP)**

*(FOR HHS SBIR/STTR PHASE II Awardees)*

The Commercialization Accelerator Program (CAP) assists small companies with getting their SBIR/STTR-developed technologies more rapidly into the marketplace. It provides assistance with developing and implementing an appropriate business strategy aimed at commercializing the products or services that have resulted from HHS-supported SBIR/STTR awards.

CAP can include distinctive tracks that offer customized assistance to meet the specific needs of both early stage and seasoned companies: 1) Commercialization Transition Track (CTT), 2) Advanced Commercialization Track (ACT), and 3) Regulatory Training track (RTT).

The CTT is suitable and relevant for the majority of HHS SBIR/STTR Phase II companies. In this track, participants will receive the tools to understand and put into practice the commercialization plans and activities critical to your company’s stage, level, and background. It also provides you with the opportunity to receive direct industry feedback in a live (in-person) session.

The ACT is suitable and relevant to companies that have some history of accomplishment in commercializing products and/or services, generating and maintaining revenue streams, or servicing a well-defined and steady customer base, and that have established partnerships. In this track, participants will focus on addressing a specific “gap” or applicable issue, which resolution is crucial for your continued progress and development. These issues may include (provided as examples only): Financial Issues and Valuation (financial modeling, budget analysis), Intellectual Property (license-focused IP strategy, refresh of patent portfolio), Market Strategy (related to a specific customer or opportunity), Marketing/Branding (marketing materials, branding/website), and Strategic Partnering (investor/go to market presentation, term sheet for investor/partnership).
The RTT is suitable and relevant to companies that have some history of accomplishment in commercializing products and/or services, generating and maintaining revenue streams, or servicing a well-defined and steady customer base, and that have established partnerships. In this track, participants will focus on addressing a specific “gap” or applicable issue, which resolution is crucial for your continued progress and development. These issues may include (provided as examples only): developing a detailed regulatory plan in anticipation of near-term FDA submission, addressing feedback from the FDA on a current regulatory application, preparing for 510k approval, etc.

Participation in CAP is open to HHS SBIR and STTR Phase II awardees (grants, cooperative agreements, and contracts) from the previous five years. Participation is free to the HHS SBIR/STTR awardee; however, participants are responsible for travel and lodging expenses associated with attending workshops and partnering events. Detailed information about the CAP is available at https://sbir.nih.gov/cap.

**NIH, CDC, AND FDA AWARDING COMPONENT CONTACT INFORMATION**

Questions of a general nature about the NIH SBIR/STTR program may be directed to:

NIH SBIR/STTR Program Office
Telephone: 301-435-2688
Fax: 301-480-0146
Email: sbir@od.nih.gov

For Agency, Institute and Center Scientific/Research (Program) and Financial/Grants Management contacts, please see here:

https://sbir.nih.gov/engage/ic-contacts
NATIONAL INSTITUTE ON AGING (NIA)

NIA’s mission is to:
- Support and conduct genetic, biological, clinical, behavioral, social, and economic research on aging.
- Foster the development of research and clinician scientists in aging.
- Provide research resources.
- Disseminate information about aging and advances in research to the public, health care professionals, and the scientific community, among a variety of audiences.

The NIA SBIR-STTR Programs support research and product development focusing on aging and aging-related condition and diseases, as well as other problems and needs unique to older Americans. NIA supports SBIR and STTR research and product development under four divisions: Behavioral and Social Research, Biology of Aging (Aging Biology), Geriatrics and Clinical Gerontology, and Neuroscience.

For additional information about NIA’s SBIR and STTR programs please visit: https://www.nia.nih.gov/research/dea/small-business-innovation-research-and-technology-transfer-programs.

Limited Amount of Award

For budgetary, administrative, or programmatic reasons, the NIA may not fund an application or may decrease the length of an award and/or the budget recommended by a review committee. For topics listed in APPENDIX A: National Institutes of Health SBA-Approved SBIR/STTR Topics for Awards over Statutory Budget Limitations, the NIA generally will not fund Phase I applications greater than $300,000 total costs or project periods greater than 2 years; or Phase II applications greater than $2,000,000 total costs or project periods greater than 3 years. For all other topics, the NIA does not generally fund Phase I applications greater than $225,000 total costs or project periods greater than 2 years; or Phase II applications greater than $1,500,000 total costs or project periods greater than 3 years. Applicants considering a requested budget greater than these limits are strongly encouraged to contact program staff before submitting an application.

Phase IIB Competing Renewal Awards

NIA welcomes submission of Phase IIB Competing Renewal grant applications from Phase II SBIR/STTR awardees to continue the process of developing a wide range of aging- and health-focused products, including digital-mobile/cyber-health technology, pharmaceutical compounds, and medical devices. The Phase IIB Competing Renewal award is intended to allow small businesses the opportunity to realize further progress in commercialization, including stimulating interest in and investment by third parties.

Prospective Phase IIB Competing Renewal applicants are strongly encouraged to contact NIA’s SBIR-STTR program coordinator prior to consideration and preparation of a Phase IIB application--& well in advance of the SBIR-STTR submission due dates.

For questions about NIA’s participation in the Phase IIB program, please contact:

Michael-David ARR Kerns, M.M., M.S., Ph.D.
Director, NIA Small Business R & D Programs
Telephone: 301-402-7713
Email: kernsmd@mail.nih.gov
Bio: https://www.nia.nih.gov/about/staff/dea/kerns-michael-david
Research Topics of Interest to NIA

The specific set of topics that are funded by a particular IC/Office/Agency depends on whether the IC/Office/Agency funds/supports Clinical Trials under SBIR/STTR Awards. Use the following table and explanations to determine which list of topics is applicable.

<table>
<thead>
<tr>
<th>Does IC/Office/Agency Fund/Support Clinical Trials under SBIR/STTR Awards?</th>
<th>No*</th>
<th>Yes**</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td>X</td>
</tr>
</tbody>
</table>

*If No,
- This IC/Office/Agency funds only those topics listed under the Non-Clinical Trials Topics section below, UNLESS the IC/Office/Agency funds a Small Business Concern for clinical trials under a NON-SBIR/STTR award.

**If Yes or the IC/Office/Agency funds small businesses for clinical trials under a NON-SBIR/STTR funding opportunity,
- See the table below for which mechanisms the IC/Office/Agency will allow for clinical trials research. Also, see the Clinical Trials Topics section below for a list of funded topics. This IC/Office/Agency also funds research listed under the Non-Clinical Trials Topics section below.

<table>
<thead>
<tr>
<th>Does IC/Office/Agency accept clinical trials applications under this mechanism?</th>
<th>Yes</th>
<th>No</th>
<th>Other Information: If funding an SBC for clinical trials under a NON-SBIR/STTR award, please identify activity code(s) and other relevant information.</th>
</tr>
</thead>
<tbody>
<tr>
<td>Clinical Trials SBIR/STTR IC/Office/Agency - Specific Funding Opportunity Announcement/s</td>
<td>X</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
NIA Non-Clinical Trials Topics:

Division of Behavioral and Social Research (DBSR)

DBSR areas of research that may be of interest to small businesses include, but are not limited to:

A. Development and translation of behavioral economics approaches (incentives or disincentives) to motivate sustainable behavior change to improve health and well-being.
   1. Increasing levels of physical activity or promoting treatment adherence or social connectedness;
   2. Addressing biases such as loss aversion, errors in affective forecasting, present bias, ambiguity effect, base-rate neglect, and susceptibility to framing effects in health and financial decision making;
   3. Using information, or the mode of data presentation to systematically improve decision making (e.g., through "nudges", policies, or practices that constrain choices).

B. Development of robotics applications to aid elderly.
   1. Socially assistive robots allowing elderly to remain independent in their homes. Technology could support machine cognition, language understanding and production, human-robot interaction (cognition, perception, action control, linguistics, psychological, and developmental science), and perception;
   2. Use of robots to motivate elderly to exercise;
   3. Socially assistive robots with psychological sensitivity could promote responsiveness, improve and facilitate communication, increase social interactions, elicit negative event self-disclosure, and serve in a caregiving role.

C. Development of cognitive training applications/intervention to improve cognitive function in elderly
   1. Rapidly develop novel, engaging computer-based cognitive training programs that are based on efficacious approaches and which use cognitive training to target a specific neural system/functional domain.
   2. Augment existing computerized cognitive interventions to be personalized, engaging, adaptive, sufficiently challenging, and optimal for maximizing real world functional improvements.

D. Development of blood-spot technology for biological data collection:
   1. Development of multiple and reliable assays for limited blood-spot specimens for large surveys.
E. Social, behavioral, environmental and/or technical interventions on the individual, institutional, family, community or national level intended to maintain older adult independence or functioning, increase well-being and prevent disease and/or disability.
   1. Interventions that can promote a safe home environment, including those which make use of technological innovations for improved monitoring, surveillance, and communication.
   2. Interventions directed at self-management of chronic diseases among the elderly, including behavioral change and applications to enhance compliance.
   3. Interventions designed for caregivers to promote self-awareness and attention to self-care health and well-being needs in managing stress, maintaining a healthy diet, creating and maintaining contact with a supportive social network, and attending to one’s own physical health.
   4. Interventions that can promote productive and effective communication with health care providers, to increase understanding and communication of changes in symptomology, promote transparency of care needs, increase receipt of family-centered optimal care, and make informed health care decisions, and for informed advance care planning and directives.
   5. Interventions and/or assistive devices to promote the individual’s independence outside the home, e.g., driving, wayfinding and navigation.
   6. Development of methods and technologies predicated on evidence-based behavioral interventions to reduce the burden of caregiving for Alzheimer’s disease caregivers and development of related training materials to be used by community-based agencies or health care organizations.

F. Genetics and Genome Wide Association Approaches
   1. Develop online genetic counseling for users to interface with professionals regarding issues that may have arisen after learning about genetic risk for disease.
   2. Create smartphone applications which will crowd source new phenotype information from participants who have been genotyped.

G. New sampling and data collection methodologies for use in large population-based household surveys and behavioral interventions of relevance to aging. These include:
   1. Experience sampling and new devices for real-time collection of data; particularly, for recording and analysis of social interactions;
   2. Develop, test and market assays useful for analysis of bio-specimens collected as part of large longitudinal studies of aging.

H. Survey Development/Archiving/Database support:
   1. Development of new databases and database support infrastructure to satisfy data and research needs in aging as well as the development of innovative data archives to make current statistical and epidemiological data more accessible as per NIH rigor/reproducibility policy;
   2. Development of data extraction web tools and archiving for public use databases;
   3. Development of innovative methods and software to provide improved access to complex longitudinal studies or surveys that preserve confidentiality;
   4. Development of innovative methods and software to facilitate analysis of personal data linked to geocoded data, biological, cognitive or genetic measures, with improved protection for confidentiality of respondents;
   5. Development of data infrastructure and tools for assessing the economic impact of federally-funded research.
6. Development and enhancements of existing NIA supported longitudinal surveys/studies by creating longitudinal data files and corresponding codebook similar to RAND HRS files/codebook.

7. Test, validate and process already collected samples for analysis of bio-specimens in biorepository collected as part of large longitudinal studies of aging.

8. Development for remote data enclave infrastructure which will enable researchers to share and analyze restricted data (e.g. CMS claims records and other sensitive data) remotely.

I. Develop risk reduction programs (also referred to as health promotion, health management, demand management, and disease prevention programs) among those aged 45-64 within the private sector or health. The goal of these interventions is to improve the health of older workers, reduce avoidable health care utilization, and be cost-effective for employee insurance plans.

J. Integration of technology, big data, artificial intelligence and machine learning for early diagnosis of aging related ailment

K. Use of technology and innovative statistical methods (e.g., machine learning, development of artificial intelligence algorithms) as appropriate for analysis of “big data” (i.e., time intensive, multisource data) to inform a deeper understanding of mechanisms underlying aging, in both treatment (e.g. early diagnosis of aging related disease such as dementia, and multiple co-morbidities in using EHR data) and naturalistic settings (e.g. home assessment using technology to mining and combining big data to predict early diagnosis aging related diseases).

L. Development of new and/or validation of existing sensitive, specific and standardized tests for diagnostic screening of MCI as distinguished from normative age-related change; for example, the development of novel technology and/or methods or the validation of existing measures/methods/technology for the early detection of cognitive impairment and MCI. This includes biosensors and prosthetic devices, technologies, and related software development to aid in the assessment, diagnosis, and remediation of age-related cognitive decline.

M. Discovery, development, and/or evaluation of behavioral methods to remediate age-related cognitive decline, and to treat the cognitive impairment and/or behavioral symptoms associated with MCI, as well as to slow and/or reverse the course of cognitive decline or to prevent it entirely.

**Division of Aging Biology (DAB)**

DAB areas of research that may be of interest to small businesses include, but are not limited to:

A. Effects of metabolism on the aging process, e.g., how metabolic regulation influences longevity, and the development of anti-oxidants or other interventions to reduce oxidative or other stresses and aging-related diseases.

B. Development of minimally-perturbing techniques for collecting blood from mice, rats, and other animals several times a day in sufficient quantities for measurement of hormone levels and other circulating factors in young and old animals, or development of non-invasive research and test methods for use in animals.

C. 1. Development of molecular probes such as antibodies, DNA sequences and expression vectors useful in studying aging, senescence, and longevity both *in vivo* and *in vitro*.

   2. Validation and further development of candidate interventions which have been found to enhance longevity or slow aging, either in cultured cells, animal models, and humans, and which may affect other age-related conditions or diseases such as cancer and cardiovascular diseases.

   3. Development of interventions that improve the immune response to foreign molecules or reduce the response to self or suppress age-induced inflammation.
D. Development of novel strategies for treating age-related renal, pulmonary, urology, reproductive disorders, and age-related changes in hormone production and function. The topics could include devices, pharmacological targets and their validation, small molecules and other approaches to treat these disorders in the elderly. Early-stage pharmacological validation of novel targets and accompanying pre-therapeutic leads for these age-related diseases are encouraged.

E. 1. Development of treatments for wound healing in the aged. These would include devices, processes, and pharmacological agents with the potential to (1) promote wound healing in aged tissues, or (2) reduce scar formation without compromising effective healing. Wounds produced by accidental damage or resulting from surgery would be appropriate for consideration.

2. Development of novel methodology for treating osteoarthritis. These could include devices, processes and pharmacological agents with the potential to (1) Slow the rate of joint deterioration, (2) promote the remodeling of damaged joints, (3) reduce the likelihood of progression to osteoarthritis, and/or (4) improve outcomes for patients with active osteoarthritis.

3. Development of anabolic treatments to delay bone loss and or promote new bone deposition for the treatment of metabolic bone disorders.

F. 1. Development of cell-based therapies or other treatments to repair myocardial or vascular tissues after ischemia. The work should include consideration of age-related effects on the therapy or treatment.

2. Early development to re-purpose FDA-approved drugs or interventions for common diseases (cancer, cardiovascular, etc.) on aging-related diseases or conditions using senescence cell culture or animal models.

3. Development of biologics or mimetics to slow the rate of aging.

G. 1. Development of tools and technologies to characterize cellular heterogeneity in aging tissues at the single cell level.

2. Development of interventions to alter the senescence status of cells in tissues and organs of old animals.


4. Development of new interventions using screens for senescence in cell culture or animal models.

5. Development of interventions that reduce the level of damage to nucleic acids, proteins and lipids and the macromolecular complexes formed from these molecules, and improve the damage surveillance and repair potential of cells.

H. 1. Development of tools and resources in genetics and genomics to study molecular mechanisms of normal aging or aging-related diseases.

2. Development of biomarkers for prognosis, diagnosis, or treatment monitoring of aging or aging-related diseases. Analysis and integration of large data sets are encouraged for developing such biomarkers or biomarker signatures.

3. Development of computational, statistical, or bioinformatics tools and resources to manage, integrate, and mine large aging-related data sets; Development of databases, methods, or data analysis systems for aging research; Development of technologies, tools, methods, and resources useful for the study of aging and aging-related diseases at the systems biology level.

4. Development of probiotics or prebiotics which are beneficial for age-related diseases or conditions.

5. Research and development of commercial pharmaceutical interventions, that are known to extend lifespan and/or healthspan, to prevent, treat, and/or slow the progression of symptoms associated with Alzheimer’s disease (AD) or Alzheimer’s disease related dementia (ADRD) in human cells and/or tissue, in-vitro models, and/or non-human animals.
6. Research and development of commercial pharmaceutical interventions, that are known to extend lifespan and/or healthspan, to prevent, treat, and/or slow the progression of symptoms associated with other age-related diseases.

Division of Neuroscience (DN)

Areas that may be of interest to small businesses include, but are not limited to:

A. Development of sensitive, specific and standardized tests for diagnostic screening of MCI and dementia; for example, the development of novel neuropsychological, biochemical and neuroimaging methods for the early detection of cognitive impairment and MCI and the early diagnosis of AD, and development of new tests for detection of pre-clinical AD.

B. Discovery, development, and/or evaluation of drugs, biological or natural products, including central-nervous-system delivery systems to remediate age-related cognitive decline, and to treat the cognitive impairment and/or behavioral symptoms associated with MCI, AD, and other dementias of aging as well as to slow and/or reverse the course of the disease or to prevent it entirely.

C. AD target discovery and validation through the application of systems biology and systems pharmacology approaches.

D. The development of practical applications using innovative technologies (e.g. hand-held, internet, telemedicine GPS, robotics, social networking and communications technologies) to support and improve quality of life, well-being, and the ability of people with MCI, AD or other dementias of aging to live independently and safely at home for an extended period of time. Examples include systems and devices to: evaluate, monitor and improve or adapt to changes in cognition; improve health service delivery; support independent living and the conduct of everyday tasks at home; provide information to health care providers and family members with which to evaluate the need for intervention; and promote communication and interaction between individuals living in the community or in institutional settings and their health care providers, friends and family members.

E. Testing in clinical trials of drug, nutritional, behavioral, cognitive or other types of interventions to remediate age-related cognitive decline, and to treat cognitive impairment and/or behavioral symptoms associated with MCI, AD, and other dementias of aging as well as to slow and/or reverse the course of disease or to prevent the onset of disease.

F. Devices or intervention strategies that may prolong functional independence when there are dysfunctions of the central nervous system.

G. Behavioral, environmental, pharmacological, & nutritional interventions to prevent and/or remediate brain biochemical and/or neurophysiological changes caused by normal aging and neurodegenerative diseases, including age-related sensory dysfunction (e.g., pain, hearing loss, speech communication disorders, olfaction loss, & vision loss), motor dysfunction (including Parkinson’s disease & other age-related psychomotor disorders) or age-related decrements in balance & postural control, gait performance, and mobility.

H. Biosensors and prosthetic devices, technologies, and related software development to aid in the assessment, diagnosis, and remediation of age-related cognitive decline or sensory dysfunction (including pain, age-related vision loss, and age-related hearing loss), motor dysfunction (including Parkinson’s disease and other motor disorders of aging), or age-related changes in balance, postural control, and gait. Novel markers of normal age-dependent cognitive decline or sensory and/or motor system changes at the molecular cellular, circuitry, physiological or behavioral level in humans or relevant animal models.
I. New technologies to screen for the presence of sleep disorders in older persons, to aid in the
diagnosis of these disorders, and to enable their remediation.

J. Minimally invasive technologies to detect prion diseases early in the course of the disease process in older adults, as well as effective treatment strategies to slow, halt or prevent these diseases.

K. Improved instrumentation, imaging technology, related devices, and software packages for use in visualizing neural activity during cognitive or sensory behavior in older adults. Also of interest would be new technologies to combine neural imaging and behavioral assessment in awake animals.

L. Development of technology and analysis tools to examine, in a systematic way, genetic, epigenetic, transcriptomic, metabolomic, and cell stress pathways in neurons and glia of the aging brain. Development of molecular imaging technology for the in vitro and in vivo analysis of gene, epigenome, proteostasis and metabolic function in the normal aging brain and in the diseased aging nervous system.

M. Improved technology for the analysis of structural and functional brain connectivity at the cell, neural circuitry and global network levels to define the normal trajectory of brain structure and function over the adult lifespan. Development of technology, including non-invasive methods and novel probes, to monitor and manipulate the plasticity of neural circuits in the adult and aged nervous system. Development of novel markers of neural stem cell function (proliferation, migration, and differentiation) as well as methods to assess the integration and function of stem cells in the nervous system.

N. Novel approaches for analysis of next-generation sequence data.

Division of Geriatrics and Clinical Gerontology (DGCG)

Areas of interest include but are not limited to:

A. Improved, non-invasive measures (imaging or sensor technologies) of physiologic changes with age. Of particular interest are unobtrusive sensing and wearable technologies which will facilitate the collection of data on a variety of physiological parameters in longitudinal studies.

B. Techniques/devices (e.g., non-invasive, portable) for improved monitoring of caloric intake and/or energy expenditure in epidemiological studies.

C. Development and validation of human aging mechanistic markers predictive for various age-related conditions or responses to interventions. Products of interest include the development and validation of commercial assays which could be used in clinical/epidemiologic research to assess mechanisms of aging (e.g., cell senescence, autophagy, DNA damage and repair) in human blood, tissues or cells. This may involve refinement of existing assays (e.g., conversion of lab assay to high-throughput screening) and/or de novo assay development for use in clinical research. Novel molecular imaging techniques (in vitro and in vivo) to study aging mechanisms in humans are also encouraged.

D. Potential new therapeutics and/or interventions targeting fundamental mechanisms of aging. This may include identification of new therapeutic targets or repurposing of existing FDA-approved medications.

E. Development of bioinformatic tools for big data integration, visualization and in-depth analysis of “omics” data for predictive markers of aging, molecular pathways associated with aging and age related diseases, and omic targets for therapeutic translation.
F. Development of high throughput drug screening platforms to identify small molecules for enhancing
the functions of protective genetic/metabolic factors associated with exceptional longevity or health
span in humans.

G. Development of vaccines and other agents for preventing and treating infections in older persons,
including development of new vaccines or preventive interventions, and new methods using currently
available vaccines or preventive medications.

H. Development of clinical decision support tools that help physicians caring for patients with multiple
chronic conditions to prioritize the interventions that are most beneficial and relevant within the
context of these patients’ lives; or tools for patient self-management of multiple chronic conditions.
Development of patient-focused tools for prioritizing and making decisions about the most significant
health concerns to help select and order their self-management behaviors related to 3 or more
chronic conditions.

I. Devices and/or techniques for preventing or treating urinary incontinence.

J. Development of improved post-surgical treatments/technologies promoting wound healing, prevention
of chronic wounds, or reduced scar formation.

K. New therapeutic interventions targeting putative aging mechanisms that influence the risk or
progression of multiple age-related conditions.

L. Measuring ambulation and assessing factors contributing to problems in and/or related to ambulation
and mobility through development of improved instrumentation for biomechanical assessment of
ambulation and falls; development of assessments for balance, sway, gait, or postural control to
identify stable and unstable patterns of movement during activities of daily living; or a development of
improved quantitative methods of assessing postural perturbations relevant to activities of daily living.

M. Development of improved, lightweight, and absorbent materials or other interventions to prevent,
protect against and minimize injuries suffered from falls.

N. Development of assistive technologies/robotics/sensors to enable and support older persons to live
independently and safely at home through devices/assistive technologies addressing complications of
limited mobility among older persons; or socially-assistive robots, robots for caregiver and mobility
assistance, or for exercise and rehabilitation assistance.

O. Development of technologies to assist in the improvement of physical function and mobility in older
persons prior to (prehabilitation) or following (rehabilitation) elective/planned surgery.

P. Development and validation of non-invasive methods of examining bone quality (density, architecture,
and strength of bone); development, testing, and validation of new surrogate measures of clinically
relevant outcomes and endpoints of osteoporosis (e.g., fractures) for more immediate and accurate
assessment of the risk or progression of age-related diseases, or to predict or monitor efficacy,
response to treatment or enhanced risk or progression of adverse effects/events.

Q. Development of new diagnostic tests to predict adverse and/or costly, or favorable, health outcomes
with aging or in the setting of chronic diseases, injuries, surgery, hospitalization, or other health-
related conditions.

R. Development and validation of instruments or methods to evaluate fatiguability—the level of fatigue
related to the intensity, duration, and/or frequency of activity (in contrast to measures of fatigue),
particularly in adults with or at-risk of developing age-related conditions or diseases leading to
physical disability.
S. Development and validation of innovative approaches to pain control that consider age-related
physiologic changes such as gastrointestinal absorption, cutaneous integrity, and musculoskeletal
structure and function.


U. Development of methods to accurately determine renal glomerular filtration rate (GFR) in older
persons and patients with chronic kidney disease, considering the effects of age-related changes in
muscle mass, levels of serum creatinine, renal blood flow, and renal concentrating ability.

V. Identification of novel biomarkers of acute kidney injury and chronic kidney disease in older persons,
including identification of biomarkers and evaluation of their clinical utility for early diagnosis,
prediction of the course of progression of diseases, and/or monitoring the effects of treatment.

W. Development and validation of new technology such as non-invasive methods to examine blood-flow
velocity in arteries, individual coronary arteries, renal arteries, and cerebral arteries; or improved
techniques for hemodynamic monitoring of older adults in emergency and/or critical care settings.

X. Development and validation of improved approaches for evaluation, monitoring or treatment of
diastolic dysfunction in older adults.

Y. Development and effectiveness testing of innovative, practical, cost-effective technologies, data
collection and extraction systems and devices that could enhance the participation in clinical trials of
older vulnerable people who are typically under-represented in clinical trials.

Z. Development and validation of novel, practical, cost-effective and reliable assays of multiple markers
of age-related chronic inflammation, designed for use in comprehensive geriatric assessment and for
research purposes

**NIA Clinical Trials Topics:**

**Division of Behavioral and Social Research (DBSR)**

DBSR areas of research that may be of interest to small businesses include, but are not limited to:

A. Development and translation of behavioral economics approaches (incentives or disincentives) to
motivate sustainable behavior change to improve health and well-being.

   1. Increasing levels of physical activity or promoting treatment adherence or social connectedness;
   2. Addressing biases such as loss aversion, errors in affective forecasting, present bias, ambiguity
effect, base-rate neglect, and susceptibility to framing effects in health and financial decision
making;
   3. Using information, or the mode of data presentation to systematically improve decision making
(e.g., through “nudges”, policies, or practices that constrain choices).

B. Development of robotics applications to aid elderly.

   1. Socially assistive robots allowing elderly to remain independent in their homes. Technology could
support machine cognition, language understanding and production, human-robot interaction
(cognition, perception, action control, linguistics, psychological, and developmental science), and
perception;
   2. Use of robots to motivate elderly to exercise;
3. Socially assistive robots with psychological sensitivity could promote responsiveness, improve and facilitate communication, increase social interactions, elicit negative event self-disclosure, and serve in a caregiving role.

C. Development of cognitive training applications/intervention to improve cognitive function in elderly
   1. Rapidly develop novel, engaging computer-based cognitive training programs that are based on efficacious approaches and which use cognitive training to target a specific neural system/functional domain.
   2. Augment existing computerized cognitive interventions to be personalized, engaging, adaptive, sufficiently challenging, and optimal for maximizing real world functional improvements.

D. Development of blood-spot technology for biological data collection:
   1. Development of multiple and reliable assays for limited blood-spot specimens for large surveys.

E. Social, behavioral, environmental and or/technical interventions on the individual, institutional, family, community or national level intended to maintain older adult independence or functioning, increase well-being and prevent disease and/or disability.
   1. Interventions that can promote a safe home environment, including those which make use of technological innovations for improved monitoring, surveillance, and communication.
   2. Interventions directed at self-management of chronic diseases among the elderly, including behavioral change and applications to enhance compliance.
   3. Interventions designed for caregivers to promote self-awareness and attention to self-care health and well-being needs in managing stress, maintaining a healthy diet, creating and maintaining contact with a supportive social network, and attending to one’s own physical health.
   4. Interventions that can promote productive and effective communication with health care providers, to increase understanding and communication of changes in symptomology, promote transparency of care needs, increase receipt of family-centered optimal care, and make informed health care decisions, and for informed advance care planning and directives.
   5. Interventions and/or assistive devices to promote the individual’s independence outside the home, e.g., driving, wayfinding and navigation.
   6. Development of methods and technologies predicated on evidence-based behavioral interventions to reduce the burden of caregiving for Alzheimer’s disease caregivers and development of related training materials to be used by community-based agencies or health care organizations

F. Genetics and Genome Wide Association Approaches
   1. Develop online genetic counseling for users to interface with professionals regarding issues that may have arisen after learning about genetic risk for disease.
   2. Create smartphone applications which will crowd source new phenotype information from participants who have been genotyped

G. New sampling and data collection methodologies for use in large population-based household surveys and behavioral interventions of relevance to aging. These include:
   1. Experience sampling and new devices for real-time collection of data; particularly, for recording and analysis of social interactions;
   2. Develop, test and market assays useful for analysis of bio-specimens collected as part of large longitudinal studies of aging.
H. Survey Development/Archiving/Database support:
1. Development of new databases and database support infrastructure to satisfy data and research needs in aging as well as the development of innovative data archives to make current statistical and epidemiological data more accessible as per NIH rigor/reproducibility policy;
2. Development of data extraction web tools and archiving for public use databases;
3. Development of innovative methods and software to provide improved access to complex longitudinal studies or surveys that preserve confidentiality;
4. Development of innovative methods and software to facilitate analysis of personal data linked to geocoded data, biological, cognitive or genetic measures, with improved protection for confidentiality of respondents;
5. Development of data infrastructure and tools for assessing the economic impact of federally-funded research.
6. Development and enhancements of existing NIA supported longitudinal surveys/studies by creating longitudinal data files and corresponding codebook similar to RAND HRS files/codebook
7. Test, validate and process already collected samples for analysis of bio-specimens in biorepository collected as part of large longitudinal studies of aging.
8. Development for remote data enclave infrastructure which will enable researchers to share and analyze restricted data (e.g. CMS claims records and other sensitive data) remotely.

I. Develop risk reduction programs (also referred to as health promotion, health management, demand management, and disease prevention programs) among those aged 45-64 within the private sector or health. The goal of these interventions is to improve the health of older workers, reduce avoidable health care utilization, and be cost-effective for employee insurance plans.

J. Integration of technology, big data, artificial intelligence and machine learning for early diagnosis of aging related ailment

K. Use of technology and innovative statistical methods (e.g., machine learning, development of artificial intelligence algorithms) as appropriate for analysis of "big data" (i.e., time intensive, multisource data) to inform a deeper understanding of mechanisms underlying aging, in both treatment (e.g. early diagnosis of aging related disease such as dementia, and multiple co-morbidities in using EHR data) and naturalistic settings (e.g. home assessment using technology to mining and combining big data to predict early diagnosis aging related diseases).

L. Development of new and/or validation of existing sensitive, specific and standardized tests for diagnostic screening of MCI as distinguished from normative age-related change; for example, the development of novel technology and/or methods or the validation of existing measures/methods/technology for the early detection of cognitive impairment and MCI. This includes biosensors and prosthetic devices, technologies, and related software development to aid in the assessment, diagnosis, and remediation of age-related cognitive decline.

M. Discovery, development, and/or evaluation of behavioral methods to remediate age-related cognitive decline, and to treat the cognitive impairment and/or behavioral symptoms associated with MCI, as well as to slow and/or reverse the course of cognitive decline or to prevent it entirely.

**Division of Aging Biology (DAB)**

DAB areas of research that may be of interest to small businesses include, but are not limited to:
A. Effects of metabolism on the aging process, e.g., how metabolic regulation influences longevity, and the development of anti-oxidants or other interventions to reduce oxidative or other stresses and aging-related diseases.

B. Development of minimally-perturbing techniques for collecting blood from mice, rats, and other animals several times a day in sufficient quantities for measurement of hormone levels and other circulating factors in young and old animals, or development of non-invasive research and test methods for use in animals.

C. 1. Development of molecular probes such as antibodies, DNA sequences and expression vectors useful in studying aging, senescence, and longevity both in vivo and in vitro.

2. Validation and further development of candidate interventions which have been found to enhance longevity or slow aging, either in cultured cells, animal models, and humans, and which may affect other age-related conditions or diseases such as cancer and cardiovascular diseases.

3. Development of interventions that improve the immune response to foreign molecules or reduce the response to self or suppress age-induced inflammation.

D. Development of novel strategies for treating age-related renal, pulmonary, urology, reproductive disorders, and age-related changes in hormone production and function. The topics could include devices, pharmacological targets and their validation, small molecules and other approaches to treat these disorders in the elderly. Early-stage pharmacological validation of novel targets and accompanying pre-therapeutic leads for these age-related diseases are encouraged.

E. 1. Development of treatments for wound healing in the aged. These would include devices, processes, and pharmacological agents with the potential to (1) promote wound healing in aged tissues, or (2) reduce scar formation without compromising effective healing. Wounds produced by accidental damage or resulting from surgery would be appropriate for consideration.

2. Development of novel methodology for treating osteoarthritis. These could include devices, processes and pharmacological agents with the potential to (1) slow the rate of joint deterioration, (2) promote the remodeling of damaged joints, (3) reduce the likelihood of progression to osteoarthritis, and/or (4) improve outcomes for patients with active osteoarthritis.

3. Development of anabolic treatments to delay bone loss and or promote new bone deposition for the treatment of metabolic bone disorders.

F. 1. Development of cell-based therapies or other treatments to repair myocardial or vascular tissues after ischemia. The work should include consideration of age-related effects on the therapy or treatment.

2. Early development to re-purpose FDA-approved drugs or interventions for common diseases (cancer, cardiovascular, etc.) on aging-related diseases or conditions using senescence cell culture or animal models.

3. Development of biologics or mimetics to slow the rate of aging.

G. 1. Development of tools and technologies to characterize cellular heterogeneity in aging tissues at the single cell level.

2. Development of interventions to alter the senescence status of cells in tissues and organs of old animals.


4. Development of new interventions using screens for senescence in cell culture or animal models.

5. Development of interventions that reduce the level of damage to nucleic acids, proteins and lipids and the macromolecular complexes formed from these molecules, and improve the damage surveillance and repair potential of cells.
H.  1. Development of tools and resources in genetics and genomics to study molecular mechanisms of normal aging or aging-related diseases.
   2. Development of biomarkers for prognosis, diagnosis, or treatment monitoring of aging or aging-related diseases. Analysis and integration of large data sets are encouraged for developing such biomarkers or biomarker signatures.
   3. Development of computational, statistical, or bioinformatics tools and resources to manage, integrate, and mine large aging-related data sets; Development of databases, methods, or data analysis systems for aging research; Development of technologies, tools, methods, and resources useful for the study of aging and aging-related diseases at the systems biology level.
   4. Development of probiotics or prebiotics which are beneficial for age-related diseases or conditions.
   5. Research and development of commercial pharmaceutical interventions, that are known to extend lifespan and/or healthspan, to prevent, treat, and/or slow the progression of symptoms associated with Alzheimer's disease (AD) or Alzheimer's disease related dementia (ADRD) in human cells and/or tissue, in-vitro models, and/or non-human animals.
   6. Research and development of commercial pharmaceutical interventions, that are known to extend lifespan and/or healthspan, to prevent, treat, and/or slow the progression of symptoms associated with other age-related diseases.

Division of Neuroscience (DN)

Areas that may be of interest to small businesses include, but are not limited to:

A. Development of sensitive, specific and standardized tests for diagnostic screening of MCI and dementia; for example, the development of novel neuropsychological, biochemical and neuroimaging methods for the early detection of cognitive impairment and MCI and the early diagnosis of AD, and development of new tests for detection of pre-clinical AD.

B. Discovery, development, and/or evaluation of drugs, biological or natural products, including central-nervous-system delivery systems to remediate age-related cognitive decline, and to treat the cognitive impairment and/or behavioral symptoms associated with MCI, AD, and other dementias of aging as well as to slow and/or reverse the course of the disease or to prevent it entirely.

C. AD target discovery and validation through the application of systems biology and systems pharmacology approaches.

D. The development of practical applications using innovative technologies (e.g. hand-held, internet, telemedicine GPS, robotics, social networking and communications technologies) to support and improve quality of life, well-being, and the ability of people with MCI, AD or other dementias of aging to live independently and safely at home for an extended period of time. Examples include systems and devices to: evaluate, monitor and improve or adapt to changes in cognition; improve health service delivery; support independent living and the conduct of everyday tasks at home; provide information to health care providers and family members with which to evaluate the need for intervention; and promote communication and interaction between individuals living in the community or in institutional settings and their health care providers, friends and family members.

E. Testing in clinical trials of drug, nutritional, behavioral, cognitive or other types of interventions to remediate age-related cognitive decline, and to treat cognitive impairment and/or behavioral symptoms associated with MCI, AD, and other dementias of aging as well as to slow and/or reverse the course of disease or to prevent the onset of disease.
F. Devices or intervention strategies that may prolong functional independence when there are
dysfunctions of the central nervous system.

G. Behavioral, environmental, pharmacological, & nutritional interventions to prevent and/or remediate
brain biochemical and/or neurophysiological changes caused by normal aging and neurodegenerative
diseases, including age-related sensory dysfunction (e.g., pain, hearing loss, speech communication
disorders, olfaction loss, & vision loss), motor dysfunction (including Parkinson's disease & other age-
related psychomotor disorders) or age-related decrements in balance & postural control, gait
performance, and mobility.

H. Biosensors and prosthetic devices, technologies, and related software development to aid in the
assessment, diagnosis, and remediation of age-related cognitive decline or sensory dysfunction
(including pain, age-related vision loss, and age-related hearing loss), motor dysfunction (including
Parkinson's disease and other motor disorders of aging), or age-related changes in balance, postural
control, and gait. Novel markers of normal age-dependent cognitive decline or sensory and/or motor
system changes at the molecular cellular, circuitry, physiological or behavioral level in humans or
relevant animal models.

I. New technologies to screen for the presence of sleep disorders in older persons, to aid in the
diagnosis of these disorders, and to enable their remediation.

J. Minimally invasive technologies to detect prion diseases early in the course of the disease process in
older adults, as well as effective treatment strategies to slow, halt or prevent these diseases.

K. Improved instrumentation, imaging technology, related devices, and software packages for use in
visualizing neural activity during cognitive or sensory behavior in older adults. Also of interest would
be new technologies to combine neural imaging and behavioral assessment in awake animals.

L. Development of technology and analysis tools to examine, in a systematic way, genetic, epigenetic,
transcriptomic, metabolomic, and cell stress pathways in neurons and glia of the aging brain.
Development of molecular imaging technology for the in vitro and in vivo analysis of gene,
epigenome, proteostasis and metabolic function in the normal aging brain and in the diseased aging
nervous system.

M. Improved technology for the analysis of structural and functional brain connectivity at the cell, neural
circuitry and global network levels to define the normal trajectory of brain structure and function over
the adult lifespan. Development of technology, including non-invasive methods and novel probes, to
monitor and manipulate the plasticity of neural circuits in the adult and aged nervous system.
Development of novel markers of neural stem cell function (proliferation, migration, and
differentiation) as well as methods to assess the integration and function of stem cells in the nervous
system.

**Division of Geriatrics and Clinical Gerontology (DGCG)**

Areas of interest include but are not limited to:

A. Improved, non-invasive measures (imaging or sensor technologies) of physiologic changes with age.
Of particular interest are unobtrusive sensing and wearable technologies which will facilitate the
collection of data on a variety of physiological parameters in longitudinal studies.

B. Techniques/devices (e.g., non-invasive, portable) for improved monitoring of caloric intake and/or
energy expenditure in epidemiological studies.

C. Development and validation of human aging mechanistic markers predictive for various age-related
conditions or responses to interventions. Products of interest include the development and validation
of commercial assays which could be used in clinical/epidemiologic research to assess mechanisms of aging (e.g., cell senescence, autophagy, DNA damage and repair) in human blood, tissues or cells. This may involve refinement of existing assays (e.g., conversion of lab assay to high-throughput screening) and/or de novo assay development for use in clinical research. Novel molecular imaging techniques (in vitro and in vivo) to study aging mechanisms in humans are also encouraged.

D. Potential new therapeutics and/or interventions targeting fundamental mechanisms of aging. This may include identification of new therapeutic targets or repurposing of existing FDA-approved medications.

E. Development of bioinformatic tools for big data integration, visualization and in-depth analysis of “omics” data for predictive markers of aging, molecular pathways associated with aging and age related diseases, and omic targets for therapeutic translation.

F. Development of high throughput drug screening platforms to identify small molecules for enhancing the functions of protective genetic/metabolic factors associated with exceptional longevity or health span in humans.

G. Development of vaccines and other agents for preventing and treating infections in older persons, including development of new vaccines or preventive interventions, and new methods using currently available vaccines or preventive medications.

H. Development of clinical decision support tools that help physicians caring for patients with multiple chronic conditions to prioritize the interventions that are most beneficial and relevant within the context of these patients’ lives; or tools for patient self-management of multiple chronic conditions. Development of patient-focused tools for prioritizing and making decisions about the most significant health concerns to help select and order their self-management behaviors related to 3 or more chronic conditions.

I. Devices and/or techniques for preventing or treating urinary incontinence.

J. Development of improved post-surgical treatments/technologies promoting wound healing, prevention of chronic wounds, or reduced scar formation.

K. New therapeutic interventions targeting putative aging mechanisms that influence the risk or progression of multiple age-related conditions

L. Measuring ambulation and assessing factors contributing to problems in and/or related to ambulation and mobility through development of improved instrumentation for biomechanical assessment of ambulation and falls; development of assessments for balance, sway, gait, or postural control to identify stable and unstable patterns of movement during activities of daily living; or a development of improved quantitative methods of assessing postural perturbations relevant to activities of daily living.

M. Development of improved, lightweight, and absorbent materials or other interventions to prevent, protect against and minimize injuries suffered from falls.

N. Development of assistive technologies/robotics/sensors to enable and support older persons to live independently and safely at home through devices/assistive technologies addressing complications of limited mobility among older persons; or socially-assistive robots, robots for caregiver and mobility assistance, or for exercise and rehabilitation assistance.

O. Development of technologies to assist in the improvement of physical function and mobility in older persons prior to (prehabilitation) or following (rehabilitation) elective/planned surgery.

P. Development and validation of non-invasive methods of examining bone quality (density, architecture, and strength of bone); development, testing, and validation of new surrogate measures of clinically
relevant outcomes and endpoints of osteoporosis (e.g., fractures) for more immediate and accurate assessment of the risk or progression of age-related diseases, or to predict or monitor efficacy, response to treatment or enhanced risk or progression of adverse effects/events.

Q. Development of new diagnostic tests to predict adverse and/or costly, or favorable, health outcomes with aging or in the setting of chronic diseases, injuries, surgery, hospitalization, or other health-related conditions.

R. Development and validation of instruments or methods to evaluate fatiguability—the level of fatigue related to the intensity, duration, and/or frequency of activity (in contrast to measures of fatigue), particularly in adults with or at-risk of developing age-related conditions or diseases leading to physical disability.

S. Development and validation of innovative approaches to pain control that consider age-related physiologic changes such as gastrointestinal absorption, cutaneous integrity, and musculoskeletal structure and function.


U. Development of methods to accurately determine renal glomerular filtration rate (GFR) in older persons and patients with chronic kidney disease, considering the effects of age-related changes in muscle mass, levels of serum creatinine, renal blood flow, and renal concentrating ability.

V. Identification of novel biomarkers of acute kidney injury and chronic kidney disease in older persons, including identification of biomarkers and evaluation of their clinical utility for early diagnosis, prediction of the course of progression of diseases, and/or monitoring the effects of treatment.

W. Development and validation of new technology such as non-invasive methods to examine blood-flow velocity in arteries, individual coronary arteries, renal arteries, and cerebral arteries; or improved techniques for hemodynamic monitoring of older adults in emergency and/or critical care settings.

X. Development and validation of improved approaches for evaluation, monitoring or treatment of diastolic dysfunction in older adults.

Y. Development and effectiveness testing of innovative, practical, cost-effective technologies, data collection and extraction systems and devices that could enhance the participation in clinical trials of older vulnerable people who are typically under-represented in clinical trials.

Z. Development and validation of novel, practical, cost-effective and reliable assays of multiple markers of age-related chronic inflammation, designed for use in comprehensive geriatric assessment and for research purposes.

For more information on research topics, contact:

**Director, NIA Small Business R & D Programs:**
Michael-David ("M-D") A.R.R. Kerns, M.M., M.S., Ph.D.
National Institute on Aging (NIA)
Telephone: 301-402-7713
Email: kernsmd@mail.nih.gov
Bio: [https://www.nia.nih.gov/about/staff/dea/kerns-michael-david](https://www.nia.nih.gov/about/staff/dea/kerns-michael-david)

**Division of Aging Biology:**
Max Guo, Ph.D.
National Institute on Aging (NIA)
Telephone: 301-402-7747
Email: qmguo@mail.nih.gov
Division of Behavioral and Social Research:
Dana Plude, Ph.D.
National Institute on Aging (NIA)
Telephone: 301-435-2309
Email: pluded@mail.nih.gov

Division of Geriatrics and Clinical Gerontology:
Lyndon Joseph, Ph.D.
National Institute on Aging (NIA)
Telephone: 301-496-6761
Email: josephlj@mail.nih.gov

Division of Neuroscience:
Larry Refolo, Ph.D.
National Institute on Aging (NIA)
Telephone: 301-594-7576
Email: refolol@mail.nih.gov
NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM (NIAAA)

NIAAA supports research on the causes, prevention, control, and treatment of the major health problems associated with alcohol use. Through its extramural research programs, NIAAA funds a wide range of basic and applied research to develop new and/or improved technologies and approaches for increasing the effectiveness of diagnosis, treatment, and prevention. NIAAA also is concerned with strengthening research dissemination, scientific communications, public education, and data collection activities in the areas of its research programs.

Limited Amount of Award

NIAAA will make awards compliant with all statutory guidelines as outlined above. Total funding support (direct costs, indirect costs, fees) normally may not exceed $150,000 for Phase I awards and $1,000,000 for the duration of the Phase II awards. With appropriate justification from the applicant, NIAAA may consider awards that exceed these amounts by up to 50% ($225,000 for Phase I and $1,500,000 for Phase II, a hard cap). NIAAA has received a budgetary guideline waiver from the Small Business Administration for applications relating to the limited list of scientific topics (Appendix A). Applicants considering a requested budget greater than the standard limits are strongly encouraged to contact program staff before submitting an application. For budgetary, administrative, or programmatic reasons, NIAAA may decrease the length of an award and/or the budget recommended by a review committee, or not fund an application.

Phase IIB Competing Renewal Awards

NIAAA will accept SBIR/STTR Phase IIB Competing Renewal grant applications from Phase II SBIR/STTR awardees to continue the process of developing products that require approval of a Federal regulatory agency (e.g., FDA, FCC). Such products include, but are not limited to, medical implants, drugs, vaccines, biologicals, and new treatment or diagnostic tools that require FDA approval. This renewal grant should allow small businesses to get to a stage where interest and investment by third parties is more likely. To be eligible for Phase IIB consideration, the project must retain high significance in the light of current market conditions.

Prospective applicants are strongly encouraged to contact NIH staff well in advance of submitting a Phase IIB Competing Renewal application by submitting to Dr. Kathy Jung (contact information below) a letter of intent that includes the following information:

- Name, address, and telephone number of the Principal Investigator
- Names of other key personnel
- Participating institutions
- Grant number and title
- Progress of the Phase II award
- Goals and justification for the Phase IIB request

It is expected that only a portion of NIAAA SBIR/STTR Phase II awards will be eligible for a Phase IIB Competing Renewal grant.

NIAAA supports Investigational New Drug (IND)-enabling studies for therapeutic candidates under separate FOAs (https://niaaa.nih.gov/grant-funding/funding-opportunities).

Commercialization Assistance Programs

NIAAA Phase I grantees may consider applying for the Niche Assessment Program or the I-Corps at NIH pilot program. NIAAA Phase II grantees are eligible to apply for the Commercialization Accelerator Program (CAP).
Research Topics of Interest to NIAAA

The specific set of topics that are funded by a particular IC/Office/Agency depends on whether the IC/Office/Agency funds/supports Clinical Trials under SBIR/STTR Awards. Use the following table and explanations to determine which list of topics is applicable.

<table>
<thead>
<tr>
<th>Does IC/Office/Agency Fund/Support Clinical Trials under SBIR/STTR Awards?</th>
<th>X</th>
</tr>
</thead>
</table>

*If No,
- This IC/Office/Agency funds only those topics listed under the Non-Clinical Trials Topics section below, **UNLESS** the IC/Office/Agency funds a Small Business Concern for clinical trials under a NON-SBIR/STTR award.

**If Yes or the IC/Office/Agency funds small businesses for clinical trials under a NON-SBIR/STTR funding opportunity,**
- See the table below for which mechanisms the IC/Office/Agency will allow for clinical trials research. Also, see the Clinical Trials Topics section below for a list of funded topics. This IC/Office/Agency also funds research listed under the Non-Clinical Trials Topics section below.

<table>
<thead>
<tr>
<th>Does IC/Office/Agency accept clinical trials applications under this mechanism?</th>
<th>Yes</th>
<th>No</th>
<th>Other Information: If funding an SBC for clinical trials under a NON-SBIR/STTR award, please identify activity code(s) and other relevant information.</th>
</tr>
</thead>
<tbody>
<tr>
<td>Clinical Trials SBIR/STTR Omnibus/Parent Funding Opportunity Announcement/s</td>
<td>X</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
| Clinical Trials SBIR/STTR IC/Office/Agency - Specific Funding Opportunity Announcement/s | X | | https://niaaa.nih.gov/grant-funding/funding-opportunities
https://sbir.nih.gov/funding/individual-announcements |
NIAAA Non-Clinical Trials Topics:

Medications Development

Alcohol use disorder (AUD) is a global health problem, affecting over 76 million adults world-wide, including over 17 million Americans, resulting in a myriad of medical, psychological, social, economic, and personal problems. NIAAA is committed to the preclinical and clinical development of new pharmacological agents to treat AUD.

Pharmacotherapy offers a promising means for treating AUD. During the past two decades, progress has been made in developing medications to treat alcohol problems. Currently, there are four Food and Drug Administration (FDA)-approved pharmacotherapies for the treatment of alcohol dependence: disulfiram (Antabuse®), oral naltrexone (Revia®), acamprosate (Campral®), and the injectable suspension formulation of naltrexone (Vivitrol®). In addition, nalmefene (Selincro®) has recently been approved by the European Medicines Agency (EMA). However, given the heterogeneous nature of AUD, many patients have limited or no response to the aforementioned medications. Because of this, developing and evaluating new, more efficacious medications remains a high priority.

During the past three decades, alcohol research has enriched our understanding of biological mechanisms underlying alcohol dependence. Various neurotransmitter systems, neuromodulators, and intracellular signaling pathways have a role in alcohol dependence. Currently, over 35 promising targets have been shown to alter alcohol drinking behavior. Some of the new promising targets include, but are not limited to, corticotrophin-releasing factor1 (CRF-1), adrenergic α1 and α2, vasopressin 1B, orexin 1 and 2, opioid receptor-like (NOP), opioid kappa, 5-HT2, GABA-A and GABA-B, metabotropic glutamate (mGluR), glutamate transporter (GLT), nicotinic acetylcholine (nAChR), phosphodiesterase (PDE), glial
derived neurotrophic factor (GDNF), and neuroimmune and epigenetic modulators. New medications that bind to these and additional targets are needed.

Candidate medications may include novel and re-purposed compounds. However, grant applications that propose to study compounds already extensively investigated or currently being studied in alcohol dependent patients will not be accepted. Thus, applications proposing the use of naltrexone, acamprosate, disulfiram, topiramate, ondansetron, varenicline, gabapentin, and baclofen are not responsive to this topic.

Specific areas of interest include medications that target one or more domains of alcohol addiction, including reward, stress and negative affect, incentive salience, executive function, habituation, and impulsivity/compulsivity.

For questions, contact:
Raye Z. Litten, Ph.D.
Telephone: 301-443-0636
Email: Raye.Litten@nih.gov

Additional targets for pharmaceutical development include, but are not limited to: development of agents to attenuate excessive alcohol drinking and other symptoms of alcohol dependence, e.g., craving, sleep problems, negative affect. Drugs for the treatment of alcoholic hepatitis, liver fibrosis, cirrhosis, pancreatitis, cardiomyopathy, or other alcohol-induced tissue damage

For pre-clinical questions, contact:
Mark Egli, Ph.D. (Neuroscience and behavior)
Telephone: 301-594-6382
Email: Mark.Egli@nih.gov

Svetlana Radaeva, Ph.D. (Organ damage)
Telephone: 301-433-1189
Email: Svetlana.Radaeva@nih.gov

Innovative Technologies to Measure and Enhance Medication Adherence in Clinical Studies

Maximizing and measuring treatment exposure is critical to understanding the impact of medications, especially in a clinical trial setting. Monitoring medication adherence in a clinical trial setting is both challenging and time consuming. Applications are sought that will provide new options or expand on current technologies to measure and/or enhance medication adherence in clinical research. Areas that may be of interest to small businesses include, but are not limited to:

- Development of a device/technique to evaluate and measure a participant’s adherence to study medication. The main objective is to provide investigators with systematic data on daily medication exposure during clinical trials. The technology must be suitable for assessment of medication adherence in a clinical setting (i.e., affordable, quantitative, rapid results, no impact on subject daily activities, confidential, portable).

- Development or improvement of a device/technique to enhance medication adherence. The technology must be portable, affordable, inconspicuous, and user-friendly.

Megan Ryan, MBA
Telephone: 301-443-4225
Email: mryan1@mail.nih.gov
Technological Methods for the Treatment of Hazardous Drinking and Alcohol Use Disorders

- Develop, improve, and validate ecological momentary assessment (EMA) methods for capturing real-time data for use in clinical trials and treatment paradigms.
- Use technology (e.g., EMA, brain imaging) and innovative statistical methods (e.g., machine learning, systems science dynamic models) appropriate for analysis of “big data” (i.e., time intensive, multisource data) to inform our understanding of mechanisms underlying the initiation, maintenance, and recovery from problematic drinking in both treatment and naturalistic settings.
- Leverage unique features of mobile technologies to provide personalized monitoring and just-in-time interventions
- Optimize existing technologies to increase their utilization and effectiveness in specific treatment contexts (e.g., primary care) and improve patient-provider communication to decrease harmful drinking
- Develop and test computerized versions of empirically-supported treatments
- Develop and test novel computerized interventions which capitalize on hypothesized brain-based or behavioral mechanisms underlying drinking
- Develop software to train potential treatment professionals how to provide evidence-based treatments
- Devise novel methods (e.g., Web-mining software of social networking sites) that capture social network information among groups at risk for alcohol use disorder and high-risk drinking.
- Develop and test the efficacy of neurophysiological treatment approaches such as transcranial magnetic stimulation, neurofeedback, and deep brain stimulation.

Anita Bechtholt, Ph.D.
Telephone: 301-443-9334
Email: anita.bechtholt@nih.gov

Prevention

This area of interest focuses on the development and evaluation of innovative prevention and intervention programs, or specific materials for integration into existing programs, which utilize state-of-the-art technology and are based on currently accepted clinical and behavioral strategies. Applicants are strongly encouraged to consult with research methodologists and statisticians to ensure that state-of-the-art approaches to design, analysis, and interpretation of studies under this topic are used. Areas that may be of interest to small businesses include, but are not limited to:

- Development and evaluation of innovative prevention/intervention programs, or specific materials for integration into existing programs, which utilize state-of-the-art technology and are based on currently accepted clinical and behavioral strategies. Special emphasis should be placed on the needs of high-risk groups, ethnic and minority populations, youth, children of alcoholics, women, the handicapped, and the elderly. Examples of such materials include school-based curricula, interactive videos, computer-based multimedia programs, training manuals for teachers or parents, and community-based programs.
- Development and evaluation of educational materials designed to intervene with the elderly around specific age-related risks for alcohol problems. Particular attention should be given to age-related reductions in alcohol tolerance, interactions between alcohol and prescription and
over-the-counter medications, possible exacerbation of some medical conditions common among the elderly, potential biomedical and behavioral consequences of excessive alcohol use, and the role of alcohol in falls, fires, burns, pedestrian and traffic injuries, and other unintentional injuries.

- Development and evaluation of statistical analysis programs tailored to the design and analysis of alcohol prevention-relevant research. Programs could focus on a variety of areas including: imputation of missing data under varying design assumptions; simulation of distributions of outcomes based on varying mixtures of sample populations; application of chronic or infectious disease models to targeted communities; and models of the potential effect of various policy-based interventions, such as increased taxation or reduction of outlet density by license revocation and control.

Robert C. Freeman, Ph.D.
Telephone: 301-443-8820
Email: Robert.Freeman@nih.gov

### Improving the Delivery of Alcohol Treatment Services

NIAAA’s treatment services research program studies the organization, management, and financing of alcohol treatment services, and how these affect service availability, access, utilization, cost, and quality. Needed innovations in this area include the development of state-of-the-art technologies, software, and protocols to expand and improve the delivery of evidence-based treatment for alcohol use disorders.

Areas that may be of interest to small businesses include, but are not limited to, the development and assessment of software or tools to:

- assist clinicians in selecting and delivering evidence-based treatments consistent with patient needs and available staff and program resources. Special attention should be paid to promoting fidelity of treatment delivery in real-world contexts. For example: software to enable the creation or use of clinical decision support systems, screening protocols, or patient registries; prescription medication management tools; scripts or guides for delivery of brief interventions; and interactive training resources.

- support long-term recovery, by facilitating patients’ continued engagement in recovery support services as an adjunct to or after treatment. For example: software to assist patients in self-management and self-monitoring of drinking behaviors, cues, or triggers, and/or in locating treatment resources or recovery support services.

- assist treatment programs and service agencies in measuring clinically relevant performance indicators or improvements in quality of service provision.

- promote engagement and mitigate burnout among counselors and others engaged in direct treatment service delivery. Tools are needed to reinforce training on therapeutic techniques; provide minimally-obtrusive methods for monitoring and enhancing fidelity of service delivery; engage counselors in mindfulness or other strategies to manage job stress and reduce burnout; and provide front-line counselors with supports essential to maintaining productive therapeutic relationships with patients.

Lori Ducharme, Ph.D.
Telephone: 301-451-8507
Email: Lori.Ducharme@nih.gov
Fetal Alcohol Spectrum Disorder (FASD) and Alcohol-Related Birth Defects

FASD is the collective term for the broad array of adverse effects resulting from in utero alcohol exposure. Fetal Alcohol Syndrome (FAS), the first form of FASD discovered and most well-known, is characterized by craniofacial abnormalities, growth retardation, and nervous system impairments that often include mental retardation. Other diagnostic categories include partial FAS, alcohol-related neurodevelopmental disorder (ARND), and alcohol-related birth defects (ARBD). Children and adults with FASD may exhibit multiple cognitive, behavioral, and emotional deficits that impair daily functioning in many domains. The NIAAA supports research leading to improved diagnosis and assessment of prenatal exposure, impairment and disability, as well as the development of therapeutic interventions, including tools to enhance academic and daily living skills. Areas that may be of interest to small businesses include, but are not limited to:

- Development and assessment of diagnostic and/or screening methods, tools or technology that can be used prenatally to identify fetuses affected by ethanol.
- Development and validation of biomarkers that can be used to verify prenatal alcohol exposure in neonates.
- Development and validation of assessment methods to provide more accurate clinical diagnosis of FASD at all life stages.
- Development and testing of skill-building, therapeutic, and education program products that enhance the social, cognitive, adaptive and motor abilities of individuals with FASD.
- Development of neurobehavioral tools or instruments to assess responsiveness of individuals with FASD to medications and/or cognitive/behavioral therapies.
- Development of accurate measures of the responsiveness of children affected by prenatal exposure to alcohol to stress and predictors of vulnerability to alcohol-drinking or other psychopathology during adolescence and adulthood.
- Development and evaluation of educational and training programs designed to enhance the skills of non-professional caregivers in dealing with the problems associated with FAS.
- Development and validation of innovative methods, tools or technology to prevent harmful drinking during pregnancy.

For basic research questions, contact:
Dale Hereld, MD, Ph.D.
Telephone: 301-443-0912
Email: Dale.Hereld@nih.gov

William Dunty, Ph.D.
Telephone: 301-443-7351
Email: William.Dunty@nih.gov

For prevention research questions, contact:
Marcia Scott, Ph.D.
Telephone: 301-402-6328
Email: Marcia.Scott@nih.gov

Deidra Roach
Telephone: 301-443-5820
Email: Deidra.Roach@nih.gov
Development of Clinical Biomarkers of Alcohol Exposure and Alcohol-Induced Organ Damage

There is a well-recognized need for prognostic and diagnostic biomarkers of alcohol exposure, for biomarkers of the response to clinical treatment, and for biomarkers to monitor abstinence in high-risk individuals. Quantitative and qualitative markers of high-risk drinking behavior and alcohol-induced tissue damage would greatly improve medical efforts to recognize and treat alcohol-related disorders. Currently, no clinically available laboratory test can reliably diagnose duration of alcohol use or predict the progression of alcohol-induced organ damage. Traditional alcohol biomarkers fail to provide long-term information. More recently developed alcohol biomarkers (ethanol metabolites phosphatidylethanol (PEth), ethyl glucuronide (EtG) and ethyl sulfate (EtS)) display improved sensitivity, specificity, and accuracy over classical biomarkers. Their useful range of a few days (EtG) to 2-4 weeks (PEth) addresses many, but not all, clinical needs.

Effective biomarkers are essential to early detection of alcohol use disorder or early stages of organ damage. Early detection will make it possible for patients to consider intervention to prevent long-term medical, psychological, and social consequences of alcohol use.

Several separate, distinct diagnostic settings and circumstances are in need of reliable specific biomarkers. Alcohol biomarkers that address the following are needed:

- Biomarkers that detect cumulative intake of alcohol over a period of months or more; thus a biomarker that is stable over months, reflecting duration and amount of alcohol exposure.
- Biomarkers that detect failure of compliance after withdrawal; thus a biomarker with a short half-life.
- Biomarker signatures of alcohol-induced organ damage, which are likely to be organ-specific.
- Biomarker signatures of familial risk factors for alcoholism. Early identification of subjects predisposed to alcoholism will allow for early intervention, possible prevention, and allow the subjects to make informed personal decisions.

Characteristics of useful biomarkers are:

- Sensitivity, specificity, accuracy, and reliability
- Ease of use and acceptability to patient and provider
- Found in easily obtained specimens, such as serum or plasma, urine, saliva, or hair.
- Validity, reproducibility, affordability, and transportability to a variety of settings, including alcoholism treatment centers, hospitals, primary care offices, or the workplace.

Pattern-based molecular signatures —as opposed to single component biomarkers --may be predicted to provide greater sensitivity, specificity, accuracy, and reliability than single component biomarkers. Thus, high throughput discovery approaches using genomics, epigenomics, transcriptomics, proteomics, metabolomics, lipomics, or glycomics are encouraged.

Also of interest:

- Improvement of turn-around time and cost efficiency of current assays for PEth, EtS, EtG and other alcohol biomarkers.
- Design and development of point of care devices, for use in rural or remote primary care and hospital settings.

Small business efforts for improvements at any stage in the biomarker pipeline are of interest, including discovery, validation, development, and implementation to real world settings.

For clinical questions, contact:
Raye Z. Litten, Ph.D.
Alcohol Biosensors

Small business applications proposing to design and produce a wearable device to monitor blood alcohol levels in real time are sought. The device should be able to quantitate blood alcohol level, and interpret and store the data or transmit it to a smartphone or other device by wireless transmission. The device should have the ability to verify standardization at regular intervals and to indicate loss of functionality. The power source should be dependable and rechargeable. Data storage and transmission must be completely secure in order to protect the privacy of the individual. A form of subject identification would be an added benefit. The device can be removable.

The alcohol biosensor device should be unobtrusive, passive in action, appealing to the wearer, and can take the form of clothing, bracelet, jewelry, or any other format located in contact with the human body. A non-invasive technology is preferred. Novel and innovative approaches to detecting blood alcohol, rather than alcohol that has exuded across the skin, are especially encouraged.

Alcohol detection technology for personal alcohol monitoring will serve useful purposes in research, clinical and treatment settings, will play a role in public safety, and will be of interest to individuals interested in keeping track of personal health parameters.

This topic also includes the opportunity to develop appropriate data analysis systems for individual level evaluation as well as for assessment of trends in research populations.

Alcohol Use and HIV Infection, and HIV Co-infection with HCV, HBV, or TB

Alcohol consumption is widely recognized as a co-factor in the sexual transmission, susceptibility to infection, and progression of the infectious diseases, including HIV and HIV co-infection with HCV, HBV, or TB. However, detailed relationships between alcohol use and viral infections, diseases progression, anti-viral (or anti-TB) therapy and adverse outcomes, notably in liver disease progression, are less recognized or understood. Recent research indicates that inflammatory pathways predominate in liver disease including alcoholic hepatitis whereas adaptive immunity plays a primary role in viral hepatitis, offering multiple targets for novel preventive and therapeutic interventions. Comprehensive studies to improve understanding of the factors underlying alcohol and viral etiologies in liver disease and the impact of anti-viral drugs on liver disease progression are needed. A better understanding of alcohol’s effects on liver disease in patients with HIV and co-infections may improve diagnosis and treatment outcomes. NIAAA supports research leading to improved diagnosis and treatment of alcohol-induced disorders in people infected with HIV, and HIV co-infection with HCV, HBV, or TB.

Areas that may be of interest to small businesses include, but are not limited to:
• New preventive and therapeutic approaches designed to protect the liver from alcohol and antiretroviral drug-induced liver injury in patients infected with HIV, and HIV co-infection with HCV, HBV, or TB

• Development of therapies aimed at molecular targets that play a role in the development of alcoholic and viral liver and or lung diseases.

• Development and evaluation of drugs that mitigate the effects of oxidative stress on mitochondrial function thereby preventing liver disease progression.

• Development of biomarkers for individuals who are most prone to alcohol-induced damage in those patients infected with HIV and comorbid mono- or co-infection.

For basic research questions on alcohol and HIV, and HIV co-infections, contact:
H. Joe Wang, Ph.D.
Telephone: 301-451-0747
Email: Joe.wang1@nih.gov

For clinical or epidemiological questions on HIV, contact:
Kendall J. Bryant, Ph.D.
Telephone: 301-402-9389
Email: Kendall.Bryant@nih.gov

Electronic Diagnostic Clinical Assessment of Frailty among HIV+ Individuals with Past and/or Current Alcohol Use Disorders: Severity and Patterns

Innovative self-report, biological, and/or common clinical measures for the identification and diagnosis of frailty related to alcohol use among alcohol-using HIV patients and those with related comorbidities are sought. Measurement of frailty should be calibrated for severity of alcohol use and be both clinically useful and predictive of morbidity and mortality. Applications proposing the development of medical decision-making algorithms to inform clinical care of HIV+ individuals who drink and include frailty index(es) through an internet site are sought. The primary goal of this site will be to provide normative and educational information for providers and patients related to medical care to reduce frailty index(es) related to morbidity and mortality as primarily a useful tool for clinicians who encounter HIV patients who continue to drink and may or may not be compliant with antiretroviral treatment for suppression of viral replication and restoration of immune function.

• Development of this site should be tested in the widest range of individuals at various trajectories of progression of HIV disease and patterns of alcohol use. In particular, information from measures should be able to accurately identify individuals who are “sick quitters” and/or have high degree of frailty due to either past and/or current alcohol use.

• This clinical decision-making tool should be of greatest value to diagnostic assessment and interventions within clinical settings and may include the development of audio, visual, and/or training modules to support the use of appropriate diagnostic index(es).

• Support of an electronic internet site for scoring and collection of information on HIV disease characteristics, frailty and patterns of alcohol use in clinical populations, and to provide information on a range of options for assessment of alcohol use severity in HIV+ populations (e.g. brief assessment instruments, calendar methods, biological markers, etc.).

• Identify current and emerging methods for behavioral and/or biological intervention to reduce alcohol use in the context of HIV and improve clinical outcomes
Kendall J. Bryant, Ph.D.
Telephone: 301-402-0332
Email: Kendall.Bryant@nih.gov

Monitoring Alcohol Use among HIV+ Patients

Of particular importance is the measurement of patterns of alcohol use among HIV+ individuals. Wearable alcohol biosensors (see related topic) should be developed to maximize acceptability and minimize stigmatization among the widest range of users. It is expected that the most effective devices will be unobtrusive devices (perhaps wrist-worn) that assess a variety of physiological measures in addition to alcohol use and that interact with smart phone technologies for additional assessment or data management features (e.g. momentary ecological assessment) related to medication adherence for HIV and related comorbidities.

Kendall J. Bryant, Ph.D.
Telephone: 301-402-0332
Email: Kendall.Bryant@nih.gov

Stem Cell Research for Alcohol-induced Disorders

Stem cells are master cells in the body and they have the remarkable potential to develop into many different cell types. Stem cells may become a renewable source of replacement cells to treat alcohol related diseases. They can also be used to study disease processes, and to develop new and more effective drugs.

Recent research progress on stem cells has offered great opportunities to study conditions and diseases related to alcohol abuse and alcoholism. Stem cells can come from embryos or adult tissues. They are generally categorized into 1) Embryonic stem cells; 2) induced pluripotent stem cells (iPS cells); and 3) adult stem cells. The NIAAA supports SBIR/STTR research using any of these 3 types of stem cell, which can lead to improved understanding of alcohol related diseases and conditions, and better treatment.

Areas that may be of interest to small businesses include, but are not limited to:

- Generate and disseminate induced pluripotent stem cells (iPS) from mature human cells to resemble diverse individual variations regarding alcohol metabolism. Use these genetic variant models to study alcohol dependence and pharmacotherapy development. Examples of these genetic variations include Alcohol Dehydrogenase (ADH), Aldehyde Dehydrogenase (ALDH), cytochrome P450 isozyme CYP2E1, and Glutathione S transferase (GST).

- Generate and disseminate disease-specific iPS cell lines for studies on the biology and signaling pathways that contribute to the alcohol-related disease pathology.

- Models derived from human iPS cells to study biological and pathological effects of alcohol and its metabolites.

- Using CRISPR (Clustered Regularly Interspaced Short Palindromic Repeats) gene editing technology on iPS cells to study alcohol related disease

Peter Gao, M.D.
Telephone: 301-443-6106
Email: Peter.Gao@nih.gov

Role of Non-coding RNAs in the Neuroadaptation to Alcoholism

Gene expression changes after alcohol exposure are well documented. In particular, a vast network of expression changes is found in the brain (and other tissues) following both acute and chronic alcohol exposure. These neuroadaptations are thought to underlie tolerance and dependence on alcohol as well
as mediating the toxic effects of alcohol on neurodevelopment. The discovery of gene expression regulation mediated by RNA molecules that are transcribed from DNA, but do not code for protein, has set into motion a revolution in molecular biology. These novel RNAs are classified broadly as non-coding RNAs (ncRNAs) and include both small (microRNAs or miRNAs) and large classes (long non-coding RNAs or lncRNAs) that function to alter the expression of genes to which they bind and modify chromatin states. Because it is estimated that the majority of the genome consists of non-protein coding regions, of which ncRNAs make up a substantial portion, understanding how alcohol alters the expression of ncRNAs and their targets has significant potential for understanding the mechanisms of alcohol neuroadaptation. However, because of their diverse role in cellular functions and combinatorial mechanisms of action, many challenges still exist in gaining a full appreciation of the role of ncRNAs in alcohol neuroadaptation.

NIAAA seeks the development of novel technologies to both measure and interpret ncRNA gene expression signatures in the brain and/or primary neuronal cultures following alcohol exposure. These technologies could include, but are not limited to: novel methods to tag and measure ncRNAs, new imagining techniques to monitor changes in ncRNAs, and novel bioinformatic algorithms to interpret alcohol-induced alterations in ncRNAs and predict and validate target genes.

Hemin Chin, Ph.D.
Telephone: 301-443-1282
Email: Hemin.Chin@nih.gov

In vivo Detection of Neuromodulators in Behaving Animals

Neuromodulators, such as neuroimmune factors, modulate a wide range of brain functions and play an important role in neurodevelopment and synaptic function. To understand how activities of neuromodulators contribute to alcohol use disorders and how changes at the molecular level link to behavior, effective tools are needed to detect changes of neuromodulators in real time in the brain of behaving animals. Currently available methods that measure neuromodulator levels in the CSF fluid would not allow the analysis of dynamic changes of neuromodulators with spatial and temporal precision. To facilitate the understanding of how neuromodulators shape neuronal activity and contribute to alcohol use disorders, more accurate methods of detection are needed.

Recent advances in a variety of in vivo neurotechniques provide a great opportunity to achieve this goal. For example, cell-based fluorescent reporters, which detect the activity of G protein-coupled receptors through a fluorescent Ca2+ sensor, can be developed to detect neuromodulators that activate G protein-coupled receptors, such as chemokines. In addition, in vivo fluorescence imaging using target-activated small-molecule fluorochromes coupled with nanotechnology may also provide a powerful tool to visualize neuromodulator changes in the intact brain.

With this SBIR/STTR solicitation, NIAAA seeks the development and application of techniques that can detect neuromodulator changes in real time with spatial and temporal precision in behaving animals. Techniques that allow the in vivo detection of neuromodulators over an extended time period, such as implantable cell- or probe-based biosensors, will be particularly encouraged.

Changhai Cui, Ph.D.
Telephone: 301-443-1678
Email: Changhai.Cui@nih.gov

Ex vivo Efficacy Screens to Identify Pharmacotherapies for Alcohol Dependence

High throughput screening efforts have identified many small molecules acting at biological targets thought to be important modulators of excessive alcohol drinking and other alcohol dependence phenotypes. Concurrently, in vivo animal models of alcohol drinking and related behavioral measures are
Currently used to assess potential therapeutic efficacy of medications under development. *Ex vivo* efficacy screens are an important link between these two activities. In contrast to many behavioral models, *ex vivo* tissue-based assays are desirable for their simplicity, speed, and capacity to test small drug quantities. To date, little attention has been devoted toward developing and validating neuronal tissue and cell based screening platforms that can be used to inform go/no go decisions for subsequent *in vivo* preclinical efficacy testing.

With this SBIR/STTR grant solicitation, NIAAA seeks the development and validation of *ex vivo* screens capable of predicting efficacy test results in preclinical behavioral models of alcohol dependence. Such assays may include arrays of parameters capable of differentiating the alcohol dependent from the non-dependent state. They should also discriminate positive and negative control drugs found in the alcohol dependence pharmacotherapy literature and be sensitive to drugs with diverse mechanisms of action. In addition, the assays developed under this solicitation should be relatively rapid, simple and produce consistent and reliable results in multiple laboratories.

Mark Egli, Ph.D.
Telephone: 301-594-6382
Email: Mark.Egli@nih.gov

Changhai Cui, Ph.D.
Telephone: 301-443-1678
Email: Changhai.Cui@nih.gov

**Develop Network Pharmacology Strategy for Preclinical Medication Development**

The frequent failure of using highly selective drugs for disease treatment has challenged the concept of “one gene, one drug and one disease” and led to the emergence of a new paradigm, network pharmacology, as a drug development and treatment strategy. This strategy combines the knowledge of biological networks with multiple drug targets to simultaneously regulate multiple pathways perturbed by disease conditions. Given the multi-target nature of alcohol action, alcoholism arises from brain network perturbation. The network pharmacology/combined pharmacological approach, either using drug combinations or multi-target drugs, may serve as an effective strategy for the treatment of alcohol-induced brain dysfunction and behavior disorders.

NIAAA seeks preclinical development of combined pharmacological approaches to synergistically regulate multiple drug targets for alcoholism. Areas that may be of interest to small businesses include, but are not limited to:

**Objective 1:** Develop and validate new target combinations using cellular and animal models.

**Objective 2:** Prioritize multi-drug targets and identify the effective drug combinations or multi-target drugs for the medication development.

**Objective 3:** Use high-throughput screening of compound libraries to identify multi-target drugs.

**Objective 4:** Encourage adaption of low throughput assays to high throughput screening, development of lead compounds, and identification of drug candidate(s) with proper pharmaceutical properties for medication development.

Changhai Cui, Ph.D.
Telephone: 301-443-1678
Email: Changhai.Cui@nih.gov
Novel Tools and Technologies to Detect the Effects of Alcohol on the CNS Structure and Activities

Alcohol affects virtually all of the major neurotransmission systems in the brain by interacting with membrane ion channels, neurotransmitter release machineries and receptors, signal transduction pathways, genes and epigenetic factors. In order to better understand the acute and chronic effects of alcohol and mechanisms of alcohol intoxication and dependence, it is important to be able to simultaneously detect the structure and activities of large numbers of neurons with intact connections to facilitate the analysis of neurocircuits. Equally important, structure and activities in different subcellular domains (soma, dendrites, spines, axon, etc.) of CNS neurons need to be monitored with high temporal resolution. Additionally, recent developments indicate that glial cells play more important roles in the normal function of the brain and may be important alcohol targets. There is a need to monitor glia-neuron interactions.

There have been great advances in recent years in chemical and optogenetic methodologies, enabling improved ability to monitor CNS structure and activities in larger numbers and at much higher spatial and temporal resolution. Building upon these advances, NIAAA seeks SBIR/STTR research to develop the novel tools and technologies to detect the effects of alcohol on activities of specific cell types, neuron-glia interactions, and the structure and activities of large numbers of neurons in alcohol-drinking/exposure settings, preferentially with intact neural network. These include, but are not limited to, the following:

- Improving chemical or genetic sensors to detect dynamic changes in calcium, voltage, cAMP etc.
- Developing tools and sensors to monitor structure and activities of neurons and glial cells, and their interactions
- Developing tools and sensors to monitor synaptic activities
- Defining cell types in the neurocircuits
- Developing miniature and nanoscale apparatus and sensors, or miniaturizing and optimizing detection apparatus for the study of alcohol effects
- Developing computational methods for the acquisition and analysis of large scale data

Qi-Ying Liu, M.D., M.Sci.
Telephone: 301-443-2678
Email: liuqiy@mail.nih.gov

Changhai Cui, Ph.D.
Telephone: 301-443-1678
Email: changhai.cui@nih.gov

Research Tools

The NIAAA supports the development of new or improved tools to enhance the ability to conduct alcohol-related laboratory studies on humans and animals and to more effectively analyze data from large databases. Areas that may be of interest to small businesses include, but are not limited to:

A. Development of novel animal models, including transgenic animals, possessing specific traits of significance for the study of alcoholism, or for the study of specific pathologic disease states which arise from excessive alcohol consumption.

B. Development of a hepatocyte cell line capable of maintaining viability and metabolic functions in culture systems for an indefinite period.
C. Development of specialized cell culture chambers to provide controlled administration of ethanol to *in vitro* cell systems.

D. Development of experimental systems that mimic organ function, including, but not limited to, co-culture and novel approaches to three dimensional culture.

E. Development of new methods of ethanol administration to animals that produce precise dose control or that closely mimic types of alcohol exposure occurring in humans, including, but not limited to, binge drinking, acute consumption, moderate consumption and chronic consumption.

F. Development of ligands which will enhance the potential usefulness of PET and SPECT neuroimaging technologies for the study of the etiology of alcoholism and related brain pathology.

G. Development of computational, statistical or bioinformatics tools to organize and manage high throughput data obtained by genomic, functional genomic or other ‘omic strategies.

H. Development of databases, methods for integration of databases, or data analysis systems for alcohol research.

Kathy Jung, Ph.D.
Telephone: 301-443-8744
Email: Kathy.Jung@nih.gov

Roadside Driver Tests to Detect Marijuana or Other Drug Use Immediately Before Driving

- tests that can rapidly identify ingestion of drugs within six hours of driving
- tests whose results can be compared with current saliva and blood tests to see if testing can be improved for law enforcement purposes

Greg Bloss
Telephone: 301-443-3865
Email: gbloss@willco.niaaa.nih.gov

**NIAAA Clinical Trials Topics:**

**Medications Development**

Alcohol use disorder (AUD) is a global health problem, affecting over 76 million adults world-wide, including over 17 million Americans, resulting in a myriad of medical, psychological, social, economic, and personal problems. NIAAA is committed to the preclinical and clinical development of new pharmacological agents to treat AUD.

Pharmacotherapy offers a promising means for treating AUD. During the past two decades, progress has been made in developing medications to treat alcohol problems. Currently, there are four Food and Drug Administration (FDA)-approved pharmacotherapies for the treatment of alcohol dependence: disulfiram (Antabuse®), oral naltrexone (Revia®), acamprosate (Campral®), and the injectable suspension formulation of naltrexone (Vivitrol®). In addition, nalmefene (Selincro®) has recently been approved by the European Medicines Agency (EMA). However, given the heterogeneous nature of AUD, many patients have limited or no response to the aforementioned medications. Because of this, developing and evaluating new, more efficacious medications remains a high priority.

During the past three decades, alcohol research has enriched our understanding of biological mechanisms underlying alcohol dependence. Various neurotransmitter systems, neuromodulators, and intracellular signaling pathways have a role in alcohol dependence. Currently, over 35 promising targets
have been shown to alter alcohol drinking behavior. Some of the new promising targets include, but are not limited to, corticotrophin-releasing factor1 (CRF-1), adrenergic α1 and α2, vasopressin 1B, orexin 1 and 2, opioid receptor-like (NOP), opioid kappa, 5-HT2, GABA-A and GABA-B, metabotropic glutamate (mGluR), glutamate transporter (GLT), nicotinic acetylcholine (nAChR), phosphodiesterase (PDE), glial derived neurotrophic factor (GDNF), and neuroimmune and epigenetic modulators. New medications that bind to these and additional targets are needed.

Candidate medications may include novel and re-purposed compounds. However, grant applications that propose to study compounds already extensively investigated or currently being studied in alcohol dependent patients will not be accepted. Thus, applications proposing the use of naltrexone, acamprosate, disulfiram, topiramate, ondansetron, varenicline, gabapentin, and baclofen are not responsive to this topic.

Specific areas of interest include medications that target one or more domains of alcohol addiction, including reward, stress and negative affect, incentive salience, executive function, habituation, and impulsivity/compulsivity.

For questions, contact:
Raye Z. Litten, Ph.D.
Telephone: 301-443-0636
Email: Raye.Litten@nih.gov

Additional targets for pharmaceutical development include, but are not limited to: development of agents to attenuate excessive alcohol drinking and other symptoms of alcohol dependence, e.g., craving, sleep problems, negative affect. Drugs for the treatment of alcoholic hepatitis, liver fibrosis, cirrhosis, pancreatitis, cardiomyopathy, or other alcohol-induced tissue damage

For pre-clinical questions, contact:
Mark Egli, Ph.D. (Neuroscience and behavior)
Telephone: 301-594-6382
Email: Mark.Egli@nih.gov

Svetlana Radaeva, Ph.D. (Organ damage)
Telephone: 301-433-1189
Email: Svetlana.Radaeva@nih.gov

Innovative Technologies to Measure and Increase Medication Adherence in Clinical Trials

Maximizing and measuring treatment exposure is critical to understanding the impact of medications, especially in a clinical trial setting. Monitoring medication adherence in a clinical trial setting is both challenging and time consuming. Applications are sought that will provide new options or expand on current technologies to measure and/or enhance medication adherence in clinical research. Areas that may be of interest to small businesses include, but are not limited to:

- Development of a device/technique to evaluate and measure a participant’s adherence to study medication. The main objective is to provide investigators with systematic data on daily medication exposure during clinical trials. The technology must be suitable for assessment of medication adherence in a clinical setting (i.e., affordable, quantitative, rapid results, no impact on subject daily activities, confidential, portable).

- Development or improvement of a device/technique to enhance medication adherence. The technology must be portable, affordable, inconspicuous, and user-friendly.

Megan Ryan, MBA
Technological Methods for the Treatment of Hazardous Drinking and Alcohol Use Disorders

- Develop, improve, and validate ecological momentary assessment (EMA) methods for capturing real-time data for use in clinical trials and treatment paradigms.
- Use technology (e.g., EMA, brain imaging) and innovative statistical methods (e.g., machine learning, systems science dynamic models) appropriate for analysis of “big data” (i.e., time intensive, multisource data) to inform our understanding of mechanisms underlying the initiation, maintenance, and recovery from problematic drinking in both treatment and naturalistic settings.
- Leverage unique features of mobile technologies to provide personalized monitoring and just-in-time interventions.
- Optimize existing technologies to increase their utilization and effectiveness in specific treatment contexts (e.g., primary care) and improve patient-provider communication to decrease harmful drinking.
- Develop and test computerized versions of empirically-supported treatments.
- Develop and test novel computerized interventions which capitalize on hypothesized brain-based or behavioral mechanisms underlying drinking.
- Develop software to train potential treatment professionals how to provide evidence-based treatments.
- Devise novel methods (e.g., Web-mining software of social networking sites) that capture social network information among groups at risk for alcohol use disorder and high-risk drinking.
- Develop and test the efficacy of neurophysiological treatment approaches such as transcranial magnetic stimulation, neurofeedback, and deep brain stimulation.

Anita Bechtholt, Ph.D.
Telephone: 301-443-9334
Email: anita.bechtholt@nih.gov

Prevention

This area of interest focuses on the development and evaluation of innovative prevention and intervention programs, or specific materials for integration into existing programs, which utilize state-of-the-art technology and are based on currently accepted clinical and behavioral strategies. Applicants are strongly encouraged to consult with research methodologists and statisticians to ensure that state-of-the-art approaches to design, analysis, and interpretation of studies under this topic are used. Areas that may be of interest to small businesses include, but are not limited to:

- Development and evaluation of innovative prevention/intervention programs, or specific materials for integration into existing programs, which utilize state-of-the-art technology and are based on currently accepted clinical and behavioral strategies. Special emphasis should be placed on the needs of high-risk groups, ethnic and minority populations, youth, children of alcoholics, women, the handicapped, and the elderly. Examples of such materials include school-based curricula, interactive videos, computer-based multimedia programs, training manuals for teachers or parents, and community-based programs.
- Development and evaluation of educational materials designed to intervene with the elderly around specific age-related risks for alcohol problems. Particular attention should be given to
age-related reductions in alcohol tolerance, interactions between alcohol and prescription and over-the-counter medications, possible exacerbation of some medical conditions common among the elderly, potential biomedical and behavioral consequences of excessive alcohol use, and the role of alcohol in falls, fires, burns, pedestrian and traffic injuries, and other unintentional injuries.

- Development and evaluation of statistical analysis programs tailored to the design and analysis of alcohol prevention-relevant research. Programs could focus on a variety of areas including: imputation of missing data under varying design assumptions; simulation of distributions of outcomes based on varying mixtures of sample populations; application of chronic or infectious disease models to targeted communities; and models of the potential effect of various policy-based interventions, such as increased taxation or reduction of outlet density by license revocation and control.

Robert C. Freeman, Ph.D.
Telephone: 301-443-8820
Email: Robert.Freeman@nih.gov

Improving the Delivery of Alcohol Treatment Services

NIAAA’s treatment services research program studies the organization, management, and financing of alcohol treatment services, and how these affect service availability, access, utilization, cost, and quality. Needed innovations in this area include the development of state-of-the-art technologies, software, and protocols to expand and improve the delivery of evidence-based treatment for alcohol use disorders.

Areas that may be of interest to small businesses include, but are not limited to, the development and assessment of software or tools to:

- assist clinicians in selecting and delivering evidence-based treatments consistent with patient needs and available staff and program resources. Special attention should be paid to promoting fidelity of treatment delivery in real-world contexts. For example: software to enable the creation or use of clinical decision support systems, screening protocols, or patient registries; prescription medication management tools; scripts or guides for delivery of brief interventions; and interactive training resources.

- support long-term recovery, by facilitating patients’ continued engagement in recovery support services as an adjunct to or after treatment. For example: software to assist patients in self-management and self-monitoring of drinking behaviors, cues, or triggers, and/or in locating treatment resources or recovery support services.

- assist treatment programs and service agencies in measuring clinically relevant performance indicators or improvements in quality of service provision.

- promote engagement and mitigate burnout among counselors and others engaged in direct treatment service delivery. Tools are needed to reinforce training on therapeutic techniques; provide minimally-obtrusive methods for monitoring and enhancing fidelity of service delivery; engage counselors in mindfulness or other strategies to manage job stress and reduce burnout; and provide front-line counselors with supports essential to maintaining productive therapeutic relationships with patients.

Lori Ducharme, Ph.D.
Telephone: 301-451- 8507
Lori.Ducharme@nih.gov
Fetal Alcohol Spectrum Disorder (FASD) and Alcohol-Related Birth Defects

FASD is the collective term for the broad array of adverse effects resulting from in utero alcohol exposure. Fetal Alcohol Syndrome (FAS), the first form of FASD discovered and most well-known, is characterized by craniofacial abnormalities, growth retardation, and nervous system impairments that often include mental retardation. Other diagnostic categories include partial FAS, alcohol-related neurodevelopmental disorder (ARND), and alcohol-related birth defects (ARBD). Children and adults with FASD may exhibit multiple cognitive, behavioral, and emotional deficits that impair daily functioning in many domains. The NIAAA supports research leading to improved diagnosis and assessment of prenatal exposure, impairment and disability, as well as the development of therapeutic interventions, including tools to enhance academic and daily living skills. Areas that may be of interest to small businesses include, but are not limited to:

- Development and assessment of diagnostic and/or screening methods, tools or technology that can be used prenatally to identify fetuses affected by ethanol.
- Development and validation of biomarkers that can be used to verify prenatal alcohol exposure in neonates.
- Development and validation of assessment methods to provide more accurate clinical diagnosis of FASD at all life stages.
- Development and testing of skill-building, therapeutic, and education program products that enhance the social, cognitive, adaptive and motor abilities of individuals with FASD.
- Development of neurobehavioral tools or instruments to assess responsiveness of individuals with FASD to medications and/or cognitive/behavioral therapies.
- Development of accurate measures of the responsiveness of children affected by prenatal exposure to alcohol to stress and predictors of vulnerability to alcohol-drinking or other psychopathology during adolescence and adulthood.
- Development and evaluation of educational and training programs designed to enhance the skills of non-professional caregivers in dealing with the problems associated with FAS.
- Development and validation of innovative methods, tools or technology to prevent harmful drinking during pregnancy.

For basic research questions, contact:
Dale Hereld, MD, Ph.D.
Telephone: 301-443-0912
Email: Dale.Hereld@nih.gov

William Dunty, Ph.D.
Telephone: 301-443-7351
Email: William.Dunty@nih.gov

For prevention research questions, contact:
Marcia Scott, Ph.D.
Telephone: 301-402-6328
Email: Marcia.Scott@nih.gov

Deidra Roach
Development of Clinical Biomarkers of Alcohol Exposure and Alcohol-Induced Organ Damage

There is a well-recognized need for prognostic and diagnostic biomarkers of alcohol exposure, for biomarkers of the response to clinical treatment, and for biomarkers to monitor abstinence in high-risk individuals. Quantitative and qualitative markers of high-risk drinking behavior and alcohol-induced tissue damage would greatly improve medical efforts to recognize and treat alcohol-related disorders. Currently, no clinically available laboratory test can reliably diagnose duration of alcohol use or predict the progression of alcohol-induced organ damage. Traditional alcohol biomarkers fail to provide long-term information. More recently developed alcohol biomarkers (ethanol metabolites phosphatidylethanol (PEth), ethyl glucuronide (EtG) and ethyl sulfate (EtS)) display improved sensitivity, specificity, and accuracy over classical biomarkers. Their useful range of a few days (EtG) to 2-4 weeks (PEth) addresses many, but not all, clinical needs.

Effective biomarkers are essential to early detection of alcohol use disorder or early stages of organ damage. Early detection will make it possible for patients to consider intervention to prevent long-term medical, psychological, and social consequences of alcohol use.

Several separate, distinct diagnostic settings and circumstances are in need of reliable specific biomarkers. Alcohol biomarkers that address the following are needed:

- Biomarkers that detect cumulative intake of alcohol over a period of months or more; thus a biomarker that is stable over months, reflecting duration and amount of alcohol exposure.
- Biomarkers that detect failure of compliance after withdrawal; thus a biomarker with a short half-life.
- Biomarker signatures of alcohol-induced organ damage, which are likely to be organ-specific.
- Biomarker signatures of familial risk factors for alcoholism. Early identification of subjects predisposed to alcoholism will allow for early intervention, possible prevention, and allow the subjects to make informed personal decisions.

Characteristics of useful biomarkers are:

- Sensitivity, specificity, accuracy, and reliability
- Ease of use and acceptability to patient and provider
- Found in easily obtained specimens, such as serum or plasma, urine, saliva, or hair.
- Validity, reproducibility, affordability, and transportability to a variety of settings, including alcoholism treatment centers, hospitals, primary care offices, or the workplace.

Pattern-based molecular signatures—as opposed to single component biomarkers—may be predicted to provide greater sensitivity, specificity, accuracy, and reliability than single component biomarkers. Thus, high throughput discovery approaches using genomics, epigenomics, transcriptomics, proteomics, metabolomics, lipomics, or glycomics are encouraged.

Also of interest:

- Improvement of turn-around time and cost efficiency of current assays for PEth, EtS, EtG and other alcohol biomarkers
- Design and development of point of care devices, for use in rural or remote primary care and hospital settings.
Small business efforts for improvements at any stage in the biomarker pipeline are of interest, including
discovery, validation, development, and implementation to real world settings.

For clinical questions, contact:
Raye Z. Litten, Ph.D.
Telephone: 301-443-0636
Email: Raye.Litten@nih.gov

Anita Bechtholt, Ph.D.
Telephone: 301-443-9334
Email: anita.bechtholt@nih.gov

For pre-clinical questions, contact:
Kathy Jung, PhD.
Telephone: 301-443-8744
Email: Kathy.jung@nih.gov

Alcohol Biosensors

Small business applications proposing to design and produce a wearable device to monitor blood alcohol
levels in real time are sought. The device should be able to quantitate blood alcohol level, and interpret
and store the data or transmit it to a smartphone or other device by wireless transmission. The device
should have the ability to verify standardization at regular intervals and to indicate loss of functionality.
The power source should be dependable and rechargeable. Data storage and transmission must be
completely secure in order to protect the privacy of the individual. A form of subject identification would be
an added benefit. The device can be removable.

The alcohol biosensor device should be unobtrusive, passive in action, appealing to the wearer, and can
take the form of clothing, bracelet, jewelry, or any other format located in contact with the human body. A
non-invasive technology is preferred. Novel and innovative approaches to detecting blood alcohol, rather
than alcohol that has exuded across the skin, are especially encouraged.

Alcohol detection technology for personal alcohol monitoring will serve useful purposes in research,
clinical and treatment settings, will play a role in public safety, and will be of interest to individuals
interested in keeping track of personal health parameters.

This topic also includes the opportunity to develop appropriate data analysis systems for individual level
evaluation as well as for assessment of trends in research populations.

Kathy Jung, PhD.
Telephone: 301-443-8744
Email: Kathy.jung@nih.gov

Alcohol Use and HIV Infection, and HIV Co-infection with HCV, HBV, or TB

Alcohol consumption is widely recognized as a co-factor in the sexual transmission, susceptibility to
infection, and progression of the infectious diseases, including HIV and HIV co-infection with HCV, HBV,
or TB. However, detailed relationships between alcohol use and viral infections, diseases progression,
anti-viral (or anti-TB) therapy and adverse outcomes, notably in liver disease progression, are less
recognized or understood. Recent research indicates that inflammatory pathways predominate in liver
disease including alcoholic hepatitis whereas adaptive immunity plays a primary role in viral hepatitis,
offering multiple targets for novel preventive and therapeutic interventions. Comprehensive studies to
improve understanding of the factors underlying alcohol and viral etiologies in liver disease and the
impact of anti-viral drugs on liver disease progression are needed. A better understanding of alcohol’s
effects on liver disease in patients with HIV and co-infections may improve diagnosis and treatment
outcomes. NIAAA supports research leading to improved diagnosis and treatment of alcohol-induced disorders in people infected with HIV, and HIV co-infection with HCV, HBV, or TB.

Areas that may be of interest to small businesses include, but are not limited to:

- New preventive and therapeutic approaches designed to protect the liver from alcohol and antiretroviral drug-induced liver injury in patients infected with HIV, and HIV co-infection with HCV, HBV, or TB.
- Development of therapies aimed at molecular targets that play a role in the development of alcoholic and viral liver and or lung diseases.
- Development and evaluation of drugs that mitigate the effects of oxidative stress on mitochondrial function thereby preventing liver disease progression.
- Development of biomarkers for individuals who are most prone to alcohol-induced damage in those patients infected with HIV and comorbid mono- or co-infection.

For basic research questions on alcohol and HIV, and HIV co-infections, contact:
H. Joe Wang, Ph.D.
Telephone: 301-451-0747
Email: Joe.wang1@nih.gov

For clinical or epidemiological questions on HIV, contact:
Kendall J. Bryant, Ph.D.
Telephone: 301-402-9389
Email: Kendall.Bryant@nih.gov

Electronic Diagnostic Clinical Assessment of Frailty among HIV+ Individuals with Past and/or Current Alcohol Use Disorders: Severity and Patterns

Innovative self-report, biological, and/or common clinical measures for the identification and diagnosis of frailty related to alcohol use among alcohol-using HIV patients and those with related comorbidities are sought. Measurement of frailty should be calibrated for severity of alcohol use and be both clinically useful and predictive of morbidity and mortality. Applications proposing the development of medical decision-making algorithms to inform clinical care of HIV+ individuals who drink and include frailty index(es) through an internet site are sought. The primary goal of this site will be to provide normative and educational information for providers and patients related to medical care to reduce frailty index(es) related to morbidity and mortality as primarily a useful tool for clinicians who encounter HIV patients who continue to drink and may or may not be compliant with antiretroviral treatment for suppression of viral replication and restoration of immune function.

- Development of this site should be tested in the widest range of individuals at various trajectories of progression of HIV disease and patterns of alcohol use. In particular, information from measures should be able to accurately identify individuals who are “sick quitters” and/or have high degree of frailty due to either past and/ or current alcohol use.
- This clinical decision-making tool should be of greatest value to diagnostic assessment and interventions within clinical settings and may include the development of audio, visual, and/or training modules to support the use of appropriate diagnostic index(es).
- Support of an electronic internet site for scoring and collection of information on HIV disease characteristics, frailty and patterns of alcohol use in clinical populations, and to provide information on a range of options for assessment of alcohol use severity in HIV+ populations (e.g. brief assessment instruments, calendar methods, biological markers, etc.).
• Identify current and emerging methods for behavioral and/or biological intervention to reduce alcohol use in the context of HIV and improve clinical outcomes

Kendall J. Bryant, Ph.D.
Telephone: 301-402-0332
Email: Kendall.Bryant@nih.gov

Monitoring Alcohol Use among HIV+ Patients

Of particular importance is the measurement of patterns of alcohol use among HIV+ individuals. Wearable alcohol biosensors (see related topic) should be developed to maximize acceptability and minimize stigmatization among the widest range of users. It is expected that the most effective devices will be unobtrusive devices (perhaps wrist-worn) that assess a variety of physiological measures in addition to alcohol use and that interact with smart phone technologies for additional assessment or data management features (e.g. momentary ecological assessment) related to medication adherence for HIV and related comorbidities.

Kendall J. Bryant, Ph.D.
Telephone: 301-402-0332
Email: Kendall.Bryant@nih.gov

Roadside Driver Tests to Detect Marijuana or Other Drug Use Immediately Before Driving

• tests that can rapidly identify ingestion of drugs within six hours of driving
• tests whose results can be compared with current saliva and blood tests to see if testing can be improved for law enforcement purposes

Greg Bloss
Telephone: 301-443-3865
Email: gbloss@willco.niaaa.nih.gov

Direct your questions about scientific/research issues to:

Megan Ryan, M.B.A.
National Institute on Alcohol Abuse and Alcoholism
5635 Fishers Lane, 2051
Rockville, MD 20852-1705

For administrative and business management questions, contact:

Ms. Judy Fox
Grants Management Officer
National Institute on Alcohol Abuse and Alcoholism
Phone: 301-443-4704, Fax: 301-443-3891
Email: jfox@mail.nih.gov
NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES (NIAID)

NIAID conducts and supports basic and applied research to better understand, treat, and ultimately prevent infectious, immunologic, and allergic diseases.

The NIAID’s Division of AIDS, Division of Allergy, Immunology, and Transplantation, and Division of Microbiology and Infectious Diseases fund SBIR/STTR grants on topics related to their mission and activities as described below. Questions on specific research areas may be addressed to the NIAID Program Officials listed below. General questions on the NIAID SBIR and STTR programs and on administrative and business management may be addressed to contacts listed for the NIAID section. When possible, applicants are encouraged to use email for communication.

For information about NIAID’s Small Business Programs, please visit https://www.niaid.nih.gov/grants-contracts/small-businesses.

Limited Total Amounts for Phase I and Phase II Awards

According to SBIR/STTR statutory guidelines, total funding support (direct costs, indirect costs, fee) for grants in Phase I is $150,000 and Phase II is $1 million. Current SBIR/STTR Program authorization allows agencies to make awards at higher levels, capped at 50% above guidelines. Unless otherwise stated in the funding opportunity, HHS applicants can make well justified budget requests up to $225,000 for a Phase I grant and $1,500,000 in Phase II.

The SBA is authorized by statute to waive these hard caps for specific research topics. NIH has a standing waiver for many topics, which can be reviewed in Appendix A of PHS 2018 SBIR/STTR Program Descriptions and Research Topics for NIH, CDC, and FDA. Specific topics are listed for each Division within NIAID, but satisfying any topic from any Institute or Center is sufficient to consider budget requests that exceed the hard caps. These requests must be very well justified in the “Budget Justification” attachment to the Research and Related Budget form and be consistent with the scope of the proposal.

NIAID will allow Phase I applications with budgets of up to $300,000 total costs per year for up to 2 years; and Phase II or Phase IIB applications with budgets of up to $1,000,000 total costs per year for up to 3 years. Requests for these budget levels must be very well-justified.

Applicants are strongly encouraged to contact NIH program officials prior to submitting any application in excess of the guidelines. In all cases, applicants should propose a budget that is reasonable and appropriate for completion of the research project. Confirmation of compliance with a pre-approved topic is handled at time of award by the applicant’s Grants Management Specialist and Program Officer.

NIAID will generally not fund applications at budget levels exceeding these budget guidelines. For budgetary, administrative, or programmatic reasons, NIAID may decide not to fund an application or may decrease the length of an award and/or the budget recommended by a review committee.

Phase IIB Competing Renewal Awards

NIAID welcomes Phase IIB Competing Renewal Applications (SBIR only) for NIAID Phase II awards via the Omnibus Solicitation for SBIR Grant Applications and other NIAID SBIR Funding Opportunity Announcements that explicitly allow Phase IIB Applications.

Research Topics of Interest to NIAID

The specific set of topics that are funded by a particular IC/Office/Agency depends on whether the IC/Office/Agency funds/supports Clinical Trials under SBIR/STTR Awards. Use the following table and explanations to determine which list of topics is applicable.
<table>
<thead>
<tr>
<th>Does IC/Office/Agency Fund/Support Clinical Trials under SBIR/STTR Awards?</th>
<th>No*</th>
<th>Yes**</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>X</td>
<td></td>
</tr>
</tbody>
</table>

*If No,
- This IC/Office/Agency funds only those topics listed under the Non-Clinical Trials Topics section below, **UNLESS** the IC/Office/Agency funds a Small Business Concern for clinical trials under a NON-SBIR/STTR award.

**If Yes or the IC/Office/Agency funds small businesses for clinical trials under a NON-SBIR/STTR funding opportunity,**
- See the table below for which mechanisms the IC/Office/Agency will allow for clinical trials research. Also, see the Clinical Trials Topics section below for a list of funded topics. This IC/Office/Agency also funds research listed under the Non-Clinical Trials Topics section below.

<table>
<thead>
<tr>
<th>Does IC/Office/Agency accept clinical trials applications under this mechanism?</th>
<th>Yes</th>
<th>No</th>
<th>Other Information: If funding an SBC for clinical trials under a NON-SBIR/STTR award, please identify activity code(s) and other relevant information.</th>
</tr>
</thead>
<tbody>
<tr>
<td>Clinical Trials SBIR/STTR Omnibus/Parent Funding Opportunity Announcement/s</td>
<td>X</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
NIAID Non-Clinical Trials Topics:

Division of AIDS

The Division of AIDS (DAIDS) supports a global research portfolio to advance biological knowledge of HIV/AIDS, its related co-infections, and co-morbidities. With the ultimate goal of creating an “AIDS-Free Generation,” the division develops and supports the infrastructure and biomedical research needed to: 1) halt the spread of HIV through the development of an effective vaccine and biomedical prevention strategies that are safe and desirable; 2) develop novel approaches for the treatment and cure of HIV infection; 3) treat and/or prevent HIV co-infections and co-morbidities of greatest significance; and 4) partner with scientific and community stakeholders to efficiently implement effective interventions.

Director: Dr. Carl Dieffenbach
Telephone: 301-496-0545
Email: CDieffenba@niaid.nih.gov

Basic Sciences Program

Supports basic and applied research on the causes, diagnosis, treatment and prevention of HIV and AIDS.

Director: Dr. Diana Finzi
Telephone: 301-451-2598
Email: Dfinzi@niaid.nih.gov

A. **Epidemiology Branch.** Population-based research, modeling, and comparative effectiveness studies (not including clinical trials) that assess the natural history, biologic, and clinical course of HIV/AIDS, and related outcomes, and could advance treatment and prevention of HIV. Specific interests include phylodynamics and other factors related to HIV transmission and associated biological and behavioral factors, basic research on immunology, virology, and antiretroviral therapy, issues surrounding care for HIV and other co-morbidities, interactions and impact on clinical outcomes. Development of novel electronic tools, including devices and computer programs to enhance behaviors such as treatment adherence or uptake of treatment guidelines, is also of interest.

Contact: Lori Zimand
Telephone: 240-627-3212
Email: lzimand@niaid.nih.gov

B. **Basic Research Branch.** Innovative technologies for detection of acute HIV infection or HIV rebound following long-term suppression of viremia. Identification and validation of new targets for discovery or design of strategies to prevent HIV transmission, inhibit replication, control viremia in the absence of antiretroviral drugs, or eradicate reservoirs of HIV that persist despite long-term antiretroviral therapy. Innovative approaches for monitoring changes in the size of the persistent HIV reservoir.

Contact: Dr. Karl Salzwedel
Telephone: 301-496-5332
Email: salzwedelkd@niaid.nih.gov

C. **Targeted Interventions Branch.** Discovery and development of small molecule inhibitors with novel or underexplored mechanisms of action using standard and high-throughput technologies; cell-based and gene therapies; RNA-based therapeutics; next-generation biologics; novel targeting and delivery vehicles for agents active against HIV; therapeutic vaccines and monoclonal antibodies; protein
chemistry-based anti-HIV approaches; assays to quantitate latent virus; animal models to facilitate evaluation of agents to treat or cure HIV infection.

Contact: Brigitte Sanders
Telephone: 240-627-3209
E-mail: sandersbe@niaid.nih.gov

Vaccine Research Program

Supports the discovery, development and clinical evaluation of an HIV/AIDS vaccine.

Director: Dr. Mary Marovich
Telephone: 301-435-3727
Email: mary.marovich@nih.gov

A. **Vaccine Clinical Research and Development Branch.** Research areas: (1) phase I, II, and III domestic and international clinical trials of candidate AIDS vaccines; (2) evaluation and characterization of immune responses in HIV-infected and uninfected immunized volunteers, using micro and macro assays; and (3) studies to identify, validate, and standardize immunologic and virologic markers for monitoring response of participants in vaccine clinical trials.

Contact: Jim Lane
Telephone: 240-627-3033
Email: laneji@mail.nih.gov

B. **Preclinical Research and Development Branch.** Preclinical research and development of candidate AIDS vaccines, delivery methods, novel vaccine vectors, and adjuvants for the prevention of AIDS; promotion and evaluation of safety and efficacy of the prevention modalities, especially novel vaccine concepts identified in preclinical models including studies using non-human primates, humanized mouse, and other animal models; genetic and immunologic variation studies in relation to AIDS vaccine development; and mucosal and innate immunity in SIV, HIV, and SHIV models.

Contact: Dr. Anjali Singh
Telephone: 240-627-3030
Email: anjalisingh@niaid.nih.gov

C. **Vaccine Translational Research Branch (VTRB).** Translational research by advancing innovative HIV vaccine concepts into the development products for clinical testing. Phase-appropriate novel technologies and manufacturing processes that may accelerate development of HIV vaccines for early phase preventive human clinical trials. Strategies for cGMP manufacturing and scalable process development of HIV proteins, viral vectors, nucleic acid (DNA or RNA), improving antigen expression and yields in cell substrates, and optimization of downstream purification steps are currently being evaluated. Research interests for SBIR/STTR include support for: the manufacture of HIV envelope proteins; cell line development to increase expression and quality of HIV envelope proteins; novel purification methods to isolate HIV envelope protein (e.g., immune-affinity capture steps with antibodies); scalable upstream and downstream product development activities with a focus on HIV envelope proteins; analytics development to support characterization, in-process operations, release, and stability testing; formulation development; evaluation of novel viral/non-viral delivery technologies, such as nanoparticles and RNA, for enhanced HIV antigen presentation and/or antigen-adjuvant codelivery; and preclinical safety and toxicology testing.

Contact: Mike Pensiero, Ph.D.
Telephone: 301-435-3740
Email: mpensiero@niaid.nih.gov
Therapeutics Research Program

Develops and oversees research and development of therapies for HIV disease, including complications, co-infections and co-morbidities, in adults.

Director: Dr. Sarah Read
Telephone: 301-451-2757
Email: readsa@niaid.nih.gov

A. **Drug Development and Clinical Sciences Branch.** Preclinical development of experimental therapies for HIV, TB and other HIV/AIDS-related infectious diseases; including long-acting/extended release approaches; maintenance of a database of potential anti-HIV and anti-opportunistic infection compounds; immunologic, virologic, and pharmacologic research related to the design and conduct of clinical trials; development and evaluation of practical and affordable tests to measure viral load, drug toxicities, and drug resistance to monitor populations in resource-poor settings; development of tests to detect early infection in seropositive HIV-infected adult and pediatric individuals.

Contact: Dr. Joe Fitzgibbon
Telephone: 240-627-3088
Email: jfitzgibbon@niaid.nih.gov

B. **HIV Research Branch.** Clinical research of treatments for acute and chronic HIV infection and approaches to achieve sustained remission or cure; strategies to augment HIV specific immune responses, general host immunity to control or clear HIV infection, and prevention of HIV disease-associated end organ disease.

Contact: Tia Morton
Telephone: 240-627-3073
Email: frazierti@niaid.nih.gov

C. **Complications & Co-Infections Research Branch.** Preclinical and clinical research to evaluate new or improved therapies for the treatment and prevention of HIV-related serious infectious and non-infectious complications in HIV-infected adults.

Contact: Dr. Chris Lambros
Telephone: 240-627-3093
Email: clambros@niaid.nih.gov

D. **For evaluation of therapeutic agents or diagnostics for hepatitis B in HIV infected in adults.**

Contact: Dr. Chris Lambros
Telephone: 240-627-3093
Email: clambros@niaid.nih.gov

E. **Tuberculosis Clinical Research Branch.** Translational and clinical research for tuberculosis, with and without HIV co-infection, to facilitate the development of biomarkers/diagnostics, therapies, and prevention/vaccines.

Contact: Lakshmi Jayashankar
Telephone: 240-292-0382
Email: lakshmi.jayashankar@nih.gov

Prevention Science Program

Supports basic research on mechanisms of HIV transmission supportive of new biomedical strategies for interrupting transmission. Domestic and international phase I, II, and III clinical trials to evaluate HIV/AIDS...
prevention strategies, including microbicides, chemoprophylactic agents, and other biomedical and behavioral risk reduction interventions.

Acting Director: Sheryl Zwerski, MSN, CRNP
Telephone: 301-402-4032
Email: szwerski@niaid.nih.gov

A. **Preclinical Microbicides and Prevention Research Branch.** Preclinical pipeline for non-vaccine biomedical prevention products including topical microbicides, pre-exposure prophylaxis (PrEP) and multipurpose prevention technologies (MPT) with a focus on sustained release prevention (>30 days protection form HIV from a single dose or continuous delivery device). Role of vaginal and rectal microenvironment factors in determining susceptibility to HIV and their impact on the efficacy and safety of nBP products and strategies.

Chief: Dr. Jim Turpin
Telephone: 301-451-2732
Email: jturpin@niaid.nih.gov

B. **Clinical Microbicide Research Branch.** Clinical development of promising microbicides to prevent HIV infection with the ultimate goal to advance safe, effective and acceptable microbicide products toward licensure.

Chief: Dr. Roberta Black
Telephone: 301-496-8199
Email: rblack@niaid.nih.gov

C. **Clinical Prevention Research Branch.** Development of safe and effective non-vaccine biomedical and integrated HIV prevention interventions to reduce the number of new HIV infections in adults and adolescents. Support the development of HIV incidence assays, biomarkers of adherence, mathematical modeling, and other tools needed to accomplish these objectives.

Chief: Dr. David Burns
Telephone: 301-435-8896
Email: burnsda@niaid.nih.gov

D. **Maternal, Adolescent and Pediatric Medicine Branch.** Therapies for cure, management, treatment and prevention of HIV and HIV associated complications in pregnant women, infants, children and adolescents. Strategies to reduce transmission of HIV and HIV co-infections from mother to child.

Contact: Judi Miller, R.N.
Telephone: 240-292-4801
Email: jmillera@niaid.nih.gov

**Division of Allergy, Immunology, and Transplantation**

The Division of Allergy, Immunology, and Transplantation (DAIT) supports studies of the immune system in health and the cause, pathogenesis, diagnosis, prevention, and treatment of disease caused by immune dysfunction.

Director: Daniel Rotrosen, M.D.
Telephone: 301-496-1886
Email: drotrosen@niaid.nih.gov

A. **Allergy, Asthma and Airway Biology Branch.** Conditions of interest: asthma, food allergy, eosinophilic esophagitis and gastroenteritis in relation to food allergy, atopic
dermatitis, urticaria, rhinitis, rhinosinusitis, drug allergy, sepsis. The Branch supports basic and clinical studies investigating mechanisms of disease and new approaches to diagnose, treat or prevent these conditions. Special interest for SBIR/STTR includes a) the development of biomarkers as diagnostic markers, markers of disease severity and predictive markers for treatment effectiveness, particularly of immunologic interventions such as allergen immunotherapy for food and respiratory allergy; b) the development of new forms of allergen immunotherapy aiming at increased tolerogenic immune responses and decreased allergenicity.

Chief: Alkis Togias, M.D.
Telephone: 301-496-8973
Email: togiasa@niaid.nih.gov

B. **Basic Immunology Branch.** The Branch supports basic and clinical research in the following areas: adjuvant discovery and development; origin, maturation, and interactions of immune cells; immune cell receptors, and ligands; cytokine biology; molecular basis of immune activation, antigen recognition, and immune tolerance; immune response regulation; hematopoiesis and stem cell biology; computational immunology; immunologic mechanisms associated with Myalgic Encephalomyelitis/Chronic Fatigue Syndrome; enhancement of vaccine effectiveness in neonates and adults, and basic immunology of vaccines and immunotherapeutics as medical countermeasures for biodefense. Special interests for SBIRs include: adjuvant discovery and/or development; bioinformatics tools for immune epitope predictions/visualization, and/or for the analysis of multi-parameter or systems immunology data; and development of novel/improved methods to analyze human immune responses from limited amounts of human sample (tissue, cells, serum, etc.).

Chief: Dr. Alison Deckhut-Augustine
Telephone: 301-496-7551, Fax: 301-480-2381
Email: augustine@niaid.nih.gov

C. **Autoimmunity and Mucosal Immunology Branch.** Preclinical and clinical research to develop and improve therapies for the treatment of autoimmune diseases and primary immune deficiencies (not HIV); basic research of autoimmune disease mechanisms and biomarkers; immunotherapy of disease processes; disorders mediated by lymphocyte products; and mucosal immunity.

Chief: Dr. James McNamara
Telephone: 301-451-3121, Fax: 301-480-1450
Email: jmcnamara@niaid.nih.gov

D. **Transplantation Branch.** Preclinical and clinical research in organ, vascularized composite tissue and cellular transplantation: acute and chronic graft rejection, allogeneic and xenogeneic transplantation, development of immunomodulatory agents to prevent and treat graft rejection and to promote acute and long term graft acceptance and immunologic tolerance, genomics of the alloimmune response, graft versus host disease and engraftment for hematopoietic stem cell transplantation, minor histocompatibility antigens, complications of immunosuppression in transplantation, and major histocompatibility complex (MHC) region genomics and technologies for MHC typing.

Chief: Nancy D. Bridges
Telephone: 301-496-5598
Email: nbridges@niaid.nih.gov

E. **Radiation Countermeasures Program.** The Radiation and Nuclear Countermeasures Program will consider preclinical research on the identification and evaluation of medical countermeasures (MCMs) for public health emergencies involving ionizing radiation, through: 1) development of mitigators and therapeutics for acute radiation syndrome, delayed effects of acute radiation exposure, and/or radiation combined injury; 2) advancement of radionuclide-specific therapies, including
chelating, blocking, or other novel decorporation agents; 3) improvement of methods for accurate, high-throughput radiation biodosimetry; 4) identification of biomarkers of organ-specific radiation injury; and 5) assessment of biomarkers of radiation injury in special populations and formulation of MCMs for administration to these affected groups.

Acting Chief: Charles Hackett, Ph.D., Associate Director
Telephone: 301-496-1886
Email: CHackett@niaid.nih.gov

Division of Microbiology and Infectious Diseases

The Division of Microbiology and Infectious Diseases (DMID) supports research to better understand, treat, and ultimately prevent infectious diseases caused by virtually all infectious agents, except HIV. DMID supports a broad spectrum of research from basic molecular structure, microbial physiology and pathogenesis, to the development of new and improved vaccines and therapeutics. DMID also supports medical diagnostics research, which is defined as research to improve the quality of patient assessment and care that would result in the implementation of appropriate therapeutic or preventive measures. DMID does not support research directed at decontamination or the development of environmentally oriented detectors, whose primary purpose is the identification of specific agents in the environment. Note that some of the organisms and toxins listed below are considered NIAID priority pathogens or toxins for biodefense and emerging infectious disease research.

Division Small Business Representative: Dr. Barbara Mulach
Telephone: 240-627-3322
Email: bmulach@niaid.nih.gov

Division Small Business Representative: Dr. Chelsea Lane
Telephone: 240-627-3741
Email: lanemc@niaid.nih.gov

A. Bacteriology and Mycology Branch.

The branch oversees research and product development related to:

- Bacterial infections with emphasis on hospital-related infections, including Acinetobacter, Klebsiella, Serratia, Legionella, Pseudomonas, Aeromonas, Enterobacter, Proteus, non-enteric E. coli, staphylococci, enterococci, actinomycetes among others;
- Bacterial zoonoses, including plague, anthrax, tularemia, glanders, melioidosis, Lyme disease, rickettsial diseases, anaplasmosis, ehrlichiosis and Q fever, and leptospirosis;
- Fungal infections including Candida, Aspergillus, Cryptococcus, Coccidiodes, Histoplasma, Blastomyces, Pneumocystis, Microsporidia, and other pathogenic fungi.

Research is encouraged in the following general areas: (1) vaccines, adjuvants, therapeutics and diagnostics (including target identification and characterization, device or apparatus development, novel delivery, and preclinical evaluation); (2) strategies to combat antibacterial and antifungal drug resistance; (3) applied proteomics and genomics; (4) host-pathogen interactions, including pathogenesis and host response; (5) genetics, molecular, and cell biology; and (6) microbial structure and function.

Research on all of the above is welcome, but the following areas are of particular interest to the branch:

- Vaccines, therapeutics, and medical diagnostics for hospital infections
- Adjunctive therapies and non-traditional approaches to combat and treat antimicrobial resistance
• Diagnostics for invasive fungal diseases
• Novel approaches for the diagnosis of Lyme disease
• Vaccines against Coccidioidomycosis

Contact: Dr. Alec Ritchie
Telephone: 240-627-3356
Email: aritchie@niaid.nih.gov

B. **Enteric and Hepatic Diseases Branch.**

Research portfolios focus on enteric viruses including caliciviruses and rotaviruses; hepatitis viruses A, B, C, D, and E; enteric bacterial pathogens such as *Campylobacter* spp., *Clostridia* spp., pathogenic *Escherichia coli*, *Helicobacter* spp., *Listeria* spp., *Vibrio* spp., enteric *Yersinia* spp., *Salmonella* serovars, *Shigella* spp., and *Bacteroides* spp. Also within the branch portfolio are toxins such as ricin toxin, *Staphylococcus* enterotoxin B, and botulinum neurotoxins; gastrointestinal diseases associated with diarrhea, dysbiosis; and the gastrointestinal microbiota and microbiome.

Special emphasis areas include:

• Development of vaccines against viral infections including norovirus and hepatitis C virus infection; pediatric vaccines to prevent the major worldwide causes of diarrhea; vaccines against neurotoxins and enterotoxins, and vaccines for enteric diseases where waning immunity is an issue (i.e., *C. difficile* and *Salmonella* infection).

• Development of novel therapeutics for chronic hepatitis B; antimicrobials and antivirals that focus on novel targets such as host-pathogen interactions to combat the development of resistance; therapies that target toxins once they enter cells; therapies to treat recurrent diseases.

• Development of simple, rapid point-of-care diagnostic tools for the simultaneous identification of multiple pathogens that includes their antimicrobial resistance profiles, particularly for hepatitis viruses; diagnostics for use in low-resource settings, especially for typhoid; and novel diagnostics that differentiate *C. difficile* colonization from infection.

Contact: Dr. Rodolfo Alarcon
Telephone: 240-292-0871
Email: alarconrm@niaid.nih.gov

C. **Parasitology and International Programs Branch.**

Research areas: (1) protozoan infections, including amebiasis, cryptosporidiosis, cyclosporiasis, giardiasis, leishmaniasis, malaria, trypanosomiasis, toxoplasmosis; helminth infections, including cestodiasis, echinococcosis, lymphatic filariasis, schistosomiasis, onchocerciasis, others (e.g., roundworms, tapeworms, and flukes); invertebrate vectors/ectoparasites, black flies, sandflies, tsetse flies, mosquitoes, ticks, snails, and mites; (2) parasite biology (genetics, genomics, physiology, molecular biology, and biochemistry); (3) protective immunity, immunopathogenesis, and evasion of host responses; (4) clinical, epidemiological, and natural history studies of parasitic diseases; (5) research and development of vaccines, drugs, immunotherapeutics, and medical diagnostics; and (6) vector biology and management, mechanisms of pathogen transmissions.

Research on the above is welcome, but research on the following is of particular interest to the branch:

• New drug discovery or re-purposing of existing drugs to treat protozoal diseases
• Highly sensitive diagnostics tools for parasitic diseases
• Vaccines and vaccine technologies applicable to prevention or elimination of parasitic diseases
• Technologies or approaches that address arthropod vector monitoring, management, and control, to prevent transmission of vector-borne pathogens to humans

Contact: Dr. Annie Mo  
Telephone: 240-627-3420  
Email: moa@niaid.nih.gov

D. Respiratory Diseases Branch.

Research areas include: (1) **viral respiratory diseases** caused by influenza viruses, human coronaviruses including SARS, MERS, and novel emerging coronaviruses, rhinoviruses, respiratory syncytial virus and other related paramyxoviruses; (2) **mycobacterial diseases**, including tuberculosis (TB) caused by bacteria of the *Mycobacterium tuberculosis* complex, leprosy, Buruli ulcer and non-tuberculous mycobacterial (NTM) diseases, particularly pulmonary infections in persons not afflicted with HIV/AIDS; (3) **other bacterial respiratory diseases** including acute otitis media, pharyngitis, community acquired pneumonia, acute exacerbations of chronic obstructive pulmonary disease, diphtheria, pertussis, acute rhinosinusitis, other streptococcal diseases; and (4) **mixed viral/bacterial respiratory infections**.

Special emphasis areas include:

• Development of new or improved antimicrobials and antivirals, including immunotherapeutics, immunomodulators, and host-directed therapies to augment anti-infectives;

• Methodologies for rapid, point-of-care evaluation of drug levels in TB patients to facilitate therapeutic drug monitoring;

• New or improved vaccines (with and without adjuvants);

• Improved delivery systems and formulations for drugs/vaccines;

• Microbial and host biomarkers and biosignatures suitable for diagnostic tests;

• Rapid multiplex diagnostic tests, including low cost point-of-care, or other tools to detect infection prior to active disease and to identify drug resistance;

• Diagnostics to distinguish viral from bacterial infections.

There is particular need for preventive and treatment countermeasures for influenza, including universal vaccine platforms and broad-spectrum antivirals; for diagnostics (including drug susceptibility tests), novel therapeutics, and vaccines (including adjuvants) against *Mycobacterium tuberculosis* (TB); for relevant diagnostics, preventive and curative interventions against non-HIV associated pulmonary Non-tuberculous mycobacteria (NTM); and improved vaccine, diagnostic and treatment options for *Bordetella pertussis* and *Streptococcus pneumoniae*.

Contact: Dr. Xin-Xing Gu  
Telephone: 240-627-3265  
Email: guxx@niaid.nih.gov

E. Sexually Transmitted Infections Branch.

Areas of emphasis include the development of medical diagnostics including better and more rapid multiplex point of care tests, ability to rapidly determine antibiotic sensitivity, and novel technologies enabling testing in low resource settings while maintaining high sensitivity/specificity; development of new classes of antimicrobials and non-antimicrobial treatment approaches, particularly those focused on reducing the development of antibiotic resistance; novel delivery systems for multipurpose prevention technologies, vaccines and therapeutics for Sexually Transmitted Infections (STIs) and other reproductive tract syndromes such as bacterial vaginosis and pelvic inflammatory disease; understanding vaginal ecology and immunology and approaches to developing synthetic microbiota for use as biotherapeutics or as adjunct therapy to antibiotic treatment; development of epidemiologic and behavioral strategies to reduce transmission of STIs; developing and evaluating
interventions and products to better serve adolescents, medically underserved populations, and minority groups who are disproportionately affected by STIs; development of multipurpose prevention technologies to prevent STIs, HIV, and unintended pregnancies; better understanding of the role of STIs in infertility, premature birth, and adverse outcomes of pregnancy and how to improve outcomes; and better understanding of the role of STIs in HIV transmission and the role of HIV in altering the natural history of STIs.

Contact: Dr. Carolyn Deal
Telephone: 301-402-0443
Email: cdeal@niaid.nih.gov

F. **Virology Branch.**

The Virology Branch focuses on the following: acute viral infections (including Nipah and Hendra viruses), arthropod-borne and rodent-borne viral diseases (including Dengue, Zika, West Nile, Japanese encephalitis, Chikungunya, yellow fever, hantavirus, etc.), viral hemorrhagic fevers (Ebola, Lassa fever, etc.), measles, polio, coxsackie virus, enteroviruses, poxviruses, rabies, rubella, and persistent viral diseases (including adenoviruses, BK virus, bornaviruses, coronaviruses, herpesviruses, human T-lymphotrophic virus, JC virus, human papillomaviruses, parvoviruses, emerging human polyomaviruses, and prion diseases).

Areas of emphasis for SBIR/STTR applications include: 1) development of vaccines; 2) development of techniques to improve vaccine stability; 3) approaches to identify antiviral targets and agents; 4) chemical design and synthesis of novel antiviral agents; 5) development of therapeutic interventions; 6) development and validation of assays for disease diagnosis and to measure response to therapy; 7) development of new preclinical animal model systems that predict clinical efficacy of vaccines, therapeutics and diagnostics. The Virology Branch does not support applications covering environmental detection and decontamination.

Contact: Dr. Mindy Davis
Telephone: 301-761-6689
Email: mindy.davis@nih.gov

**NIAID Clinical Trials Topics:**

NIAID will generally consider clinical trial proposals consistent with the topics listed above. However, applicants are strongly encouraged to consult with NIAID Program Staff at least 10 weeks before the receipt date.

For further information, please consult NIAID’s Investigator-Initiated Clinical Trial Resources page: https://www.niaid.nih.gov/grants-contracts/investigator-initiated-clinical-trial-resources

For more information on research topics, contact:

Dr. Natalia Kruchinin
SBIR/STTR Program Coordinator Division of Extramural Activities
National Institute of Allergy and Infectious Diseases
Phone: 240-669-2919
Fax: 240-627-3162
Email: kruchininn@niaid.nih.gov
NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES (NIAMS)

The mission of the National Institute of Arthritis and Musculoskeletal and Skin Diseases is to support research into the causes, treatment, and prevention of arthritis and musculoskeletal and skin diseases, the training of basic and clinical scientists to carry out this research, and the dissemination of information on research progress in these diseases.

For additional information about areas of interest to the NIAMS, please visit NIAMS Long Range Plan at http://www.niams.nih.gov/About_Us/Mission_and_Purpose/long_range.asp.

Limited Amount of Award

For budgetary, administrative, or programmatic reasons, NIAMS may decide not to fund an application or may decrease the length of an award and/or the budget recommended by a review committee. Generally, NIAMS does not fund Phase I applications with a total cost greater than $225,000 or a project period greater than 2 years and Phase II applications with a total cost greater than $1,500,000 or a project period greater than 3 years. Applicants considering a requested budget greater than these limits are strongly encouraged to contact program staff before submitting an application. It is not the intent of NIAMS to support clinical trials through the SBIR/STTR mechanism. Applicants who wish to submit clinical trials applications to the NIAMS are encouraged to utilize one of the NIAMS FOAs listed HERE.

Research Topics of Interest to NIAMS

The specific set of topics that are funded by a particular IC/Office/Agency depends on whether the IC/Office/Agency funds/supports Clinical Trials under SBIR/STTR Awards. Use the following table and explanations to determine which list of topics is applicable.

<table>
<thead>
<tr>
<th>Does IC/Office/Agency Fund/Support Clinical Trials under SBIR/STTR Awards?</th>
<th>No*</th>
<th>Yes**</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>X</td>
<td></td>
</tr>
</tbody>
</table>

*If No,
- This IC/Office/Agency funds only those topics listed under the Non-Clinical Trials Topics section below, UNLESS the IC/Office/Agency funds a Small Business Concern for clinical trials under a NON-SBIR/STTR award.

**If Yes or the IC/Office/Agency funds small businesses for clinical trials under a NON-SBIR/STTR funding opportunity,
- See the table below for which mechanisms the IC/Office/Agency will allow for clinical trials research. Also, see the Clinical Trials Topics section below for a list of funded topics. This IC/Office/Agency also funds research listed under the Non-Clinical Trials Topics section below.
<table>
<thead>
<tr>
<th>Does IC/Office/Agency accept clinical trials applications under this mechanism?</th>
<th>Yes</th>
<th>No</th>
<th>Other Information: If funding an SBC for clinical trials under a NON-SBIR/STTR award, please identify activity code(s) and other relevant information.</th>
</tr>
</thead>
<tbody>
<tr>
<td>Clinical Trials SBIR/STTR Omnibus/Parent Funding Opportunity Announcement/s</td>
<td>X</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Clinical Trials SBIR/STTR IC/Office/Agency - Specific Funding Opportunity Announcement/s</td>
<td>X</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Clinical Trials NON-SBIR/STTR Funding Opportunity Announcement/s where Small Businesses are eligible to apply</td>
<td>X</td>
<td></td>
<td><a href="https://www.niams.nih.gov/grants-funding/conducting-clinical-research/investigator-clinical-trial-policies">https://www.niams.nih.gov/grants-funding/conducting-clinical-research/investigator-clinical-trial-policies</a>.</td>
</tr>
</tbody>
</table>

**NIAMS Non-Clinical Trials Topics:**

**Arthritis and Musculoskeletal and Skin Diseases**

A. *Division of Skin and Rheumatic Diseases.* This division promotes and supports studies of the skin in normal and disease states; and research leading to prevention, diagnosis and cure of rheumatic and related diseases. In the area of Skin Diseases, the division has a wide range of skin diseases under study with NIAMS support, to include keratinizing disorders such as psoriasis and ichthyosis, atopic dermatitis and other chronic inflammatory skin disorders, the vesiculobullous diseases such as epidermolysis bullosa and pemphigus, acne, and vitiligo. In the area of Rheumatic Diseases, the division supports research on etiology, pathogenesis, course, interventions, and outcomes in rheumatic and related diseases.

This is not an inclusive list of all research topics covered by the Division of Skin and Rheumatic Diseases. To learn more, please visit the Division page at [http://www.niams.nih.gov/Funding/Funding_Opportunities/Supported_Scientific_Areas/Skin_Rheumatic_Diseases/default.asp](http://www.niams.nih.gov/Funding/Funding_Opportunities/Supported_Scientific_Areas/Skin_Rheumatic_Diseases/default.asp).

B. *Division of Musculoskeletal Diseases.* The musculoskeletal system is composed of the skeleton, which provides mechanical support and determines shape; the muscles, which power movement; and connective tissues such as tendon and ligament, which hold the other components together. The cartilage surfaces of joints and the intervertebral discs of the spine allow for movement and flexibility.

The Division of Musculoskeletal Diseases of the NIAMS supports research aimed at improving the diagnosis, treatment, and prevention of diseases and injuries of the musculoskeletal system and its component tissues. Key public health problems addressed by this research include osteoporosis, osteoarthritis, and muscular dystrophy.
This is not an inclusive list of all research topics covered by the Division of Musculoskeletal Diseases. To learn more, please visit the Division page at http://www.niams.nih.gov/Funding/Funding_Opportunities/Supported_Scientific_Areas/Musculoskeletal_Diseases/default.asp.

Special Emphasis Areas of Interest to Small Businesses:

NIAMS supports all Research and Development activities within its mission. Particular areas of programmatic interest relative to small business initiatives include, but are not limited to:

A. Innovation research on rare musculoskeletal, rheumatic and skin diseases
B. Multiplex assay development for arthritis and musculoskeletal and skin diseases
C. Lab to marketplace: translation of scientific discoveries in NIAMS mission areas from labs into products on the market
D. Test and/or validation of novel, state-of-the-art candidate biomarker platforms for predicting the onset and progression of inflammatory diseases of interest to the NIAMS and for determining the pharmacodynamics, safety and/or efficacy of therapeutic agents targeting those diseases.

NIAMS Clinical Trials Topics:

NIAMS does not participate in the SBIR/STTR clinical trial funding opportunities. NIAMS NON-SBIR/STTR clinical trial funding opportunities support all research within the NIAMS mission areas.

For general SBIR/STTR program information, contact:

Dr. Xibin Wang, NIAMS SBIR/STTR Coordinator
Telephone: 301-451-3884, Fax: 301-480-1284
Email: wangx1@mail.nih.gov

For administrative and business management questions, contact:

Ms. Aleisha S. James
Telephone: 301-594-3968, Fax: 301-480-5450
Email: jamesaleisha@mail.nih.gov
NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERING (NIBIB)

The mission of the National Institute of Biomedical Imaging and Bioengineering (NIBIB) is to improve health by leading the development and accelerating the application of biomedical technologies. The Institute is committed to integrating the physical and engineering sciences with the life sciences to advance basic research and medical care. This is achieved through: research and development of new biomedical imaging and bioengineering techniques and devices to fundamentally improve the detection, treatment, and prevention of disease; enhancing existing imaging and bioengineering modalities; supporting related research in the physical and mathematical sciences; encouraging research and development in multidisciplinary areas; supporting studies to assess the effectiveness and outcomes of new biologics, materials, processes, devices, and procedures; developing technologies for early disease detection and assessment of health status; and developing advanced imaging and engineering techniques for conducting biomedical research at multiple scales.

Research Topics of Interest to NIBIB

The specific set of topics that are funded by a particular IC/Office/Agency depends on whether the IC/Office/Agency funds/supports Clinical Trials under SBIR/STTR Awards. Use the following table and explanations to determine which list of topics is applicable.

<table>
<thead>
<tr>
<th>Does IC/Office/Agency Fund/Support Clinical Trials under SBIR/STTR Awards?</th>
<th>No*</th>
<th>Yes**</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td>X</td>
</tr>
</tbody>
</table>

*If No,
- This IC/Office/Agency funds only those topics listed under the Non-Clinical Trials Topics section below, UNLESS the IC/Office/Agency funds a Small Business Concern for clinical trials under a NON-SBIR/STTR award.

**If Yes or the IC/Office/Agency funds small businesses for clinical trials under a NON-SBIR/STTR funding opportunity,
- See the table below for which mechanisms the IC/Office/Agency will allow for clinical trials research. Also, see the Clinical Trials Topics section below for a list of funded topics. This IC/Office/Agency also funds research listed under the Non-Clinical Trials Topics section below.

<table>
<thead>
<tr>
<th>Does IC/Office/Agency accept clinical trials applications under this mechanism?</th>
<th>Yes</th>
<th>No</th>
</tr>
</thead>
<tbody>
<tr>
<td>Clinical Trials SBIR/STTR Omnibus/Parent Funding Opportunity Announcement/s</td>
<td>X</td>
<td>Other Information: If funding an SBC for clinical trials under a NON-SBIR/STTR award, please identify activity code(s) and other relevant information.</td>
</tr>
</tbody>
</table>
NIBIB Non-Clinical Trials Topics:

A. **Biomaterials.** Development of new or novel biomaterials that can be used for a broad spectrum of biomedical applications such as implantable devices; drug and gene delivery; tissue engineering; imaging agents; and biosensors and actuators. Research that is supported includes the design, synthesis, characterization, processing and manufacturing of these materials as well as the design and development of devices constructed of these materials and their clinical performance.

B. **Biosensors.** Development of sensor technologies for the detection and quantitation of clinically relevant analytes in complex matrices. Application areas include (among others) biomedical research, clinical laboratory diagnostics, and biodefense, covering *in vitro* diagnostics, noninvasive monitoring, and implantable devices. Technologies encompassed include novel signal transduction approaches, materials for molecular recognition, biocompatibility, signal processing, fabrication technologies, actuators, and power sources.

C. **Biomedical Informatics.** Development of structures and algorithms to improve the collection, storage, classification, retrieval, integration, analysis, and dissemination of quantitative and qualitative biomedical data. Examples of informatics tools and resources supported by this program are: databases, standards for enhanced interoperability, collaborative analysis environments, data modeling and representation, and techniques for the integration of heterogeneous data, rational data-driven design of experiments, visualization of data, and digital representation of rich qualitative data. This program is intended to support NIBIB’s other program areas in biomedical imaging and bioengineering researchers.

D. **Connected Health.** Development of enabling technologies that emphasize the integration of wireless technologies with human and biological interfaces. This program includes the development of software and hardware for telehealth and mobile health studies. This category includes methods for medical evaluation at one location and transmission of this information to another location for analysis of the disease status, methods to address affordability, usability and implementation issues in remote settings.

E. **Delivery Systems and Devices for Drugs and Biologics.** Development of new and improved technologies for the controlled and targeted release of therapeutic agents, including nucleic acids, peptides, proteins, vaccines, genes, small molecules, and theranostics. Emphasis is on the engineering of new delivery vehicles that may include (but are not limited to) novel biomaterials,
liposomes, micelles, nanoparticles, and dendrimers; or various delivery modalities that may include, for example, ultrasound, electroporation, implantable pumps, or stimulators.

F. **Image-Guided Interventions.** Research on use of images for guidance, navigation and orientation in minimally invasive procedures to reach specified targets. Examples include image-guided interventions for minimally invasive therapies such as surgery and radiation treatment, for biopsies, and for the delivery of drugs, genes and therapeutic devices.

G. **Image Processing, Visual Perception, and Display.** Design and development of algorithms for post-acquisition image processing and analysis. These algorithms include methods for image segmentation, image registration, atlas generation, morphometry measurement, and the determination of function and structure from medical images. Also supported by this program is the development of theoretical models and analysis tools to evaluate and improve the perception of medical images. This may include diagnostic-performance evaluation, assessment of computer-aided diagnosis technologies, statistical models for evaluation of observer performance, and assessment of observer variability.

H. **Immunoeengineering.** Development and/or application of engineering principles, tools, methods, and technologies to manipulate and control the immune system to prevent, diagnose, and/or treat diseases to improve human health. Appropriate tools may include biomaterials, engineered tissues, synthetic biology approaches, therapeutic delivery systems, probes and devices for monitoring immune cell trafficking, mathematical models, and other methods. Technology development and application within the program must focus on engineering design-based approaches, and may include, but is not limited to, novel vaccines, cancer therapies, control of the immunological environment for regenerative medicine and drug delivery applications, control of the inflammatory response, and methods to ameliorate autoimmune disorders.

I. **Magnetic, Biomagnetic and Bioelectric Devices.** Development of magnetic, biomagnetic and bioelectric devices, e.g., EEG, MEG, etc. Examples include (but are not restricted to) novel detectors, increased sensitivity and spatial resolution, improved reconstruction algorithms, multiplexing with other imaging techniques, etc.

J. **Magnetic Resonance Imaging and Spectroscopy.** Development of MR imaging and MR spectroscopic imaging, for both animal and human research, and potential clinical applications. Examples include (but are not restricted to) fast imaging, high field imaging, design of novel RF and gradient coils, novel pulse sequences, design of novel contrast mechanisms, imaging informatics, *in vivo* EPR imaging, molecular imaging, etc. The emphasis should be on technological development rather than detailed applications to specific diseases or organs.

K. **Mathematical Modeling, Simulation and Analysis.** Development of mathematical models and computational algorithms with potential clinical or biomedical applications, including multi-scale modeling, modeling at or above the cellular level, and modeling at subcellular level, including those developed to support technology development in other program areas related to the NIBIB mission. Research includes mathematical, statistical, transport, network, population, mechanical, electrical and electronic models applied to a broad range of biomedical fields.

L. **Microfluidic Bioanalytical Systems.** Design, development and implementation of systems for the precise control and manipulation of biological fluids on a small, sub-millimeter scale. Technology development in research areas include, but are not limited to in-vitro micro-total analysis systems, arrays and biochips for detection of clinically relevant analytes in complex matrices.

M. **Molecular Imaging.** Development, optimization, and application of targeting imaging agents, imaging methods and related software/hardware for the detection of normal biological and pathophysiological processes in living subjects at the cellular and molecular levels. Imaging agents may include surface modified, molecular targeting or bioreactive nanoparticles, radionucleate-labeled agents, theranostic agents, and high sensitivity/specificity molecular imaging approaches, etc. The goal of this program is to generate robust molecular imaging agents and platforms.
applicable to basic, preclinical and clinical research across all disease areas for better understanding of disease progression and therapeutic developments.

N. **Nuclear Medicine.** Research and development of technologies that create images out of the gamma-ray or positron (and resulting photon) emissions from radioactive agents that are injected, inhaled, or ingested into the body and then concentrate in specific biological compartments. Active areas supported include the wedding of positron emission tomography (PET) and single photon emission computed tomography (SPECT) to CT and/or to MRI; the design of higher spatial and temporal resolution systems including the compensation of artifacts, improved reconstruction algorithms and the development of new cameras, scintillators and collimators; new approaches to increasing sensitivity and tracking/lowering radiation dose; lower cost and portable systems and kits; and the synthesis and study of targeted radio-labeled molecular probes, particularly multimodal, environmentally-sensitive and switchable agents.

O. **Optical Imaging and Spectroscopy.** Development and application of optical imaging, microscopy, and spectroscopy techniques; and development and application of optical imaging contrasts. Examples of research areas include fluorescence imaging, bioluminescence imaging, OCT, SHG, IR imaging, diffuse optical tomography, optical microscopy and spectroscopy, confocal microscopy, multiphoton microscopy, flow cytometry, development of innovative light sources and fiber optic imaging devices.

P. **Point of Care Technologies.** Development of rapid in-vitro diagnostic technologies and monitoring platforms that provide real time medical evaluation and analysis of the disease status or condition at the time and place of patient care. Technology development area examples within the program include but are not limited to disposable lateral flow assays, nucleic acid testing platforms, glucose monitoring devices, etc. The program includes the delivery of healthcare that is safe, effective, timely, patient centered, efficient, and available in centralized and decentralized locations.

Q. **Rehabilitation Engineering and Implantable Medical Devices.** Development of next generation engineering technology for implantable and assistive medical devices. Technologies for implantable medical devices include early stage technology development for implantable neuroprosthesis and neuroengineering systems, and next generation neural interfaces. Technologies for assistive medical devices include medical robotics for rehabilitation, surgery, preventive health and therapy; and next generation prosthetics and Brain Computer Interface (BCI) technology.

R. **Surgical Tools, Techniques and Systems.** Research and development of next generation tools, technologies and systems to improve the outcomes of surgical interventions. Examples include: medical simulators for surgical training and increased patient safety, surgical robotics, and devices for minimally invasive surgeries.

S. **Synthetic Biology.** Design and wholesale construction of new biological parts and systems and the re-design of existing, natural biological systems for tailored purposes. This program may include, for example, the use of synthetic biology approaches for the development of signal-sensing biomaterials; genetic switches for the control of gene delivery; synthetically engineered viruses and bacteriophages as therapies; synthetic circuits for gene therapy; synthetic control of biosensors through environmentally responsive promoters; and synthetic control systems for the production of biomaterials.

T. **Tissue Chips.** Development of *in vitro* tools for assessing the function of engineered tissues; high-throughput assays and instruments to reduce the cost, time, and complexity of tissue engineering; as well as novel bioreactor techniques for growing tissues and organs on a large scale, for drug development and study of normal physiology and pathophysiology..

U. **Tissue Engineering and Regenerative Medicine.** Development of enabling technologies including real-time, non-invasive tools for assessing the function of engineered tissues; real-time assays that monitor the interaction of cells and their environment at the molecular and organelle level; predictive computational models for engineering function 3D tissues; high-throughput assays and instruments to reduce the cost, time, and complexity of tissue engineering; novel bioreactor techniques for
expanding stem cells and growing tissues and organs on a large scale; and strategies for preserving, sterilizing, packaging, and transporting living-tissue products. The program also supports applications of rational engineering design principles to functional engineered tissues; the development of novel biomaterials for use as tissue scaffolds that mimic the extracellular matrix and support multiple cell types in defined spatial orientation; and engineering approaches to study how biomaterials interact with cells and guide cell growth, differentiation, and migration.

V. **Ultrasound.** Improvement of technologies for diagnostic, interventional and therapeutic uses of ultrasound. The diagnostic ultrasound program includes, but is not limited to the design, development and construction of transducers, transducer arrays, and transducer materials, innovative image acquisition and display methods, innovative signal processing methods and devices, and optoacoustic and thermoacoustic technology. It also includes the development of image-enhancement devices and methods, such as contrast agents, image and data presentation and mapping methods, such as functional imaging and image fusion. The interventional ultrasound program includes the use of ultrasound for therapeutic use, or as an adjunct for enhancement of non-ultrasound therapy applications. Examples include, but are not limited to, high-intensity focused ultrasound (HIFU) as a non-invasive or minimally invasive interventional surgical or therapy tool, and as an adjunct interventional tool. It also includes the use of ultrasound contrast agents for therapy and for targeted drug delivery, and the use of ultrasound for image-guided surgery, biopsy, and other interventions.

W. **X-ray, Electron, and Ion Beam.** Enhancement of computed tomography (CT), computed radiography (CR), digital radiography (DR), digital fluoroscopy (DF), and related modalities. Research areas of support include the development of: flat panel detector arrays and other detector systems; flat-panel CT; CT reconstruction algorithms for the cone-beam geometry of multi-slice CT; approaches to radiation dose reduction, especially with CT; and novel x-ray applications, such as those utilizing scattered radiation, tissue-induced x-ray phase shifts, etc.

**NIBIB Clinical Trials Topics:**

NIBIB will accept clinical trials in any area listed above in the non-clinical trials topics.

For additional information on research topics, contact:

Mr. Todd Merchak  
National Institute of Biomedical Imaging and Bioengineering  
Telephone: 301-496-8592, Fax: 301-480-1614  
Email: todd.merchak@nih.gov

For administrative and business management questions, contact:

Mr. James Huff  
National Institute of Biomedical Imaging and Bioengineering  
Telephone: 301-451-4786, Fax: 301-451-5735  
Email: huffj@mail.nih.gov
NATIONAL CANCER INSTITUTE (NCI)

The National Cancer Institute’s SBIR Development Center program is one of the nation’s largest sources of financing for small businesses engaged in technology innovation. Its funding, mentoring and networking assistance is offered to small businesses demonstrating promising next-generation cancer cure technologies, with the ultimate goal being successful commercialization and life-changing public benefit. NCI’s SBIR/STTR Programs offer funding for therapeutic agents and devices; in vitro and in vivo diagnostics, including companion diagnostics and imaging agents; agents and technologies for cancer prevention; tools for research in cancer biology, cancer control, and epidemiology; digital health, including health information technology and bioinformatics; and many more areas of interest to the NCI.

The goal of NCI’s SBIR/STTR program is to increase small business participation and private-sector commercialization of novel technologies that can prevent, diagnose and treat cancer. The major NCI SBIR/STTR portfolio areas are listed below as a guide to general technology areas funded through the program. Applications proposing innovative cancer-related technologies with strong commercial potential that fall outside these topic areas are also encouraged through this Omnibus solicitation.

Major NCI SBIR/STTR Portfolio Areas:

- Therapeutics (e.g., Small Molecules, Biologics, Radiomodulators, and Cell-based Therapies)
- In Vitro and In Vivo Diagnostics (e.g., Companion Diagnostics and Prognostic Technologies)
- Imaging Technologies (e.g., Agents, Devices, and Image-Guided Interventions)
- Devices for Cancer Therapy (e.g., Interventional Devices, Surgical, and Radiation and Ablative Therapies, Hospital Devices)
- Agents and Technologies for Cancer Prevention
- Technologies for Cancer Control (e.g., Behavioral Health Interventions, Tools for Genetic, Epidemiologic, Behavioral, Social, and/or Surveillance Cancer Research)
- Tools for Cancer Biology Research

NCI is committed to lessening the impact of cancer by propelling technological innovation. The NCI SBIR/STTR Programs are aligned with recommendations laid out by the Cancer Moonshot Blue Ribbon Panel Report: [https://www.cancer.gov/research/key-initiatives/moonshot-cancer-initiative/blue-ribbon-panel](https://www.cancer.gov/research/key-initiatives/moonshot-cancer-initiative/blue-ribbon-panel)

For more information on NCI SBIR/STTR high priority areas, please visit the NCI SBIR Development Center’s Research Topics of Interest page: [http://sbir.cancer.gov/funding/researchtopicsinterest](http://sbir.cancer.gov/funding/researchtopicsinterest)

For up-to-date information on high priority technology areas, and to learn about programmatic initiatives and upcoming events, visit the NCI SBIR Development Center homepage: [http://sbir.cancer.gov/](http://sbir.cancer.gov/)

In addition, please see the contact list at the end of the NCI section to identify the NCI SBIR/STTR Program Director that specializes in your technology area.

Limited Amount of Award

For budgetary, administrative, or programmatic reasons, NCI may decide not to fund an application or may decrease the length of an award and/or the budget recommended by a review committee. Generally, NCI will fund Phase I applications with budgets up to $225,000 total costs or project periods up to 2 years; Phase II applications with budgets up to $1,500,000 total costs or with project periods up to 3 years will be considered, as well. For certain topical areas, the Small Business Administration has approved an NIH SBIR/STTR Topic Waiver list for which the NCI generally will fund Phase I applications with budgets up to $300,000 total costs or project periods up to 2 years; NCI will also consider Phase II applications with budgets up to $2,000,000 total costs or project periods up to 3 years. NCI SBIR/STTR
Waiver Topic areas can be found in Appendix A below. Applicants considering a requested budget greater than these limits are strongly encouraged to contact program staff before submitting an application.

Phase IIB Competing Renewal Awards

The NCI does not accept applications for Phase IIB SBIR competing renewal awards through this Omnibus solicitation. However, the NCI offers Phase IIB opportunities in the form of the NCI SBIR Phase IIB Bridge Award, which is announced via a separate funding solicitation: https://sbir.cancer.gov/bridge. The NCI Phase IIB Bridge Award is designed to support the next stage of development for cancer-related technologies previously funded under SBIR or STTR Phase II awards from any Federal agency. The purpose of this award is to address the funding gap known as the "Valley of Death" between the end of the SBIR Phase II award and the subsequent round of financing needed to advance a product or service toward commercialization. To achieve this goal, the Bridge Award funding opportunity is specifically designed to incentivize partnerships between Federally-funded SBIR Phase II awardees and third-party investors and/or strategic partners. Competitive preference and funding priority will be given to applicants that demonstrate the ability to secure substantial independent third-party investor funds (i.e., third-party funds that equal or exceed the requested NCI funds).

To ensure that you will be notified upon the release of the NCI SBIR Phase IIB Bridge Award solicitation, please sign up for the NCI SBIR mailing list: https://sbir.cancer.gov/emailsignup. If you have any questions regarding the NCI SBIR Phase IIB Bridge Award, please contact your Phase II program director.

Research Topics of Interest to NCI

The specific set of topics that are funded by a particular IC/Office/Agency depends on whether the IC/Office/Agency funds/supports Clinical Trials under SBIR/STTR Awards. Use the following table and explanations to determine which list of topics is applicable.

<table>
<thead>
<tr>
<th>Does IC/Office/Agency Fund/Support Clinical Trials under SBIR/STTR Awards?</th>
<th>No*</th>
<th>Yes**</th>
</tr>
</thead>
</table>

*If No,
- This IC/Office/Agency funds only those topics listed under the Non-Clinical Trials Topics section below, UNLESS the IC/Office/Agency funds a Small Business Concern for clinical trials under a NON-SBIR/STTR award.

**If Yes or the IC/Office/Agency funds small businesses for clinical trials under a NON-SBIR/STTR funding opportunity,
- See the table below for which mechanisms the IC/Office/Agency will allow for clinical trials research. Also, see the Clinical Trials Topics section below for a list of funded topics. This IC/Office/Agency also funds research listed under the Non-Clinical Trials Topics section below.
**Does IC/Office/Agency accept clinical trials applications under this mechanism?**

<table>
<thead>
<tr>
<th></th>
<th>Yes</th>
<th>No</th>
<th>Other Information: If funding an SBC for clinical trials under a NON-SBIR/STTR award, please identify activity code(s) and other relevant information.</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Clinical Trials SBIR/STTR</strong></td>
<td>X</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Omnibus/Parent Funding Opportunity Announcement/s</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Clinical Trials SBIR/STTR</strong></td>
<td>X</td>
<td></td>
<td></td>
</tr>
<tr>
<td>IC/Office/Agency - Specific Funding Opportunity Announcement/s</td>
<td></td>
<td></td>
<td><a href="https://sbir.nih.gov/funding/individual-announcements">https://sbir.nih.gov/funding/individual-announcements</a></td>
</tr>
<tr>
<td><strong>Clinical Trials NON-SBIR/STTR</strong></td>
<td>X</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Funding Opportunity Announcement/s where Small Businesses are eligible to apply</td>
<td></td>
<td></td>
<td><a href="https://www.cancer.gov/grants-training/grants-funding/funding-opportunities">https://www.cancer.gov/grants-training/grants-funding/funding-opportunities</a></td>
</tr>
</tbody>
</table>

**NCI Non-Clinical Trials Topics:**

A. Therapeutics (e.g., Small Molecules, Biologics, Radiomodulators, and Cell-based Therapies)
B. In Vitro and In Vivo Diagnostics (e.g., Companion Diagnostics and Prognostic Technologies)
C. Imaging Technologies (e.g., Agents, Devices, and Image-Guided Interventions)
D. Devices for Cancer Therapy (e.g., Interventional Devices, Surgical, and Radiation and Ablative Therapies, Hospital Devices)
E. Agents and Technologies for Cancer Prevention
F. Technologies for Cancer Control (e.g., Behavioral Health Interventions, Tools for Genetic, Epidemiologic, Behavioral, Social, and/or Surveillance Cancer Research)
G. Digital health tools and software platforms for cancer control, prevention and care.
H. Tools for Cancer Biology Research
I. Research Tools (e.g., Animal Models, Cell Lines)
J. Low-cost prevention/diagnostic/therapeutic products for low-resource settings (cancer global health)

**NCI Clinical Trials Topics:**

A. Therapeutics (e.g., Small Molecules, Biologics, Radiomodulators, and Cell-based Therapies)
B. In Vitro and In Vivo Diagnostics (e.g., Companion Diagnostics and Prognostic Technologies)
C. Imaging Technologies (e.g., Agents, Devices, and Image-Guided Interventions)
D. Devices for Cancer Therapy (e.g., Interventional Devices, Surgical, and Radiation and Ablative Therapies, Hospital Devices)
E. Agents and Technologies for Cancer Prevention
F. Technologies for Cancer Control (e.g., Behavioral Health Interventions, Tools for Genetic, Epidemiologic, Behavioral, Social, and/or Surveillance Cancer Research)

G. Digital health tools and software platforms for cancer control, prevention and care.

H. Low-cost prevention/diagnostic/therapeutic products for low-resource settings (cancer global health)

For additional information about the NCI SBIR/STTR programs, please contact the NCI SBIR Development Center:

Small Business Innovation Research (SBIR) Development Center National Cancer Institute
9609 Medical Center Drive
Rockville, MD 20850
Website: http://sbir.cancer.gov
Email: NCIsbir@mail.nih.gov
Phone: 240-276-5300

For additional information on research topics, please contact a Program Officer with the relevant area of expertise:

Michael Weingarten, MA
Director, NCI SBIR Development Center
Email: weingartenm@mail.nih.gov

Gregory Evans, PhD
Program Director and Team Leader
Email: evansgl@mail.nih.gov
Areas of expertise: Therapeutics (Immunotherapy, Gene Therapy), Cancer Imaging, Cancer Control, Tools for Cancer Biology Research, and Digital Health

Andrew Kurtz, PhD
Program Director and Team Leader
Email: kurtza@mail.nih.gov
Areas of expertise: Therapeutics (Small Molecules, Biologics, Nanotherapeutics), and Molecular Diagnostics

Patricia Weber, DrPH
Program Director
Email: weberpa@mail.nih.gov
Areas of expertise: Digital Health and Therapeutics (Small Molecules, Biologics, Immunotherapy)

Xing-Jian Lou, PhD
Program Director
Email: loux@mail.nih.gov
Areas of expertise: In Vitro Diagnostics and Therapeutics (Gene Therapy, Biologics, Small Molecules)

Deepa Narayanan, MS, CCDM
Program Director
Email: narayanand@mail.nih.gov
Areas of expertise: Radiation Therapy, Cancer Imaging, Medical Devices, and Clinical Trials

Amir Rahbar, PhD, MBA
Program Director
Email: amir.rahbar@nih.gov
Areas of expertise: In Vitro Diagnostics, Proteomics, and Therapeutics (Biologics, Small Molecules)
Todd Haim, PhD  
Program Director  
Email: haimte@mail.nih.gov  
Areas of expertise: Therapeutics (Small Molecules, Biologics, Immunotherapy) and Tumor Microenvironment

Ming Zhao, PhD  
Program Director  
Email: zhaoming3@mail.nih.gov  
Areas of expertise: In Vitro Diagnostics, Cancer Stem Cells, Molecular Imaging, Bioinformatics, Therapeutics (Small Molecules, Biologics, Immunotherapy), and Cancer Control (Community-Based Participatory Research)

Jonathan Franca-Koh PhD, MBA  
Program Director  
Email: jonathan.franca-koh@nih.gov  
Areas of expertise: Cancer Biology, Biologics, Small Molecules, and Cell Based Therapies

Christie Canaria, PhD  
Program Director  
Email: Christie.canaria@nih.gov  
Areas of Expertise: Cancer/Biological Imaging, Research Tools and Devices

Kory Hallett, PhD  
Program Director  
Email: kory.hallett@nih.gov  
Areas of expertise: Immunology, Immunotherapy/Immuno-Oncology, Monoclonal Antibodies, Hematopoietic Stem Cell Transplantation, and Cell-Based Therapies

Ashim Subedee, PhD  
Program Director  
Email: ashim.subedee@mail.nih.gov  
Areas of Expertise: Therapeutics and Theranostics, Cancer Imaging, Radiation Therapy, Cancer Prevention, and Digital Health

For administrative and grants management questions, please contact:

Jacquelyn Saval  
Grants Management Specialist  
Office of Grants Administration  
National Cancer Institute  
9609 Medical Center Drive  
West Tower, 2W514  
Rockville MD  20850  
Telephone: 240-507-6871  
Fax: (240) 276-7913  
Email: savalj@mail.nih.gov

For NCI-related SBIR Information, visit: http://sbir.cancer.gov.
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)

The mission of the NICHD is to ensure that every person is born healthy and wanted, that women suffer no harmful effects from reproductive processes, and that all children have the chance to achieve their full potential for healthy and productive lives, free from disease or disability, and to ensure the health, productivity, independence, and well-being of all people through optimal rehabilitation.

For up-to-date information on priority research areas of scientific interest to the NICHD, please visit our home page at http://www.nichd.nih.gov.

Pre-submission Resources

There are several programs designed to help entrepreneurs with limited commercialization experience maximize their potential to achieve success in the health care research area. These programs provide support, education, and market expertise designed to assist you in the development of your team as well as the translation of your innovation to the marketplace.

Pediatric Device Consortia (PDC)

This grant program, from the U.S. Food and Drug Administration (FDA), supports the development of nonprofit consortia to stimulate projects promoting pediatric device development. The funded PDC help accelerate commercialization of safe and effective technologies for pediatric clinical care by connecting innovators with an extensive network of clinicians, researchers, technologists, and business development specialists located at institutions in their region. Currently, FDA funds 8 PDC across the country. Applicants interested in developing devices for pediatrics are encouraged to utilize the resources, programs, and seed funding that is available through a regional PDC. Visit the PDC website for more information.

NIH Research Evaluation and Commercialization Hub (REACH)

REACH is a program for STTR-funded academic or other research institutions. Hubs are NIH-funded centers that provide the infrastructure, investment, and resources to nurture innovators of high-priority technologies within the NIH’s mission. This can include funding for feasibility studies and coordinated access to expertise in areas required for early stage technology development, including scientific, regulatory, reimbursement, business, legal, and project management. Visit the REACH website for more information.

Center for Translation of Rehabilitation Engineering Advances and Technology (TREAT)

TREAT provides pilot funds for the development of rehabilitation devices or medical devices for persons with disabilities. Visit the TREAT website for more information.

Resources for Funded Grantees

After competing successfully for an NICHD SBIR/STTR grant, awardees are encouraged to participate in additional programs to help them move their products into the market place. Identify a program that advances your commercialization efforts such as:

Niche Assessment Program (NAP)

NAP is a program for SBIR/STTR Phase I awardees that provides market insight and data that can be used to help small businesses strategically position their technology in the marketplace. The results of this program can help small businesses develop their commercialization plans for their Phase II application, and be exposed to potential partners. Services are provided by Foresight Science & Technology of Providence, RI. Visit the NAP website for more information.
Innovation Corps at NIH (I-Corps™)

Open to SBIR/STTR Phase 1 awardees, the goal of I-Corps™ is to accelerate the translation of biomedical research to the marketplace by training grantees in the areas of innovation and entrepreneurship. Visit the I-Corps website for more information.

Commercialization Accelerator Program (CAP)

SBIR/STTR Phase II awardees are eligible for this 9-month program that enables participants to establish market and customer relevance, build commercial relationships, and focus on revenue opportunities available to them. Visit the CAP website for more information.

Limited Amount of Award

For NICHD award topic areas included in PHS 2018-2 Omnibus SBIR/STTR Solicitation, the NICHD will accept SBIR/STTR applications up to $225K total costs for Phase I, generally, for a time period no greater than 2 years and $1.5M for Phase II, generally, for a time period no greater than 3 years. Requests for costs above the SBIR/STTR budgetary guidelines of $150K for Phase I and $1M for Phase II must be very well justified.

The NICHD received a budgetary guideline waiver from the Small Business Administration for applications relating to a limited list of scientific topics in Appendix (A). For these the NICHD will accept applications up to $300K total costs for Phase I and $2M for Phase II. Requests for costs above the guidelines of $150K for Phase I and $1M for Phase II must be very well justified.

Applicants are strongly encouraged to contact the listed NICHD Branch Contact Program Officer for scientific-related questions about a project’s eligibility for a budgetary waiver. For general budgetary questions applicants are encouraged to contact the Institute’s SBIR/STTR Grants Management Coordinator. For budgetary, administrative or programmatic reasons the NICHD may decrease the budget or length of an award or decide not to fund an application recommended by scientific review.

Phase IIB Competing Renewal Awards

NICHD will accept Phase IIB SBIR Competing Renewal grant applications to continue the process of developing products that require approval of a Federal regulatory agency (e.g., FDA, FCC). Such products include, but are not limited to: medical implants, pediatric devices, drugs, vaccines, and new treatment or diagnostic tools that require FDA approval. Applicants who received NICHD SBIR Phase I or Phase II support and who are currently Phase II awardees are eligible (NICHD SBIR only and only competing renewals of NICHD supported Phase II awards). Budgets for Phase IIB renewals should not exceed 3 million dollars total costs for three years. Depending on the research proposed the amounts may vary each year for the time requested. The purpose of this mechanism is to provide additional support for later stage research and development necessary to move closer to commercialization. Funding priority will be given to those small business concerns that show the ability to develop innovative products, and demonstrate growth towards independence from the SBIR/STTR programs.

NICHD Supported Funding Opportunity Announcements (FOAs)

In addition to the Omnibus program announcement, for up-to-date NICHD releases on targeted funding announcements and programmatic initiatives visit: https://sbir.nih.gov/funding/individual-announcements or https://www.nichd.nih.gov/grants-funding/SBIR_STTR/Pages/default.aspx.
Research Topics of Interest to NICHD

The specific set of topics that are funded by a particular IC/Office/Agency depends on whether the IC/Office/Agency funds/supports Clinical Trials under SBIR/STTR Awards. Use the following table and explanations to determine which list of topics is applicable.

<table>
<thead>
<tr>
<th>Does IC/Office/Agency Fund/Support Clinical Trials under SBIR/STTR Awards?</th>
<th>No*</th>
<th>Yes**</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>X</td>
<td></td>
</tr>
</tbody>
</table>

*If No,
- This IC/Office/Agency funds only those topics listed under the Non-Clinical Trials Topics section below, **UNLESS** the IC/Office/Agency funds a Small Business Concern for clinical trials under a NON-SBIR/STTR award.

**If Yes or the IC/Office/Agency funds small businesses for clinical trials under a NON-SBIR/STTR funding opportunity,
- See the table below for which mechanisms the IC/Office/Agency will allow for clinical trials research. Also, see the Clinical Trials Topics section below for a list of funded topics. This IC/Office/Agency also funds research listed under the Non-Clinical Trials Topics section below.

<table>
<thead>
<tr>
<th>Does IC/Office/Agency accept clinical trials applications under this mechanism?</th>
<th>Yes</th>
<th>No</th>
</tr>
</thead>
<tbody>
<tr>
<td>Clinical Trials SBIR/STTR Omnibus/Parent Funding Opportunity Announcement/s</td>
<td>X</td>
<td></td>
</tr>
<tr>
<td>Clinical Trials SBIR/STTR IC/Office/Agency - Specific Funding Opportunity Announcement/s</td>
<td>X</td>
<td>RFAs: <a href="https://sbir.nih.gov/funding/individual-announcements">https://sbir.nih.gov/funding/individual-announcements</a></td>
</tr>
<tr>
<td>Clinical Trials NON-SBIR/STTR Funding Opportunity Announcement/s where Small Businesses are eligible to apply</td>
<td>X</td>
<td>Check the NICHD website for active FOAs: <a href="https://www.nichd.nih.gov/grants-funding/opportunities-mechanisms/active-foa/Pages/default.aspx">https://www.nichd.nih.gov/grants-funding/opportunities-mechanisms/active-foa/Pages/default.aspx</a></td>
</tr>
</tbody>
</table>
**NICHD Non-Clinical Trials Topics:**

The major NICHD research priority areas for each Branch are listed below. Investigator initiated applications that have commercial potential that fall outside these topic areas, but fall within the research mission of the NICHD are also considered through this Omnibus solicitation.

A. **Child Development and Behavior Branch**

The CDBB encourages innovative developmentally-sensitive theoretically-grounded evidence-based small business initiatives that develop technology and products addressing the psychological, social and emotional, psychobiological, language, numerical, literacy, cognitive and intellectual development and health of persons from infancy to maturity recognizing the important role others have in contributing to the healthy development of an individual. Products that target at-risk populations and/or exploit new technologies that can expand the effective reach or inclusion of underserved populations in order to encourage healthy development and/or our understanding of the influences of context and/or behavior on development are especially encouraged.

Foci of specific interest include, but are not limited to (please also see the CDBB description):

- **Enhancing Bilingual and Biliteracy Development:** Adaptive learning technology to enhance bilingual and/or biliteracy development in English-language learning children and youth.
- **Measures of Neurodevelopment:** Develop easy to administer neurodevelopmental measures from evidence-based neurocognitive research specific to typically developing infants and toddlers that are shown to correlate with development of brain connectivity and activation.
- **Pediatric Primary Care Behavioral and Health Promotion Interventions:** Facilitate research on the impact of behavioral and health promotion interventions in pediatric primary care and related clinical settings with a focus on end result child and adolescent health outcomes.
- **Psychosocial Adjustment for Individuals in High-Risk Environments:** Develop measures to identify and tools to stimulate developmental factors and mechanisms which promote short- and long-term psychosocial adjustment for children and adolescents exposed to high-risk family and neighborhood environments.
- **School Readiness Skills in Economically and Socially Disadvantaged Children:** Develop mobile device apps and/or hand-held devices that promote the development of school readiness skills and abilities in diverse populations of children as well as measures of home, child care and preschool environments and practices that are related to child learning and development.
- **Reading, Writing, and Mathematics Struggling Learners:** Develop assistive technology to enhance learner outcomes for individuals that struggle to acquire literacy and numeracy skills.
- **Assessment and Enhancement of Reasoning Development:** Develop validated and specific assessment tools that are sensitive to contributing factors (e.g., biobehavioral, environmental, cultural, academic, and cognitive factors) to facilitate research on and the promotion of neurocognitive development of reasoning (e.g., quantitative, deductive, inductive, causal) in typically developing populations.

Dr. Kathy Mann Koepke
Telephone: 301-435-6855; eFax: 301-451-5650
Email: KMK@nih.gov

B. **Contraceptive Reproductive Branch**
The CRB supports research with an emphasis on developing new and improved methods of fertility regulation as well as research on the benefits and risks of contraceptive drugs, devices and surgical procedures.

Areas of interest include, but are not limited to:

- Development of new and improved methods of fertility regulation, for men and women, that are safe, effective, inexpensive, reversible and acceptable
- Synthesis and testing of novel chemical compounds that are potential contraceptives
- Multipurpose technologies designed to prevent sexually transmitted infections, such as HIV, as well as pregnancy

Dr. Steven Kaufman  
Telephone: 301-435-6989; eFax: 301-480-3901  
Email: Kaufmans@exchange.nih.gov

C. Developmental Biology and Structural Variation Branch

The DBSVB supports biomedical research on the cellular, molecular, and genetic aspects of normal and aberrant embryonic and fetal development including early embryogenesis, organogenesis, causative factors in teratogenesis, and topics in regenerative biology.

Areas of interest include but are not limited to:

- Development of new animal model systems to understand developmental mechanisms and causes of structural birth defects
- Innovative technologies for in vivo imaging of developmental processes (cell and tissue dynamics) and gene expression
- Development of antibodies, novel ligands and other probes to facilitate our understanding of normal and abnormal embryonic development in model organisms
- Technologies for quantitative measurement of physical properties of cells/tissues in vivo
- Innovative and high throughput genomic and proteomic techniques
- Technologies to facilitate and advance systems biology approaches to the study of embryonic development and structural birth defects
- Innovative technologies to facilitate and advance high throughput chemical screening (including small molecules) for advancing structural birth defects research
- Software development to facilitate the collection and analyses of data generated using high throughput screening platforms in model organisms
- Technologies/methodologies to generate and software to mine data related to wound healing and regenerative responses across animal species
- Novel reagents for activation and mobilization of endogenous/adult stem cells to promote in vivo tissue regeneration
- High throughput screening technologies of small molecules in human Embryonic Stem (ES) Cells or Induced Pluripotent Stem Cells (iPSCs) and disease specific iPSCs for targeted modification of signaling pathways affected in structural birth defects
- Technologies for iPSC-based regenerative medicine in the context of structural birth defect
- Innovative technologies for studying metabolomics in developing vertebrate embryos

Dr. Mahua Mukhopadhyay  
Telephone: 301-435-6886  
Email: mukhopam@mail.nih.gov

D. Fertility and Infertility Branch
The FIB supports research on the reproductive processes of men and women and of animals with similar reproductive systems related to developing safer and more effective means of regulating, preserving or achieving fertility.

Particular areas of programmatic interest relative to small business initiatives include, but are not limited to:

- Development of reagents to facilitate study of reproductive and developmental processes
- Development of improved methods of growing and differentiating stem cell lines in vitro, including feeder cell-free approaches
- Development of novel assays, kits, and devices to monitor fertility and treat infertility and gynecological disorders
- Use of genomics and proteomics to develop novel diagnostics and treatments for reproductive diseases and disorders
- Development of high resolution technologies to provide invasive or noninvasive assessments of reproductive and developmental competence
- Development of experimental animal models that would be useful for studying the physiology and pathophysiology of reproductive processes
- Development of techniques and identification of novel biomarkers to produce, identify, and use healthy gametes
- Development of improved and novel technologies for the preservation of human gametes
- Development of improved technologies for preimplantation genetic diagnosis
- Development of in vitro model systems that are useful for understanding human embryo implantation.
- Development of improved technologies for the reprogramming of cells, including embryonic stem cells or adult cells, into eggs and sperm
- Development of innovative technologies for point-of-care testing for infertility and reproductive diseases and disorders
- Development of new methods to alter the function of trophoblast cells so that the embryo/fetus can be protected from ill effects of maternal viral infection

Dr. Ravi Ravindranath
Telephone: 301-435-6889, Fax: 301-480-2389
Email: ravindrn@mail.nih.gov

E. Gynecologic Health and Disease Branch

The GHDB supports biomedical research related to gynecologic health throughout the reproductive lifespan, beginning at puberty and extending through early menopause.

Areas of interest include, but are not limited to:

- Development of new diagnostic approaches and treatments for female pelvic floor disorders, including drugs, and devices used for treatment of pelvic organ prolapse, urinary incontinence, fecal incontinence and other female pelvic floor disorders
- Development of new diagnostic methods and novel surgical and non-surgical treatments for uterine fibroids, endometriosis, adenomyosis, and benign ovarian cysts
- Production of marketable novel or improved methods, devices, and technologies for the diagnosis, monitoring and therapy of gynecologic pain disorders including chronic pelvic pain, vulvodynia, and dysmenorrhea
- Generation of new approaches for the diagnosis, monitoring and treatment of abnormal menstrual cyclicity

Dr. Lisa Halvorson
Phone: 301-480-1646; eFax: 301-480-3886
F. Intellectual and Developmental Disease Branch

The IDDB sponsors research aimed at preventing, diagnosing, and ameliorating intellectual and developmental disabilities (IDD). Emphasis is on studies related IDD, including common and rare neuromuscular and neurodevelopmental disorders, such as Down, Fragile X, and Rett syndromes, mitochondrial conditions, inborn errors of metabolism, autism spectrum disorders, and others.

Areas of interest include, but are not limited to:

- Innovative tools, including molecular, imaging, statistical or behavioral tools, to characterize the etiology and pathophysiology of abnormal nervous system development.
- Methods and devices to delineate genetic, genomic, and epigenetic causes of IDD and develop gene-based treatments.
- Methods or devices designed to screen for and diagnose IDD and other conditions, particularly those identified or identifiable by newborn screening.
- Assessment tools for use in the clinic or community settings to enable the accurate measurement of change in response to interventions.
- Development of early interventions leading toward the prevention, diagnosis and treatment of IDD.
- Methods or devices to develop or apply smart technologies to enhance screening, diagnosis, prevention, treatment or management of IDD conditions.
- Development of assessment measures or treatments for co-morbid symptoms in IDD that can include: disordered sleep, self-injurious behaviors, obesity, gastrointestinal dysfunction, seizures/epilepsy, ADHD and other mental health disorders.

Dr. Danuta Krotoski
Telephone: 301-402-7015, Fax: 301-496-3791
Email: krostoskd@mail.nih.gov

G. Maternal and Pediatric Infection Disease Branch

The MPIDB supports domestic and international research on human immunodeficiency virus (HIV)/acquired immune deficiency syndrome (AIDS) and related infections (such as tuberculosis, hepatitis and malaria) in women of child bearing age, pregnant women, mothers, fetuses, infants, children and adolescents. Specific areas of interest include but are not limited to epidemiology, clinical manifestations, pathogenesis, transmission, treatment and prevention (including vaccines and other biomedical modalities) of HIV infection, Zika infection and other infectious diseases in children, adolescents and pregnant women, including prevention of mother to child transmission of HIV and other congenital infections, and HIV-related and other infectious-disease related complications in these populations.

Additional areas of interest include:

- New technologies relevant to resource-limited countries for:
  - Screening, diagnosis, and management of infectious diseases in pregnant women, infants and children, including but not limited to HIV (e.g. congenital CMV, Zika virus)
  - Rapid assays to monitor disease activity and response to therapy for as well as immune response to vaccinations against relevant infections in infants and children (e.g. malaria, tuberculosis), which can be used at the individual level and/or as part of public health campaigns (e.g. eradication of outbreaks and prevention of spread)
Diagnosis and treatment of HIV-related co-morbidities (e.g., diagnosis of tuberculosis in children)
Diagnosis and treatment of Zika-related outcomes in mothers and infants
Simple and less technologically demanding point of care assays to monitor CD4 cell percentage/count, HIV viral load, or other surrogate markers of HIV disease progression in children
Interventions designed to promote or optimize medication adherence

- Child-friendly formulations (preferably not liquid preparations) -of drugs- used to treat or prevent HIV infection, complications of HIV infection, and/or other high-priority infections such as tuberculosis, hepatitis, and malaria relevant to children, particularly in resource-limited countries; Fixed-dose drug formulations and innovative methodologies for development of solid heat stable formulations capable of being administered to young children (e.g., sustained release beads, etc.) and/or improve pill or volume burden
- Innovative long-lasting drug formulations for antiretroviral and other anti-infective drugs that would allow less frequent drug administration (e.g., once daily, weekly or monthly)
- Simple, standardized, validated tools to evaluate neurodevelopmental outcomes in children in resource-limited settings
- Biomedical modalities, including vaccines, to prevent acquisition of HIV and other infectious diseases in children, adolescents and women.
- Topical microbicide agents, alone or as part of multipurpose prevention technologies (MPTs), to prevent sexual acquisition of HIV and other sexually transmitted infections in adolescents, adult women, and pregnant or postpartum women.
- New, non-invasive technologies to evaluate complications of antiretroviral drugs (e.g., mitochondrial toxicity, bone toxicity) in HIV-infected infants, children, adolescents, pregnant women, and their fetuses.
- New technologies for measuring the HIV latent reservoir, including high-throughput, reliable and sensitive assays.

Dr. Sonia Lee
Telephone: 301-594-4783
Email: leesonia@mail.nih.gov

H. Obstetric and Pediatric Pharmacology and Therapeutics Branch

The OPPTB promotes research to improve the safety and efficacy of pharmaceuticals and to ensure centralization and coordination of research, clinical trials, and drug development activities for obstetric and pediatric populations. This includes developing and supporting a comprehensive national effort to increase the knowledge base for understanding how to appropriately treat disease during pregnancy, infancy, and childhood using pharmaceuticals that are appropriately tested within their target populations.

Applications to advance the study of obstetric and pediatric pharmacology include:

- Research and tools to better characterize the impact of physiological and developmental changes on pharmacokinetics, pharmacodynamics, drug disposition and response
- Advancements in pharmacokinetic/pharmacodynamic modeling which improve therapy therapeutic approaches during pregnancy, among premature infants, children, and adolescents
- Research on devices to monitor the state of various organ systems during therapy in pregnancy or infancy
- Development of novel technologies for blood sampling for limited blood volumes
- Development of novel models for drug assay development that can be utilized across therapeutic areas
• Development of non-invasive devices for evaluating adherence to chronic therapy in life-threatening conditions (e.g., HIV, diabetes, asthma, and liver and kidney transplantation)
• Development of novel approaches for oral mucosal, transdermal, nasal, ocular and pulmonary drug delivery systems and device technologies
• Use of a materials science approach to overcome solubility limitations of pediatric drugs, increase bioavailability, decrease excipient exposure, and provide effective taste masking.
• Development of nanosized formulations to optimize efficacy and minimize toxicity of pediatric drugs
• Identification of targets for pregnancy associated/induced diseases that can lead to the development of new targeted therapeutics for diseases like pre-eclampsia, gestational diabetes, and preterm labor

Dr. Katerina Tsilou  
Telephone: 301-496-6287; eFax: 301-480-3876  
E-mail: tsiloue@mail.nih.gov

I. Pediatric Growth and Nutrition Branch

The PGNB supports research designed to support short and long-term health so that children can achieve their full potential through an expanded understanding of those factors that influence metabolism, growth (body composition and linear growth) and neurodevelopment. An additional focus is on those biological (e.g., genetic, nutritional, endocrinological) factors that contribute the early life origins of non-communicable disease (e.g., obesity, diabetes, cardiovascular disease, osteoporosis). The PGNB encourages research that focuses on detecting the biological antecedents of these conditions during pregnancy, infancy and childhood.

Areas of interest include, but are not limited to:

New research tools, improved measurement methods, and technologies that enhance our understanding of:

• Growth:
  o Physical growth, body composition, bone health, nutrition, and obesity
  o Determinants of normal bone mineral accretion and peak bone mass. Interactions of muscle and bone during infancy and childhood
  o Neuroendocrinology of puberty, linear growth, body composition
  o Mechanisms of hormone action during linear growth, pubertal maturation, and other aspects of physical development

• Biological antecedents of childhood obesity and its short and long-term consequences:
  o Genetic and molecular mechanisms of obesity, psychosocial risks of obesity, and therapeutic interventions for obesity in children and adolescents
  o Impact of early life exposures including infant feeding practices on short and long-term health and development

• Biology of nutrition as it pertains to health and development (physical and neurological function) during pregnancy, infancy and childhood including discovery, development and deployment of biomarkers for early detection of:
  o Mal-(over-/under) nutrition; including biomarkers of exposure, status, function and effect (i.e., impact on early life development including neurodevelopment)
  o Enhanced understanding of the role of human milk in child health and development.
    o Maternal nutrition (pre-pregnancy, pregnancy, and lactation)
  o Novel approaches to enhanced infant feeding practices in term and pre-term infants

• Developmental origins of adult disease including:
  o AscertAIN biomarkers early in life that predict the onset of chronic diseases such as diabetes, osteoporosis, and the metabolic syndrome later in life. The PGN Branch
emphasizes the life course model to develop primary preventive approaches to these chronic diseases.
  
  o Develop platforms for implementation of biomarkers of disease status, nutritional status, and biological function from infancy through adolescence

Dr. Daniel J. Raiten
Telephone: 301-435-7568; Fax: 301-480-9791
Email: raitend@mail.nih.gov

J. Pediatric Trauma and Critical Illness Branch

The PTCIB supports research and research training in pediatric trauma, injury prevention, and critical illness across the continuum of care. These efforts include:

Research on the prevention, treatment, and management of physical and psychological trauma and the surgical, medical, psychosocial, and systems interventions needed to improve outcomes for critically ill and injured children and youth.

Studies of the continuum of psychosocial, behavioral, biological, and physiological influences that affect child health outcomes in trauma, injury, and critical care.

Basic, clinical, and translational studies that explore short- and long-term consequences of such traumatic experiences as exposure to natural or man-made disasters, all forms of violence against children, as well as experiences of bereavement, grief and loss.

Research linking the science of pediatric emergency and critical care medicine to the epidemiology, prevention, and treatment of trauma and injury in infants, children and adolescents.

Applications of interest include, but are not limited to:

- Research and development of pediatric-specific technologies, devices and equipment used by emergency and trauma care as well as pediatric critical care personnel.
- Research and development of novel strategies or approaches in caring for injured children prior to and during transport to treatment settings.
- Development of tools and technologies for screening and determination of the nature and extent of injuries related to forms of child maltreatment.
- Research and development of devices and innovative therapeutic technologies for management of medical conditions and related problems stemming from critical illness and serious or life-threatening injuries.
- Development and testing of preventive intervention tools, materials, and technologies designed to improve clinical practice, parenting and social system support for injured or traumatized children.
- Development and testing of preventive intervention tools, materials, and technologies designed to reduce pediatric trauma exposure and the number and severity of pediatric injuries and deaths.
- Research and development of effective tools and technologies to improve the environment of pediatric intensive care including resources to promote patient safety and to enhance clinical education and training of critical care personnel.
- Development of tools and technologies that support the diagnoses and treatment of critical illness in children, including nosocomial infections and iatrogenic injury.

Dr. Valerie Maholmes
Telephone: 301-496-1514; eFax: 301-480-3887
Email: maholmes@mail.nih.gov
K. **Population Dynamics Branch**

The PDB supports research and research training in demography, reproductive health, and population health. In demography, the Branch supports research on the scientific study of human populations, including fertility, mortality and morbidity, migration, population distribution, nuptiality, family demography, population growth and decline, and the causes and consequences of demographic change. In reproductive health, the Branch supports behavioral and social science research on sexually transmitted diseases, HIV/AIDS, family planning, and infertility. In population health, the Branch supports data collection and research on human health, productivity, behavior, and development at the population level, using such methods as inferential statistics, natural experiments, policy experiments, statistical modeling, and gene/environment interaction studies.

Applications are encouraged, but are not limited to these areas:

- Technological innovations or inventions to improve collection of biomarker data in large population-representative surveys
- Hardware or software to improve collection of accurate cause of death information or health diagnosis in large population-representative surveys or in administrative data sets
- Methods for integrating geographical information systems (GIS), spatial network analysis, and/or simulation methods for demographic research
- Methods for improving collection, documentation, archiving, and dissemination of population representative data sets, especially data sets that are complex, multilevel or multimodal
- Methods for protecting and assuring confidentiality for human subjects when collecting, archiving, or disseminating population-representative data sets, especially data sets that are longitudinal or that include both spatial and individual-level data
- Methods for reducing cost of collecting and disseminating large-population-representative data sets
- Development of effective tools for prevention research and intervention programs related to STD/HIV, pregnancy, contraceptive use, child health, at risk youth, and other health-related topics, and to the dissemination of such tools
- Innovative approaches to teaching population studies and other behavioral and social sciences at the undergraduate and graduate level
  Innovative approaches for research design, data collection techniques, measurement, and data analysis techniques in the social and behavioral sciences, with particular attention to methodology and measurement issues in studying diverse populations, sensitive behaviors, confidential behaviors; in issues related to the protection of research subjects; and in issues related to the archiving and disseminating complex datasets

Dr. Juanita J. Chinn  
Telephone: 301-827-4901  
Email: juanita.chinn@nih.gov

L. **Pregnancy and Perinatology Branch**

The PPB supports research in the following areas: the physiology of pregnancy and labor; high-risk pregnancies, including those with hypertensive disorders, diabetes or seizure disorders; fetal pathophysiology; premature labor and birth; diagnostic, monitoring, and therapeutic devices and instruments for newborn infants in the nursery and in Neonatal ICU setting; improving the existing products or developing new products that would improve the routine and extended care of the newborn infants; products and agents related to breastfeeding; hospital supplies specifically related to use in the care of newborn infants; nanotechnology and its application for the care of newborn infants; instruments and devices for assessing and monitoring the nursery environment
noise, lighting, and odor); disorders of the newborn; sudden infant death syndrome; and biological and behavioral antecedents of low birth weight.

The following topic areas are of high priority:

- Neonatal/Perinatal:
  - Non-invasive (or minimally invasive) methods to assess fetal well-being; spontaneous preterm birth; pre eclampsia, and stillbirth.
  - Methods to longitudinally assess the structure and functions of human placenta.
  - Lab-on-a-chip, non-, or minimally-invasive approaches for assessing: metabolic profile (e.g., glucose and lactate/pyruvate); ketone body bilirubin (unconjugated, free, indirect, and total); major chemicals (Na+, Ca+, Cl-, K+ etc.); and serum levels of administered medications; fetal and neonatal kidney functions.
  - Rapid methods for diagnosis of bacterial infections and inflammation; antibiotic sensitivity.
  - Improved syringes, needles and injection set ups to help administer small doses of medications over prolonged periods (example: insulin for treating hyperglycemia).

Dr. Tonse Raju
Telephone: 301-496-5575; eFax: 301-480-3884
Email: rajut@mail.nih.gov

M. National Center for Medical Rehabilitation Research

This Center supports innovative research on the restoration, replacement, enhancement or adaptation of function for people with chronic physical disabilities. This includes rehabilitative approaches across etiologies and the lifespan, as well as the environmental and policy factors that promote full participation. We encourage studies that integrate biomedical, engineering and/or psychosocial approaches to develop practical and creative solutions to the daily functioning of people with disabilities and their families. The mission of the NCMRR is to increase the effectiveness of medical rehabilitation practices through research. Information about specific program areas within NCMRR can be found [here](#).

Examples may include but are not limited to:

- **Adaptation and Plasticity:** Develop non-invasive and surrogate measures of plasticity that would be appropriate for use in a clinical setting to target rehabilitation therapies and monitor treatment effectiveness (e.g., biomarkers, imaging).
- **Novel Technology:** Orthotics, prosthetics, and robotics devices and interfaces; Assistive technologies; Invasive and non-invasive biological sensors, prosthetic systems or implants to improve function; New control methods and improved sensory feedback; Strategies for controlling and adapting to the environment; Advanced wheelchair designs and enhancements and other mobility devices; Biomaterials and tissue interfaces, nanotechnology, bionics.
- **Rehabilitation Interventions:** Development and use of robotics; Gaming applications; Virtual and Augmented Reality; Simulations; M-health and other approaches to promote participation, understand and support healthy behaviors, reduce health disparities and enhance clinical compliance, especially in children with physical disabilities.
- **Chronic Symptom Management:** Methods to increase screening for chronic conditions or preventable secondary conditions in individuals with physical disability; Prevention and treatment strategies for mitigating symptoms associated with multiple chronic conditions in individuals with physical impairments, including persistent pain, symptoms of obesity, diabetes, cardiovascular deconditioning, fatigue, symptoms of overuse injuries, pressure ulcers, sleep disturbances, and depressive symptoms; Improving muscle capacity in chronic physical disability to include therapeutic or adaptive exercise and muscle...
stimulation; muscle-disuse syndromes and contractures; Rehabilitation interventions for improvement of physical disability and comorbid cognitive, sensory, or somatic consequences of impairment, disease or injury; Autonomic function in the context of injury or specific conditions.

- **Rehabilitation in the Community**: Strategies to build or modify community and/or environmental resources that provide effective rehabilitation and health promotion services within the individual’s own community. Development of engineering, crowdsourcing, and social science approaches to promote, monitor, and sustain outcomes in real world settings.

Investigators proposing budgets exceeding the guidelines are encouraged to contact program staff six weeks prior to submitting the application.

For additional information on research topics, contact:

Dr. Louis A. Quatrano  
Telephone: 301-402-4221; eFax: 301-480-3854  
Email: quatranol@mail.nih.gov

**NICHD Clinical Trials Topics:**

The major NICHD research priority areas for each Branch are listed below. Investigator initiated applications that have commercial potential that fall outside these topic areas, but fall within the research mission of the NICHD are also considered through this Omnibus solicitation.

**A. Child Development and Behavior Branch**

The CDBB encourages innovative developmentally-sensitive theoretically-grounded evidence-based small business initiatives that develop technology and products addressing the psychological, social and emotional, psychobiological, language, numerical, literacy, cognitive and intellectual development and health of persons from infancy to maturity recognizing the important role others have in contributing to the healthy development of an individual. Products that target at-risk populations and/or exploit new technologies that can expand the effective reach or inclusion of underserved populations to encourage healthy development and/or our understanding of the influences of context and/or behavior on development are especially encouraged.

Foci of specific interest include, but are not limited to (please also see the CDBB description):

- **Enhancing Bilingual and Biliteracy Development**: Adaptive learning technology to enhance bilingual and/or biliteracy development in English-language learning children and youth.
- **Measures of Neurodevelopment**: Develop easy to administer neurodevelopmental measures from evidence-based neurocognitive research specific to typically developing infants and toddlers that are shown to correlate with development of brain connectivity and activation.
- **Pediatric Primary Care Behavioral and Health Promotion Interventions**: Facilitate research on the impact of behavioral and health promotion interventions in pediatric primary care and related clinical settings with a focus on end result child and adolescent health outcomes.
- **Psychosocial Adjustment for Individuals in High-Risk Environments**: Develop measures to identify and tools to stimulate developmental factors and mechanisms which promote short- and long-term psychosocial adjustment for children and adolescents exposed to high-risk family and neighborhood environments.
• **School Readiness Skills in Economically and Socially Disadvantaged Children:** Develop mobile device apps and/or hand-held devices that promote the development of school readiness skills and abilities in diverse populations of children as well as measures of home, child care and preschool environments and practices that are related to child learning and development.

• **Reading, Writing, and Mathematics Struggling Learners:** Develop assistive technology to enhance learner outcomes for individuals that struggle to acquire literacy and numeracy skills.

• **Assessment and Enhancement of Reasoning Development:** Develop validated and specific assessment tools that are sensitive to contributing factors (e.g., biobehavioral, environmental, cultural, academic, and cognitive factors) to facilitate research on and the promotion of neurocognitive development of reasoning (e.g., quantitative, deductive, inductive, causal) in typically developing populations.

Dr. Kathy Mann Koepke
Telephone: 301-435-6855; eFax: 301-451-5650
Email: KMK@nih.gov

B. **Contraceptive Reproductive Branch**

The CRB supports research with an emphasis on developing new and improved methods of fertility regulation as well as research on the benefits and risks of contraceptive drugs, devices and surgical procedures.

Areas of interest include, but are not limited to:

• Development of new and improved methods of fertility regulation, for men and women, that are safe, effective, inexpensive, reversible and acceptable
• Synthesis and testing of novel chemical compounds that are potential contraceptives
• Multipurpose technologies designed to prevent sexually transmitted infections, such as HIV, as well as pregnancy

Dr. Steven Kaufman
Telephone: 301-435-6989; eFax: 301-480-3901
Email: Kaufmans@exchange.nih.gov

C. **Developmental Biology and Structural Variation Branch**

The DBSVB supports biomedical research on the cellular, molecular, and genetic aspects of normal and aberrant embryonic and fetal development including early embryogenesis, organogenesis, causative factors in teratogenesis, and topics in regenerative biology.

Areas of interest include but are not limited to:

• Diagnostics and therapeutics aimed at ameliorating structural birth defects

Dr. Mahua Mukhopadhyay
Telephone: 301-435-6886
Email: mukhopam@mail.nih.gov

D. **Fertility and Infertility Branch**

The FIB supports research on the reproductive processes of men and women and of animals with similar reproductive systems related to developing safer and more effective means of regulating, preserving or achieving fertility.
Particular areas of programmatic interest relative to small business initiatives include, but are not limited to:

- Development of reagents to facilitate study of reproductive and developmental processes
- Development of improved methods of growing and differentiating stem cell lines in vitro, including feeder cell-free approaches
- Development of novel assays, kits, and devices to monitor fertility and treat infertility and gynecological disorders
- Use of genomics and proteomics to develop novel diagnostics and treatments for reproductive diseases and disorders
- Development of high resolution technologies to provide invasive or noninvasive assessments of reproductive and developmental competence
- Development of experimental animal models that would be useful for studying the physiology and pathophysiology of reproductive processes
- Development of techniques and identification of novel biomarkers to produce, identify, and use healthy gametes
- Development of improved and novel technologies for the preservation of human gametes
- Development of improved technologies for preimplantation genetic diagnosis
- Development of in vitro model systems that are useful for understanding human embryo implantation.
- Development of improved technologies for the reprogramming of cells, including embryonic stem cells or adult cells, into eggs and sperm
- Development of innovative technologies for point-of-care testing for infertility and reproductive diseases and disorders
- Development of new methods to alter the function of trophoblast cells so that the embryo/fetus can be protected from ill effects of maternal viral infection

Dr. Ravi Ravindranath  
Telephone: 301-435-6889, Fax: 301-480-2389  
Email: ravindrn@mail.nih.gov

E. Gynecologic Health and Disease Branch

The GHDB supports biomedical research related to gynecologic health throughout the reproductive lifespan, beginning at puberty and extending through early menopause.

Areas of interest include, but are not limited to:

- Development of new diagnostic approaches and treatments for female pelvic floor disorders, including drugs, and devices used for treatment of pelvic organ prolapse, urinary incontinence, fecal incontinence and other female pelvic floor disorders
- Development of new diagnostic methods and novel surgical and non-surgical treatments for uterine fibroids, endometriosis, adenomyosis, and benign ovarian cysts
- Production of marketable novel or improved methods, devices, and technologies for the diagnosis, monitoring and therapy of gynecologic pain disorders including chronic pelvic pain, vulvodynia, and dysmenorrhea
- Generation of new approaches for the diagnosis, monitoring and treatment of abnormal menstrual cyclicity

Dr. Lisa Halvorson  
Phone: 301-480-1646; eFax: 301-480-3886  
Email: lisa.halvorson@nih.gov

F. Intellectual and Developmental Disease Branch
The IDDB sponsors research aimed at preventing, diagnosing, and ameliorating intellectual and developmental disabilities (IDD). Emphasis is on studies related IDD, including common and rare neuromuscular and neurodevelopmental disorders, such as Down, Fragile X, and Rett syndromes, mitochondrial conditions, inborn errors of metabolism, autism spectrum disorders, and others.

Areas of interest include, but are not limited to:

- Innovative tools, including molecular, imaging, statistical or behavioral tools, to characterize the etiology and pathophysiology of abnormal nervous system development.
- Methods and devices to delineate genetic, genomic, and epigenetic causes of IDD and develop gene-based treatments.
- Methods or devices designed to screen for and diagnose IDD and other conditions, particularly those identified or identifiable by newborn screening.
- Assessment tools for use in the clinic or community settings to enable the accurate measurement of change in response to interventions.
- Development of early interventions leading toward the prevention, diagnosis and treatment of IDD.
- Methods or devices to develop or apply smart technologies to enhance screening, diagnosis, prevention, treatment or management of IDD conditions.
  - Development of assessment measures or treatments for co-morbid symptoms in IDD that can include: disordered sleep, self-injurious behaviors, obesity, gastrointestinal dysfunction, seizures/epilepsy, ADHD and other mental health disorders.

Dr. Danuta Krotoski
Telephone: 301-402-7015, Fax: 301-496-3791
Email: krostoskd@mail.nih.gov

G. Maternal and Pediatric Infection Disease Branch

The MPIDB supports domestic and international research on human immunodeficiency virus (HIV)/acquired immune deficiency syndrome (AIDS) and related infections (such as tuberculosis, hepatitis and malaria) in women of child bearing age, pregnant women, mothers, fetuses, infants, children and adolescents. Specific areas of interest include but are not limited to epidemiology, clinical manifestations, pathogenesis, transmission, treatment and prevention (including vaccines and other biomedical modalities) of HIV infection, Zika infection and other infectious diseases in children, adolescents and pregnant women, including prevention of mother to child transmission of HIV and other congenital infections, and HIV-related and other infectious-disease related complications in these populations.

Additional areas of interest include:

- New technologies relevant to resource-limited countries for:
  - Screening, diagnosis, and management of infectious diseases in pregnant women, infants and children, including but not limited to HIV (e.g. congenital CMV, Zika virus)
  - Rapid assays to monitor disease activity and response to therapy for as well as immune response to vaccinations against relevant infections in infants and children (e.g. malaria, tuberculosis), which can be used at the individual level and/or as part of public health campaigns (e.g. eradication of outbreaks and prevention of spread)
  - Diagnosis and treatment of HIV-related co-morbidities (e.g., diagnosis of tuberculosis in children)
  - Diagnosis and treatment of Zika-related outcomes in mothers and infants
Simple and less technologically demanding point of care assays to monitor CD4 cell percentage/count, HIV viral load, or other surrogate markers of HIV disease progression in children

- Interventions designed to promote or optimize medication adherence
  - Child-friendly formulations (preferably not liquid preparations) -of drugs- used to treat or prevent HIV infection, complications of HIV infection, and/or other high-priority infections such as tuberculosis, hepatitis, and malaria relevant to children, particularly in resource-limited countries; Fixed-dose drug formulations and innovative methodologies for development of solid heat stable formulations capable of being administered to young children (e.g., sustained release beads, etc.) and/or improve pill or volume burden
  - Innovative long-lasting drug formulations for antiretroviral and other anti-infective drugs that would allow less frequent drug administration (e.g., once daily, weekly or monthly)
  - Simple, standardized, validated tools to evaluate neurodevelopmental outcomes in children in resource-limited settings
  - Biomedical modalities, including vaccines, to prevent acquisition of HIV and other infectious diseases in children, adolescents and women.
  - Topical microbicide agents, alone or as part of multipurpose prevention technologies (MPTs), to prevent sexual acquisition of HIV and other sexually transmitted infections in adolescents, adult women, and pregnant or postpartum women.
  - New, non-invasive technologies to evaluate complications of antiretroviral drugs (e.g., mitochondrial toxicity, bone toxicity) in HIV-infected infants, children, adolescents, pregnant women, and their fetuses.
  - New technologies for measuring the HIV latent reservoir, including high-throughput, reliable and sensitive assays.

Dr. Sonia Lee
Telephone: 301-594-4783
Email: leesonia@mail.nih.gov

H. Obstetric and Pediatric Pharmacology and Therapeutics Branch

The OPPTB promotes research to improve the safety and efficacy of pharmaceuticals and to ensure centralization and coordination of research, clinical trials, and drug development activities for obstetric and pediatric populations. This includes developing and supporting a comprehensive national effort to increase the knowledge base for understanding how to appropriately treat disease during pregnancy, infancy, and childhood using pharmaceuticals that are appropriately tested within their target populations.

Applications to advance the study of obstetric and pediatric pharmacology include:

- Research and tools to better characterize the impact of physiological and developmental changes on pharmacokinetics, pharmacodynamics, drug disposition and response
- Advancements in pharmacokinetic/pharmacodynamic modeling which improve therapy therapeutic approaches during pregnancy, among premature infants, children, and adolescents
- Research on devices to monitor the state of various organ systems during therapy in pregnancy or infancy
- Development of novel technologies for blood sampling for limited blood volumes
- Development of novel models for drug assay development that can be utilized across therapeutic areas
- Development of non-invasive devices for evaluating adherence to chronic therapy in life-threatening conditions (e.g., HIV, diabetes, asthma, and liver and kidney transplantation)
- Development of novel approaches for oral mucosal, transdermal, nasal, ocular and pulmonary drug delivery systems and device technologies
• Use of a materials science approach to overcome solubility limitations of pediatric drugs, increase bioavailability, decrease excipient exposure, and provide effective taste masking.
• Development of nanosized formulations to optimize efficacy and minimize toxicity of pediatric drugs
• Identification of targets for pregnancy associated/induced diseases that can lead to the development of new targeted therapeutics for diseases like pre-eclampsia, gestational diabetes, and preterm labor

Dr. Katerina Tsilou
Telephone: 301-496-6287; eFax: 301-480-3876
E-mail: tsiloue@mail.nih.gov

I. Pediatric Growth and Nutrition Branch

The PGNB supports research designed to support short and long-term health so that children can achieve their full potential through an expanded understanding of those factors that influence metabolism, growth (body composition and linear growth) and neurodevelopment. An additional focus is on those biological (e.g., genetic, nutritional, endocrinological) factors that contribute the early life origins of non-communicable disease (e.g., obesity, diabetes, cardiovascular disease, osteoporosis). The PGNB encourages research that focuses on detecting the biological antecedents of these conditions during pregnancy, infancy and childhood.

Areas of interest include, but are not limited to:

New research tools, improved measurement methods, and technologies that enhance our understanding of:

• Growth:
  o Physical growth, body composition, bone health, nutrition, and obesity
  o Determinants of normal bone mineral accretion and peak bone mass. Interactions of muscle and bone during infancy and childhood
  o Neuroendocrinology of puberty, linear growth, body composition
  o Mechanisms of hormone action during linear growth, pubertal maturation, and other aspects of physical development

• Biological antecedents of childhood obesity and its short and long-term consequences:
  o Genetic and molecular mechanisms of obesity, psychosocial risks of obesity, and therapeutic interventions for obesity in children and adolescents
  o Impact of early life exposures including infant feeding practices on short and long-term health and development

• New approaches to understanding the biology of nutrition as it pertains to health and development (physical and neurological function) during pregnancy, infancy and childhood including discovery, development and deployment of biomarkers for early detection of:
  o Mal-(over/-under) nutrition; including biomarkers of exposure, status, function and effect (i.e., impact on early life development including neurodevelopment)
  o Enhanced understanding of the role of human milk in child health and development.
  o Maternal nutrition (pre-pregnancy, pregnancy, and lactation)
  o Novel approaches to enhanced infant feeding practices in term and pre-term infants

• Developmental origins of adult disease including:
  o Ascertain biomarkers early in life that predict the onset of chronic diseases such as diabetes, osteoporosis, and the metabolic syndrome later in life. The PGN Branch emphasizes the life course model to develop primary preventive approaches to these chronic diseases.
Develop platforms for implementation of biomarkers of disease status, nutritional status, and biological function from infancy through adolescence

Dr. Daniel J. Raiten  
Telephone: 301-435-7568; Fax: 301-480-9791  
Email: raitend@mail.nih.gov

J. Pediatric Trauma and Critical Illness Branch

The PTCIB supports research and research training in pediatric trauma, injury prevention, and critical illness across the continuum of care. These efforts include:

Research on the prevention, treatment, and management of physical and psychological trauma and the surgical, medical, psychosocial, and systems interventions needed to improve outcomes for critically ill and injured children and youth.

Studies of the continuum of psychosocial, behavioral, biological, and physiological influences that affect child health outcomes in trauma, injury, and critical care.

Basic, clinical, and translational studies that explore short- and long-term consequences of such traumatic experiences as exposure to natural or man-made disasters, all forms of violence against children, as well as experiences of bereavement, grief and loss.

Research linking the science of pediatric emergency and critical care medicine to the epidemiology, prevention, and treatment of trauma and injury in infants, children and adolescents.

Applications of interest include, but are not limited to:

- Research and development of pediatric-specific technologies, devices and equipment used by emergency and trauma care as well as pediatric critical care personnel.
- Research and development of novel strategies or approaches in caring for injured children prior to and during transport to treatment settings.
- Development of tools and technologies for screening and determination of the nature and extent of injuries related to forms of child maltreatment.
- Research and development of devices and innovative therapeutic technologies for management of medical conditions and related problems stemming from critical illness and serious or life-threatening injuries.
- Development and testing of preventive intervention tools, materials, and technologies designed to improve clinical practice, parenting and social system support for injured or traumatized children.
- Development and testing of preventive intervention tools, materials, and technologies designed to reduce pediatric trauma exposure and the number and severity of pediatric injuries and deaths.
- Research and development of effective tools and technologies to improve the environment of pediatric intensive care including resources to promote patient safety and to enhance clinical education and training of critical care personnel.
- Development of tools and technologies that support the diagnoses and treatment of critical illness in children, including nosocomial infections and iatrogenic injury.

Dr. Valerie Maholmes  
Telephone: 301-496-1514; eFax: 301-480-3887  
Email: maholmes@mail.nih.gov

K. Population Dynamics Branch
The **PDB** supports research and research training in demography, reproductive health, and population health. In **demography**, the Branch supports research on the scientific study of human populations, including fertility, mortality and morbidity, migration, population distribution, nuptiality, family demography, population growth and decline, and the causes and consequences of demographic change. In **reproductive health**, the Branch supports behavioral and social science research on sexually transmitted diseases, HIV/AIDS, family planning, and infertility. In **population health**, the Branch supports data collection and research on human health, productivity, behavior, and development at the population level, using such methods as inferential statistics, natural experiments, policy experiments, statistical modeling, and gene/environment interaction studies.

Applications are encouraged, but are not limited to these areas:

- Technological innovations or inventions to improve collection of biomarker data in large population-representative surveys
- Hardware or software to improve collection of accurate cause of death information or health diagnosis in large population-representative surveys or in administrative data sets
- Methods for integrating geographical information systems (GIS), spatial network analysis, and/or simulation methods for demographic research
- Methods for improving collection, documentation, archiving, and dissemination of population representative data sets, especially data sets that are complex, multilevel or multimodal
- Methods for protecting and assuring confidentiality for human subjects when collecting, archiving, or disseminating population-representative data sets, especially data sets that are longitudinal or that include both spatial and individual-level data
- Methods for reducing cost of collecting and disseminating large-population-representative data sets
- Development of effective tools for prevention research and intervention programs related to STD/HIV, pregnancy, contraceptive use, child health, at risk youth, and other health-related topics, and to the dissemination of such tools
- Innovative approaches to teaching population studies and other behavioral and social sciences at the undergraduate and graduate level
- Innovative approaches for research design, data collection techniques, measurement, and data analysis techniques in the social and behavioral sciences, with particular attention to methodology and measurement issues in studying diverse populations, sensitive behaviors, confidential behaviors; in issues related to the protection of research subjects; and in issues related to the archiving and disseminating complex datasets

---

**Dr. Juanita J. Chinn**
Telephone: 301-827-4901
Email: juanita.chinn@nih.gov

---

**L. Pregnancy and Perinatology Branch**

The **PPB** supports research in the following areas: the physiology of pregnancy and labor; high-risk pregnancies, including those with hypertensive disorders, diabetes or seizure disorders; fetal pathophysiology; premature labor and birth; diagnostic, monitoring, and therapeutic devices and instruments for newborn infants in the nursery and in Neonatal ICU setting; improving the existing products or developing new products that would improve the routine and extended care of the newborn infants; products and agents related to breastfeeding; hospital supplies specifically related to use in the care of newborn infants; nanotechnology and its application for the care of newborn infants; instruments and devices for assessing and monitoring the nursery environment (noise, lighting, and odor); disorders of the newborn; sudden infant death syndrome; and biological and behavioral antecedents of low birth weight.
The following topic areas are of high priority:

- **Neonatal/Perinatal**:
  - Non-invasive or minimally invasive methods for assessing cardiovascular, cerebrovascular, renal, gastrointestinal, neurosensory and pulmonary functions, including methods to predict long-term outcomes.
  - Devices, instruments, and tools to minimize bacterial colonization, reduce proclivity for thrombus formation; reduce healthcare associated infection risks
  - Methods to assess pain in the newborn, analgesia, and evaluate neonatal abstinence syndrome (NAS) secondary to withdrawal of narcotic dependence developed during the fetal life
  - Non-invasive measures to assess brain energy utilization in the newborn, especially glucose, oxygen, lactate, ketones, and other energy substrates; methods for prognostication
  - Improved devices and instruments for assisted ventilators for use in neonatal ICU

Dr. Tonse Raju  
Telephone: 301-496-5575; eFax: 301-480-3884  
Email: rajut@mail.nih.gov

**M. National Center for Medical Rehabilitation Research**

This Center supports innovative research on the restoration, replacement, enhancement or adaptation of function for people with chronic physical disabilities. This includes rehabilitative approaches across etiologies and the lifespan, as well as the environmental and policy factors that promote full participation. We encourage studies that integrate biomedical, engineering and/or psychosocial approaches to develop practical and creative solutions to the daily functioning of people with disabilities and their families. The mission of the NCMRR is to increase the effectiveness of medical rehabilitation practices through research. Information about specific program areas within NCMRR can be found [here](#).

Examples may include but are not limited to:

- **Adaptation and Plasticity**: Develop non-invasive and surrogate measures of plasticity that would be appropriate for use in a clinical setting to target rehabilitation therapies and monitor treatment effectiveness (e.g., biomarkers, imaging)

- **Novel Technology**: Orthotics, prosthetics, and robotics devices and interfaces; Assistive technologies; Invasive and non-invasive biological sensors, prosthetic systems or implants to improve function; New control methods and improved sensory feedback; Strategies for controlling and adapting to the environment; Advanced wheelchair designs and enhancements and other mobility devices; Biomaterials and tissue interfaces, nanotechnology, bionics

- **Rehabilitation Interventions**: Development and use of robotics; Gaming applications; Virtual and Augmented Reality; Simulations; M-health and other approaches to promote participation, understand and support healthy behaviors, reduce health disparities and enhance clinical compliance, especially in children with physical disabilities.

- **Chronic Symptom Management**: Methods to increase screening for chronic conditions or preventable secondary conditions in individuals with physical disability; Prevention and treatment strategies for mitigating symptoms associated with multiple chronic conditions in individuals with physical impairments, including persistent pain, symptoms of obesity, diabetes, cardiovascular deconditioning, fatigue, symptoms of overuse injuries, pressure ulcers, sleep disturbances, and depressive symptoms; Improving muscle capacity in
chronic physical disability to include therapeutic or adaptive exercise and muscle stimulation; muscle-disuse syndromes and contractures; Rehabilitation interventions for improvement of physical disability and comorbid cognitive, sensory, or somatic consequences of impairment, disease or injury; Autonomic function in the context of injury or specific conditions.

- **Rehabilitation in the Community**: Strategies to build or modify community and/or environmental resources that provide effective rehabilitation and health promotion services within the individual’s own community. Development of engineering, crowdsourcing, and social science approaches to promote, monitor, and sustain outcomes in real world settings.

Investigators proposing budgets exceeding the guidelines are encouraged to contact program staff six weeks prior to submitting the application.

For additional information on research topics, contact:

Dr. Louis A. Quatrano  
Telephone: 301-402-4221; eFax: 301-480-3854  
Email: quatranol@mail.nih.gov

For additional SBIR/STTR program administrative information and research topics contact:

Louis Quatrano, PhD  
*Eunice Kennedy Shriver* National Institute of Child Health and Human Development  
Phone: 301-402-4221  
Email: Quatranol@mail.nih.gov

For additional financial/business management questions contact:

Mindy Bixby  
Grants Management Specialist  
*Eunice Kennedy Shriver* National Institute of Child Health and Human Development  
Contractor  
Phone: 301-402-3204  
Email: Mindy.bixby@nih.gov

OR

Mr. Ted Williams  
Grants Management Specialist  
*Eunice Kennedy Shriver* National Institute of Child Health and Human Development  
Telephone: 301-435-6996  
Email: williate@mail.nih.gov
NATIONAL INSTITUTE ON DRUG ABUSE (NIDA)

NIDA is the lead federal agency supporting scientific research on drug use and its consequences. Our mission is to advance science on the causes and consequences of drug use and addiction and to apply that knowledge to improve individual and public health through: 1) Strategically supporting and conducting basic and clinical research on drug use (including nicotine), its consequences, and the underlying neurobiological, behavioral, and social mechanisms involved and 2) Ensuring the effective translation, implementation, and dissemination of scientific research findings to improve the prevention and treatment of substance use disorders and enhance public awareness of addiction as a brain disorder. For additional information about areas of interest to the NIDA, please visit our home page at https://sbir.nih.gov/nida/divisions.

SBIR and STTR programs at NIH are primarily intended to encourage private-sector commercialization of technology and to increase small business participation in federally funded R&D.

Both the SBIR and STTR programs consist of the three phases. During Phase I, NIDA supports the projects which establish the technical merit and feasibility of proposed research / R&D efforts and determines the quality of performance of the applicant (small business concern or SBC) before providing further Federal support in Phase II. Provided that the feasibility is established, during Phase II, NIDA supports research or R&D efforts initiated in Phase I. During Phase III, SBC is to pursue commercialization with non-SBIR/STTR funds (either Federal or non-Federal). Applicants are encouraged to seek commitment(s) of funds and/or resources from an investor or partner organization for commercialization of the product(s) or service(s) resulting from the SBIR/STTR grant. Phase III funding may be from any of a number of different sources including, but not limited to: private, venture capital firms, investment companies, joint ventures, R&D limited partnerships, strategic alliances, research contracts, sales of prototypes (built as part of this and/or other project), public offering, state finance programs, non SBIR-funded R&D or production commitments from a Federal agency for use by the United States government or other industrial firms. NIDA monitors SBC efforts to pursue, with non-SBIR/STTR funds, the commercialization of the results of the research or R&D funded in Phases I and II of the SBIR/STTR Program.

NIDA funding decisions will be based on combination of factors:

- Programmatic priorities (for current priorities, see NOT-DA-17-013)
- Potential for commercialization and public health impact
- Whether the similar projects have already been funded (for reference, search NIH RePORTER)
- The results of Phase I and the commercial potential and scientific/technical merit of the Phase II application (for Phase II applications)
- The quality of performance of the applicant, with emphasis on prior applicant success in Phase III
- The peer review scores and critique
- Availability of funds

SPECIAL FEATURES OF NIDA SBIR PROGRAM

Limited Amount of Award

According to the statutory guidelines, total funding support levels (including direct costs, indirect costs, and fee) are $150,000 for Phase I awards and $1,000,000 for Phase II awards. In certain cases, the US Congress allows awards to exceed these amounts by up to 50% ($225,000 for Phase I and $1,500,000 for Phase II- hard cap). NIDA will only consider 50% allowable increase for applications in the areas of programmatic priority (NOT-DA-17-013), and with appropriate and strong justification from the applicant.

Budgets that exceed the hard caps (more than $225,000 for Phase I and more than $1,500,000 for Phase II) must receive a waiver of from US SBA. NIH - not the applicant - must apply for this waiver. The list of
NIDA waivers can be found in the Program Descriptions and Research Topics and APPENDIX A. If adequate justification is provided and research focus is within NIDA’s SBA approved waiver, applicants may request up to $350,000 in total costs with the project period up to 2 years; or up to $3,000,000 in total costs with the project period up to 3 years for Phase II.

Applications outside of the areas of current strategic interest can be funded at the levels of statutory guidelines only ($150,000 for Phase I and $1,000,000 for Phase II, total costs).

Applicants are strongly encouraged to contact NIDA Division SBIR and STTR Representatives prior to submitting any application in excess of the guidelines. In all cases, applicants should propose a budget that is reasonable and appropriate for completion of the research project. For programmatic, budgetary or administrative reasons, NIDA may decrease the length of an award and/or the budget, or not fund an application. If applicants choose to request funds above the approved hard caps (more than $225,000 for Phase I and more than $1,500,000 for Phase II), they are strongly advised to contact NIDA Division SBIR and STTR Representatives prior to application submission.

Fast-Track Applications

Important consideration for NIDA Fast-Track Mechanism:

- Preliminary data that clearly supports the project feasibility
- Clear, measurable, achievable milestones. Milestones for Phase I must be written with the goal of addressing all significant questions of technical feasibility. Phase I milestones must be quantitative, not qualitative (e.g., “an affinity of x nM,” rather than “twice as potent as Y” or the “twice as potent as the best analog”). Milestones should also be written utilizing the appropriate controls. Completion of Phase I Milestones must fully demonstrate product/service feasibility.
- Well-conceived Commercialization Plan
- Letters of Phase III support/interest encouraged
- Track record/previous success in commercializing product or services
- Discussion with NIH Program Staff strongly encouraged

The NIH Fast-Track mechanism expedites the decision and award of SBIR and STTR Phase II funding by incorporating a submission and review process in which both Phase I and Phase II grant applications are submitted and reviewed together. The Fast-Track application will receive a single rating for the entire proposed project (i.e., it will receive a numerical score or it will receive an “unscored” designation). To be eligible for the Fast-Track option, the Phase I Research Plan must include well-defined, quantifiable milestones that should be achieved as Go/No-Go requirements prior to initiating Phase II work. In addition, as is required for all Phase II applications, the Phase II portion of a Fast-Track application must present a well-defined Commercialization Plan. NIDA encourages Fast-Track mechanism for scientifically meritorious applications that have expressly high potential for near term commercialization. Applicants considering a Fast-Track application are strongly encouraged to contact program staff BEFORE submitting an application. NIDA staff will assist the applicant in determining whether the proposed project addresses NIDA’s programmatic priorities, and whether the proposed project satisfies NIDA’s criteria for Fast Track mechanism. Potential Fast-Track applicants are encouraged and expected to discuss with the NIDA program staff the following:

- **Value of the SBIR/STTR Project** - the public/market need addressed, specifying weaknesses in the current approaches to meet this need; the commercial applications of the research and the innovation inherent in this application.
- **Justification** of the pertinence of the Fast Track mechanism to the proposed research.
- **Expected Outcomes and Impact** - the proposed project and its key technology objectives; the product, process, or service to be developed in Phase III; the potential societal, educational, and scientific benefits of this work; the non-commercial impacts to the overall significance of the project.
• **Market, Customer, and Competition** - the market and/or market segments targeted, a brief profile of the potential customer, significant advantages SBC's innovation will bring to the market, e.g., commercial viability, better performance, lower cost, faster, more efficient or effective, new capability; the hurdles to overcome in order to gain market/customer acceptance of the proposed innovation; any strategic alliances, partnerships, or licensing agreements already in place to market and sell the product, FDA approval (if required), marketing and sales strategy, overview of the current competitive landscape and any potential competitors over the next several years, etc.

**Phase IIB Competing Renewal Awards**

NIDA will only accept SBIR Phase IIB Competing Renewal grant applications, Phase IIB STTR applications will not be accepted. However, in accordance with 2011 SBIR Reauthorization Act, when applicable, STTR applications can be converted into SBIR (e.g. upon completion Phase II, STTR applications can be supported as Phase IIB SBIR applications).

Phase IIB Competing Renewal grant applications are intended to help companies to continue advancing the development of medication or medical devices for the treatment of Substance Use Disorders (SUDs) to the marketplace. Such products might include (but are not limited to) the small molecule drugs and biological agents such as antibodies and vaccines. The financial and time constraints of Phase I and Phase II SBIR/STTRs present significant obstacles in the advanced stage development of medications. While Phase I and Phase II SBIR/STTR support may be sufficient for initial discovery and development efforts (e.g., compound synthesis and some in vitro and in vivo preclinical pharmacological testing), it may not be sufficient to conduct clinical trials or even fully support generation of the preclinical data package needed for an Investigational New Drug (IND) application.

The purpose of Phase IIB Competing Renewal Award is, therefore, to provide a Phase II project the opportunity of another three years of support. Only a fraction of NIDA SBIR/STTR Phase II awards will likely be eligible for a Phase IIB Competing Renewal award, and applications are considered in a similar pool as new Phase II applications.

First key criterion for eligibility for a Phase IIB Competing Renewal award is that the project is sufficiently close to a marketable position so that a Phase IIB award could significantly advance the product to the marketplace. A second and equally important criterion is that the Phase II award results and current market conditions are such that the project continues to be deemed of high impact i.e., a high significance project with a similarly high likelihood of a successful outcome. Therefore, the outcome of studies conducted under the previous grant phases should be included in the justification and should provide a sound and convincing rationale for continued development of the medication. Prospective Phase IIB Competing Renewal applicants are strongly encouraged to consult with NIDA staff prior to submission in order to gauge programmatic interest in continued development. The consultation should include provision of a letter of intent that includes the following information:

- Descriptive title of the proposed research
- Name, address, and telephone number of the Principal Investigator
- Names of other key personnel
- Participating institutions

Phase IIB Competing Renewal applications may focus on development efforts for medications targeted towards attainment of abstinence and/or relapse prevention for SUD patients with stimulant (e.g., cocaine and methamphetamine), opiate, cannabis, or nicotine dependence. Medications for emergency room management / stabilization of patients with acute toxic reactions to drugs, would also be appropriate for Phase IIB Competing Renewal applications. Agents currently recognized as presenting such concerns include stimulants such as cocaine, amphetamines and cathinones (Bathsalts), as well as synthetic drugs such as phenethylamines and the thermogenic empathogens (e.g., “Ecstasy”/ “Molly”).
Applicants proposing projects for medication development are generally expected to have completed most of the following steps in the development process:

- Target validation
- Screening of candidates and identification of active entities (small molecules, biologics, etc.)
- Confirmation of hits based on repeat assay/concentration response curve (CRC)
- Structure-Activity Relationship (SAR) studies
- Identification of lead compound(s) or biologic(s) suitable for further development
- Process development to support clinical manufacturing (e.g., scale-up feasibility)
- In vivo pharmacokinetics and toxicity studies
- In vivo preclinical efficacy studies; and/or
- Other activities leading to the selection of a development candidate.
- Demonstration of acceptable pharmacokinetics and pharmacodynamics
- Completion of in vivo preclinical efficacy studies (properly powered)
- Demonstration of acceptable safety (toxicity in rodents and large animals)

Appropriate activities that may be proposed for medication development may include (but are not limited to) the following examples:

- Manufacturing of acceptable clinical dosage form [i.e., meeting Good Manufacturing Practices (GMP) quality];
- Other R&D activities that might be needed to complete an IND application
- Human laboratory clinical trials (First in Man) / Escalating Dose studies to determine a medication's safety profile, metabolism, cardiovascular effects, interaction with drugs of abuse, etc.
- Clinical studies to assess the efficacy of the medication under development.

For more information, contact:

Aidan Hampson, Ph.D.
Phone: 301-443-8039
Email: aidan.hampson@nida.nih.gov

Research Topics of Interest to NIDA

The specific set of topics that are funded by a particular IC/Office/Agency depends on whether the IC/Office/Agency funds/supports Clinical Trials under SBIR/STTR Awards. Use the following table and explanations to determine which list of topics is applicable.

<table>
<thead>
<tr>
<th>Does IC/Office/Agency Fund/Support Clinical Trials under SBIR/STTR Awards?</th>
<th>No*</th>
<th>Yes**</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td>X</td>
</tr>
</tbody>
</table>

*If No,
- This IC/Office/Agency funds only those topics listed under the Non-Clinical Trials Topics section below, UNLESS the IC/Office/Agency funds a Small Business Concern for clinical trials under a NON-SBIR/STTR award.

**If Yes or the IC/Office/Agency funds small businesses for clinical trials under a NON-SBIR/STTR funding opportunity,
- See the table below for which mechanisms the IC/Office/Agency will allow for clinical trials research. Also, see the Clinical Trials Topics section below for a list of funded
topics. This IC/Office/Agency also funds research listed under the Non-Clinical Trials Topics section below.

<table>
<thead>
<tr>
<th>Does IC/Office/Agency accept clinical trials applications under this mechanism?</th>
<th>Yes</th>
<th>No</th>
<th>Other Information: If funding an SBC for clinical trials under a NON-SBIR/STTR award, please identify activity code(s) and other relevant information.</th>
</tr>
</thead>
<tbody>
<tr>
<td>Clinical Trials SBIR/STTR Omnibus/Parent Funding Opportunity Announcement/s</td>
<td>X</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Clinical Trials SBIR/STTR IC/Office/Agency - Specific Funding Opportunity Announcement/s</td>
<td></td>
<td>X</td>
<td></td>
</tr>
<tr>
<td>Clinical Trials NON-SBIR/STTR Funding Opportunity Announcement/s where Small Businesses are eligible to apply</td>
<td></td>
<td>X</td>
<td></td>
</tr>
</tbody>
</table>

### NIDA Non-Clinical Trials Topics:

#### High Programmatic Priority Research Topics

NIDA emphasizes its need to discover, develop and clinically evaluate treatments for the substance use disorders (SUDs). Specifically, in this Omnibus, NIDA underscores the high programmatic priority given to research that seeks to achieve this goal in the following ways:

1. **Drug (Medication) discovery and development-enabling activities for Substance Use Disorders SUDs.**
   - Innovative in vitro, in situ, or in vivo tools for the analysis of the central nervous system, normal and/or diseased.
   - Technologies, including molecular imaging, gene expression profiling, and genotyping and sequencing approaches designed to better inform SUD diagnosis and treatment.
   - Tools to simplify the design and preclinical development of medications for SUDs
   - Discovery of SUD-related biomarkers and/or related biomarker assay development with a particular emphasis on peripheral measures

2. **Drug (Medication) discovery and development activities**

   Application of emerging and existing technologies and platforms for SUD medication development with the focus on products with the potential to minimize drug seeking, compulsive behavior:
• Early therapeutic discovery activities ranging from Target ID and validation through lead development
• Assay development (e.g., biochemical, functional) and validation, especially, hiPSC-based assays, human organoid, or 3-D culture systems with the intention of developing medium to high-throughput assays
• Preclinical drug development

**NIDA Clinical Trials Topics:**

**High Programmatic Priority Research Topics**

NIDA emphasizes its need to discover, develop and clinically evaluate treatments for the substance use disorders (SUDs). Specifically, in this Omnibus, NIDA underscores the high programmatic priority given to research that seeks to achieve this goal in the following ways:

1. Drug (Medication) discovery and development-enabling activities for Substance Use Disorders SUDs.
   - Predictors of clinical outcomes in SUDs, e.g. physiological, electroencephalographic, cognitive tests, and biochemical, epigenetic, and genetic assays.
   - Point of care monitoring systems to improve quantitative assessment of subject adherence to clinical trial protocols

2. Drug (Medication) discovery and development activities

   Application of emerging and existing technologies and platforms for SUD medication development with the focus on products with the potential to minimize drug seeking, compulsive behavior:
   - Clinical drug development
   - Technologies or formulations to improve medication delivery

3. Development of portable, efficacious neuromodulatory devices

   Development of portable neuromodulatory devices to treat SUDs or reduce patients’ reliance on opioids for pain control. The development of such devices should be grounded in validated, well-controlled, peer-reviewed research.
   - Portable, commercially viable neuromodulatory devices for the treatment of SUDs either in a home environment or non-specialized clinical setting. These devices should be suitable for use by patients or professionals with a general medical training.
   - Miniaturization (portable implementations) of scientifically validated technologies as tools for further therapeutic clinical research in the treatment of SUDs.

**Examples of Topics of NIDA Interest Are Presented Below by Division:**

**Division of Neuroscience and Behavior**

The Division of Neuroscience and Behavior (DNB) supports basic and clinical biomedical neuroscience and behavioral research to address the public health problem of drug abuse and addiction.

Applications are encouraged, but are not limited to these areas:
• Early chemical discovery activities ranging from Target ID/validation through ‘hit-to-lead’
development
• Bioinformatics/Data management tools or technologies
• Development of in vitro/in cellulo screening assays
• Animal model development
• Imaging tools and biotechnologies
• Biomarker discovery

Dr. Kristopher Bough
Telephone: 301-443-9800
Email: boughk@mail.nih.gov

Division of Therapeutics and Medical Consequences

The Division of Therapeutics and Medical Consequences (DTMC) develops and administers a program of
pre-clinical and clinical research to develop innovative pharmacological (both chemical and biological)
and non-pharmacological approaches to treat substance use disorders (SUDs) and related medical and
psychiatric conditions. It also supports research to investigate the medical consequences of drug abuse,
including HIV/AIDS and identify valid and reliable outcome measures for clinical trials of therapeutics for
SUDs.

Applications are encouraged, but are not limited to these areas:

Clinical Drug Development. DTMC seeks to support the clinical development of novel
pharmacotherapeutic compounds or immunological treatments that have successfully completed (or are
nearing completion of) preclinical evaluation as treatments for SUDs. Projects of interest can evaluate
products in any clinical development phase, with the aim of helping subjects become drug free, reduce
drug use, prolong abstinence, reduce craving or facilitate survival from drug overdose.

Therapies of interest include, but are not limited to the following:

• Novel compounds or drug formulations that could be used to treat SUDs. Any well rationalized
target with a lead compound (at least) ready for “First in Man” studies would be considered.
• Repurposing of compounds previously developed for other indications, as novel treatments of
SUDs.
• New or improved technologies (devices, markers, systems, services or software) to assess /
remediate medication regimen adherence during clinical trials.
• New pharmacological strategies to reduce dependence on opioid medications to treat pain in
outpatient subjects (opioid sparing strategies). These could be agents that can improve opioid-
analgesia and therefore reduce the opioid dose required for pain management or analgesic
medications can substitute for opioids in clinical indications where opioids are regularly employed
• Medications to treat benzodiazepine overdose. CDC Mortality numbers show deaths caused by
alprazolam or diazepam rival those seen with oxycodone or morphine. A rescue medication that
can reverse overdose symptoms in benzodiazepine abusers, without the potential for producing
seizures in dependent individuals would be a significant public health value.
• Improved assays / devices that can quantitatively detect recent consumption of a substance of
abuse and accurately assess a narrow time since ingestion. The system should be superior to
urinalysis, which is the current gold-standard. The analytical test/device should be non-invasive,
portable and easy-to-use by a person with limited training in its use, such as a trial subject or a
nurse at the point of care.
• Vaccines for substances of abuse (e.g., cocaine, nicotine)
• Development of biomarkers related to SUDs treatment outcomes.
Late Stage drug discovery and development activities: Application of emerging and existing technologies and platforms to SUD drug development. This includes the evaluation, development, approvability, and efficacy testing of new and improved pharmaco-therapeutic agents, as well as the testing of marketed medications, and of behavioral treatments used alone or integrated with medications. Medical products with potential to minimize drug seeking, compulsive behavior, and/or addictive processes are strongly encouraged.

- Chemistry / pharmaceutical drug development
- Formulation and/or enhanced delivery of drugs
- Lead optimization and IND-enabling preclinical projects and/or clinical drug development
- Development of biomarkers related to treatment outcomes

Bioassays for drugs of abuse based on pharmacologic activity, not chemical structure. New "designer" drugs of abuse such as cathinone stimulants sold as “bath salts” and synthetic cannabinoids found in "herbal incense", are a diverse range of structures identified from the medicinal chemistry literature with structures that have been modified to be novel but retain pharmacological activity. Frequently even the pharmacophore (structural skeleton) bear little resemblance to the canonical drug of abuse e.g., alkylindoles with cannabinoid activity. These untested drugs can be dangerous to users and those with whom they come in contact. Their attraction is their invisibility to drug testing laboratories, but they are similarly invisible to emergency room toxicology screens whose assays typically rely on either antibodies raised to a specific structure or mass-spectrometry libraries that can detect agents for which a finger print has been identified and validated. The NIDA would like to promote the development of assays based on pharmacologic activity rather than chemical structure. Examples of such assays would include (but be not limited to) scintillation proximity assays, robust cell-based assays to detect activation of pharmacological pathways, or cells expressing engineered receptors activated solely by synthetic ligands, designed to pick up a range of metabolites. Other examples might include microfluidic surface plasmon resonance devices, which can both concentrate and detect receptor or antibody-bound substances.

Such assays should be:

- Non-invasive and able to detect quantities of illicit materials or metabolites in a range of concentrations typically found biofluids of substance users within a few days of use.
- Ideally assays should be designed with a standard clinical or analytical laboratory in mind, i.e., to be analyzed in a high throughput format by technicians with a moderate scientific training.
- The assays can be either designed to be analyzed with standard existing equipment, or include both the assay and development of analytical hardware, provided that the ultimate system can be commercially viable in a clinical and drug testing market place.

Dr. Aidan Hampson
Telephone: 301.443.8039
Email: aidan.hampson@nida.nih.gov

- Innovative neuromodulatory and behavioral technologies, tools and approaches designed for targeted substance abuse treatment.
- Non-invasive brain stimulation tools (e.g., TMS, TDCS) and other advanced methods to improve substance use disorder treatment outcomes and relapse prevention.
- Technologies to access and record adherence to neurobehavioral and behavioral interventions to increase substance use disorder treatment effects and treatment fidelity.
- Research on individual differences in neurobiological, genetic, and neurobehavioral factors that underlie increased risk for and/or resilience to drug abuse, addiction, and drug-related disorders to inform therapeutic development
- Development and testing of provider training materials (including mobile and web-based) to help ensure that interventions are delivered appropriately
• IT-based booster treatments or post-treatment support to extend and sustain the behavior change and increase the chances for treatment success
• Research aimed at improving the adoption of evidence-based approaches and treatments in real-world settings
• Research to develop technological devices in the delivery of initial drug abuse treatment or medication adherence interventions
• Validation of devices to increase treatment effects and insure treatment fidelity, efficiency, and safety.

Dr. Will M. Aklin
Telephone: 301.827.5909
Email: aklinwm@nida.nih.gov

Division of Epidemiology, Services and Prevention Research

The Division of Epidemiology, Services and Prevention Research (DESPR) is interested in advancing solutions for drug addiction and pain at the population level. Some examples of areas of research DESPR would consider supporting include:

• Research on new and dynamic ways to monitor changes in the legislative landscape of substance abuse, particularly marijuana and prescription drugs, and how those changes impact health at the population level.
• Research on the implementation and impact of opioid prescribing guidelines on prescribing behavior, and the impact of opioid prescribing guidelines on adverse consequences of opioid treatment and quality of pain treatment.
• Digital and social media technologies that allow for the identification of substance use problems in individuals and populations, the prevention of those problems, and the provision of the resources necessary for providing those with substance use problems with the services they need.
• The expansion of HIV, HCV and TB services and testing in the context of drug abuse (particularly injection drug use).
• The implementation of existing evidence-based substance abuse treatment and prevention services among populations at risk for substance abuse, and among underserved or represented populations, such as minorities, criminal justice populations, American Indian and Alaska Native populations, and those suffering from co-morbid psychological disorders.
• The use and implementation of developmentally based interventions to prevention and mitigate risk for substance abuse problems, particularly among youth and adolescents.
• Development of technologies and tools that promote provider education about treating pain and substance use disorders, and the development and validation of clinical decision support tools.
• Development of clinically available tools to better measure biological/behavioral correlates of pain or substance use problems, to diagnose and to suggest potential efficacious treatment approaches.
• Use of technologies to promote evidence-based prevention and treatment approaches for substance use and pain. Some examples of these technologies include smart phone apps, web-based training, and virtual reality/augmented reality approaches.

Dr. Samia Noursi
Telephone: 301.594.5622
Email: snoursi@nida.nih.gov

Dr. David Thomas
Telephone: 301.435-1313
Email: dthomas1@nida.nih.gov
Special Research Topics

In addition to areas of research identified by each NIDA Division, NIDA is also interested in Special Research Topics that aim to bridge the gap between the science of drug treatment and its practice though the study of scientifically based interventions in the real world setting. Examples include:

- Develop efficacious web-based training programs using advances in telemedicine to improve skills in managing clinical trials or delivering treatment interventions.
- Develop eHealth technologies that improve substance abuse treatment in a manner that enables rapid diffusion and adoption of science-based interventions and is cost-effective.
- Develop an evidence-based, online continuing medical education-approved curriculum to train psychiatrists on science-based practices to help patients address problems of chronic pain and its role in worsening co-occurring unhealthy drug use or substance use disorders

Dr. Udi Ghitza
Telephone: 301.480.2529
Email: ghitzau@nida.nih.gov

Mrs. Quandra Blackeney
Telephone: 301.480.2516
Email: quandra.blackeney@nih.gov
NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS (NIDCD)

The NIDCD supports research on the normal mechanisms of, as well as on diseases and disorders of hearing, balance, smell, taste, voice, speech and language. The Institute also supports research related to disease prevention and health promotion. The NIDCD addresses special biomedical and behavioral problems associated with people who have communication impairments or disorders. The NIDCD also supports efforts to create and refine devices, as well as develop cellular-based applications that may replace or substitute for lost and impaired sensory and communication functions. For more information about areas of interest to the NIDCD, please visit our home page at http://www.nidcd.nih.gov. Potential applicants are encouraged to contact the program staff listed in the following descriptions of NIDCD program areas early in the process of preparing the application.

Limited Amount of Award

For budgetary, administrative, or programmatic reasons, NIDCD may decrease the length of an award and/or the budget recommended by a review committee, or not fund an application. According to statutory guidelines, total funding support (direct costs, indirect costs, fee) normally may not exceed $150,000 for Phase I awards and $1,000,000 for Phase II awards. With appropriate justification from the applicant, Congress will allow awards to exceed these amounts by up to 50% ($225,000 for Phase I and $1,500,000 for Phase II). Applicants considering a requested budget greater than these limits are strongly encouraged to contact program staff before submitting the application.

Phase IIB Competing Renewal Awards

The NIDCD will accept Phase IIB SBIR/STTR Competing Renewal grant applications to support use of the final product in:

- Studies required by the FDA to validate safety or efficacy.
- Clinical trials with a larger number of participants to adequately validate efficacy.

Research Topics of Interest to NIDCD

The NIDCD accepts a broad range of small business applications that are significant, innovative, and relevant to its mission. Some examples of research topics within the NIDCD mission areas include topics shown below; further example can be found on the NIDCD Strategic Plan website (https://www.nidcd.nih.gov/about/strategic-plans). Priority is given to meritorious applications that are likely to develop innovative technologies, provide clear evidence of effectiveness, and bring novel products to the commercial marketplace.

The specific set of topics that are funded by a particular IC/Office/Agency depends on whether the IC/Office/Agency funds/supports Clinical Trials under SBIR/STTR Awards. Use the following table and explanations to determine which list of topics is applicable.

<table>
<thead>
<tr>
<th>Does IC/Office/Agency Fund/Support Clinical Trials under SBIR/STTR Awards?</th>
<th>No*</th>
<th>Yes**</th>
</tr>
</thead>
</table>

*If No,
  - This IC/Office/Agency funds only those topics listed under the Non-Clinical Trials Topics section below, **UNLESS** the IC/Office/Agency funds a Small Business Concern for clinical trials under a NON-SBIR/STTR award.
**If Yes or the IC/Office/Agency funds small businesses for clinical trials under a NON-SBIR/STTR funding opportunity,**

- See the table below for which mechanisms the IC/Office/Agency will allow for clinical trials research. Also, see the Clinical Trials Topics section below for a list of funded topics. This IC/Office/Agency also funds research listed under the Non-Clinical Trials Topics section below.

<table>
<thead>
<tr>
<th>Does IC/Office/Agency accept clinical trials applications under this mechanism?</th>
<th>Yes</th>
<th>No</th>
<th>Other Information: If funding an SBC for clinical trials under a NON-SBIR/STTR award, please identify activity code(s) and other relevant information.</th>
</tr>
</thead>
<tbody>
<tr>
<td>Clinical Trials SBIR/STTR Omnibus/Parent Funding Opportunity Announcement/s</td>
<td>X</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Clinical Trials SBIR/STTR IC/Office/Agency - Specific Funding Opportunity Announcement/s</td>
<td>X</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Clinical Trials NON-SBIR/STTR Funding Opportunity Announcement/s where Small Businesses are eligible to apply</td>
<td>X</td>
<td></td>
<td>NIDCD accepts and supports non-SBIR/STTR clinical trial applications through specific opportunities, which can be found on the NIDCD Funding Opportunities webpage: <a href="https://www.nidcd.nih.gov/funding">https://www.nidcd.nih.gov/funding</a></td>
</tr>
</tbody>
</table>

**NIDCD Non-Clinical Trials Topics:**

NIDCD will accept applications for development and commercialization of novel products in any of the areas noted below.

**Hearing and Balance Program**

Development of treatment modalities to prevent or lessen the effects of hearing disorders; development of new hearing aids, cochlear implants, and other assistive devices; development of improved screening technologies to assess hearing loss, especially in neonates and infants; development of new or improved power sources for hearing aids or cochlear implants; development of technologies that provide self-fitting, self-adjusting, or other features that increase performance, accessibility, or affordability of hearing aids; development of new outcome measures for assessing the efficacy of treatments for hearing disorders; development of technologies for the study, diagnosis and treatment of tinnitus; development of technologies for the study, diagnosis and treatment of otitis media including non-invasive diagnostics to identify middle ear pathogens, novel antibacterial strategies, and prophylactic anti-microbial strategies; development of technologies for the study, diagnosis and treatment of noise-induced and age-related hearing loss.
Development of technologies for the study, diagnosis and treatment of balance disorders, particularly for the elderly; development of clinical tests and instruments to assess balance/vestibular function; development of instruments and tests measuring head stability and vestibular function during natural stimulation of the vestibular system; development of perceptual reporting techniques and psychological indices for clinical assessment of the balance-disordered patient; development of tests and new outcome measures for assessing the efficacy of physical rehabilitative regimens for balance disorders; and development of assistive devices for balance disorders, including neural prostheses for the vestibular system.

Development of new research tools to aid in the study of the auditory and/or balance systems that can provide an improved understanding of fluctuating patterns of neural circuit structure and function over time and across large assemblies of neurons; new animal models of impaired function; improved diagnostic tools for inner ear function, including DNA-based assays and biochemical markers of disease. Development of improved tests and instruments for screening and diagnosis of inner ear function; development of technologies to enable gene transfer to the inner ear, including viral vectors; development of cell type specific markers and probes to examine cell lineage in inner ear regeneration.

Roger L. Miller, Ph.D.
National Institute on Deafness and Other Communication Disorders
301-402-3458, Fax: 301-402-0390
Email: millerr@nidcd.nih.gov

Voice, Speech, and Language Programs

Development of technologies for the study, diagnosis and treatment of voice, speech, and language disorders is strongly encouraged, as are projects that focus on determining the nature, causes, treatment and prevention of communication disorders such as stuttering, Specific Language Impairment, spasmodic dysphonia, dysarthria, and aphasia. Emphasis is on research and development of diagnostic measures and intervention strategies for voice, speech, and language disorders; development of communication and other assistive devices for individuals with voice, speech, and language disorders; development of speech and language assessments and interventions for nonverbal individuals with autism; development of new systems for visual communication by individuals who are deaf or severely hearing impaired; development of new systems of communication for individuals with motor speech impairment, including a brain computer interface (BCI) communication prosthesis; development of innovative treatment delivery systems or intervention protocols; design and development of diagnostic measures or materials for early identification of voice, speech and language impairment in children; development of assessments and treatments for childhood and adult voice, speech and language impairment associated with bilingual or multi-cultural populations; development of assessment measures of sign language abilities; development of improved artificial larynges and tracheoesophageal shunts; development of artificial intelligence computer models that simulate normal and disordered voice, speech and language.

Judith A. Cooper, Ph.D. [Language Program]
National Institute on Deafness and Other Communication Disorders
301-496-5061, Fax: 301-402-0390
Email: cooperj@nidcd.nih.gov

Lana Shekim, Ph.D. [Voice & Speech Program]
National Institute on Deafness and Other Communication Disorders
301-496-5061, Fax: 301-402-0390
Email: shekiml@nidcd.nih.gov
Taste and Smell Program

Development of easily administered diagnostic tools for testing human chemosensory function throughout the lifespan; development of intervention strategies and targeted drugs for the treatment of taste and smell disorders; preventive measures to limit the deleterious effects of infections, airborne toxins, radiation, chemotherapy and other drugs on chemosensory function; novel therapies to stimulate regeneration of mature sensory neurons in damaged and/or aged tissue; development of olfactory biomarkers for neurodegenerative disease; development of tools to facilitate chemosensory research including mouse models of chemosensory dysfunction and improved neuroimaging, cell labeling, and axonal tracing techniques.

Roger L. Miller, Ph.D.
National Institute on Deafness and Other Communication Disorders
301-402-3458, Fax: 301-402-0390
Email: millerr@nidcd.nih.gov

NIDCD Clinical Trials Topics:

NIDCD will accept applications for support of clinical trials in any of the areas noted above.

For additional information on research topics, contact:

Roger L. Miller, Ph.D.
National Institute on Deafness and Other Communication Disorders
301-402-3458, Fax: 301-402-0390
Email: millerr@nidcd.nih.gov

For administrative and business management questions, contact:

Mr. Christopher P. Myers
Grants Management Officer
National Institute on Deafness and Other Communication Disorders
301-435-0713, Fax: 301-451-5370
Email: myersc@nidcd.nih.gov
NATIONAL INSTITUTE OF DENTAL AND CRANIOFACIAL RESEARCH (NIDCR)

The NIDCR conducts and fosters research on the etiology, pathogenesis, prevention, diagnosis, and treatment of oral, craniofacial and dental diseases and conditions. For more specific information about areas of interest to the NIDCR, please visit our home page at http://www.nidcr.nih.gov.

NIDCR’s small business programs are highly focused on maximizing translational science opportunities – moving rapidly and translating basic dental and orofacial biology into useful products.

Research Topics of Interest to NIDCR

The specific set of topics that are funded by a particular IC/Office/Agency depends on whether the IC/Office/Agency funds/supports Clinical Trials under SBIR/STTR Awards. Use the following table and explanations to determine which list of topics is applicable.

<table>
<thead>
<tr>
<th>Does IC/Office/Agency Fund/Support Clinical Trials under SBIR/STTR Awards?</th>
<th>No*</th>
<th>Yes**</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>X</td>
<td></td>
</tr>
</tbody>
</table>

*If No,
  - This IC/Office/Agency funds only those topics listed under the Non-Clinical Trials Topics section below, **UNLESS** the IC/Office/Agency funds a Small Business Concern for clinical trials under a NON-SBIR/STTR award.

**If Yes or the IC/Office/Agency funds small businesses for clinical trials under a NON-SBIR/STTR funding opportunity,
  - See the table below for which mechanisms the IC/Office/Agency will allow for clinical trials research. Also, see the Clinical Trials Topics section below for a list of funded topics. This IC/Office/Agency also funds research listed under the Non-Clinical Trials Topics section below.

<table>
<thead>
<tr>
<th>Does IC/Office/Agency accept clinical trials applications under this mechanism?</th>
<th>Yes</th>
<th>No</th>
<th>Other Information: If funding an SBC for clinical trials under a NON-SBIR/STTR award, please identify activity code(s) and other relevant information.</th>
</tr>
</thead>
<tbody>
<tr>
<td>Clinical Trials SBIR/STTR Omnibus/Parent Funding Opportunity Announcement/s</td>
<td>X</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Clinical Trials SBIR/STTR IC/Office/Agency - Specific Funding Opportunity Announcement/s</td>
<td>X</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
Does IC/Office/Agency accept clinical trials applications under this mechanism?

<table>
<thead>
<tr>
<th>Yes</th>
<th>No</th>
</tr>
</thead>
<tbody>
<tr>
<td>Clinical Trials NON-SBIR/STTR Funding Opportunity Announcement/s where Small Businesses are eligible to apply</td>
<td>X</td>
</tr>
</tbody>
</table>

Other Information:
If funding an SBC for clinical trials under a NON-SBIR/STTR award, please identify activity code(s) and other relevant information.

- NIDCR Clinical Trial Planning and Implementation Cooperative Agreement (UG3/UH3) - Clinical Trial Required
- NIDCR Behavioral and Social Intervention Clinical Trial Planning and Implementation Cooperative Agreement (UG3/UH3) - Clinical Trial Required

**NIDCR Non-Clinical Trials Topics:**

**Developmental Biology and Mammalian Genetics**

Emphasis is on understanding the development of tooth and bone, and on the identification of the genetic and environmental contributions to craniofacial disorders. The objective of this scientific program is to elucidate the underlying causes of craniofacial disorders, thereby advancing the fields of diagnosis, treatment, and prevention. Interests in this area include but are not limited to:

A. Develop early pregnancy genetic tests to screen fetal cells in maternal blood for genetic mutations involved in inherited syndromic and non-syndromic craniofacial defects.

B. Develop instrumentation to improve the diagnosis and treatment of inherited and acquired craniofacial defects.

**Infectious Diseases and Immunity**

Research relating to the etiology, pathogenesis, prevention, diagnosis and treatment of infectious diseases of the oral cavity is supported by the NIDCR. This includes research on practical ways to effectively use the host immune system to prevent or treat oral infectious diseases and microbial-induced inflammation. Infectious diseases of the oral cavity include caries, periodontitis, candidiasis, peri-implantitis, pulpite, and various viral, bacterial, and fungal infections of the oral mucosa and research on the diagnosis and prevention of oral manifestations and malignancies of HIV infection and AIDS. Specific examples of technology development needs include but are not limited to:

A. Develop ways to overcome or eliminate the risk of oral infections in persons who smoke or chew tobacco, drink alcohol, or are immunosuppressed, have diabetes, are malnourished, or are psychologically stressed.

B. Explore novel methods or agents to eradicate oral biofilms (dental plaque) on teeth, oral soft tissues, and dental implants without adversely affecting the normal oral flora.

C. Isolate, synthesize or prepare new antibiotics and antimicrobial agents that can overcome bacterial and fungal resistance to current compounds. Formulate combinatorial drug regimens to attack microbes growing in oral biofilms (dental plaque).

D. Develop controlled release systems for local delivery of synthetic peptides, recombinant proteins, or other chemical or immunotherapeutic agents to prevent, control, and/or treat oral infectious diseases, or the oral manifestations of HIV infection.
E. Develop biological response modifiers or other immunological approaches to reduce or eliminate microbial-induced chronic inflammation or the tissue destruction associated with chronic inflammation in the oral cavity.

F. Develop ways to interfere with microbial colonization and growth through the use of antimicrobial agents and chemotherapy.

G. Identify and exploit the structural features of oral biofilms for increased therapeutics delivery.

H. Develop computer programs and apply systems biology approaches to model biologically active peptide regions of oral components that have anti-fungal, anti-bacterial and anti-viral activities.

I. Develop substitutes of naturally occurring chemicals (phytochemicals) known to have a role in controlling opportunistic infections induced by HIV.

J. Develop synthetic peptides and recombinant proteins of oral components with anti-fungal, anti-bacterial and anti-viral activities including those against HIV and oral opportunistic pathogens.

K. Develop oral topical formulations with combined microbicide, analgesic, and anti-inflammatory activities to enhance oral mucosal defenses and prevent and/or control oral infections and lesions in HIV-infected and/or immunosuppressed subjects.

L. Discover, test, standardize, and validate novel biomarkers present in oral biospecimens for screening and clinical diagnosis of HIV, and oral opportunistic pathogens infections and AIDS malignancies. Apply similar strategies as listed below for oral, oropharyngeal and salivary gland cancers to AIDS malignancies.

M. Develop the next generation of rapid tests and point of care devices to detect, quantify, screen, and diagnose HIV and oral opportunistic pathogens. Develop novel assays to quantify oral mucosal reservoirs for oral viruses, oral immune responses to viral prophylactic and therapeutic vaccines, and viral changes due to anti-viral treatments.

**Oral, Oropharyngeal and Salivary Gland Cancers**

Emphasis is on molecular mechanisms of oral epithelial cell deregulation that lead to oral cancers. Research related to early detection, diagnosis, and prevention, and treatment of oral cancers is of particular interest. Examples include but are not limited to:

A. Develop imaging techniques for the early detection, diagnosis and prognosis of pre-malignant lesions.

B. Develop effective pharmacological, immunological and radiological modalities for treatment of pre-malignant and malignant lesions in preclinical models.

C. Develop novel technologies for the genetic and molecular-targeted therapy (e.g. siRNAs, peptide based therapies) in preclinical models.

D. Develop genetic animal models of oral cancer premalignancy and oral cancer progression that mimic human oral cancers, including HPV-associated oropharyngeal cancers.

E. Develop animal models to facilitate the testing of therapeutic and chemopreventive agents for oral cancers.

**Temporomandibular Disorders and Orofacial Pain**

Emphasis is on research for chronic disabling painful diseases of the oral-craniofacial-dental areas including chronic pain, neuropathies, and diseases of the temporomandibular joint. NIDCR encourages applications that include but are not limited to:
A. Develop improved methods and technologies for measuring nociceptive, chemosensory, tactile, kinesthetic, or proprioceptive function involving craniofacial structures. Such measures may be useful in screening for deficits, improving diagnosis, or for evaluating responses to orofacial treatments or interventions.

B. Develop improved biomarkers for neuropathic pain conditions affecting oral-craniofacial tissues or structures.

C. Develop assays facilitating reliable evaluations of relationships between biological and other risk factors as they relate to onset, and exacerbation of pain and for examining transition from acute pain to chronic pain conditions.

D. Identify and develop novel pharmacologic or biologic agents, including but not limited to small molecules, peptides, recombinant proteins and nucleic acids to prevent, control, and/or treat orofacial pain.

F. Develop animal models to facilitate testing of therapeutic agents for orofacial pain.

**Saliva, Salivary Diagnostics, and Salivary Gland Diseases**

Emphasis is on salivary gland physiology and pathophysiology and in the repair and restoration of the damaged gland. Examples include but are not limited to:

A. Develop viral, non-viral and gene therapy-based approaches to address compromised salivary gland function. Develop cell and tissue-based strategies and technologies for restoration of damaged or destroyed salivary gland function.

B. Develop novel compounds or materials that protect and preserve salivary glands from head and neck cancer irradiation therapy.

C. Develop non-invasive methods for the determination of efficacy and safety of artificial saliva, sialogogues, and their delivery vehicles used in addressing the diminution or lack of saliva (xerostomia) due to Sjögren’s Syndrome or head and neck cancer irradiation therapy.

D. Develop biomarker-based technologies for the identification of Sjögren’s Syndrome using blood or saliva as body fluids.

E. Identify biomarkers derived from oral fluids that are predictive of the onset, progression and recurrence of oral diseases and conditions, such as periodontal diseases, caries, and oral, oropharyngeal and salivary gland cancers.

F. Develop immunological strategies and immunotherapy-based approaches for addressing xerostomia from Sjögren’s Syndrome.

G. Improve the existing or develop new tools for early detection of salivary gland cancers.

**Biotechnology, Biomaterials, and Applications for Regeneration and Restoration of Oral, Dental and Craniofacial Tissues**

Emphasis is placed on the development of a broad range of technologies targeted at regeneration and restoration of diseased and injured hard and soft tissues of the oral and craniofacial complex and on translating these applications to the clinic. Tissues of interest include craniofacial and alveolar bone, the periodontal ligament, TMJ bone and cartilage, oral mucosa, facial skeletal muscle, vasculature and nerves. Also of interest are multi-tissue composites and organs, such as vascularized and innervated bone and muscle, salivary gland, tooth, periodontium, bone-periodontal ligament-cementum interface and osteochondral complexes. Specific topics could include but are not limited to:

A. Develop technologies for design, fabrication, and manufacturing of biomimetic and biocompatible biomaterials and scaffolds, including nanomaterials and self-assembling nano-scaffolds, for tissue
engineering and regenerative medicine applications. Projects need to include assessments demonstrating the ability of biomaterials and scaffolds to support generation and regeneration of mineralized tissues that replicate the mechanical, physical and biological properties of dentin, enamel or bone.

B. Develop cell-based technologies, including stem cell-based technologies. These include, designing strategies for isolation, purification, differentiation, scaled up production, manufacturing, standardization and quality control of stem and progenitor cells and their differentiated progenies, derivation of efficient and predictable methodologies for cellular reprogramming, and advancing technologies for reconstruction of stem cell niches for augmenting tissue regeneration.

C. Develop bioreactor systems to facilitate design, fabrication, and manufacturing of soft and hard tissues of dental, oral and craniofacial complex. These bioreactors may be able to mimic biophysical forces, such as mechanical and electrical forces that normally guide tissue morphogenesis in vivo. Among other desirable features of the bioreactors are maintenance of tissue construct oxygenation and real-time tissue imaging capabilities.

D. Develop improved dental composite materials, including biomimetic and self-healing materials and adhesive sealants. These include but are not limited to materials to replace Bis-GMA resin-based systems that are suitable for restoring crowns of posterior teeth and exposed roots of the teeth. Any novel dental composite restorative components or systems must include assessments in a physiologically relevant test system that mimics microbial and physicochemical conditions found in the oral cavity.

E. Develop methods, materials, and devices for orthodontic, prosthetic, periodontic, endodontic and craniofacial applications including those that can be used for craniofacial bone distraction, reconstruction, hard and soft craniofacial tissue healing and regeneration, and scarless craniofacial tissue repair.

F. Develop miniaturized artificial tissue and organ mimics/tissue chips that can be adapted to high-throughput formats for a broad range of applications, such as analysis of biomaterial and tissue function, drug efficacy and toxicology assays, biocompatibility assays, genetic screening and elucidating mechanisms of dental, oral and craniofacial disease.

G. Develop mathematical, computational, and bioinformatics approaches for modeling oral and craniofacial tissues and organ function and physiology to address needs of system biology, synthetic biology, and single cell analysis.

H. Develop new approaches for utilizing novel biomolecules, including growth factors, cytokines, small molecules, siRNAs, and others for counteracting diseases and injuries of oral and craniofacial tissues and promoting their healing and regeneration.

I. Develop new approaches to study molecular or cellular interactions between hard and soft tissues such as between the nervous system and mineralized tissues. Approaches can include development of new technologies or application of existing technologies that are newly applied to the dental and craniofacial field.

J. Develop advanced viral and non-viral based biomolecule delivery approaches, including nanotechnology-based technologies that can precisely deliver and release therapeutic proteins, nucleic acids, small molecules, or combinations thereof with predictable temporal kinetics to target specific tissue sites.

K. Develop imagining diagnostics to accelerate clinical implementation of reliable, reproducible, highly specific and sensitive diagnostic instruments for various applications, including but not limited to dental caries, cracked teeth, pulp vitality, bone quality, and periodontal disease.

L. Development of biosensors for noninvasive, dynamic real-time monitoring of physiological processes in the human body using the oral cavity as the sensing site. These biosensors will be able to assess health and disease states and receive feedback from body fluids and clinical compounds that are
found in or pass through the oral cavity and in certain cases, will be able to communicate these outputs wirelessly and remotely.

Preclinical Research

A. Preclinical research and development activities for dental and craniofacial technologies (including devices, diagnostic instruments, reconstructive materials, pharmaceuticals, therapeutics, vaccines and biologics) that require review and approval by the FDA as a regulated product before commercial distribution.

NIDCR Clinical Trials Topics:

Special statement regarding clinical trials:

Projects proposing a clinical trial within STTR/SBIR applications must provide detailed justification that funds available through these awards can adequately support the trial especially if the trial is testing a drug under an investigational new drug (IND) or investigational device (IDE) application. The cost and time needed to plan and deploy most Phase II and almost all Phase III clinical trials would exceed the support and project period provided under this program.

In addition to the specific clinical trial topics listed below, we also would consider clinical trials for certain program topics listed above. Products originally developed and preliminarily tested with SBIR/STTR support also can be pursued further with funding mechanisms that support clinical trials, see: http://grants.nih.gov/grants/guide/pa-files/PAR-14-346.html. Please contact the NIDCR for more information.

Biomedical Clinical Research

Emphasis is on development of methods, drugs and materials to diagnose or treat oral and craniofacial diseases and conditions. Areas of interest include but are not limited to projects that:

A. Develop improved methods to detect and predict progression of dental caries, periodontal disease, reversible and irreversible pulpitis.

B. Develop new or improved methods or materials to enhance oral and craniofacial surgery. This would include both intraoral and extra-oral surgery.

C. Develop improved methods or materials to mechanically and/or biologically repair or treat tooth structure damaged by dental caries or periodontal disease.

D. Develop improved appliances to aid suckling by newborn infants with cleft palate and cleft lip.

E. Develop safe and efficacious methods to diagnose caries, pulp vitality and/or periodontal diseases utilizing non-ionizing radiation.

F. Develop technologies for local delivery of drugs to treat oral and craniofacial diseases or disorders.

G. Develop novel non-opioid pharmacological medications for management of acute dental pain.

H. Develop tools for implementation of precision medicine in the oral cavity.

I. Develop methods and tools to detect soft tissue pathologies in the oral cavity.

J. Develop oral devices and materials for monitoring local and systemic conditions.

K. Develop and test for safety and efficacy methods for diagnosing caries, pulp vitality and/or periodontal diseases that utilize non-ionizing radiation.
Behavioral Clinical Research

Provides support for the development of evidence-based products related to behavioral and social aspects of oral health, oral health prevention or treatment interventions, and other patient-oriented aspects of oral health. This includes support for clinical trials and patient-oriented research to establish safety and initial efficacy of products. NIDCR is especially interested in applications that significantly improve oral health by: 1) being broadly applicable to many populations, 2) contributing to meaningful oral health improvements for a specific population, 3) expediting translation of research findings into oral health improvements, and/or 4) equipping oral health care providers, educators or researchers with tools to improve public oral health. Examples of studies of interest include, but are not limited to, the following:

A. Develop and test devices or methods to improve time-sampled monitoring of behavioral adherence with preventive or therapeutic regimens specifically relevant to oral diseases/conditions. Such devices or methods could be utilized in a variety of settings, including naturalistic settings, within clinical trials, within oral health care delivery systems, etc.

B. Develop and test novel compliance and survey measures or tools to identify the underlying causes of insufficient preventive dentistry for specific underserved populations.

C. Develop, or adapt for use in a new population or setting, novel measures or methods for identifying individual, family, group, or other processes that explain oral health behavior.

D. Develop and test for safety, efficacy, and/or effectiveness of measures or materials for diagnosing, preventing, or treating oral, dental, and craniofacial conditions and disorders.

E. Develop, or adapt for use in a new population or setting, oral health interventions utilizing technology to improve efficiency of delivery (e.g., management of chronic pain related to temporomandibular joint disorders, etc.).

F. Develop, or adapt for use in a new population or setting, interventions addressing health behaviors highly associated with oral health (e.g., tobacco, alcohol, and other drug use; management of diabetes, HIV infection, or other chronic illnesses; etc.).

G. Develop technologies or modules that utilize existing web-based platforms to improve preventive oral health hygiene for children and adolescents (e.g., social marketing via web-based interaction, virtual reality “worlds”, “massively multiplayer online games”, etc.).

H. Develop and test innovative methods for facilitating collaborations, referrals, and/or ongoing follow-ups between oral health professionals and other health care professionals.

I. Develop and test web-based training or other innovative approaches for oral health care professionals to accelerate accurate translation of new knowledge regarding oral diseases and their effective prevention or treatment into clinical or public health practice.

J. Develop and test the effectiveness of innovative teaching tools to inform oral health professionals or the public regarding oral cancer prevention and early detection.

K. Develop and test the effectiveness of innovative teaching or educational tools or curricula to inform oral health professionals and dental students regarding the role of genetics and genomics, including the oral microbiome, in oral diseases and conditions and in oral health care.

For additional information on research topics, contact:

R. Dwayne Lunsford, Ph.D.
Dental Small Business Coordinator
Division of Extramural Research
National Institute of Dental and Craniofacial Research-NIH
6701 Democracy Blvd., Rm. 626
Bethesda, MD 20892-4878
301-827-4635
Email: lunsforrd@nidcr.nih.gov

For administrative and business management questions, contact:

Ms. Diana Rutberg, MBA
Chief Grants Management Officer
National Institute of Dental and Craniofacial Research
6701 Democracy Blvd., Rm. 658
Bethesda, MD 20892-4878
301-594-4798, Fax: 301-480-3562
Email: rutbergd@mail.nih.gov
NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES (NIDDK)

The mission of the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) is to conduct and support medical research and research training and to disseminate science-based information on diabetes and other endocrine and metabolic diseases; digestive diseases, nutritional disorders, and obesity; and kidney, urologic, and hematologic diseases, to improve people's health and quality of life. For additional information about areas of interest to the NIDDK, please visit our home page at http://www.niddk.nih.gov. See our SBIR/STTR page at https://www.niddk.nih.gov/research-funding/research-programs/small-business.

Limited Amount of Award

For budgetary, administrative, or programmatic reasons, the NIDDK may not fund an application or may decrease the length of an award and/or the budget recommended by a review committee. For topics listed in APPENDIX A: National Institutes of Health SBA-Approved SBIR/STTR Topics for Awards over Statutory Budget Limitations, the NIDDK generally will not fund Phase I applications greater than $300,000 total costs or project periods greater than 2 years; or Phase II applications greater than $2,000,000 total costs or project periods greater than 3 years. For all other topics, the NIDDK does not generally fund Phase I applications greater than $225,000 total costs or project periods greater than 2 years; or Phase II applications greater than $1,500,000 total costs or project periods greater than 3 years. Applicants considering a requested budget greater than these limits are strongly encouraged to contact program staff before submitting an application.

Phase IIB Competing Renewal Awards

NIDDK will accept Phase IIB SBIR/STTR Competing Renewal grant applications (only) from NIDDK-supported Phase II awardees that propose to continue the process of developing products that ultimately require 1) clinical evaluation, 2) approval by a Federal regulatory agency, and 3) continuing refinements to durable medical equipment (DME) designs such as cost reduction, testing for safety, durability, and reliability, and meeting or establishing standards. This renewal grant should allow small businesses to get to a stage where interest and investment by third parties is more likely. Such products include, but are not limited to biological products, devices, drugs, medical implants, etc. related to the mission of the NIDDK. The previously funded Phase II SBIR/STTR grant need not have been submitted in response to a particular solicitation, as long as the research is appropriate to the purpose of this solicitation. Budgets up to $1,000,000 total costs per year and time periods up to 3 years may be requested for this Phase IIB Competing Renewal opportunity. These awards are intended to support completion of research needed to obtain an IND or IDE. Applicants must provide evidence that they have consulted formally with the FDA concerning the research needed for the development of a drug, biologic or medical device and that the proposed research will address these regulatory requirements. Such evidence should include FDA correspondence from a pre-IND meeting for an IND application or a pre-IDE meeting for an IDE application, and the status of the project in a timeline related to Federal regulatory approval processes.

Examples of research that would be considered responsive to this announcement are listed below for illustrative purposes and are not exclusive of other appropriate activities.

- Completion of studies as required by the Food and Drug Administration (FDA) for Investigational New Drug (IND) or Radioactive Drug Research Committee (RDRC) application.
- Assessment of devices with regard to performance standards related to the FDA approval process.
- Clinical studies in support of an application for clearance or approval by the FDA (refer to current Notices from the NIDDK, and contact program staff for guidance regarding any research involving human subjects).
Final Progress Reports

As detailed in NOT-OD-17-085, the NIH has implemented the Final Research Performance Progress Reports (Final RPPR) for SBIR/STTR Final Progress Reports.

The NIDDK is interested in tracking the progress of the small business concerns it funds and the products they develop. Funding priority will be given to those small business concerns that show not only their ability to develop products but also their growth as a small business concern towards independence from the SBIR/STTR program.

Additional Programs and Services for NIDDK SBIR/STTR Awardees

The NIDDK encourages awardees to apply for the following free programs:

- Phase I: The NIH Niche Assessment Program (https://sbir.nih.gov/nap) provides awardees with an in depth market analysis for their technology.
- Phase II: The NIH Commercialization Accelerator Program (https://sbir.nih.gov/cap) will assist awardees in transferring their products to the marketplace.

The NIDDK may offer additional programs throughout the year, and awardees are encouraged to keep their contact information is current so that they receive announcements regarding these programs.

Research Topics of Interest to NIDDK

The specific set of topics that are funded by a particular IC/Office/Agency depends on whether the IC/Office/Agency funds/supports Clinical Trials under SBIR/STTR Awards. Use the following table and explanations to determine which list of topics is applicable.

<table>
<thead>
<tr>
<th>Does IC/Office/Agency Fund/Support Clinical Trials under SBIR/STTR Awards?</th>
<th>No*</th>
<th>Yes**</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>X</td>
<td></td>
</tr>
</tbody>
</table>

*If No,
- This IC/Office/Agency funds only those topics listed under the Non-Clinical Trials Topics section below, UNLESS the IC/Office/Agency funds a Small Business Concern for clinical trials under a NON-SBIR/STTR award.

**If Yes or the IC/Office/Agency funds small businesses for clinical trials under a NON-SBIR/STTR funding opportunity,
- See the table below for which mechanisms the IC/Office/Agency will allow for clinical trials research. Also, see the Clinical Trials Topics section below for a list of funded topics. This IC/Office/Agency also funds research listed under the Non-Clinical Trials Topics section below.
<table>
<thead>
<tr>
<th>Does IC/Office/Agency accept clinical trials applications under this mechanism?</th>
<th>Yes</th>
<th>No</th>
<th>Other Information: If funding an SBC for clinical trials under a NON-SBIR/STTR award, please identify activity code(s) and other relevant information.</th>
</tr>
</thead>
<tbody>
<tr>
<td>Clinical Trials SBIR/STTR Omnibus/Parent Funding Opportunity Announcement/s</td>
<td>X</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Clinical Trials SBIR/STTR IC/Office/Agency - Specific Funding Opportunity Announcement/s</td>
<td>X</td>
<td></td>
<td>SBIR Phase II, Phase IIB, and Fast-Track applications with NIH-defined clinical trials can be submitted in response to PAR-18-108. This funding opportunity announcement does not accept STTR applications or SBIR Phase I applications. NIDDK may issue other clinical trials allowed or optional SBIR funding opportunity announcements for specific topics.</td>
</tr>
<tr>
<td>Clinical Trials NON-SBIR/STTR Funding Opportunity Announcement/s where Small Businesses are eligible to apply</td>
<td>X</td>
<td></td>
<td>Small businesses are eligible to apply for several non-SBIR/STTR funding opportunities. Comprehensive information on Human Subjects Research at NIDDK can be found here: <a href="https://www.niddk.nih.gov/research-funding/human-subjects-research">https://www.niddk.nih.gov/research-funding/human-subjects-research</a> R01 applications with clinical trials may be submitted to PA-18-330, Investigator-Initiated Clinical Trials Targeting Diseases within the Mission of NIDDK (R01Clinical Trial Required). Multi-center trials are not appropriate to this FOA. Applications for clinical trials requiring three or more investigator sites should be submitted to NIDDK multi-center clinical study implementation planning cooperative agreement (U34) and NIDDK multi-center clinical study cooperative agreement (U01) FOAs. Clinical trial allowed and optional funding opportunities to which NIDDK is subscribed can be found on NIDDK’s Current Funding Opportunities page: <a href="https://www.niddk.nih.gov/research-funding/current-opportunities">https://www.niddk.nih.gov/research-funding/current-opportunities</a>.</td>
</tr>
</tbody>
</table>
NIDDK Non-Clinical Trials Topics:

Diabetes, Endocrinology and Metabolic Diseases

The Division of Diabetes, Endocrinology and Metabolic Diseases supports basic and clinical research on the etiology, pathogenesis, prevention, diagnosis, and treatment of diabetes mellitus and its complications of diabetic wound healing and diabetic neuropathy; endocrine diseases; osteoporosis; cystic fibrosis, and other metabolic disorders; as well as research on basic endocrine and metabolic processes. Research topics of potential interest to small businesses include, but are not limited to:

I. SENSORS, HORMONE REPLACEMENT, AND DELIVERY DEVICES:

A. Assessment of non-invasive, minimally invasive or implantable sensors for monitoring blood or interstitial fluid glucose for prevention of hypo- and hyperglycemia in diabetic patients. NIDDK will give priority to research that has already progressed to an in vivo model or to be clinically tested.

B. Integration of glucose sensor and hormone delivery systems to create an artificial pancreas.

C. Development of improved insulin and other pancreatic hormone delivery methods or devices.

D. Development of novel insulin and glucagon formulations showing improved kinetics and stability.

E. Development of novel and more accurate non-enzymatic based glucose detection technologies.

F. Development of telemedicine/remote monitoring approaches that can be incorporated as components/and or adjuvants of an artificial pancreas for better diabetes self-management.

G. Development of technologies that may promote and facilitate adherence/compliance by users of glucose monitoring and control devices.

H. Development of biomaterials that can deliver drugs or biologics to a diabetic foot ulcer to improve healing.

II. SCREENING TESTS, DIAGNOSTICS AND BIOLOGIC TOOLS:

A. Development of techniques or products/biomarkers useful for predicting, preventing or delaying progression of diabetes, including tests for identifying patients at risk, and methods of monitoring disease progression.

B. High throughput - Point of care technologies (reliable, accurate, cost-effective, highly sensitive, standardized having rapid turnaround time) for autoantibody detection, T cell –subsets-auto-reactivity and other immune parameters for autoimmune diabetes diagnosis and follow-up.

C. Development of methods to measure changes in the immune status that may be used as markers to follow the immune-modulatory activity and beneficial effect (beta cell mass preservation, reduction of inflammation at the target organ, etc..) of biologic agents tested in clinical trials for the prevention and/or treatment of T1D.

D. Development of high throughput assays based on biologic pathways likely involved in the pathogenesis of diabetes and its complications.

E. Development of methods/techniques/assays to measure adipose tissue in different depots in humans, including marrow fat.

F. Develop validated, highly sensitive, and specific assays for glucagon detection.

G. Development of reagents for assessment/manipulation of glucagon receptor activity in the pancreatic islet and other tissues.
H. Reagents to be used to improve our understanding of pancreatic alpha-cell biology particularly in response to glucagon and incretins.

I. Reagents and assays for the accurate expression and quantitation of functional incretin receptors in the endocrine/exocrine cells of the pancreas and relevant extrapancreatic tissues.

J. Development of materials and technologies for the support of microphysiological platforms used for pre-clinical testing and/or modeling of physiological and pathophysiological aspects of diabetes and metabolic disorders.

K. Development and validation of tools for use by health care providers/systems to improve diabetes care and prevention.

L. Development of techniques and tools to identify islet cell progenitors, methods to predict transplant success with recovered islet preparations, and non-invasive imaging as well as other methods for the in vivo measurement/evaluation of pancreatic beta cell mass, function or inflammation after transplantation of pancreatic islet/beta cells.

M. Point of care low cost/portable technologies for diabetes and pre-diabetes diagnosis.

N. Development of innovative technologies to predict and prevent hypoglycemia.

O. Development of clinical measures of the molecular and cellular damage from diabetes, such as oxidative stress, advanced glycation end-products and chronic inflammation that can be used as predictive or diagnostic biomarkers for diabetes complications.

P. Development and validation of biomarkers to monitor disease progression and response to therapy for diabetic neuropathy.

Q. Development of diagnostic and predictive biomarkers for diabetic foot ulcers that can be used to diagnose infections, predict healing, select treatment strategies or determine risk of primary or secondary occurrence of foot ulcers.

III. INTERVENTIONS AND THERAPIES:

**Diabetes**

A. Development of immunomodulation/tolerance induction strategies to prevent or slow progression of type 1 diabetes.

B. Development of methods that protect islet grafts after transplantation, including the evaluation of alternative transplantation sites, minimize the use of immunosuppression through immunomodulation/tolerance induction or immunoisolation/encapsulation of the graft from the host immune system, or support the use of single donors for transplantation.

C. Development of methods for the ex-vivo expansion of human islets/insulin producing cells while still retaining appropriate functional islet characteristics and the ability to be successfully transplanted.

D. Development of methods utilizing replenishable cell sources, especially stem cells that produce functional islet like cells/tissues that can be successfully transplanted or tested in microphysiological systems and/or in vivo models of the disease.

E. Development of more reproducible methods that improve yield/viability/function of islets prior to transplantation and the engraftment and long term function of islets after transplantation.

F. Development of educational or psychosocial approaches that increase adherence to recommended diabetes treatment regimens or that reduce co-morbidities and complications (e.g., depression or foot ulcers).

G. Development of novel technologies that may facilitate self-management of diabetes and adherence to treatment.
H. New implantable and easy to replace technologies that may mimic the beneficial effect of gastric bypass/bariatric surgery for the treatment of diabetes without the need of a major invasive surgical procedure.

I. Development of new therapies or devices to prevent and treat diabetic neuropathy and diabetic foot ulcers.

J. Development of new therapies to correct the underlying metabolic defects that result from diabetes, such as reactive oxygen species production and glycation of proteins.

Other Endocrine and Metabolic Disorders

K. Identification of new ligands for previously unclassified (orphan) nuclear receptors and development of partial agonists or antagonists with therapeutic potential for diseases such as diabetes and osteoporosis, hormone-dependent cancers, and for conditions such as obesity.

L. Development of Selective Receptor Modulators (SRMs) with tissue specificity and profiles that provide beneficial effects without the side effects secondary to therapies based on naturally occurring hormones.

M. Development of novel diagnostic and therapeutic strategies for autoimmune endocrine disorders.

Digestive Diseases and Nutrition

The Division of Digestive Diseases and Nutrition supports research on the function, diseases and disorders of the digestive tract; the esophagus, stomach, intestine, colon, anorectum, pancreas, liver, gallbladder, and biliary tract; research on nutrition and obesity as well as information transfer in the field of digestive diseases and prevention of obesity. Innovative investigator-initiated projects that are not mentioned below are encouraged. Areas that may be of interest to small businesses include, but are not limited to:

I. DIGESTIVE AND LIVER DISEASES (CLINICAL)

A. Development of assays and new genetic screening methods for detection of biomarkers for genetic predisposition to GI-relevant diseases and liver.

B. Development of improved means for detecting Barrett’s esophagus, GERD, and other GI disorders.

C. Development of methods for gastrointestinal endoscopy without the need for sedation.

D. Development of agents to treat motility disorders (e.g., pseudo-obstructive disorder, chronic constipation, and slow bowel transit).

E. Development of surrogate markers and non-invasive imaging methods to quantitatively assess GI and liver disease.

F. Development of non- or minimally-invasive tools that have improved therapeutic capabilities and visualization capabilities for detecting GI disorders (e.g., mucosal abnormalities and pathologies).

G. Development of novel antifibrotic therapies for progressive liver failure.

H. Development of quantitative tests of hepatic “reserve” which would be of use, for example, in assessing the risk of surgery in patients with liver disease.

I. Development of humanized monoclonal antibodies against HCV and HBV to be used for prevention of recurrent disease in liver transplant patients.
J. Development of and validation of therapeutic interventions for treatment and/or progression of pancreatitis and its complications.

K. Development of more accurate and useful approaches to the diagnosis of chronic pancreatitis by functional, radiologic, endoscopic, or pathologic/cytologic means.

II. DIGESTIVE AND LIVER DISEASES (BASIC)

A. Development of molecular probes for the diagnosis of mucosal dysplasia in inflammatory bowel disease.

B. Development of gut immune-modulators, or non-antigenic gliadin in celiac disease.

C. Development of new techniques, including non-invasive imaging, to measure motility/intestinal transit at various sites within the gastrointestinal tract.

D. Development of techniques for the preservation and transplantation of the liver, small intestine, and pancreas.

E. Development of novel proteomic or metabolomic technologies designed to study digestive and liver diseases, and their complications.

F. Development of a test for determining the hepatotoxic potential of drugs, agents or additives that is more sensitive than testing in mice and reflects the human response to the test compound.

G. Development of animal models to study hepatotoxic agents.

H. Development of non-invasive techniques to detect liver disease.

I. Creation of artificial organs or development of effective xenographic techniques for liver transplantation.

J. Development of biomarkers that quantitatively assess the degree of cold and warm ischemia injury in donor liver organs.

K. Development of non-invasive measures of pancreatic exocrine function.

L. Development of humanized mouse models of multi-allelic diseases.

M. Development of measurements to quantitate phenotypic or metabolic markers of disease progression in animal models, thus reducing the numbers of animals needed.

III. NUTRITION, OBESITY, AND EATING DISORDERS

A. Development of novel methods and tools to accurately evaluate nutritional status, physical activity, and energy expenditure.

B. Development of a non-invasive breath or blood test to accurately measure dietary intake.

C. Development of better means to detect food borne pathogens with the goals of (1) preventing their inclusion in foodstuffs and (2) better treatment of acute infections.

D. Development of safe drugs that inhibit appetite or increase energy expenditure.

Kidney, Urologic and Hematologic Diseases

The Division of Kidney, Urologic, and Hematologic Diseases supports research into basic mechanisms of the organ and tissue function, and the diseases of the kidney, urologic and hematologic systems. Projects are expected to help develop an understanding of the physiology, pathophysiology, and related diseases of the kidney, urinary tract, and blood and blood forming systems so that rational treatments, prevention strategies, and/or arrest of diseases may be devised. Support for advances in the technology of cell and
molecular biology that will enhance research in kidney, urologic and hematologic diseases is encouraged. Development of –omics, bioinformatics, and multi-scale technologies for the study of these systems, especially where these systems interact, is also encouraged. Research opportunities of interest to small businesses include, but are not limited to:

I. KIDNEY DISEASES

Areas of research include chronic kidney disease, end-stage renal disease, diabetic nephropathy, polycystic kidney disease, hypertensive nephrosclerosis, acute kidney injury, kidney donation, congenital kidney disorders, IgA nephropathy, hemolytic uremic syndrome, fluid and electrolyte disorders, kidney repair and regeneration, and normal and abnormal kidney development and physiology.

**Dialysis, Devices and Medical Technologies**

A. Development of innovative forms of renal dialysis which improve efficiency and/or have lower associated morbidity (e.g., artificial kidney, implantable or wearable dialyzers).

B. Development of pharmacological agents, devices, techniques, or diagnostics that enhance maturation and longevity of a vascular access.

C. Development of dialysis membrane technologies with enhanced biocompatibility and anti-fouling properties.

D. Development of a means to provide continuous anticoagulation.

E. Development of reliable, non-invasive, online monitoring systems for real-time assessment of treatment parameters such as blood volume, access flow, and urea clearance.

F. Development of new agents for sterilizing dialysis membranes and development of agents or methods to reduce catheter-related infections in hemodialysis or peritoneal dialysis.

G. Development of hemodialysis or peritoneal dialysis catheters using improved biomaterials, which decrease the foreign body response, biofouling, and biofilm formation.

H. Development of devices or techniques to enhance the success of kidney transplantation (e.g., techniques for kidney storage and preservation).

I. Development of health information technologies or mobile technologies that enhance delivery of care for patients with kidney diseases.

**Diagnostics and Imaging**

J. Development of non- or minimally-invasive methods for evaluating kidney function, including in individuals with congenital genitourinary conditions.

1. Reliable, non-invasive, non-radioactive methods of measuring glomerular filtration rate (GFR).
2. Translation of biomarkers of acute kidney injury or chronic kidney disease with clinical utility into commercial assays.
3. Translation of biomarkers for early detection of kidney diseases or prediction of kidney disease progression, recovery, or drug response.

K. Development of improved renal imaging techniques, differential renal function assessment, diagnostic assessment of non-malignant kidney diseases, or measurement of perinatal nephron endowment.
L. Development of technology to improve collection of real-time data (e.g., biomarkers, diet, physical activity, vital signs, psychological parameters, environmental factors), patient outcomes, and adherence for clinical studies (e.g., studies of gene-environment interactions in the manifestation of kidney diseases).

M. Development of imaging or molecular analysis technologies to enhance information extraction from renal biopsies and development of antibodies or other probes for unique cell types of the kidney.

**Drug Discovery and Development**

N. Lead optimization and preclinical development of pharmacological agents that might be used to intervene in acute or chronic renal disorders and in disorders of renal hemodynamics, blood pressure, electrolyte metabolism, and extracellular volume regulation.

O. Development of technologies to enhance the validation of kidney disease targets (e.g., more relevant animal models of acute kidney injury).

P. Development of data and cell banks (e.g., of diabetic kidney disease families and polycystic kidney disease families) for use by the research community.

Q. Development of preventative measures for acute kidney injury (e.g., during coronary artery bypass grafting, sepsis, or treatment with nephrotoxic agents).

**II. UROLOGIC DISEASES**

Areas of research include benign prostatic hyperplasia, lower urinary tract symptoms (LUTS) including urinary incontinence, urinary tract infections, urinary stones, erectile dysfunction, urologic chronic pelvic pain syndromes (including interstitial cystitis and chronic prostatitis), congenital urologic disorders, repair and regeneration of lower urinary tract organs, and normal and abnormal lower urinary tract development, and genitourinary physiology.

**Diagnostics and Imaging**

A. Translation of urine biomarkers of inflammatory processes in the lower urinary tract or other urologic disorders into commercial assays with clinical utility.

B. Development of non-invasive or minimally-invasive methods to diagnose bladder inflammation or changes in the urothelium that are not of a cancerous origin.

C. Development of new technologies or methods with reduced radiation dose for evaluating vesico-ureteral reflux in children and infants.

D. Development of diagnostic modes to clinically and non-invasively or minimal-invasively measure bladder outlet obstruction before and after surgical or pharmaceutical intervention.

E. Development of objective diagnostic devices or methods for the assessment of urinary storage and voiding disorders, including stress, urge, and mixed incontinence, in both adults and children.

F. Development of wireless and non-invasive or minimally-invasive measurement technologies for real-time assessment of lower urinary tract function, which can include neuro-pharmacological/neuro-physiological urodynamics.

**Drug and Device (Therapeutic) Interventions**
G. Lead optimization and preclinical development of pharmacological agents for treatment or prevention of urinary stone disease (urolithiasis), urological chronic pelvic pain syndromes, urinary tract infections, or other benign urologic diseases.

H. Development of novel neuromodulation devices, which restore function or mitigate pain conditions of the lower urinary tract.

I. Development of urinary catheters which reduce the incidence of infection in the urinary tract and decrease urethral and bladder inflammation.

J. Development of technologies for treatment of bladder outlet obstruction.

K. Development of health information technologies or mobile/wireless technologies that enhance delivery of care for patients with benign urologic diseases, including transition in lifelong care of congenital genitourinary conditions.

L. Development of bioengineered materials or structures, including cell-laden structures, for the repair or regeneration of lower urinary tract organs.

Research Tools

M. Development of tools for elucidating the role of urinary or gut microbiome in urinary stone disease or other benign urologic diseases.

N. Development of novel models of benign prostate hyperplasia.

O. Development of technology to improve collection of real-time data (e.g., biomarkers, diet, physical activity, vital signs, psychological parameters, and environmental factors), patient-reported outcomes, and adherence for clinical studies (e.g., studies of gene-environment interactions in the manifestation of urologic diseases).

III. HEMATOLOGIC DISEASES

The NIDDK hematology research program focuses on understanding basic cellular and molecular mechanisms that underlie the production and function of blood cells in health and disease. The program emphasizes translational applications of new insights and knowledge gained from basic research in these areas toward the development of novel or improved approaches for the diagnosis, stratification, and treatment of hematologic diseases. This includes the development of disease biomarkers, gene targeted therapies, hematopoietic stem cell transplantation in heritable blood diseases, and the measurement and chelation of tissue iron in iron overload disorders. The NIDDK hematology research program provides resources for basic and preclinical development efforts leading up to IND or IDE submissions but does not fund clinical trials. The program has a particular focus on myeloid lineage and hematopoietic stem cells, including the effects of aging on hematopoiesis.

Drug Discovery and Development

A. Establishment of robust in vitro or animal models of benign hematologic diseases for drug discovery or development.

B. Development of therapeutics that target elements of hematopoietic stem cell niches (e.g., stromal cells, osteoblasts, endothelium, macrophages, pericytes, nerve cells).

C. Development of therapeutics that modulate blood cell production from hematopoietic stem cells and progenitors based upon understanding of physical and chemical regulatory pathways.
D. Development of therapeutics that modulate metabolism, storage, and transport of iron.

**Cell Therapies**

E. Development of equipment, chemically-defined reagents, and methods for high volume ex vivo expansion, isolation, and/or differentiation of highly purified human hematopoietic stem and progenitor cells.

F. Development of therapeutics that induce fetal hemoglobin synthesis by chemical means, genome editing, or other means.

G. Development of therapeutics that target blood cell membrane structure.

**Diagnostics and Imaging, Medical Technologies, and Research Tools**

H. Development and validation of sensitive, specific, reproducible, quantitative, and clinically applicable assays for measuring levels or expression of iron regulatory molecules (e.g., hepcidin).

I. Development of technologies to track, purify, monitor or assay single-cells in vivo or in vitro.

J. Development of non-invasive systems for monitoring circulating blood cells, blood chemistry or blood cell production.

K. Development of imaging technology for the non-invasive measurement of bone marrow cellularity and function.

L. Development of imaging technology for the non-invasive measurement of tissue iron loading and distribution.

M. Development of technologies to understand the roles of mitochondria in benign hematologic diseases.

**NIDDK Clinical Trials Topics:**

NIDDK will accept clinical trials in any area listed above in the non-clinical trials topics.

For additional information on research topics, contact:

**DIABETES, ENDOCRINOLOGY AND METABOLIC DISEASES**

Dr. Guillermo Arreaza-Rubín  
National Institute of Diabetes and Digestive and Kidney Diseases  
301-594-4724  
Email: ga96b@nih.gov

Dr. Yan Li  
National Institute of Diabetes and Digestive and Kidney Diseases  
301-435-3721  
Email: liy7@mail.nih.gov
**DIABETES COMPLICATIONS**

Dr. Teresa L. Z. Jones  
National Institute of Diabetes and Digestive and Kidney Diseases  
301-435-2996  
Email: teresa.jones@nih.gov

**DIGESTIVE DISEASES AND NUTRITION**

Ms. Christine Densmore  
National Institute of Diabetes and Digestive and Kidney Diseases  
301-402-8714  
Email: densmorec@mail.nih.gov

**KIDNEY, UROLOGIC AND HEMATOLOGIC DISEASES**

Dr. Daniel R. Gossett  
National Institute of Diabetes and Digestive and Kidney Diseases  
301-594-7723  
Email: daniel.gossett@nih.gov

For administrative and business management questions, contact:

Ms. Pamela Love  
National Institute of Diabetes and Digestive and Kidney Diseases  
301-435-6198  
Email: pl48m@nih.gov
NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES (NIEHS)

The mission of the National Institute of Environmental Health Sciences [www.niehs.nih.gov](http://www.niehs.nih.gov) is to discover how the environment affects people in order to promote healthier lives, with a vision of providing global leadership for innovative research that improves public health by preventing disease and disability. NIEHS achieves its mission and vision through a multidisciplinary biomedical research program, prevention and intervention efforts, and a communication strategy that encompasses training, education, technology transfer and community outreach. For additional information about NIEHS’s Small Business Programs, please visit [www.niehs.nih.gov/sbir](http://www.niehs.nih.gov/sbir). Join our listserv for program announcements [https://list.nih.gov/cgi-bin/wa.exe?SUBED1=sbir-niehs&A=1](https://list.nih.gov/cgi-bin/wa.exe?SUBED1=sbir-niehs&A=1). The major NIEHS SBIR/STTR research topics of potential interest include:

### Research Topics of Interest to NIEHS

The specific set of topics that are funded by a particular IC/Office/Agency depends on whether the IC/Office/Agency funds/supports Clinical Trials under SBIR/STTR Awards. Use the following table and explanations to determine which list of topics is applicable.

<table>
<thead>
<tr>
<th>Does IC/Office/Agency Fund/Support Clinical Trials under SBIR/STTR Awards?</th>
<th>No*</th>
<th>Yes**</th>
</tr>
</thead>
<tbody>
<tr>
<td>X</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

*If No,
- This IC/Office/Agency funds only those topics listed under the Non-Clinical Trials Topics section below, UNLESS the IC/Office/Agency funds a Small Business Concern for clinical trials under a NON-SBIR/STTR award.

**If Yes or the IC/Office/Agency funds small businesses for clinical trials under a NON-SBIR/STTR funding opportunity,
- See the table below for which mechanisms the IC/Office/Agency will allow for clinical trials research. Also, see the Clinical Trials Topics section below for a list of funded topics. This IC/Office/Agency also funds research listed under the Non-Clinical Trials Topics section below.

<table>
<thead>
<tr>
<th>Does IC/Office/Agency accept clinical trials applications under this mechanism?</th>
<th>Yes</th>
<th>No</th>
<th>Other Information: If funding an SBC for clinical trials under a NON-SBIR/STTR award, please identify activity code(s) and other relevant information.</th>
</tr>
</thead>
<tbody>
<tr>
<td>Clinical Trials SBIR/STTR Omnibus/Parent Funding Opportunity Announcement/s</td>
<td>X</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Clinical Trials SBIR/STTR IC/Office/Agency - Specific Funding Opportunity Announcement/s</td>
<td>X</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
Does IC/Office/Agency accept clinical trials applications under this mechanism?

<table>
<thead>
<tr>
<th>Yes</th>
<th>No</th>
</tr>
</thead>
</table>

Clinical Trials NON-SBIR/STTR Funding Opportunity Announcement/s where Small Businesses are eligible to apply

Clinical Trials NON-SBIR/STTR Funding Opportunity Announcement/s where Small Businesses are eligible to apply

X

NIEHS Non-Clinical Trials Topics:

**Exposure Assessment Tools**

The NIEHS Exposure Biology Program encompasses the totality of the exposures that a person experiences from conception to death along with the associated biological responses to those exposures. Validated tools are needed to measure, analyze, and predict a wide range of internal and external exposures and health outcomes across diverse geographic populations. These tools should be designed fit-for-purpose in collaboration with the stakeholders (e.g., community outreach programs, citizen scientists, disaster response personnel, epidemiologists, or clinical researchers). Examples include:

**Sensors**
- Technologies to assess personal exposure in population studies, including networks of fixed site and wearable monitors
- Personal, wearable, real-time devices for measurements across multiple stressors and scales (e.g., time, space, route of exposures, distribution), with an emphasis on high sensitivity and specificity and low-cost devices, when feasible. High-priority analytes include ultrafine particulates, PAHs, and pesticide exposures
- Sensor technologies that can be integrated into existing smart devices for sensing personal environment
- Personal sensors that are easily worn and durable that can be rapidly deployed after a disaster by researchers to emergency response workers and individuals in the community to help understand dermal and/or airborne exposure levels, locations, and times.

**Computational and informatics-based tools and methods**
- Computational and statistical approaches to integrate exposure data from different sources, including publicly available databases, and monitoring approaches (e.g., sensors, remote sensing, and biomonitoring), to provide quantitative exposure estimates
- Novel tools and methodologies to collect, analyze, and visualize exposure data from large population studies, especially temporally and spatially-resolved exposure data (such as crowdsourcing and exposure mapping)
- Informatics tools and platforms to organize, store and retrieve complex exposure and health data
- Improved identification and characterization methods for untargeted, high-throughput metabolomics analysis of xenobiotics
- Informatic tools that can be used by the research community to rapidly build environmental health disaster research protocols similar to the NIEHS RAPIDD Protocol [https://dr2.nlm.nih.gov/protocols#rapidd](https://dr2.nlm.nih.gov/protocols#rapidd) from existing information, tools, and platforms (e.g., PhenX, PROMIS, and Disaster Research Response DR2 Repository) to support rapid research response efforts in the U.S. and globally.
• Informatic and data management tools for disaster response that enable rapid collation and integration of data from stationary sources and personal exposure monitors and survey information collected from individuals using mobile platforms
• Mobile Apps for collecting health and exposure survey information from study participants involved in disaster research responses.
• Mobile devices and Apps for collecting information on environmental exposures from study participants involved in disaster research responses.

Information on the NIEHS Exposure Biology Program can be found at http://www.niehs.nih.gov/research/supported/exposure/bio/

Nano Environmental Health and Safety

The NIEHS Nano Environmental Health and Safety (Nano EHS) program is interested in the detection of engineered nanomaterials (ENMs) in the environment, in consumer products, and in biological samples, and is interested in technologies or methods that can predict toxicity potential of ENMs.

High priority engineered nanomaterials of interest are those with a potential for human exposure.

Examples include:
• Sensors that can detect metal, carbonaceous engineered nanomaterials in air, water, and consumer products, and provide a contextual assessment of the toxicological potential
• Biomonitoring technologies for personal monitoring that can detect engineered nanomaterials using non- or minimally-invasive approaches

Information on the Nano EHS program can be found at http://www.niehs.nih.gov/research/supported/exposure/nanohealth/index.cfm

Toxicity Screening, Testing, and Modeling

NIEHS supports research to identify the hazards, as well as the mechanistic understanding, of effects of environmental stressors on biological systems that can lead to adverse health outcomes. To increase the ability to characterize or predict the toxicity of environmental stressors, the National Toxicology Program (NTP) http://ntp.niehs.nih.gov/ at NIEHS is interested in technologies to support the goals and initiatives of the Tox21 Program http://ntp.niehs.nih.gov/results/tox21/index.html. Phase III of Tox21 is focused on expanding biological endpoints and relevance to humans. The following efforts support Tox21 and other NTP goals:

Improved or expanded testing methods for toxicity screening

These approaches should include the development of physiologically-relevant cell-based systems or phylogenetically lower-order animal models. In vitro approaches should effectively model cellular functions and responses to chemical exposure reflective of responses in humans or animals, and may be used to reduce or replace in vivo animal use. High priority areas are the development of metabolically competent in vitro screening models and assay systems for various tissue types (e.g., liver, GI tract, kidney, neurological, mammary gland, lung, and cardiac). Examples include:

• Improved human organotypic models that more accurately predict in vivo function for characterizing toxicity and/or disease processes
• Organotypic models using isolated primary cells from rat or mouse models or other experimental animal models, which can enable comparisons between in vivo and in vitro toxicity endpoints
• Data-rich in vitro approaches that incorporate medium-throughput ‘omics and/or high-content imaging for toxicity screening
- **In vitro** toxicology screening models to predict ‘idiosyncratic’ compound-induced effects in humans (e.g., drug-induced liver injury or cytokine storm)
- **In vitro** model systems that incorporate barrier functionality and transport functions into tissue models (e.g., kidney, placenta, or blood-brain barrier)
- Enhanced lower organism models (e.g., zebrafish or C. elegans) for toxicity screening
- Stem cell models and assays for evaluating the effects of toxicants on cell differentiation with multiple functional endpoints
- Screening systems that incorporate genetic diversity into toxicity testing (e.g., panels of human iPS cells or rodent stem cells)
- **In vitro** assays to model inflammatory responses to xenobiotics
- Short-term tests, assays, or systems designed specifically to reduce or replace existing regulatory animal studies for acute toxicity (oral or inhalation), reproductive or developmental toxicity, carcinogenicity, or ocular toxicity
- Short-term tests, assays, or multiplex-systems/approaches designed specifically to help provide rapid toxicology screening level characterization of complex mixed chemical exposures in response to disasters

**Computational approaches for predictive toxicology**
- New computational systems and tools for integrating toxicity data, including in vivo data, which analyze and visualize data across different screening systems
- Improved experimental and computational tools for in vitro to in vivo extrapolation of xenobiotic exposures across a range of assay types
- Computational tools for quantitatively modeling metabolic transformation of xenobiotics
- Computational tools or systems for rapidly assessing results of relevant literature and short-term tests, assays, or other relevant testing to help provide screening level risk characterization of complex mixed chemical exposures in response to disasters

**Other technologies for enhanced toxicology testing**
- Alternative or improved methods for fixing and preserving tissues that maintain cellular structure for histopathology while minimizing degradation of nucleic acids (RNA, miRNA, DNA, methylated DNA), proteins or metabolites, so that archival tissue blocks can be better used for molecular analysis

**Biomarkers of Exposure and Response**

To better understand the risks to human health from environmental agents, NIEHS supports the development and validation of biomarkers of exposure, including improved measures of internal dose, DNA adduct identification, and untargeted analysis for metabolite identification, and biomarkers of response, including assays that can distinguish reversible from irreversible changes in target organs or surrogate tissues. Examples include:

**Biomonitoring technology**
- Personal or point-of-care monitoring technologies for rapid detection of multiple exposures in biospecimens using non- or minimally-invasive approaches
- Devices that can continuously monitor and report exposures in real-time
- Improved methods to detect DNA or protein adducts resulting from exogenous exposures

**Biological response markers**
- Markers of oxidative stress, inflammation, DNA damage response, immune function, mitochondrial dysfunction, or altered epigenetic regulation
- High priority human biomarkers include, but are not limited to: inflammation biomarkers, plasma- or serum-based markers that reflect altered RNA, protein expression, or metabolite profiles, markers developed in exhaled breath, buccal cells, or other easily accessible, non-
invasive biological samples, miRNA or other exosome biomarkers, and epigenetic markers in surrogate tissue reflecting modifications in target tissues

**Intervention Technologies**

NIEHS supports efforts to prevent or reduce exposures to environmental stressors that affect human health. Technologies to reduce exposure may include:

- Technologies for removing contaminants from drinking water for home use
- Approaches for reducing volatile compounds and other inhaled toxicants for use in the home, workplace, and school settings. Examples may include improved air filtration systems as well as technologies to monitor the efficacy of filtration systems
- Technologies and applications that can provide real-time alert about relevant environmental exposures in sensitive populations (such as asthmatic population)

**Education/Outreach**

As part of its Partnerships for Environmental Public Health (PEPH) Program, NIEHS is interested in developing tools that build capacity, improve environmental health literacy, and support citizen science endeavors. These approaches or resources should be fit for purpose to meet the needs of the following audiences: community members, health care and public health professionals, educators, and students of all ages. Approaches may include:

- Mobile applications that provide environmental health information about exposures of concern in food, air, water, or consumer products. These may include
  - Apps that provide the context for the exposures such as single or multiple, interacting exposures, level of exposure, frequency and proximity to source
  - Apps that can be adapted for various age groups (e.g., children or the elderly), races, ethnicities and/or languages
  - Apps that visualize exposure risks with respect to levels of exposure, sources and health risks
- Devices for collecting and reporting information on exposures in environmental samples for educational purposes in schools or communities
- Systems that can utilize public and voluntary population data from sensors, activity trackers, GIS enabled devices, social communications, and surveillance cameras; for example, to assist disaster response and communication
- Educational resources related to environmental health in school settings or community education programs (e.g., Photovoice projects or GIS mapping)
- Training materials for wider dissemination of risk information (e.g., resources for high school students to train younger students; or community leaders to build capacity of other community residents)
- Continuing medical education classes, on-line courses, or on-line tools to build the environmental health literacy of health care professionals
- Documentaries, short films, or television shows on environmental health science topics with accompanying discussion guides, lessons, or activities to facilitate broader use of the programming

Information on the PEPH program can be found at [https://www.niehs.nih.gov/research/supported/translational/peph/index.cfm](https://www.niehs.nih.gov/research/supported/translational/peph/index.cfm)

**Hazardous Substances Remediation and Site Characterization SBIR Program**

The NIEHS Superfund Hazardous Substance Basic Research and Training Program (SRP) supports the "Hazardous Substances Remediation and Site Characterization Small Business Innovation Research
Program” (SBIR R43, R44) to foster the commercialization of technologies, products, and devices for remediation and detection of hazardous substances in the environment. The SRP is specifically interested in proposals applying innovative engineering, bioengineering, biotechnology, computational, and materials science approaches to significantly improve the cost-effectiveness, efficiency, and speed of remediation and site characterization. Topics of interest include, but are not limited to:

**Remediation**
- Novel technologies for *in situ* remediation of contaminated sediments, soils, and groundwater
- Innovative bio Remediation and phytoremediation technologies including development and culturing/propagation of plants, bacterial strains, or fungal species optimized for bioremediation
- Technologies to remediate chemical mixtures in environmental media
- Portable adsorption systems for removing chlorinated volatile organic compounds (VOCs) from indoor air to achieve risk-based indoor air standards
- Nano-enabled structures, electrochemical methods, photocatalytic processes, thermal treatments, or filtration-based methods of remediation
- New strategies for delivery of reagents for groundwater remediation: *in situ* chemical oxidation ISCO), zero valent iron (ZVI), and hydraulic fracturing (note: this excludes gas exploration)
- New strategies for delivery of reagents for recovery/extraction of contaminants in groundwater

**Site Characterization**
- Computational, geographical information system-based, or modeling products for predicting fate and transport of contaminants, rates of remediation, or for identifying contamination sources
- Real-time, on-site monitoring: soil, surface water, groundwater, subsurface, sediments, air (such as volatile releases from sites), etc.
- Nanotechnology-based sensors and probes, biosensors, lab-on-chip, and miniaturized analytical probes; miniaturized data analysis tools
- Products that allow for rapid sample clean-up/preparation for analysis of environmental samples
- Self-contained miniaturized toxicity-screening kits for detecting contaminant-specific hotspots
- Non-targeted or multi-analyte field sampling devices or kits, including sample collection products that can sequester a suite of analytes for later analysis
- Assays or devices to determine the extent to which a contaminant is bioavailable

**Examples of remediation and site characterization needs:**
- Devices to detect and measure vapor intrusion or to detect non-aqueous phase liquids (NAPLs) and dense non-aqueous phase liquids (DNAPLs) in the subsurface
- Site characterization techniques and strategies for complex geology (fractured, karst and heterogeneous layered deposits)
- Technologies for rapid extraction or processing of soil for incremental sampling methodologies (ISM)
- Technologies for automated elongated mineral fiber counting (e.g. for asbestos samples)
- Active or passive remediation technologies for mining influenced water
- Remediation technologies for poly- and perfluorinated alkyl substances such as perfluorooctane sulfonic acid (PFOS) and perfluorooctanoic acid (PFOA)
- Novel green or sustainable detection technologies and remediation approaches that improve energy efficiency and reduce waste generation

Applicants must demonstrate that the proposed technologies are relevant to Superfund. Per program mandates described in the Superfund Amendment Reauthorization Act (SARA), SRP does not accept applications targeting oil or gas site characterization/remediation. Applicants are strongly encouraged to
stay within the statutory budget guidelines whereby total funding support (direct costs, indirect costs, fees) does not exceed $150,000 for Phase I awards and $1,000,000 for Phase II awards. Applicants are encouraged to contact NIH program officials prior to submitting any award budget for the "Hazardous Substances Remediation and Site Characterization Small Business Innovation Research Program" in excess of these amounts.

Please note: the NIEHS Superfund Research Program (SRP) "Hazardous Substances Remediation and Site Characterization Small Business Innovation Research Program" no longer accepts Small Business Technology Transfer Grant (STTR: R41, R42) applications.

Information on the NIEHS SRP can be found at https://www.niehs.nih.gov/research/supported/centers/srp/hwaerp/index.cfm

Worker Training Program

The NIEHS Worker Training Program (WTP) is interested in the development of Advanced Technology Training (ATT) products for the health and safety training of hazardous materials (HAZMAT) workers; skilled support personnel; emergency responders in biosafety response, infectious disease training and cleanup; and emergency responders in disasters and resiliency training. ATT as defined by the Worker Training Program (WTP) includes, but is not limited to, online training, virtual reality, and serious gaming, which complement all aspects of training from development to evaluation including advance technologies that enhance, supplement, improve, and provide health and safety training for hazardous materials workers. WTP accepts solicitations via requests for applications (RFA). Please contact Kathy Ahlmark ahlmark@niehs.nih.gov for information on the next solicitation date, which differs from the standard receipt dates of this NIH omnibus.

Information on the WTP program can be found at https://www.niehs.nih.gov/careers/hazmat/about_wetp/

NIEHS DOES NOT Fund

- Technologies for the detection and remediation of pathogens in the environment - contact EPA or DoD for information on SBIR funding opportunities for this topic.

NIEHS Clinical Trials Topics:

NIEHS will not accept SBIR applications that propose clinical trials and all of the topics listed must be for projects that do not propose clinical trials.

For additional information on research topics, contact:

Dr. Daniel Shaughnessy  
National Institute of Environmental Health Sciences  
Division of Extramural Research and Training  
POB 12233 (K3-12)  
Research Triangle Park, NC 27709  
(984) 287-3321  
Email: shaughn1@niehs.nih.gov

For information on the NIEHS Superfund Research Program - Hazardous Substances Remediation and Site Characterization SBIR Program, contact:

Dr. Heather Henry  
National Institute of Environmental Health Sciences
Division of Extramural Research and Training
POB 12233 (K3-12)
Research Triangle Park, NC 27709
(984) 287-3268
Email: henryh@niehs.nih.gov

For administrative and business management questions contact:

Ms. Pam Clark
National Institute of Environmental Health Sciences
Division of Extramural Research and Training
Grants Management Branch
POB 121233 (K3-11)
Research Triangle Park, NC 27709
(984) 287-3246
Email: evans3@niehs.nih.gov

For express mail:
530 Davis Drive (K3-12)
Morrisville, NC 27560
NATIONAL EYE INSTITUTE (NEI)

The mission of the NEI is to conduct and support research, training, health information dissemination, and other programs with respect to blinding eye diseases, visual disorders, mechanisms of visual function, preservation of sight, and the special health problems and requirements of the blind.

Limited Amount of Award

For budgetary, administrative, or programmatic reasons, NEI may decrease the length of an award and/or the budget recommended by a review committee, or not fund an application. For topics listed in APPENDIX A: National Institutes of Health SBA-Approved SBIR/STTR Topics for Awards over Statutory Budget Limitations, NEI does not generally fund Phase I applications greater than $300,000 total costs or project periods greater than 2 years; or Phase II applications greater than $2,000,000 total costs or project periods greater than 3 years.

Phase IIB Competing Renewal Awards

The NEI will only accept SBIR Phase IIB Competing Renewal grant applications from Phase II SBIR awardees to continue the process of developing technologies that ultimately require federal regulatory approval or require extraordinary time and effort in the Research and Development phase. Such technologies include, but are not limited to, pharmacologic agents, biological products, and devices. These technologies should be clearly related to the mission of the NEI. This renewal grant should allow small businesses to reach a stage in the project where interest and investment by third parties is more likely. The NEI expects that the Phase IIB grant will accelerate the transition of SBIR Phase II projects to the commercialization stage. The NEI encourages applicants to establish business relationships with third-party investors and/or strategic partners who can provide substantial financing to help accelerate the commercialization of promising new products and technologies that were initiated with SBIR funding. The Competing Renewal application must be a logical extension of a previously completed Phase II (R44) SBIR grant. NEI grantees seeking SBIR Phase IIB Competing Renewal funding must submit an application within a period no later than the first six receipt dates following expiration of the previous Phase II budget period. Budgets not to exceed $750,000 total costs per year and time periods up to two (2) years may be requested for this SBIR Phase IIB Competing Renewal opportunity.

Potential applicants are strongly advised to contact Dr. Jerome Wujek (contact information provided below) before beginning the process of putting an application together.

Research Topics of Interest to NEI

The following topics are meant for illustrative purposes only and are not exclusive of other appropriate activities.

The specific set of topics that are funded by a particular IC/Office/Agency depends on whether the IC/Office/Agency funds/supports Clinical Trials under SBIR/STTR Awards. Use the following table and explanations to determine which list of topics is applicable.

<table>
<thead>
<tr>
<th>Does IC/Office/Agency Fund/Support Clinical Trials under SBIR/STTR Awards?</th>
<th>No*</th>
<th>Yes**</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td>X</td>
</tr>
</tbody>
</table>

*If No,

- This IC/Office/Agency funds only those topics listed under the Non-Clinical Trials Topics section below, **UNLESS** the IC/Office/Agency funds a Small Business Concern for clinical trials under a NON-SBIR/STTR award.
**If Yes or the IC/Office/Agency funds small businesses for clinical trials under a NON-SBIR/STTR funding opportunity,**

- See the table below for which mechanisms the IC/Office/Agency will allow for clinical trials research. Also, see the Clinical Trials Topics section below for a list of funded topics. This IC/Office/Agency also funds research listed under the Non-Clinical Trials Topics section below.

<table>
<thead>
<tr>
<th>Does IC/Office/Agency accept clinical trials applications under this mechanism?</th>
<th>Yes</th>
<th>No</th>
<th>Other Information: If funding an SBC for clinical trials under a NON-SBIR/STTR award, please identify activity code(s) and other relevant information.</th>
</tr>
</thead>
<tbody>
<tr>
<td>Clinical Trials SBIR/STTR Omnibus/Parent Funding Opportunity Announcement/s</td>
<td>X</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Clinical Trials SBIR/STTR IC/Office/Agency - Specific Funding Opportunity Announcement/s</td>
<td>X</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Clinical Trials NON-SBIR/STTR Funding Opportunity Announcement/s where Small Businesses are eligible to apply</td>
<td>X</td>
<td>R01 PA-18-351 R24 PAR-17-099 UG1 PAR-18-521</td>
<td></td>
</tr>
</tbody>
</table>

**NEI Non-Clinical Trials Topics:**

A. **General Research and Development Topics**: NEI is interested in providing support for the development of new technologies, strategies, research tools, reagents and methods that can be applied to basic and translational research which will benefit vision health. This encompasses research and development of innovative enabling technologies in areas of genomics, proteomics and nanotechnology. More specific topics include drug and high throughput assays; drug delivery systems; gene therapy, cell-based therapy and regenerative medicine; development of in vitro and in vivo disease models; surgical devices and materials; telemedicine, mobile health, and health education; and design/fabrication of new or improved ophthalmic instruments for diagnosis and treatment of eye disorders.

B. **Retinal Diseases**: New therapeutic approaches for inflammatory and degenerative diseases and for inhibition of abnormal angiogenesis in the retina and choroid; Better methods of diagnosing and treating diabetic retinopathy and other vascular diseases; Non-invasive techniques for early diagnosis of macular degeneration and other retinal degenerative diseases; Instruments and procedures for improved surgical management of retinal detachments; Retinal prostheses to help restore visual function; Gene therapy/optogenetic methods for light sensitivity restoration in the retina; Better methods for cell or tissue transplantation.
C. **Corneal Diseases**: New diagnostic tools, therapeutic agents and drug delivery methods for the treatment of corneal injury, infection, dry eye, ocular pain, and other ocular surface disorders; New biomaterials for corneal prostheses and corneal transplants; Instruments and procedures for correcting the refractive power of the cornea and/or measuring the cornea's optical properties or other physiological properties.

D. **Lens and Cataract**: New approaches in the post-operative management of cataract surgery; New surgical instruments for cataract extraction and new biomaterials for replacement of the natural lens; Design/fabrication of aspheric, toric, multifocal and accommodating intraocular lenses.

E. **Glaucoma and Optic Neuropathies**: New therapeutic agents, instruments, and procedures for the diagnosis and treatment of glaucoma; Non-invasive methods to measure changes in the optic nerve head and retinal fiber layer.

F. **Strabismus, Amblyopia, and Refractive Error**: New approaches to detect and treat strabismus, amblyopia, and myopia; New tools and techniques for vision screening; New or improved methods and materials for correcting the refractive power of the eye and/or measuring the eye's optical properties or other physiological properties; New materials and manufacturing processes for eyeglasses and contact lenses; prosthetic devices (both cortical and subcortical) for vision restoration.

G. **Visual Impairment and Blindness**: Instruments and methods to better specify, measure, and categorize residual visual function; New or improved devices, systems, or programs that meet the rehabilitative, adaptive, and everyday living needs of visually-impaired/blind people.

**NEI Clinical Trials Topics:**

A. **General Research and Development Topics**: NEI is interested in providing support for the development of new technologies, strategies, research tools, reagents and methods that can be applied to basic and translational research which will benefit vision health. This encompasses research and development of innovative enabling technologies in areas of genomics, proteomics and nanotechnology. More specific topics include drug and high throughput assays; drug delivery systems; gene therapy, cell-based therapy and regenerative medicine; development of in vitro and in vivo disease models; surgical devices and materials; telemedicine, mobile health, and health education; and design/fabrication of new or improved ophthalmic instruments for diagnosis and treatment of eye disorders.

B. **Retinal Diseases**: New therapeutic approaches for inflammatory and degenerative diseases and for inhibition of abnormal angiogenesis in the retina and choroid; Better methods of diagnosing and treating diabetic retinopathy and other vascular diseases; Non-invasive techniques for early diagnosis of macular degeneration and other retinal degenerative diseases; Instruments and procedures for improved surgical management of retinal detachments; Retinal prostheses to help restore visual function; Gene therapy/optogenetic methods for light sensitivity restoration in the retina; Better methods for cell or tissue transplantation.

C. **Corneal Diseases**: New diagnostic tools, therapeutic agents and drug delivery methods for the treatment of corneal injury, infection, dry eye, ocular pain, and other ocular surface disorders; New biomaterials for corneal prostheses and corneal transplants; Instruments and procedures for correcting the refractive power of the cornea and/or measuring the cornea's optical properties or other physiological properties.

D. **Lens and Cataract**: New approaches in the post-operative management of cataract surgery; New surgical instruments for cataract extraction and new biomaterials for replacement of the natural lens; Design/fabrication of aspheric, toric, multifocal and accommodating intraocular lenses.
E. **Glaucoma and Optic Neuropathies:** New therapeutic agents, instruments, and procedures for the diagnosis and treatment of glaucoma; Non-invasive methods to measure changes in the optic nerve head and retinal fiber layer.

F. **Strabismus, Amblyopia, and Refractive Error:** New approaches to detect and treat strabismus, amblyopia, and myopia; New tools and techniques for vision screening; New or improved methods and materials for correcting the refractive power of the eye and/or measuring the eye's optical properties or other physiological properties; New materials and manufacturing processes for eyeglasses and contact lenses; prosthetic devices (both cortical and subcortical) for vision restoration.

G. **Visual Impairment and Blindness:** Instruments and methods to better specify, measure, and categorize residual visual function; New or improved devices, systems, or programs that meet the rehabilitative, adaptive, and everyday living needs of visually-impaired/blind people.

**Additional Information**

The NEI's programs are described in more extensive detail in documents which are available from the Institute. For additional information about the research programs of the NEI, please visit our home page at [http://www.nei.nih.gov](http://www.nei.nih.gov).

For more information on research topics, contact:

Jerome Wujek, Ph.D.
Research Resources Officer
Division of Extramural Research
National Eye Institute
Suite 1300, 5635 Fishers Lane
Bethesda, MD 20892
National Eye Institute
301-451-2020, Fax: 301-496-2297
Email: wujekjer@nei.nih.gov

For administrative and business management questions, contact:

Ms. Karen Robinson Smith
Acting Chief Grants Management Officer
Grants Management Branch
Division of Extramural Activities
National Eye Institute, NIH, DHHS
Suite 1300, 5635 Fishers Lane
Bethesda, MD 20892
301-451-2020, Fax: 301-496-9997
Email: kyr@nei.nih.gov
NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES (NIGMS)

The NIGMS supports research and research training in the basic medical sciences and related natural and behavioral sciences and in specific clinical areas (i.e., clinical pharmacology, trauma and burn injury, sepsis, wound healing, and anesthesiology). NIGMS supports research of potential interest to small businesses and their collaborators through the:

- Division of Cell Biology and Biophysics
- Division of Genetics and Developmental Biology
- Division of Pharmacology, Physiology, and Biological Chemistry
- Division of Biomedical Technology, Bioinformatics, and Computational Biology
- Division of Training, Workforce Development, and Diversity
- Center for Research Capacity Building

For additional information about areas of interest to the NIGMS, please visit our home page at http://www.nigms.nih.gov. This site includes staff contact information by program area (http://www.nigms.nih.gov/about/pages/contactbyarea.aspx).

Limited Amount of Award

According to statutory guidelines, total funding support (direct costs, indirect costs, fee) normally may not exceed $150,000 for Phase I awards and $1,000,000 for Phase II and Phase IIB awards. With appropriate justification from the applicant, awards may exceed these amounts by up to 50%, which is a hard cap ($225,000 for Phase I and $1,500,000 for Phase II and Phase IIB). NIGMS will not accept applications with budget requests exceeding this hard cap with the exception of projects fitting within the list of SBA-approved topics for awards over the statutory budget limitations; the entire list for NIH (including NIGMS) may be found in Appendix A of this document.

If considering a project with a budget exceeding the hard cap, applicants are strongly encouraged to contact NIGMS program officials prior to submission, and preferably earlier during application preparation. In all cases, applicants should propose a budget that is reasonable and appropriate for completion of the research project.

Phase IIB Competing Renewal Awards

NIGMS will accept Phase IIB SBIR-only Competing Renewal grant applications to continue the process of developing products that ultimately require 1) clinical evaluation, 2) approval by a Federal regulatory agency, or 3) continuing refinements that include but are not limited to cost reduction, testing for performance, safety, reliability and/or durability, and meeting or establishing standards, particularly for basic or clinical research instrumentation or durable medical equipment (DME) designs. This renewal grant should enhance the likelihood that small business will attract interest and investment by third parties. Such products include, but are not limited to research equipment, biological products, devices, drugs, medical implants, etc. within the mission of the NIGMS. Budgets for this Phase IIB Competing Renewal opportunity must follow the guidelines for Phase II applications (described above). For awards that are intended to support completion of research needed to obtain an Investigational New Drug application (IND) or Investigational Device Exemption (IDE), applicants must provide evidence that they have consulted formally with the FDA concerning the research needed for the development of a drug, biologic or medical device and that the proposed research will address these regulatory requirements. Such evidence should include FDA correspondence from a pre-IND meeting for an IND application or a pre-IDE meeting for an IDE application, and the status of the project in a timeline related to Federal regulatory approval processes.
Prospective applicants considering a Phase IIB Competing Renewal application are strongly encouraged to contact either the Program person of record for the Phase II award or NIH staff listed at the end of this NIGMS topics announcement.

To assist NIGMS in planning for Phase IIB applications, it is helpful for prospective applicants to submit to the NIGMS SBIR/STTR Coordinator (listed below) a letter of intent that includes the following information:

- Descriptive title of the proposed research
- Phase II grant number
- Name, address, and telephone number of the Principal Investigator
- Names of other key personnel
- Participating institutions
- Funding Opportunity Announcement Number

The letter is non-binding and does not enter into the review process. It is anticipated that only a small number of NIGMS SBIR Phase II awards would be eligible for a Phase IIB Competing Renewal award.

**Research Topics of Interest to NIGMS**

The specific set of topics that are funded by a particular IC/Office/Agency depends on whether the IC/Office/Agency funds/supports Clinical Trials under SBIR/STTR Awards. Use the following table and explanations to determine which list of topics is applicable.

<table>
<thead>
<tr>
<th>Does IC/Office/Agency Fund/Support Clinical Trials under SBIR/STTR Awards?</th>
<th>No*</th>
<th>Yes**</th>
</tr>
</thead>
</table>

*If No,

- This IC/Office/Agency funds only those topics listed under the Non-Clinical Trials Topics section below, **UNLESS** the IC/Office/Agency funds a Small Business Concern for clinical trials under a NON-SBIR/STTR award.

**If Yes or the IC/Office/Agency funds small businesses for clinical trials under a NON-SBIR/STTR funding opportunity,**

- See the table below for which mechanisms the IC/Office/Agency will allow for clinical trials research. Also, see the Clinical Trials Topics section below for a list of funded topics. This IC/Office/Agency also funds research listed under the Non-Clinical Trials Topics section below.

<table>
<thead>
<tr>
<th>Does IC/Office/Agency accept clinical trials applications under this mechanism?</th>
<th>Yes</th>
<th>No</th>
<th>Other Information: If funding an SBC for clinical trials under a NON-SBIR/STTR award, please identify activity code(s) and other relevant information.</th>
</tr>
</thead>
<tbody>
<tr>
<td>Clinical Trials SBIR/STTR Omnibus/Parent Funding Opportunity Announcement/s</td>
<td>X</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

NIH, CDC, and FDA Program Descriptions and Research Topics
### Does IC/Office/Agency accept clinical trials applications under this mechanism?

| Clinical Trials | Yes | No | Other Information: 
If funding an SBC for clinical trials under a NON-SBIR/STTR award, please identify activity code(s) and other relevant information. |
<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Clinical Trials NON-SBIR/STTR Funding Opportunity Announcement/s where Small Businesses are eligible to apply</td>
<td>X</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

---

https://www.nigms.nih.gov/Research/mechanisms/Pages/SBIR.aspx

https://www.nigms.nih.gov/Research/mechanisms/Pages/STTR.aspx

### NIGMS Non-Clinical Trials Topics:

**Division of Cell Biology and Biophysics**

Research on membrane synthesis, structure, and function; membrane models; membrane transport; cell division; cell organization; cell motility; and biophysics of proteins, nucleic acids, and biological assemblies, including viral entry, packaging, maturation, and release, as well as the development of instrumentation, components, and methods for the analysis of cellular components and macromolecules by imaging, spectroscopy, and diffraction analysis. Areas of interest, but not limited to, the topics listed below are welcome.

1. Development and improvement of methods for the expression, solubilization, and purification of milligram quantities of regulatory, cellular, and membrane associated proteins, as well as for the preparation of specifically labeled macromolecules and the recovery of proteins from inclusion bodies.
2. Development of novel ligands, inhibitors, and other probes for spectroscopic and microscopic analysis of cellular assemblies and viral structures, macromolecules and components, their localization and function *in vivo* and at a single molecule level.
3. Development of instrumentation, devices, and methods for detecting in real time, analyzing, and separating biologically important compounds, macromolecules, and their interactions.
4. Development of new methods and materials directed toward the solution of biological macromolecule structures, including membrane proteins, assemblies and complexes by, but not limited to, x-ray diffraction, electron diffraction, NMR and mass spectroscopy.

5. Imaging probes and sensors, other reagents and methods, instrumentation, software for microscopy, spectroscopy, and single molecule analysis of molecules, cells, tissues, embryos and small model organisms. Technologies for applications of microscopy, spectroscopy and single molecule analysis in basic biomedical research, including but not limited to light, electron, X-ray and scanning probe microscopy and fluorescence, magnetic and electron paramagnetic spectroscopy. NOT included are small animal and preclinical imaging and high throughput platforms for diagnostic and clinical applications.

6. Computational methods for analysis, prediction, and improving methods for determination of macromolecular structures and structure-function relationships.

7. Development of computerized tools that might be used in the presentation of the concepts of cell and structural biology to audiences at a variety of levels

**Division of Genetics and Developmental Biology**

Research on developing a better understanding of fundamental processes and mechanisms of development and inheritance in health and disease. Support of basic topics in genetics and developmental biology, including nucleic acid chemistry, the structure of genetic material, the mechanisms of transmission and expression of genetic information, cellular regulation of growth and differentiation, and population genetics. Areas that may be of interest to small businesses include, but are not limited to:

1. Development of computer software for the analysis of the primary and secondary structures of nucleic acids as these relate to genetic problems.
2. Improvement in procedures for the separation and analysis of nucleic acids and proteins as these relate to genetic problems.
3. Improvement of methodology (technology) for genetic analysis (e.g., gene expression, probes).
4. Development of probes for detection of human genetic polymorphisms, including disease genes.
5. Development of improved procedures for cytogenetics and diagnostic array technology.
6. Improvement in procedures (statistical, computational, laboratory) for the analysis of gene flow and gene dynamics in human populations.
9. Development of quantitative approaches to the analysis of complex biological systems.
10. Development of tools and technologies to detect and monitor complex human phenotypes or traits.
11. Development of technology to derive and expand pluripotent cell populations from non-embryonic sources, for example, induced pluripotent stem cells (iPS).
12. Development of improved technology to scale up the growth of induced pluripotent stem cells in culture and to regulate their differentiation state
13. Development of markers, reagents and tools to characterize the unique properties of iPS cell lines and to distinguish them from adult stem cells and more differentiated cells.
14. Development of existing human embryonic stem cell lines and new or existing iPS cells as a model system for drug discovery.
15. Development or improvement of methodology for generation of antibodies or other affinity reagents for proteins and other small molecules in non-mammalian genetic model systems.
16. Improvement in procedures (statistical, computational, laboratory) for the high- and medium-throughput analysis of gene expression patterns and regulatory networks.
17. Development or improvement of methods for high throughput detection of epigenomic changes.
18. Development or improvement of methods for characterizing the metabolic interactions of complex communities of microorganisms particularly those involved in host-microbe interactions.
19. Development of improved or novel methodology for structure/function analysis of very large macromolecular complexes involved in transmission or expression of genetic material.

Division of Pharmacology, Physiology, and Biological Chemistry

Research related to the actions of therapeutics, including anesthetics, and the development of biotechnological methods for their production and investigation. Research on cell signaling molecules and signaling intermediates, particularly those related to G-protein coupled receptors. Research in the field of carbohydrates, especially tool and methods development for this emerging field. Research on pain management as it relates to anesthesia and the perioperative period. Research on responses to traumatic injury, including burn injury, and methods to mitigate these responses. Research on wound healing and tissue repair. Research on the causes and treatments for common complications of critically ill patients (sepsis, systemic inflammatory response syndrome, multiple organ failure), especially directed towards the role of the inflammatory and innate immune responses. Research on the structure, function, and biosynthesis of cellular components and cellular metabolism, bioenergetics, and mechanisms of enzyme action, regulation, and inhibition. Research leading to the synthesis of new chemical entities or development of new chemical methods to probe biological phenomena or to alter the behavior of biological systems. Examples include, but are not limited to:

A. Biochemistry and Biorelated Chemistry
2. Development of synthetic methodology to improve the efficiency (broadly defined) of discovery and production of bio-medically relevant compounds.
3. Development of enzymes, catalytic antibodies, ribozymes, artificial enzymes, and host molecules as drugs or synthetic tools.
4. Development of technologies, including instrumentation, software, reagents, and methods for proteomics, including but not limited to robotics, sample preparation and prefractionation, analytical separations, mass spectrometry, intelligent automated data acquisition, and improved informatics technologies.
5. Development of technologies, including instrumentation, software, reagents, and methods for glycomics, including but not limited to development of: specific glycan structural databases, methodologies for synthesis of robust glycan libraries, glycan labeling reagents and glyco-enzyme inhibitors, and analytical tools for determining carbohydrate structure and biological function.
6. Development and application of methods and materials for the elucidation of membrane protein structures at or near atomic resolution.
7. Development of high-throughput methods for sequencing and re-sequencing of mitochondrial genes and relevant nuclear genes and for proteomic and/or functional profiling of mitochondria in diagnosis of mitochondrial diseases.
8. Development of new metal ion chelators and other tools to probe and/or alter the localization and concentration of metal ions in cells and in whole organisms. Research to exploit metal metabolism and metal-regulated cellular control and cell-cell signaling.
processes to probe and/or alter cell function. Research to develop investigational and therapeutic applications of metal-complexes and to understand the factors governing their pharmacology and toxicology.

9. Development of high-throughput methods and strategies to characterize the function of proteins and enzymes and/or define the functional interrelationships of proteins and enzymes.

10. Development of tools to characterize oxidative stress and oxidative stress related molecules (NO, peroxynitrite, hydrogen peroxide, lipoxidation products modified proteins, DNA modifications, etc.) including the extent and/or localization (by organ/tissue/cell/organelle) of oxidative stress.

### B. Pharmacological and Physiological Sciences

1. Isolation, characterization, and development of factors and strategies, methods, or treatments involved in tissue repair, wound healing, sepsis, and traumatic injury, emergency, peri-operative, or critical care conditions, and associated pain management.

2. Improved systems for collection, processing, and analysis of real time physiological data from injured or critically ill patients. Application of systems biology or complexity theory approaches towards understanding the physiology of injured and critically ill organisms. Development of tools, software, algorithms, etc. needed to link clinical, demographic, physiological, genomic, proteomic or other datasets of injured or critically ill organisms.

3. Metabolomics of injury and/or critical illness.

4. Development of strategies, methods, or new technologies to improve the delivery, monitoring, safety and efficacy of anesthesia.

5. Research to improve drug design and delivery.

6. Research to improve drug bioavailability by improved understanding of factors that influence absorption, metabolism, transport, or clearance of therapeutics and underlying mechanisms. Application of pharmacokinetic and pharmaceutical principles to the study of large biomolecules, such as proteins, polypeptides, and oligonucleotides.

7. Research to discover, detect, and understand the genetic basis of individual differences in drug responses (pharmacogenomics).


9. Development of bioinformatic, mathematical, and/or computational approaches/resources and/or pharmacokinetic modeling programs which utilize ADME parameters of drugs and pharmacogenomic information of individual patients or patient populations to reduce adverse drug reactions in individual patients.

10. Development of ontologies and modules useful for combining and mining databases containing genotype and phenotype information in order to discover correlations for drug effects, either therapeutic or adverse.

### Division of Biomedical Technology, Bioinformatics, and Computational Biology

This Division enables the development of research tools in two broad areas: (1) New or improved instruments, devices, and related methodologies to facilitate biomedical or behavioral research. Instrumentation includes, but is not limited to mass spectrometry, nuclear magnetic resonance, optical or laser spectroscopies, X-ray absorption/diffraction/scattering, detectors, electron or confocal microscopies, electrophoresis and other separation techniques, bioreactors, centrifugation, and flow cytometry. (2) New or innovative tools and methods in bioinformatics and computational biology, including social, population, and behavioral modeling research. Example areas that may be of interest to small businesses include, but are not limited to:
A. **Technology for Systems Biology:** Development of novel technologies for proteomics, glycomics, metabolomics, and other aspects of systems biology for discovery and clinical applications, (e.g., sample handling, separations, mass spectrometry, and computational tools for protein identification, data curation and mining, and for integrating genome variation, pathways and networks with biological function).

B. **Technology for Microscopy and Imaging:** Development of new or improved microscopic techniques, instruments, and supporting software that measures the location and dynamics or molecules in situ, organelles, cells, or tissues on the nano- and micro-scale.

C. **Technology for Structural Biology:** Development of tools including but not limited to detectors, cameras, light sources, optics, and automated data collection and analysis systems, for studying the structures of biomolecules and biospecimens in the size range of peptides to cells, using diffraction, microscopy and/or spectroscopy techniques.

D. **Bioinformatics and Computational Biology:** Development of information and communication technology from computer and other quantitative sciences in support of biomedical or behavioral research, that apply best practices and proven methods for software design, construction and implementation to promote adoption by a broad biomedical research community. These may include:

1. Development of tools and methods for the modeling, simulation or analysis of complex biological systems.
2. Development and enhancement of databases and data formats for biomedical research activities.
3. Development of collaborative environments and technologies to translate Big Data to knowledge, including but not limited to development of knowledge environments, research commons, data and metadata curation methods, and tools that address data security and privacy issues.
4. Development of tools and methods to collect, interpret, analyze and visualize scientific data through integration and interoperability of different data types.
5. Design and development of software and hardware for improving the effectiveness of computational approaches in biomedical research.
6. Development of computational biology software packages for integrative analysis of biomedical data, especially ones relevant to genomics and imaging.

**Division of Training, Workforce Development, and Diversity**

Research toward development of products or services to market discoveries derived from a broad research base and for science literacy or research capacity, focusing at the post-high school level and beyond, and particularly to enhance diversity of the scientific workforce. Example areas that may be of interest to small businesses include, but are not limited to development of products or services to:

1. Enhance graduation rates in biomedical, behavioral and clinical sciences at the post-high school level and beyond.
2. Enhance training and workforce development of the biomedical, behavioral and clinical research workforce after degree completion.
3. Enhance diversity of the biomedical, behavioral and clinical research workforce at the post-high school level and beyond.
4. Track career outcomes of students and trainees.
5. Assist in the evaluation of workforce development programs.
Center for Research Capacity Building

Research and development of products, tools, databases, or services in the mission of Center for Research Capacity Building (CRCB), which supports research, research training, faculty development and research infrastructure improvements in states that historically have not received significant levels of research funding from NIH. It also supports faculty research development at institutions that have a historical mission focused on serving students from underrepresented groups, and conducts a science education program designed to improve life science literacy. Topics of interest include, but are not limited to, research capacity building, faculty and professional development, mentoring, and development of educational software and course materials targeting undergraduate and community college students, on topics that range from basic molecular and cellular biology to human diseases, including areas of health disparities, that disproportionately affect rural, tribal and hard-to-reach populations. To meet the information needs of the target audiences, health education materials must be culturally appropriate.

CRCB is composed of four programs: Institutional Development Award (IDeA), Support of Competitive Research (SCORE) and Native American Research Centers for Health (NARCH), and Science Education Partnership Awards (SEPA).

A. Science Education Partnership Awards: Funding opportunities are available for the development of discovery-oriented educational software, Serious STEM Interactive Digital Media (IDM) and the application of educational technology and tools for health science topics that target pre-kindergarten to grade 12 (P-12) students, teachers and families, and the general public, particularly those from underserved communities. Development of software, IDM technology, or other educational tools may be focused on new products or adaptation of existing products designed to be more efficient, cost-effective, and user-friendly in promoting problem solving, interactive learning, dissemination, and promotion of health science. These resources are intended to create user-friendly, culturally appropriate and effective educational resources.

Examples of responsive applications may include but are not limited to:
1. Web-based, stand-alone computational tools, instructional software, or other interactive media for dissemination of science education;
2. Curriculum materials, interactive teaching aids, models for classroom instruction, and teacher education workshops;
3. Serious Science, Technology, Engineering and Mathematics (STEM) IDM resources;
4. Development of health promotion and disease prevention/intervention products that are culturally appropriate for the target populations and communities.

Projects that target the following constituencies are strongly encouraged:
1. P-12 students, teachers, and parents;
2. Students of community colleges, tribal colleges, undergraduate colleges, and minority-serving institutions;
3. Patients and families with health conditions that disproportionately affect minorities and other medically underserved populations, including members of disadvantaged urban and rural communities.

NIGMS Clinical Trials Topics:

NIGMS will accept clinical trials in any area listed above in the non-clinical trials topics.

For additional information on NIGMS research topics and the SBIR/STTR application process, contact:

**NIGMS SBIR/STTR COORDINATOR**

Joseph Gindhart, Ph.D.
National Institute of General Medical Sciences
45 Center Drive, MSC 6200
Bethesda, MD 20897-6200
301-594-0828 Fax: 301-480-2004
Email: joe.gindhart@nih.gov

For scientific questions about NIGMS-funded SBIR/STTR research, contact:

**CELL BIOLOGY AND BIOPHYSICS**

Michael Sakalian, Ph.D.
301-594-0828, Fax: 301-480-2004
Email: michael.sakalian@nih.gov

**GENETICS AND DEVELOPMENTAL BIOLOGY**

Darren Sledjeski, Ph.D.
301-594-0943, Fax: 301-480-2228
Email: darren.sledjeski@nih.gov

**PHARMACOLOGY, PHYSIOLOGY, AND BIOLOGICAL CHEMISTRY**

Biochemistry and Biorelated Chemistry
Pamela Marino, Ph.D.
301-594-3827, Fax: 301-480-2802
Email: marinop@nigms.nih.gov

Pharmacological and Physiological Sciences
Alison Cole, Ph.D.
301-594-3827, Fax: 301-480-2802
Email: colea@nigms.nih.gov

**BIOMEDICAL TECHNOLOGY, BIOINFORMATICS, AND COMPUTATIONAL BIOLOGY**

Dmitriy Krepkiy, Ph.D.
301-435-0752, Fax: 301-480-2802
Email: krepkiyd@mail.nih.gov

**TRAINING, WORKFORCE DEVELOPMENT, AND DIVERSITY**

Luis Cubano, Ph.D.
301-594-3900, Fax: 301-480-2753
Email: luis.cubano@nih.gov

**CENTER FOR RESEARCH CAPACITY BUILDING**

Krishan Arora, Ph.D.
301-594-3900, Fax: 301-480-2802
Email: arorak@nigms.nih.gov

Research and Development in Science Education
Tony Beck, Ph.D.
301-594-3900, Fax: 301-480-2802
Email: beckL@mail.nih.gov
For administrative and business management questions, contact:

**ADMINISTRATIVE AND BUSINESS MANAGEMENT:**

Mr. Justin Rosenzweig  
301-594-0158, Fax: 301-480-2554  
Email: [rosenzwj@nigms.nih.gov](mailto:rosenzwj@nigms.nih.gov)

Ms. Tiffany Walker  
301-594-4514, Fax: 301-480-2554  
Email: [walkerti@nigms.nih.gov](mailto:walkerti@nigms.nih.gov)
NATIONAL HEART, LUNG, AND BLOOD INSTITUTE (NHLBI)

For the most up-to-date information, please visit the NHLBI SBIR/STTR website (http://www.nhlbi.nih.gov/funding/sbir/index.htm) and subscribe to our listserv (http://bit.ly/NHLBI-SBIR-Updates). You can also follow us on Twitter @NHLBI_SBIR. NHLBI encourages potential applicants to contact us at http://bit.ly/ContactNHLBI_sbir.

NHLBI plans, conducts, and supports research, clinical trials, and demonstration and education projects related to the causes, prevention, diagnosis, and treatment of heart, blood vessel, lung, and blood diseases, and sleep disorders. It also supports research on the clinical use of blood and all aspects of the management and safety of blood resources. The NHLBI SBIR/STTR programs foster basic, applied, and clinical research on all product and service development related to the mission of the NHLBI. The NHLBI has four extramural program divisions, described below.

Phase II Applications

The NHLBI strongly encourages applicants to include a robust regulatory strategy with corresponding milestones in Phase II applications. Applicants are also encouraged to include letters of support or other evidence documenting their regulatory strategy. The NHLBI will consider the strength of the regulatory plan when making funding decisions. For assistance regarding regulatory strategy, explore the “Small Biz Hangout” series on the NHLBI YouTube channel and submit specific regulatory questions to Chris Sasiela at http://bit.ly/ContactNHLBI_sbir.

For assistance regarding the commercialization plan, watch the “Small Biz Hangout” for advice on Writing Your Phase II Commercialization Plan (http://bit.ly/Ph2CommPlanHangout) and contact Gary Robinson (nhlbi_sbir@mail.nih.gov) with specific questions.

NHLBI-Supported Funding Opportunity Announcements (FOAs)

In addition to this Omnibus program announcement, the NHLBI releases targeted Funding Opportunity Announcements (FOAs) throughout the year. Sign up for the listserv (http://bit.ly/NHLBI-SBIR-Updates) to be notified of new FOAs.

These FOAs are listed to inform potential applicants about other funding opportunities to which they can apply; applications submitted in response to this Omnibus program announcement are not limited to research and development areas described in the following targeted FOAs. The NHLBI also encourages mission-aligned applications for innovative technologies outside these targeted areas.

(Funding Opportunity Announcements can be released or expire at any time throughout the year; please refer to the NHLBI SBIR/STTR website for active announcements supported by NHLBI.)


Phase IIB Competing Renewal Awards

The NHLBI does not accept applications for Phase IIB competing renewal awards through this Omnibus solicitation; however, the NHLBI offers SBIR Phase IIB opportunities through the NHLBI Phase IIB Bridge Awards and the NHLBI Phase IIB Small Market Awards using separate funding opportunity
announcements (Bridge Award: RFA-HL-16-009; http://1.usa.gov/1q9yTyP; Small Market Award: RFA-HL-174-012; http://1.usa.gov/1v0Wxn1)

The purpose of the NHLBI Phase IIB program is to accelerate the transition of SBIR/STTR Phase II projects to the commercialization stage by promoting partnerships between SBIR/STTR Phase II awardees and third-party investors and/or strategic partners. NHLBI SBIR Phase IIB program encourages business relationships between applicant small business concerns and third-party investors stratégic partners who can provide substantial financing to help accelerate the commercialization of promising new products and technologies that were initiated with SBIR/STTR funding. In particular, applicants are expected to leverage their previous SBIR/STTR support, as well as the opportunity to compete for additional funding through the NHLBI Phase IIB program, to attract and negotiate third-party financing needed to advance a product or technology toward commercialization. Development efforts may include preclinical R&D needed for regulatory filings (e.g., IND or IDE) and/or clinical trials. The Phase IIB Small Market Award focuses on supporting technologies addressing rare diseases or pediatric populations.

The Phase IIB Bridge or Small Market application must represent a continuation of the research and development efforts performed under a previously funded SBIR or STTR Phase II award. The NHLBI welcomes applicants previously funded by any NIH Institute or Center or any other Federal agency, as long as the proposed work applies to the NHLBI mission. Applications may be predicated on a previously funded SBIR or STTR Phase II grant or contract award. Applicants with Phase II contracts or awards from another Federal agency must contact the NHLBI to ensure their application can be received.

Applicants are strongly encouraged to contact Mike Pieck at http://bit.ly/ContactNHLBIsbir for additional information.

Limited Amount of Award

For budgetary, administrative, or programmatic reasons, the NHLBI may not fund an application or may decrease the length of an award and/or the budget recommended by a review committee. NIH has received a waiver from SBA, as authorized by statute, to exceed the statutory budget limitations of $225,000 for Phase I and $1,500,000 for Phase II for specific topics relevant to the NHLBI that can be found below. Generally, the NHLBI does not fund Phase I applications greater than $300,000 total costs or project periods greater than 2 years. In addition, the NHLBI does not generally fund Phase II applications greater than $2,000,000 total costs or project periods greater than 3 years. Applicants with budget questions or considering requesting a budget greater than these amounts are strongly encouraged to contact Mike Pieck at http://bit.ly/ContactNHLBIsbir before submitting an application.

NHLBI Topics for Awards over Statutory Budget Limitations

A. Biomedical technologies (medical devices, instruments, pharmaceuticals, drugs, therapeutics, vaccines, diagnostics and biologics) for heart, lung, blood, and sleep related diseases and disorders requiring Federal regulatory approval (FDA) or clearance to be commercialized.

B. Small and large animal testing of products of tissue engineering and regenerative medicine, drugs, medical devices, therapeutics, and biologics and studies involving in vivo animal experiments for heart, lung, blood, and sleep related diseases and disorders.

C. Clinical trials and other experiments involving human subjects for heart, lung, blood, and sleep related diseases and disorders.

D. Therapeutics (drugs, devices, or biologics) development for heart, lung, blood, and sleep related diseases and disorders.

E. Device development for heart, lung, blood, and sleep related diseases and disorders.
F. Diagnostic development for heart, lung, blood, and sleep related diseases and disorders.

G. Investigation of biomarkers and biosignatures of heart, lung, blood, and sleep related diseases and disorders.

H. Technologies to enhance clinical research for heart, lung, blood, and sleep related diseases and disorders.

I. Advanced instrumentation and high throughput tools for biomedical research in heart, lung, blood, and sleep related diseases and disorders.

J. Tools and platforms to improve the dissemination and implementation of evidence-based interventions for heart, lung, blood, and sleep related diseases and disorders.

Final Progress Reports

As detailed in NOT-OD-17-085, the NIH has implemented the Final Research Performance Progress Reports (Final RPPR) for SBIR/STTR Final Progress Reports.

The NHLBI is interested in tracking the progress of the small business concerns it funds and the products they develop. Funding priority will be given to those small business concerns that show not only their ability to develop products but also their growth as a small business concern towards independence from the SBIR/STTR program.

Programs and Services for NHLBI Small Business Awardees

The NHLBI offers free assistance to applicants and awardees regarding regulatory approval, commercialization, and business plan development. Visit http://bit.ly/ContactNHLBIsbir to connect to:

- Chris Sasiela, Ph.D., RAC - Regulatory Strategist  
- Gary Robinson, Ph.D. - Business Development Advisor

The NHLBI hosts “Small Biz Hangouts” - a free educational series covering the basics of biomedical technology development. Previous Hangouts are archived on the NHLBI YouTube channel: http://bit.ly/SmallBizHangouts-YouTube

Sign up for the NHLBI listserv (http://bit.ly/NHLBI-SBIR-Updates) to learn about upcoming live events. Learn more about available resources at http://www.nhlbi.nih.gov/about/org/dera/otac/resources.

The NHLBI encourages awardees to apply for the following free programs:

- Phase I: The NIH Niche Assessment Program (http://sbir.nih.gov/nap) provides awardees with an in depth market analysis for their technology.
- Phase II: The NIH Commercialization Assistance Program (http://sbir.nih.gov/cap) will assist awardees in transferring their products to the marketplace.

Research Topics of Interest to NHLBI

The specific set of topics that are funded by a particular IC/Office/Agency depends on whether the IC/Office/Agency funds/supports Clinical Trials under SBIR/STTR Awards. Use the following table and explanations to determine which list of topics is applicable.
 Does IC/Office/Agency Fund/Support Clinical Trials under SBIR/STTR Awards? | No* | Yes** |
---|---|---|
| Does IC/Office/Agency Fund/Support Clinical Trials under SBIR/STTR Awards? | X | **

*If No,
- This IC/Office/Agency funds only those topics listed under the Non-Clinical Trials Topics section below, **UNLESS** the IC/Office/Agency funds a Small Business Concern for clinical trials under a NON-SBIR/STTR award.

**If Yes or the IC/Office/Agency funds small businesses for clinical trials under a NON-SBIR/STTR funding opportunity,
- See the table below for which mechanisms the IC/Office/Agency will allow for clinical trials research. Also, see the Clinical Trials Topics section below for a list of funded topics. This IC/Office/Agency also funds research listed under the Non-Clinical Trials Topics section below.

<table>
<thead>
<tr>
<th>Does IC/Office/Agency accept clinical trials applications under this mechanism?</th>
<th>Yes</th>
<th>No</th>
</tr>
</thead>
<tbody>
<tr>
<td>Clinical Trials SBIR/STTR Omnibus/Parent Funding Opportunity Announcement/s</td>
<td>X</td>
<td></td>
</tr>
<tr>
<td>Clinical Trials SBIR/STTR IC/Office/Agency - Specific Funding Opportunity Announcement/s</td>
<td>X</td>
<td></td>
</tr>
</tbody>
</table>
| Clinical Trials NON-SBIR/STTR Funding Opportunity Announcement/s where Small Businesses are eligible to apply | X | For information on non-SBIR/STTR clinical trials funding mechanisms for which small businesses are eligible, please visit the [NHLBI clinical trials website](#)

NHLBI Non-Clinical Trials Topics:

**Cardiovascular Sciences**

The Division of Cardiovascular Sciences (DCVS) supports basic, clinical, population, and health services research on the causes, prevention, and treatment of cardiovascular diseases. The research programs of the Division encompass investigator-initiated research, Institute-initiated research in targeted areas of research need and scientific opportunity, specialized centers of research focused on selected research topics, and clinical trials. Research supported by the Division is concerned with the etiology, pathogenesis, prevention, diagnosis, and treatment of coronary artery disease and atherothrombosis;
structural heart disease; heart failure and arrhythmias; and hypertension and vascular diseases. A broad array of epidemiological studies is supported by the DCVS to describe disease and risk factor patterns in populations and to identify risk factors for disease. Also supported are clinical trials of interventions to prevent and treat disease; studies of genetic, behavioral, sociocultural, and environmental influences on disease risk and outcomes; and studies of the application of prevention and treatment strategies to determine how to improve clinical care and public health.

**Lung Diseases**
The Division of Lung Diseases (DLD) supports research on the causes, diagnosis, prevention, and treatment of lung diseases and sleep disorders. Research is funded through investigator-initiated and Institute-initiated grant and contract programs in areas including asthma, bronchopulmonary dysplasia, chronic obstructive pulmonary disease, cystic fibrosis, respiratory neurobiology, sleep-disordered breathing, critical care and acute lung injury, developmental biology and pediatric pulmonary diseases, immunologic and fibrotic pulmonary disease, rare lung disorders, pulmonary vascular disease, and pulmonary complications of AIDS and tuberculosis.

**Blood Diseases and Resources**
The Division of Blood Diseases and Resources (DBDR) supports research on the causes, prevention, and treatment of nonmalignant blood diseases, including anemias, sickle cell disease, and thalassemia; premalignant processes such as myelodysplasia and myeloproliferative disorders; hemophilia and other abnormalities of hemostasis and thrombosis; and immune dysfunction. Research supported by the Division encompasses a broad spectrum of topics ranging from basic biology to medical management of blood diseases. The Division has a major responsibility for research to improve the adequacy and safety of the nation's blood supply. It also plays a leading role in transfusion medicine and blood banking, including research to evaluate blood donation screening, manufacturing, and processing technologies. The Division also has a major responsibility supporting research in hematopoiesis and stem cell biology and disease. It also supports hematopoietic stem cell transplantation research, and the application of stem cell biology findings to the development of new cell-based therapies to repair and regenerate human tissues and organs.

**Center for Translation Research and Implementation Science**
The Center for Translation Research and Implementation Science (CTRIS) plans, fosters, and supports an integrated and coordinated program of research to understand the multi-level processes and factors that are associated with successful integration of evidence-based interventions within specific clinical and public health settings such as worksites, communities, and schools; identifies and makes readily available to implementation and dissemination practitioners emergent knowledge about the late phases of translation research, especially the "T4" phase, for rapid and sustained adoption of effective interventions in real world settings; leads the NHLBI effort in the rigorous, systematic evidentiary reviews and subsequent NHLBI participation in the collaborative model for clinical practice guidelines development; supports training and career development of personnel in "T4" translation research and health inequities relating to heart, lung, and blood diseases; provides a focal point for advice and guidance on matters pertaining to minority health, health inequities and minority participation in research; represents the NHLBI to other governments, other Federal Departments and agencies, international organizations, and the private sector on global health issues; and provides data analytics and portfolio analysis to evaluate and inform future directions of implementation research programs.

The NHLBI encourages applications through this Omnibus solicitation proposing innovative technologies related to any area within the NHLBI mission.

The NHLBI maintains a list of topics of special interest (http://www.nhlbi.nih.gov/funding/sbir/funding/omnibus_grant_solicitation.htm) to the Institute. Instructions for submitting applications in response to these topics are posted on the web page. The list is revised
throughout the year, so please check regularly for updates. For more information, contact the NHLBI Small Business team at http://bit.ly/ContactNHLBIsbir or the Division contact associated with your technology area listed at the end of the NHLBI section.

**NHLBI Clinical Trials Topics:**

**Cardiovascular Sciences**  
The Division of Cardiovascular Sciences (DCVS) supports basic, clinical, population, and health services research on the causes, prevention, and treatment of cardiovascular diseases. The research programs of the Division encompass investigator-initiated research, Institute-initiated research in targeted areas of research need and scientific opportunity, specialized centers of research focused on selected research topics, and clinical trials. Research supported by the Division is concerned with the etiology, pathogenesis, prevention, diagnosis, and treatment of coronary artery disease and atherothrombosis; structural heart disease; heart failure and arrhythmias; and hypertension and vascular diseases. A broad array of epidemiological studies is supported by the DCVS to describe disease and risk factor patterns in populations and to identify risk factors for disease. Also supported are clinical trials of interventions to prevent and treat disease; studies of genetic, behavioral, sociocultural, and environmental influences on disease risk and outcomes; and studies of the application of prevention and treatment strategies to determine how to improve clinical care and public health.

**Lung Diseases**  
The Division of Lung Diseases (DLD) supports research on the causes, diagnosis, prevention, and treatment of lung diseases and sleep disorders. Research is funded through investigator-initiated and Institute-initiated grant and contract programs in areas including asthma, bronchopulmonary dysplasia, chronic obstructive pulmonary disease, cystic fibrosis, respiratory neurobiology, sleep-disordered breathing, critical care and acute lung injury, developmental biology and pediatric pulmonary diseases, immunologic and fibrotic pulmonary disease, rare lung disorders, pulmonary vascular disease, and pulmonary complications of AIDS and tuberculosis.

**Blood Diseases and Resources**  
The Division of Blood Diseases and Resources (DBDR) supports research on the causes, prevention, and treatment of nonmalignant blood diseases, including anemias, sickle cell disease, and thalassemia; premalignant processes such as myelodysplasia and myeloproliferative disorders; hemophilia and other abnormalities of hemostasis and thrombosis; and immune dysfunction. Research supported by the Division encompasses a broad spectrum of topics ranging from basic biology to medical management of blood diseases. The Division has a major responsibility for research to improve the adequacy and safety of the nation's blood supply. It also plays a leading role in transfusion medicine and blood banking, including research to evaluate blood donation screening, manufacturing, and processing technologies. The Division also has a major responsibility supporting research in hematopoiesis and stem cell biology and disease. It also supports hematopoietic stem cell transplantation research, and the application of stem cell biology findings to the development of new cell-based therapies to repair and regenerate human tissues and organs.

**Center for Translation Research and Implementation Science**  
The Center for Translation Research and Implementation Science (CTRIS) plans, fosters, and supports an integrated and coordinated program of research to understand the multi-level processes and factors that are associated with successful integration of evidence-based interventions within specific clinical and public health settings such as worksites, communities, and schools; identifies and makes readily available to implementation and dissemination practitioners emergent knowledge about the late phases of translation research, especially the "T4" phase, for rapid and sustained adoption of effective interventions in real world settings; leads the NHLBI effort in the rigorous, systematic evidentiary reviews and subsequent NHLBI participation in the collaborative model for clinical practice guidelines development; supports training and career development of personnel in "T4" translation research and health inequities.
relating to heart, lung, and blood diseases; provides a focal point for advice and guidance on matters pertaining to minority health, health inequities and minority participation in research; represents the NHLBI to other governments, other Federal Departments and agencies, international organizations, and the private sector on global health issues; and provides data analytics and portfolio analysis to evaluate and inform future directions of implementation research programs.

The NHLBI encourages applications through this Omnibus solicitation proposing innovative technologies related to any area within the NHLBI mission.

The NHLBI maintains a list of topics of special interest ([http://www.nhlbi.nih.gov/funding/sbir/funding/omnibus_grant_solicitation.htm](http://www.nhlbi.nih.gov/funding/sbir/funding/omnibus_grant_solicitation.htm)) to the Institute. Instructions for submitting applications in response to these topics are posted on the web page. The list is revised throughout the year, so please check regularly for updates. For more information, contact the NHLBI Small Business team at [http://bit.ly/ContactNHLBIsbir](http://bit.ly/ContactNHLBIsbir) or the Division contact associated with your technology area listed at the end of the NHLBI section.

For additional information on research areas, please contact:

**CARDIOVASCULAR SCIENCES**

Albert Lee  
Division of Cardiovascular Sciences  
Advanced Technologies and Surgery Branch  
301-435-0567  
Email: albert.lee3@nih.gov

**LUNG DISEASES AND SLEEP DISORDERS**

John Sheridan  
Division of Lung Diseases  
301-435-0233  
Email: john.sheridan@nih.gov

**BLOOD DISEASES AND RESOURCES**

Phyllis Mitchell  
Division of Blood Diseases and Resources  
Translational Blood Science and Resources Branch  
301-435-0481  
Email: phyllis.mitchell@nih.gov

**CENTER FOR TRANSLATION RESEARCH AND IMPLEMENTATION SCIENCE**

Uchechukwu Sampson  
Center for Translation Research and Implementation Science  
Translation Research Branch  
301-496-3620  
Email: uchechukwu.sampson@nih.gov
NATIONAL HUMAN GENOME RESEARCH INSTITUTE (NHGRI)

The National Human Genome Research Institute (NHGRI) has been guided, since the inception of the Human Genome Project in 1990, by a sequential series of plans, each of which has been developed with considerable input from the scientific community. These plans have always laid out ambitious goals and measurable objectives to gauge progress. NHGRI initiated its most recent planning process in 2008 and concluded with the publication in February 2011 of its newest strategic plan, “Charting a Course for Genomic Medicine from Base Pairs to Bedside,” (Nature, 10 February 2011; Volume 470). The phenomenal advances that have marked genomics and have allowed genomic applications to transform many important fields have made it an opportune time for the Institute to take a new look at genomics and its future.

Research Topics of Interest to NHGRI

The specific set of topics that are funded by a particular IC/Office/Agency depends on whether the IC/Office/Agency funds/supports Clinical Trials under SBIR/STTR Awards. Use the following table and explanations to determine which list of topics is applicable.

<table>
<thead>
<tr>
<th>Does IC/Office/Agency Fund/Support Clinical Trials under SBIR/STTR Awards?</th>
<th>No*</th>
<th>Yes**</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td>X</td>
</tr>
</tbody>
</table>

*If No,
• This IC/Office/Agency funds only those topics listed under the Non-Clinical Trials Topics section below, UNLESS the IC/Office/Agency funds a Small Business Concern for clinical trials under a NON-SBIR/STTR award.

**If Yes or the IC/Office/Agency funds small businesses for clinical trials under a NON-SBIR/STTR funding opportunity,
• See the table below for which mechanisms the IC/Office/Agency will allow for clinical trials research. Also, see the Clinical Trials Topics section below for a list of funded topics. This IC/Office/Agency also funds research listed under the Non-Clinical Trials Topics section below.

<table>
<thead>
<tr>
<th>Does IC/Office/Agency accept clinical trials applications under this mechanism?</th>
<th>Yes</th>
<th>No</th>
<th>Other Information: If funding an SBC for clinical trials under a NON-SBIR/STTR award, please identify activity code(s) and other relevant information.</th>
</tr>
</thead>
<tbody>
<tr>
<td>Clinical Trials SBIR/STTR Omnibus/Parent Funding Opportunity Announcement/s</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>X</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Clinical Trials SBIR/STTR IC/Office/Agency - Specific Funding Opportunity Announcement/s</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>X</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
Does IC/Office/Agency accept clinical trials applications under this mechanism? | Yes | No | Other Information: If funding an SBC for clinical trials under a NON-SBIR/STTR award, please identify activity code(s) and other relevant information.
---|---|---|---
Clinical Trials NON-SBIR/STTR Funding Opportunity Announcement/s where Small Businesses are eligible to apply | X | |

NHGRI Non-Clinical Trials Topics:

A. Technology and Methods Development

Technology development in DNA sequencing and genotyping are examples of activities that have changed the nature of what scientific research questions are practical to address, have enabled new approaches, and have facilitated the development of new community resource data sets. Many areas of critical importance to the realization of the genomics-based vision for biomedical research require continued technological and methodological developments before pilots and then large-scale approaches can be attempted. Accordingly, the NHGRI will continue to support the development of new, fundamental technologies in all areas of genomics. Important areas in which technology development applications would be responsive to this Program Announcement include (but are not limited to) experimental technologies and computational methods to analyze gene expression and other molecular phenotypes; discovery and characterization of genetic variation; identification of the genetic contributions to health, disease, and drug response; statistical analytic methods for understanding human genomic variation and its relationship to health and disease; and chemical genomics. There is also continued need to support technology development for the comprehensive discovery of functional elements in the human and model organism genomes, and new DNA sequencing technology. Many of these assays would benefit from the ability to work with very small amounts of starting material, to the limit of single cells, along with minimally-invasive human specimens that are easy to collect, handle, and store. As these technologies mature, emphasis should be on high throughput, cost-effective methods that consistently produce very high-quality data.

The Institute also places high priority on contributing selectively to the development of new and needed technology in related areas, such as proteomics and systems biology research, when NHGRI funding can be used to further a truly unique development that will have a significant impact on the field.

Further information on opportunities related to technology and methods development is available at this website: https://www.genome.gov/10000368/.

B. Bioinformatics, Computational Genomics and Data Science

The ongoing development of new sequencing technologies has dramatically increased the amount of data produced for genomics in basic science and translation to medicine. NHGRI encourages new computational approaches for the analysis, visualization and integration of genomic information in basic and clinical research and in applications to improve its utility in healthcare. These approaches may include the development of methods for processing, annotating, interpreting, analyzing and sharing of sequencing data with associated phenotypes.
and other large-scale genomic data sets such as haplotype maps, genetic variants, transcriptome measurements, functional elements, and in some cases protein interactions. NHGRI also encourages the development of better computational solutions for storage, access, compression, secure sharing, privacy and transfer of large genomic datasets by biomedical researchers.

Some genomic data analysis and display tools have been developed that already are used in the community but would benefit from additional work to support broader dissemination, for example making them efficient, reliable, robust, well-documented, and well-supported, or for deploying them in containers or at scale in a cloud-based platform. NHGRI will support projects to extend the support for these informatics tools to make them more easily adopted by any biomedical research laboratory that wishes to use genomic technologies to address biomedical questions.

Genomic databases are essential resources for the biological and biomedical research communities and relevant regulatory agencies. The creation and maintenance of effective and sustainable databases that take advantage of technology improvements are an important component of NHGRI research funding strategy.

Where possible, existing or emerging community data standards, models, and methods for data representation and exchange should be used in the development of these new methods and tools as well as other approaches to enhance reproducibility. Standards-based approaches are also encouraged to integrate and share genomics and phenotype data for data mining with other sources including for clinical application. Projects that will make genomic digital objects Findable, Accessible, Interoperable, Reusable (FAIR) in the broader community are highly recommended.

Further information on programs related to NHGRI supported research in computational genomics and data science is available at this web site: http://www.genome.gov/10001735.

C. Population Genomics and Genomic Medicine

Population genomics applies genomic technologies, such as genome-wide association testing and sequencing, to population studies to identify genes or variants that affect common etiologically complex conditions and predict individual risk. Genomic medicine investigates the value of applying genomic methods in clinical care for the diagnosis, treatment, and prevention of diseases. The research scope of Population Genomics and Genomic Medicine at NHGRI includes: developing resources and statistical methods for observational studies and clinical trials incorporating advanced genomic technologies; conducting proof-of-principle studies that apply genomic technologies to epidemiologic and clinical research; developing research methods and infrastructure needed for future epidemiologic and clinical studies of genetic and environmental contribution to disease; investigations of whether and how clinical genome sequencing impacts disease diagnosis and treatment; studies of approaches to improve the identification and interpretation of genomic variants for dissemination in clinical settings; assessing phenotypic manifestations of genetic variants through electronic medical records (EMRs); integrating genomic results and clinical decision support into EMRs; studies that address current barriers to the implementation of clinical genome sequencing, and assessing the impact of genetic information on clinical utility, health outcomes and delivery of care. For additional information about Genomic Medicine NHGRI, please visit this web site: http://www.genome.gov/27550079.

D. Ethical, Legal and Social Implications

NHGRI, through the ELSI Research Program, supports research studies that examine issues and, where appropriate, develop policy options regarding the ethical, legal and social implications of genomics. These studies may focus on issues associated with genomic research, genomic medicine or broader societal effects of genomic information and technologies. More detailed
information on specific ELSI research priorities within each of these broad areas is available on the ELSI Research priorities web site: http://www.genome.gov/27543732.

**NHGRI Clinical Trials Topics:**

The National Human Genome Research Institute (NHGRI) will accept applications designated as clinical trials for all program areas supported by the Institute as outlined above for non-clinical trials SBIRs/STTRs. The broadened definition of clinical trials as defined in NOT-OD-15-015 and https://grants.nih.gov/policy/clinical-trials/definition.htm is not intended to expand the scope of applications accepted by NHGRI beyond studies that have a major genomic or Ethical, Legal and Social Implications (ELSI) component and relate clearly to NHGRI’s mission. Information on areas of research interest is available on the NHGRI Research Funding Divisions homepage: https://www.genome.gov/27552836/nhgri-research-funding-divisions/ and the ELSI Research Domains website: https://www.genome.gov/27543732/elsi-research-domains/. Additionally, applicants are strongly encouraged to discuss their research plans with NHGRI Program Staff prior to submitting their application.

For more information on research topics, contact:

Michael W. Smith, Ph.D.
Technology Development Program &
Coordinator SBIR/STTR Grants
301-496-7531
Email: smithmw@mail.nih.gov

Heidi Sofia, Ph.D.
Informatics & Genomic Medicine
301-496-7531
Email: Heidi.Sofia@nih.gov
NATIONAL INSTITUTE OF MENTAL HEALTH (NIMH)

The mission of the National Institute of Mental Health (NIMH) is to transform the understanding and treatment of mental illnesses through basic and clinical research, paving the way for prevention, recovery, and cure. Mental disorders constitute an immense burden on the U.S. population, with major depression now the leading cause of disability in the U.S., and schizophrenia, bipolar disorder, and obsessive-compulsive disorder ranked among the ten leading causes of disability. NIMH also takes a leading role in understanding the impact of behavior on HIV transmission and pathogenesis, and in developing effective behavioral preventive interventions. The NIMH conducts a wide range of research, research training, research capacity development, as well as public information outreach and dissemination to fulfill its mission.

For the Institute to continue fulfilling this vital public health mission, it must foster innovative thinking and ensure that a full array of novel scientific perspectives are used to further discovery in the evolving science of brain, behavior, and experience. In this way, breakthroughs in science can become breakthroughs for all people with mental illnesses.

The NIMH SBIR/STTR programs support small businesses to develop technologies that can advance the mission of the Institute, including in basic neuroscience research relevant to mental disorders, translational and clinical research of mental disorders, clinical diagnosis or treatment of mental disorders, and dissemination of evidence-based mental health care. The NIMH Strategic Plan (http://www.nimh.nih.gov/about战略性规划-reports/index.shtml) and the National Advisory Mental Health Council’s workgroup report “From Discovery to Cure” http://www.nimh.nih.gov/about/advisory-boards-and-groups/namhc/reports/fromdiscoverytocure_103739.pdf present key scientific priorities across these domains, and describe the need for tools to realize these priorities. Research priorities for the NIMH further include aspects of HIV/AIDS prevention, treatment, and care, in accordance with the Trans-NIH Plan for HIV-Related Research (http://www.oar.nih.gov/战略规划/).

For additional information about areas of interest to the NIMH, please visit our home page at http://www.nimh.nih.gov.

Also visit the NIMH SBIR/STTR home page: http://www.nimh.nih.gov/research-funding/small-business/index.shtml.

Important notes:

1. It is very helpful for potential SBIR/STTR applicants to contact NIMH prior to submitting an application, to ensure the application is of priority/interest to NIMH. Please see the contacts section.

2. An additional criteria that the federal government considers in supporting a small business with SBIR/STTR funds, is past commercialization performance. It is expected that small businesses who have received previous SBIR/STTR grants, have had success in commercializing their previously supported technologies. Small businesses that are mostly interested in research and development (and not commercialization) should consider other grant mechanisms at NIH, rather than the SBIR/STTR program. Program staff at NIMH can help identify the most appropriate grant mechanism to use.

3. The NIH has received a waiver from the SBA, regarding the funding cap. The technology areas that are included in this waiver can be found in the topic list located in Appendix A of this document. The technologies listed in the Appendix A (under NIMH) are of priority to this institute.

Phase IIB Competing Renewal Awards

The NIMH will accept Phase IIB SBIR/STTR Competing Renewal grant applications in two categories: 1) to continue research and development of technologies that ultimately require federal regulatory approval,
and 2) to continue research and development of complex instrumentation, clinical research tools, or behavioral interventions and treatments.

Technologies in the former category (those that ultimately require federal regulatory approval) include, but are not limited to: pharmacologic agents and drugs, biological products, medical devices, vaccines, etc., related to the mission of the NIMH. Phase IIB SBIR/STTR Competing Renewal grants for such technologies should allow small businesses to get research and development to a stage where interest and investment by third parties is more likely.

Companies that are developing technologies that do not focus on drug development, but that require federal regulatory approval prior to commercialization, may be eligible to submit a Phase IIB Competing Renewal application.

For both technology areas, Phase IIB applications may be submitted through the Omnibus SBIR funding/STTR opportunity announcement. For this opportunity, budget limits of $3 million total costs and time periods up to 3 years may be requested. These budget allowances have been approved by the SBA through a waiver.

The following examples would make appropriate topics for proposed NIMH SBIR/STTR Phase IIB Competing Renewal projects. These are meant for illustrative purposes only and are not exclusive of other appropriate activities:

- Preclinical studies, including pharmacology and toxicology, beyond those conducted under the Phase I (R43/R41) and initial Phase II (R44/R42) grants. Some in vivo or in vitro studies would be expected to have been carried out in Phase I or the initial Phase II grant.
- Completion of studies as required by the Food and Drug Administration (FDA) for Investigational New Drug (IND) or Radioactive Drug Research Committee (RDRC) application.
- Studies in normal healthy volunteers to determine a drug’s safety profile, metabolism, etc.
- Assessment of devices with regard to performance standards related to the FDA approval process.
- Safety and effectiveness studies of novel medical devices.
- Evaluation of novel imaging approaches for diagnostic purposes.
- Clinical studies in support of Pre-Market Approval for biomarkers/medical devices by the FDA.

Although technologies in the latter category listed above (complex instrumentation, clinical research tools, or behavioral interventions/treatments) may not require federal regulatory approval, extraordinary time and effort is needed for their research and development. Therefore, NIMH supports Phase IIB Competing Renewal awards of existing Phase II grants for such technologies. The Phase IIB Competing Renewal award for these would provide up to an additional three years of support at total cost funding levels of up to $3 million for the project. These budget allowances have been approved by the SBA through a waiver.

Please contact the Program Director in the appropriate Division or Dr. Margaret Grabb (listed below) before beginning the process of putting an application together. In addition, prospective applicants are encouraged to submit to the program contact a letter of intent that includes the following information:

- Descriptive title of the proposed research
- Name, address, and telephone number of the Principal Investigator
- Names of other key personnel
- Participating institutions
- Funding Opportunity Announcement (e.g. PA-11-133).

Although a letter of intent is not required, is not binding, and does not enter into the review of a subsequent application, the information that it contains allows NIH staff to estimate the potential review workload and plan the review. It is expected that only a portion of NIMH SBIR Phase II awards will be eligible for a Phase IIB Competing Renewal grant.
Research Topics of Interest to NIMH

The specific set of topics that are funded by a particular IC/Office/Agency depends on whether the IC/Office/Agency funds/supports Clinical Trials under SBIR/STTR Awards. Use the following table and explanations to determine which list of topics is applicable.

<table>
<thead>
<tr>
<th>Does IC/Office/Agency Fund/Support Clinical Trials under SBIR/STTR Awards?</th>
<th>No*</th>
<th>Yes**</th>
</tr>
</thead>
<tbody>
<tr>
<td>X</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

*If No,
- This IC/Office/Agency funds only those topics listed under the Non-Clinical Trials Topics section below, UNLESS the IC/Office/Agency funds a Small Business Concern for clinical trials under a NON-SBIR/STTR award.

**If Yes or the IC/Office/Agency funds small businesses for clinical trials under a NON-SBIR/STTR funding opportunity,
- See the table below for which mechanisms the IC/Office/Agency will allow for clinical trials research. Also, see the Clinical Trials Topics section below for a list of funded topics. This IC/Office/Agency also funds research listed under the Non-Clinical Trials Topics section below.

<table>
<thead>
<tr>
<th>Does IC/Office/Agency accept clinical trials applications under this mechanism?</th>
<th>Yes</th>
<th>No</th>
<th>Other Information:</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Clinical Trials SBIR/STTR Omnibus/Parent Funding Opportunity Announcement/s</td>
<td>X</td>
<td></td>
<td>NIMH will prioritize funding for SBIR/STTR applications with a clinical trial focus that are consistent with the stated research goals and priorities relevant to clinical trials as outlined in the clinical trials FOAs. For more information see: <a href="https://www.nimh.nih.gov/funding/opportunities-announcements/clinical-trials-foas/support-for-clinical-trials-at-nimh.shtml">https://www.nimh.nih.gov/funding/opportunities-announcements/clinical-trials-foas/support-for-clinical-trials-at-nimh.shtml</a></td>
<td></td>
</tr>
<tr>
<td>Clinical Trials SBIR/STTR IC/Office/Agency - Specific Funding Opportunity Announcement/s</td>
<td>X</td>
<td></td>
<td>NIMH will prioritize funding for SBIR/STTR applications with a clinical trial focus that are consistent with the stated research goals and priorities relevant to clinical trials as outlined in the clinical trials FOAs. For more information see: <a href="https://www.nimh.nih.gov/funding/opportunities-announcements/clinical-trials-foas/support-for-clinical-trials-at-nimh.shtml">https://www.nimh.nih.gov/funding/opportunities-announcements/clinical-trials-foas/support-for-clinical-trials-at-nimh.shtml</a></td>
<td></td>
</tr>
<tr>
<td>Does IC/Office/Agency accept clinical trials applications under this mechanism?</td>
<td>Yes</td>
<td>No</td>
<td>Other Information: If funding an SBC for clinical trials under a NON-SBIR/STTR award, please identify activity code(s) and other relevant information.</td>
<td></td>
</tr>
<tr>
<td>---</td>
<td>---</td>
<td>---</td>
<td>---</td>
<td></td>
</tr>
<tr>
<td>Clinical Trials NON-SBIR/STTR Funding Opportunity Announcement/s where Small Businesses are eligible to apply</td>
<td>X</td>
<td></td>
<td>NIMH will prioritize funding for SBIR/STTR applications with a clinical trial focus that are consistent with the stated research goals and priorities relevant to clinical trials as outlined in the clinical trials FOAs. For more information see: <a href="https://www.nimh.nih.gov/funding/opportunities-announcements/clinical-trials-foas/support-for-clinical-trials-at-nimh.shtml">https://www.nimh.nih.gov/funding/opportunities-announcements/clinical-trials-foas/support-for-clinical-trials-at-nimh.shtml</a> And:</td>
<td></td>
</tr>
<tr>
<td>• First in Human and Early Stage Clinical Trials of Novel Investigational Drugs or Devices for Psychiatric Disorders (U01 Clinical Trial Required) PAR-18-427</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>• Early Stage Testing of Pharmacologic or Device-based Interventions for the Treatment of Mental Disorders (R61/R33- Clinical Trial Required) RFA-MH-18-702</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>• Early Stage Testing of Pharmacologic or Device-based Interventions for the Treatment of Mental Disorders (R33- Clinical Trial Required) RFA-MH-18-703</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>• Development of Psychosocial Therapeutic and Preventive Interventions for Mental Disorders (R61/R33- Clinical Trial Required) RFA-MH-18-704</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>• Development of Psychosocial Therapeutic and Preventive Interventions for Mental Disorders (R33 Clinical Trial Required) RFA-MH-18-705</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
Does IC/Office/Agency accept clinical trials applications under this mechanism?

<table>
<thead>
<tr>
<th>Yes</th>
<th>No</th>
<th>Other Information: If funding an SBC for clinical trials under a NON-SBIR/STTR award, please identify activity code(s) and other relevant information.</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td><img src="https://example.com" alt="Clinical Trials NON-SBIR/STTR Funding Opportunity Announcement/s where Small Businesses are eligible to apply" /></td>
</tr>
<tr>
<td></td>
<td></td>
<td>• Confirmatory Efficacy Clinical Trials of Non-Pharmacological Interventions for Mental Disorders (R01 Clinical Trial Required) <a href="https://example.com">RFA-MH-18-707</a></td>
</tr>
<tr>
<td></td>
<td></td>
<td>• Pilot Effectiveness Trials for Treatment, Preventive and Services Interventions (R34- Clinical Trial Required) <a href="https://example.com">RFA-MH-18-706</a></td>
</tr>
<tr>
<td></td>
<td></td>
<td>• Clinical Trials to Test the Effectiveness of Treatment, Preventive, and Services Interventions (R01 Clinical Trial Required) <a href="https://example.com">RFA-MH-18-701</a></td>
</tr>
<tr>
<td></td>
<td></td>
<td>• Clinical Trials to Test the Effectiveness of Treatment, Preventive, and Services Interventions (Collaborative R01 - Clinical Trial Required) <a href="https://example.com">RFA-MH-18-700</a></td>
</tr>
</tbody>
</table>

**NIMH Non-Clinical Trials Topics:**

**Division of Neuroscience and Basic Behavioral Science (DNBBS)**

The Division of Neuroscience and Basic Behavioral Science provides support for research programs in the areas of basic neuroscience, genetics, basic behavioral science, research training, resource development, technology development, drug discovery, and research dissemination. The Division has the responsibility, in cooperation with other components of the Institute and the research community, for ensuring that relevant basic science knowledge is generated and then harvested to create improved diagnosis, treatment, and prevention of mental and behavioral disorders.

In this Division, the SBIR and STTR programs support research and the development of tools related to basic brain and behavioral science, genetics, and drug discovery and development relevant to the mission of the NIMH. Such tools include: software (such as informatics tools and resources and tools for analyzing data); hardware (such as the development of instrumentation or devices); wetware (such as the use of iRNAs or other bioactive agents as research tools or molecular imaging agents or genetic approaches to label neural circuits or modify circuit functions); and drug discovery related technologies such as high throughput screening (HTS) or computational pharmacology approaches.

**AREAS OF EMPHASIS**

- Novel imaging probes to study brain structure and function at all levels, from the molecular level to the whole organ, using any imaging modality (PET, fMRI, optical, etc.).

- Drug discovery/drug development of novel compounds which act on molecular pathways (receptors, enzymes, second messengers, etc.) that are not typically targeted with currently available psychiatric drugs, and that have a strong biological justification as a novel mechanism for treatment of psychiatric disorders.

- Novel screening assays for high throughput acquisition and analysis of data about behavior and the brain, from the level of genes to behavior.
• Novel technologies that would enable researchers to study how populations of neural cells work together within and between brain regions, in order to understand how changes in neural activity contributes to mental disorders.

• New or improved technologies to advance microbiome brain research characterizing the relationship between the microbiota-gut-brain (MGB) axis and central nervous system (CNS), and its impact on psychiatric disorders.

• Develop informatics tools to facilitate the analysis and sharing of data between laboratories about behavior and the brain. This could include common data element efforts, but is not limited to that area.

• Technologies consistent with the goals of the BRAIN Initiative: http://www.braininitiative.nih.gov/.

Prospective applicants are strongly encouraged to contact Dr. Margaret Grabb (listed below) with questions about the relevance of their interests to the mission of this division.

Division of Translational Research (DTR)

The Division of Translational Research plans, supports, and administers programs of research, research training, and resource development aimed at understanding the pathophysiology of mental illness and hastening the translation of behavioral science and neuroscience advances into innovations in clinical care. The Division supports a broad research portfolio, which includes studies of the phenotypic characterization and risk factors for major psychiatric disorders; clinical neuroscience to elucidate etiology and pathophysiology of these disorders; and psychosocial, psychopharmacologic, and somatic treatment development. In addition, the Division supports an integrated program to clarify the psychopathology and underlying pathophysiology of psychiatric disorders of late life and to develop new treatments for these disorders.

In this Division, the SBIR and STTR Programs support research aimed at facilitating the validation and commercialization of new methods of assessing psychopathology and measuring treatment response to therapeutic agents. In addition, the SBIR and STTR Programs support the clinical development of novel pharmacologic treatments and technology development used to deliver novel psychosocial approaches to the treatment of mental illness in adults, pediatrics and geriatrics.

AREAS OF EMPHASIS

• Develop valid measures of the various constructs in the Research Domain Criteria (RDoC) matrix (see http://www.nimh.nih.gov/research-funding/rdoc/index.shtml), e.g., behavioral tasks, psychometrically sophisticated self-report measures, and measures of physiological and neural activity, into a commercial product.

• Web-based tools to enhance prevention, early identification and treatment of pediatric mental disorders by various educational and health professionals.

• Development of hardware and software tools to support operations of multi-site clinical trials.

• Development of novel methods to enhance efficiency of early phase clinical trials.

• Novel technologies and data analytic tools to enable quantification of behavioral data that is relevant to research or clinical trials in mental disorders and/or autism.

Prospective applicants are strongly encouraged to contact Dr. Margaret Grabb (listed below) with questions about the relevance of their interests to the mission of this division.
Division of AIDS Research (DAR)

The NIMH DAR supports scientific research to understand and alleviate the consequences of HIV infection on the central nervous system, and research to strengthen the provision and outcomes of HIV/AIDS prevention and treatment. Please refer to the NIH HIV/AIDS research priorities and guidelines for determining AIDS funding (https://grants.nih.gov/grants/guide/notice-files/NOT-OD-15-137.html). Examples of high-priority research areas for SBIR/STTR applications are described below.

- Develop and test novel, non-invasive diagnostic approaches (instrumentation, imaging, biomarkers, central nervous system [CNS] cell-based in vitro models) to detect HIV-1 induced CNS dysfunction and innovative technologies to study the mechanisms involved in HIV-1 associated neuropathogenesis and persistence of HIV-1 in the CNS. or strategies to prevent viral resurgence in the CNS upon cessation of anti-retroviral therapy.

- Design and test novel therapeutic strategies aimed at amelioration HIV-1 induced CNS dysfunction, and/or eradication of HIV-1 from CNS reservoirs, and/or strategies to prevent viral resurgence in the CNS upon cessation of anti-retroviral therapy. Designing novel therapeutic strategies could occur retrospectively (not a clinical trial – using EMR).

- Design new strategies to reduce adverse effects of anti-retroviral drugs such as neuropsychiatric side effects and drug-drug interactions. Designing strategies for adverse effects of antiretrovirals could occur retrospectively (not a clinical trial – using EMR).

- Develop or adapt neurological/neuropsychological/neurobehavioral assessments to evaluate HIV-1 associated abnormalities in adults or children in resource poor environments that are adaptable to different cultures and languages. Designing neurobehavioral assessments could occur retrospectively (not a clinical trial – using EMR).

- Develop innovative approaches to improve the scientific assessment of HIV exposure due to sexual behavior or the scientific assessment of HIV medication adherence through wireless technologies, remote sensing devices, biomarkers, assays, or other novel methods. Designing approaches for assessment could occur retrospectively (not a clinical trial – using EMR).

- Develop and test tools, curricula, and strategies that seek to reduce documented racial/ethnic, gender, and age-related disparities in HIV infection, HIV testing, HIV care engagement, or in HIV treatment adherence and treatment outcomes. Designing strategies for reducing disparities could occur retrospectively (not a clinical trial – using EMR).

- Develop novel tools and approaches to identify, recruit, enroll, and/or retain those most vulnerable to HIV/AIDS (e.g., African-American MSM, adolescents) in HIV prevention research and/or services. Developing tools for recruitment and retention of key populations could occur retrospectively (not a clinical trial – using EMR).

Prospective applicants are strongly encouraged to contact Dr. David M. Stoff (listed below) with questions about the relevance of their interests to the mission of this division.

Division of Services and Intervention Research (DSIR)

The Division of Services and Intervention Research (DSIR) supports two critical areas of research:

- Intervention research to evaluate the effectiveness of pharmacologic, psychosocial, somatic, rehabilitative and combination interventions on mental and behavior disorders—including acute and longer-term therapeutic effects on functioning across domains for children, adolescents, and adults.
• Mental health services research to improve the access, continuity, cost, quality and outcomes of mental health care, as well as to improve the dissemination and implementation of effective interventions in clinical and community settings, to strengthen the public health impact of NIMH research.

The intervention research program addresses the effectiveness of treatment and preventive interventions in usual practice and community settings with the purpose of informing clinicians, patients, families, and health policy makers on evidence based practices. In funding decisions, special emphasis is placed on the potential clinical impact of the research activities and on the implications of the research findings for improving community practice and health outcomes. Types of interventions include the full range of behavioral, psychotherapeutic, pharmacologic, and non-pharmacologic somatic or alternative interventions, as well as rehabilitation or other adjunctive services, e.g., integrated approaches to chronic mental illness. Examples of areas of interest are:

• Analyses of naturalistic databases to evaluate the effectiveness of preventive and treatment interventions.

• Identifying moderators and mediators of intervention effects as a step to design and test personalized interventions. Moderator/mediator identification could occur retrospectively (not a clinical trial – using EMR).

• Evaluating the combined or sequential use of interventions. Evaluation of combined/sequential interventions could occur retrospectively (not a clinical trial – using EMR).

• Determining the optimal duration, frequency and intensity of an intervention to optimize improvements in symptoms and functioning, establishing the utility of continuation or maintenance treatment (that is, for prevention of relapse or recurrence). Evaluation of the optimal length of an intervention could occur retrospectively (not a clinical trial – using EMR).

• Evaluating the long-term impact of therapeutic interventions on symptoms, functioning, and quality of life. Evaluation of the optimal length of an intervention could occur retrospectively (not a clinical trial – using EMR or survey data).

Services research covers all mental health services across the lifespan for all mental health disorders and aligns with NIMH strategic research priority 4 (https://www.nimh.nih.gov/about/strategic-planning-reports/strategic-research-priorities/srp-objective-4/index.shtml), which includes but is not limited to:

• Service settings at the patient, provider, health system, and cross system levels to include primary care, specialty mental health, integrated care, general health, and other delivery settings (such as employment, educational, veteran, military, and criminal justice settings).

• Enhanced capacity for conducting services research by developing and utilizing innovative and established methodologies, including health economics, to inform decisions about service delivery and financing of care.

• The clinical epidemiology of mental disorders to include development and use of data sets from health surveillance activities, decision support tools, administrative claims, mobile apps and similar technologies, electronic health record, disease registries, and other databases where epidemiological data (to include big data) reside.

In this Division, the SBIR and STTR Programs support research and development of novel tools related to clinical trials (including preventive, treatment, and rehabilitative interventions alone and/or in combination), methodology, clinical epidemiology, services research, effectiveness research, health disparities (including rural populations) and the dissemination and implementation of evidence-based
treatments/research into clinical and community settings in areas directly related to the mission of the NIMH. Such tools may include applied behavioral science and technology, software, hardware and associated technologies. Included are technology-assisted approaches to assessment (e.g., technology-assisted screening and diagnosis) and intervention (e.g., m-health and other technology platforms to support the delivery of preventive, therapeutic, and services interventions). In this realm, NIMH encourages efforts to employ technology-assisted approaches to expand the reach, efficiency, continuity, quality, and/or boost the therapeutic benefit of research-informed strategies, rather than mere translation of research-supported strategies onto new or emerging technology platforms. Collaboration with NIMH supported researchers for the development of software for new analytic techniques and/or decision-making algorithms is encouraged. Also supported is research and the development or adaptation of tools and technologies to be used to enhance the training and development of new generations of researchers and practitioners and to keep established researchers and practitioners up-to-date on the findings, implementation, and methods of interventions and services research.

Prospective applicants are strongly encouraged to contact Dr. Adam Haim (listed below) with questions about the relevance of their interests to the mission of this division.

**NIMH Clinical Trials Topics:**

**Division of Neuroscience and Basic Behavioral Science (DNBBS)**

The Division of Neuroscience and Basic Behavioral Science provides support for research programs in the areas of basic neuroscience, genetics, basic behavioral science, research training, resource development, technology development, drug discovery, and research dissemination. The Division has the responsibility, in cooperation with other components of the Institute and the research community, for ensuring that relevant basic science knowledge is generated and then harvested to create improved diagnosis, treatment, and prevention of mental and behavioral disorders.

In this Division, the SBIR and STTR programs support research and the development of tools related to basic brain and behavioral science, genetics, and drug discovery and development relevant to the mission of the NIMH. Such tools include: software (such as informatics tools and resources and tools for analyzing data); hardware (such as the development of instrumentation or devices); wetware (such as the use of iRNAs or other bioactive agents as research tools or molecular imaging agents or genetic approaches to label neural circuits or modify circuit functions); and drug discovery related technologies such as high throughput screening (HTS) or computational pharmacology approaches.

**AREAS OF EMPHASIS**

- Novel imaging probes to study brain structure and function at all levels, from the molecular level to the whole organ, using any imaging modality (PET, fMRI, optical, etc.).
- Drug discovery/drug development of novel compounds which act on molecular pathways (receptors, enzymes, second messengers, etc.) that are not typically targeted with currently available psychiatric drugs, and that have a strong biological justification as a novel mechanism for treatment of psychiatric disorders.
- Novel screening assays for high throughput acquisition and analysis of data about behavior and the brain, from the level of genes to behavior.
- Novel technologies that would enable researchers to study how populations of neural cells work together within and between brain regions, in order to understand how changes in neural activity contributes to mental disorders.
• New or improved technologies to advance microbiome brain research characterizing the relationship between the microbiota-gut-brain (MGB) axis and central nervous system (CNS), and its impact on psychiatric disorders.

• Technologies consistent with the goals of the BRAIN Initiative: http://www.braininitiative.nih.gov/.

Prospective applicants are strongly encouraged to contact Dr. Margaret Grabb (listed below) with questions about the relevance of their interests to the mission of this division.

Division of Translational Research (DTR)

The Division of Translational Research plans, supports, and administers programs of research, research training, and resource development aimed at understanding the pathophysiology of mental illness and hastening the translation of behavioral science and neuroscience advances into innovations in clinical care. The Division supports a broad research portfolio, which includes studies of the phenotypic characterization and risk factors for major psychiatric disorders; clinical neuroscience to elucidate etiology and pathophysiology of these disorders; and psychosocial, psychopharmacologic, and somatic treatment development. In addition, the Division supports an integrated program to clarify the psychopathology and underlying pathophysiology of psychiatric disorders of late life and to develop new treatments for these disorders.

In this Division, the SBIR and STTR Programs support research aimed at facilitating the validation and commercialization of new methods of assessing psychopathology and measuring treatment response to therapeutic agents. In addition, the SBIR and STTR Programs support the clinical development of novel pharmacologic treatments and technology development used to deliver novel psychosocial approaches to the treatment of mental illness in adults, pediatrics and geriatrics.

Areas of Emphasis

• Develop valid measures of the various constructs in the Research Domain Criteria (RDoC) matrix (see http://www.nimh.nih.gov/research-funding/rdoc/index.shtml ), e.g., behavioral tasks, psychometrically sophisticated self-report measures, and measures of physiological and neural activity, into a commercial product.

• Conduct early stage, proof of concept clinical trials to advance the development of novel therapeutics. The clinical trials are expected to include biological/behavioral data to assess target engagement and to help determine potential success or failure of the compound before moving on to larger clinical trials (see NOT-MH-11-015 http://grants.nih.gov/grants/guide/notice-files/NOT-MH-11-015.html).

• Develop, test and validate reliable and stable biomarkers that can identify at-risk individuals prior to disease onset, improve diagnosis and classification, predict treatment response, or to measure disease progression. Biomarkers are also needed in clinical trials to identify dose ranges, to identify a specific subpopulation of subjects to enroll in a treatment trial, or to measure efficacy or toxicity/side effects.

• Development of novel diagnostic tools and innovative measures of treatment response and disease progression, preclinical or clinical efficacy testing, or toxicity measures for drug development.

• Development of hardware and software tools to enable refined physiological and behavioral assessment of normal and atypical neurodevelopment focused on pediatrics, adult and geriatric age ranges.
• Web-based tools to enhance prevention, early identification and treatment of pediatric mental disorders by various educational and health professionals.

• Development of hardware and software tools to support operations of multi-site clinical trials.

• Development of novel methods to enhance efficiency of early phase clinical trials.

• Novel technologies and data analytic tools to enable quantification of behavioral data that is relevant to research or clinical trials in mental disorders and/or autism.

Prospective applicants are strongly encouraged to contact Dr. Margaret Grabb (listed below) with questions about the relevance of their interests to the mission of this division.

Division of AIDS Research (DAR)

The NIMH DAR supports scientific research to understand and alleviate the consequences of HIV infection on the central nervous system, and research to strengthen the provision and outcomes of HIV/AIDS prevention and treatment. Please refer to the NIH HIV/AIDS research priorities and guidelines for determining AIDS funding (https://grants.nih.gov/grants/guide/notice-files/NOT-OD-15-137.html). Examples of high-priority research areas for SBIR/STTR applications are described below.

• Design and test novel therapeutic strategies aimed at amelioration HIV-1 induced CNS dysfunction, and/or eradication of HIV-1 from CNS reservoirs, and/or strategies to prevent viral resurgence in the CNS upon cessation of anti-retroviral therapy. **Designing novel therapeutic strategies could occur prospectively (within the context of a clinical trial).**

• Discover and develop innovative technologies for targeting therapies to the brain, including antiretroviral drugs, nanotechnology, imaging tools to study HIV-aging interactions or HIV-related neurodegeneration and neuroprotective strategies with improved capability to cross the blood-brain barrier for amelioration of HAND.

• Design new strategies to reduce adverse effects of anti-retroviral drugs such as neuropsychiatric side effects and drug-drug interactions. **Designing strategies for adverse effects of antiretrovirals could occur prospectively (within the context of a clinical trial).**

• Develop or adapt neurological/neuropsychological/neurobehavioral assessments to evaluate HIV-1 associated abnormalities in adults or children in resource poor environments that are adaptable to different cultures and languages. **Designing neurobehavioral assessments could occur prospectively (within the context of a clinical trial).**

• Develop innovative approaches to improve the scientific assessment of HIV exposure due to sexual behavior or the scientific assessment of HIV medication adherence through wireless technologies, remote sensing devices, biomarkers, assays, or other novel methods. **Designing approaches for assessment could occur prospectively (within the context of a clinical trial).**

• Develop and test tools, curricula, and strategies that seek to reduce documented racial/ethnic, gender, and age-related disparities in HIV infection, HIV testing, HIV care engagement, or in HIV treatment adherence and treatment outcomes. **Designing strategies for reducing disparities could occur prospectively (within the context of a clinical trial).**

• Develop novel tools and approaches to identify, recruit, enroll, and/or retain those most vulnerable to HIV/AIDS (e.g., African-American MSM, adolescents) in HIV prevention research and/or services. **Developing tools for recruitment and retention of key populations could occur prospectively (within the context of a clinical trial).**
• Develop and test tools, curricula, or other approaches designed to facilitate the effective use and implementation of biomedical HIV prevention methods (e.g., pre-exposure prophylaxis, microbicides, circumcision, monoclonal antibodies, etc.), including but not limited to approaches that address behavioral aspects of biomedical prevention (e.g., provider knowledge and training; patient uptake and adherence, screening tools, and risk-reduction counseling, etc.).

• Develop evidence-based interventions to reduce risk for HIV among at-risk individuals or improve outcomes along the HIV care continuum for individuals living with HIV which are delivered through mobile devices or other technologies.

• Develop novel tools and approaches designed to improve HIV treatment outcomes by rapidly linking individuals diagnosed with HIV to primary medical care, enhancing patient readiness for initiation of antiretroviral medications, improving and sustaining patient adherence to antiretroviral medications, and/or improving patient retention in medical care.

• Develop innovative approaches designed to improve the quality of HIV testing, (including rapid home based HIV antibody tests), HIV counseling, prevention, and treatment services by strengthening patient-provider communication and/or modifying the decision-making processes and practice behaviors of health care providers.

• Develop innovative approaches designed to improve the uptake and understanding of rapid home based HIV antibody tests by key populations at higher risk for HIV as well as innovative interventions that can be paired with home test kits to increase linkage and engagement in HIV care for those testing positive.

• Develop novel information technology tools designed to improve dissemination of evidence-based interventions and assist healthcare providers, community-based organizations, and professional or advocacy organizations in identifying, adopting, and implementing proven HIV prevention and treatment interventions.

Prospective applicants are strongly encouraged to contact Dr. David M. Stoff (listed below) with questions about the relevance of their interests to the mission of this division.

Division of Services and Intervention Research (DSIR)

The Division of Services and Intervention Research (DSIR) supports two critical areas of research:

• Intervention research to evaluate the effectiveness of pharmacologic, psychosocial, somatic, rehabilitative and combination interventions on mental and behavior disorders—including acute and longer-term therapeutic effects on functioning across domains for children, adolescents, and adults.

• Mental health services research to improve the access, continuity, cost, quality and outcomes of mental health care, as well as to improve the dissemination and implementation of effective interventions in clinical and community settings, to strengthen the public health impact of NIMH research.

The intervention research program addresses the effectiveness of treatment and preventive interventions in usual practice and community settings with the purpose of informing clinicians, patients, families, and health policy makers on evidence based practices. In funding decisions, special emphasis is placed on the potential clinical impact of the research activities and on the implications of the research findings for improving community practice and health outcomes. Types of interventions include the full range of behavioral, psychotherapeutic, pharmacologic, and non-pharmacologic somatic or alternative interventions, as well as rehabilitation or other adjunctive services, e.g., integrated approaches to chronic mental illness. Examples of areas of interest are:
- Randomized clinical trials evaluating the effectiveness of preventive and treatment interventions.
- Identifying moderators and mediators of intervention effects as a step to design and test personalized interventions. Moderator/mediator identification could occur prospectively (within the context of a clinical trial).
- Evaluating the combined or sequential use of interventions. Evaluation of combined/sequential interventions could occur prospectively (within the context of a clinical trial).
- Determining the optimal duration, frequency and intensity of an intervention to optimize improvements in symptoms and functioning, establishing the utility of continuation or maintenance treatment (that is, for prevention of relapse or recurrence). Evaluation of the optimal length of an intervention could occur prospectively (within the context of a clinical trial).
- Evaluating the long-term impact of therapeutic interventions on symptoms, functioning, and quality of life. Evaluation of the optimal length of an intervention could occur prospectively (within the context of a clinical trial).

Services research covers all mental health services across the lifespan for all mental health disorders and aligns with NIMH strategic research priority 4 (https://www.nimh.nih.gov/about/strategic-planning-reports/strategic-research-priorities/srp-objective-4/index.shtml), which includes but is not limited to:

- Interventions and other research to improve access, continuity, engagement, quality, uptake, equity, efficiency, and cost of care.
- The dissemination and implementation of evidence-based interventions, programs, support tools, or other practices or technologies into service settings.

In this Division, the SBIR and STTR Programs support research and development of novel tools related to clinical trials (including preventive, treatment, and rehabilitative interventions alone and/or in combination), methodology, clinical epidemiology, services research, effectiveness research, health disparities (including rural populations) and the dissemination and implementation of evidence-based treatments/research into clinical and community settings in areas directly related to the mission of the NIMH. Such tools may include applied behavioral science and technology, software, hardware and associated technologies. Included are technology-assisted approaches to assessment (e.g., technology-assisted screening and diagnosis) and intervention (e.g., m-health and other technology platforms to support the delivery of preventive, therapeutic, and services interventions). In this realm, NIMH encourages efforts to employ technology-assisted approaches to expand the reach, efficiency, continuity, quality, and/or boost the therapeutic benefit of research-informed strategies, rather than mere translation of research-supported strategies onto new or emerging technology platforms. Collaboration with NIMH supported researchers for the development of software for new analytic techniques and/or decision-making algorithms is encouraged. Also supported is research and the development or adaptation of tools and technologies to be used to enhance the training and development of new generations of researchers and practitioners and to keep established researchers and practitioners up-to-date on the findings, implementation, and methods of interventions and services research.

Prospective applicants are strongly encouraged to contact Dr. Adam Haim (listed below) with questions about the relevance of their interests to the mission of this division.

Program Contacts

Margaret Grabb, Ph.D. (general questions about the NIMH SBIR program, Phase IIB program, DNBBS, DTR divisional interests)
National Institute of Mental Health
6001 Executive Boulevard, Room 7201, MSC 9645
Bethesda, MD 20892-9645
Rockville, MD 20852 (for express/courier service)
Telephone: 301-443-3563
Fax: 301-443-1731
Email: mgrabb@mail.nih.gov

Adam Haim, Ph.D. (DSIR divisional interests)
Division of Services and Intervention Research
6001 Executive Boulevard
Room 7160, MSC 9649
Bethesda, MD 20892-9635
301-445-3593
Email: haima@mail.nih.gov

David M. Stoff, Ph.D. (DAR divisional interests)
Division of AIDS Research
6001 Executive Blvd., Room 9G13B, MSC 9619
Bethesda, MD 20892
Telephone: 240-627-3876
Email: dstoff@mail.nih.gov

Gregory K. Farber, Ph.D. (general questions about technology development)
Director, Office of Technology Development and Coordination
6001 Executive Boulevard
Room 7162, MSC 9640
Bethesda, MD 20892
Telephone: 301-435-0778
Email: farberg@mail.nih.gov
NATIONAL INSTITUTE ON MINORITY HEALTH AND HEALTH DISPARITIES (NIMHD)

The mission of the National Institute on Minority Health and Health Disparities (NIMHD) is to promote minority health and to lead, coordinate, support, and assess the National Institutes of Health (NIH) effort to reduce and ultimately eliminate health disparities. In this effort, the NIMHD conducts and supports basic, clinical, social and behavioral research; facilitates the development of research infrastructure and training; fosters emerging programs; and reaches out to racial/ethnic minority and other health disparity communities.

The Small Business Innovation Research (SBIR) Program and the Small Business Technology Transfer (STTR) Program enable the Nation’s small businesses to apply their unique research and development capabilities toward accomplishing NIMHD’s mission.

Through small business Phase I, Phase II, and Fast-track awards, NIMHD supports multi- and trans-disciplinary research and development leading to novel and or improved products capable of contributing to NIMHD’s mission. Research and development may proceed or be initiated at the molecular, cellular, individual, community or population level. Funding support for focus groups, phase I/II clinical trials, and other studies as needed to develop and test the proposed product may be requested. Additionally, NIMHD seeks innovative strategies for improving minority health, elimination of health disparities, and enhancing health and well-being where small businesses engage, collaborate or partner with health disparity communities from conception, application submission, and through completion of NIMHD funding periods and beyond. Applications partnering with community health centers or other patient providers as appropriate are also encouraged and of interest. Support for the development of innovative technologies or services for enhancing minority health and well-being through partnerships with community-based small businesses, such as beauty salons, barbershops, pharmacies, etc., that engage with racial and ethnic minority or health disparity populations on a regular basis, can also be requested. Technology that leverages indigenous community advisors and supporters in health promotion or prevention efforts may contribute to overall community health improvement and well-being through the processes of community empowerment and increased community cohesion.

An overarching objective of NIMHD’s investments in SBIR/STTR programs is to ensure that racial and ethnic minorities and health disparity populations benefit equally from innovations in health promotion and prevention, biotechnology, imaging technologies, technologies for computational biology and informatics, including, for example, systems, and structural biology; and technologies designed to advance personalized medicine, electronic health records, and systems, etc. New or improved instruments, devices, and related methodologies to facilitate biomedical or behavioral research and efforts that seek to simplify via redesign or design new instruments, devices, and methods likely to increase access, reduce costs, and improve quality are of special interest.

Research Topics of Interest to NIMHD

The specific set of topics that are funded by a particular IC/Office/Agency depends on whether the IC/Office/Agency funds/supports Clinical Trials under SBIR/STTR Awards. Use the following table and explanations to determine which list of topics is applicable.

<table>
<thead>
<tr>
<th>Does IC/Office/Agency Fund/Support Clinical Trials under SBIR/STTR Awards?</th>
<th>No*</th>
<th>Yes**</th>
</tr>
</thead>
</table>

*If No,
- This IC/Office/Agency funds only those topics listed under the Non-Clinical Trials Topics section below, **UNLESS** the IC/Office/Agency funds a Small Business Concern for clinical trials under a NON-SBIR/STTR award.
**If Yes or the IC/Office/Agency funds small businesses for clinical trials under a NON-SBIR/STTR funding opportunity,**

- See the table below for which mechanisms the IC/Office/Agency will allow for clinical trials research. Also, see the Clinical Trials Topics section below for a list of funded topics. This IC/Office/Agency also funds research listed under the Non-Clinical Trials Topics section below.

<table>
<thead>
<tr>
<th>Does IC/Office/Agency accept clinical trials applications under this mechanism?</th>
<th>Yes</th>
<th>No</th>
<th>Other Information: If funding an SBC for clinical trials under a NON-SBIR/STTR award, please identify activity code(s) and other relevant information.</th>
</tr>
</thead>
<tbody>
<tr>
<td>Clinical Trials SBIR/STTR Omnibus/Parent Funding Opportunity Announcement/s</td>
<td>X</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Clinical Trials SBIR/STTR IC/Office/Agency - Specific Funding Opportunity Announcement/s</td>
<td>X</td>
<td><a href="https://sbir.nih.gov/funding/individual-announcements">https://sbir.nih.gov/funding/individual-announcements</a></td>
<td></td>
</tr>
<tr>
<td>Clinical Trials NON-SBIR/STTR Funding Opportunity Announcement/s where Small Businesses are eligible to apply</td>
<td>X</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**NIMHD Non-Clinical Trials Topics:**

Research that results in a product, process or service that will improve minority health and reduce and eliminate health disparities by one or more of the following:

A. Biological and Non-Biological Determinants of Health  
B. Community-Based Participatory Research  
C. Comparative Effectiveness Research in Community Settings  
D. Community/Minority Participation in Clinical Trials, Genomic Medicine and the Future of Health Disparities Research  
E. Faith-Based Research  
F. Global Health and Health Disparities  
G. Research Infrastructure in Minority Institutions  
H. Telehealth and Health Disparities  
I. Translating and Disseminating Scientific Knowledge into Practice and Policy
NIMHD Clinical Trials Topics:

Research that results in a product, process or service that will improve minority health and reduce and eliminate health disparities by one or more of the following:

A. Biological and Non-Biological Determinants of Health
B. Community-Based Participatory Research
C. Clinical Research and Comparative Effectiveness Research in Community Settings
D. Community/Minority Participation in Clinical Trials, Genomic Medicine and the Future of Health Disparities Research
E. Faith-Based Research
F. Global Health and Health Disparities
G. Research infrastructure in Minority Institutions
H. Telehealth and Health Disparities
I. Translating and Disseminating Scientific Knowledge into Practice and Policy

For additional information about the areas of interest to the NIMHD, please visit our home page at http://www.nimhd.nih.gov/.

For additional information on research topics, contact:

Mr. Vincent A. Thomas, Jr., MSW, MPA
Program Manager
National Institute on Minority Health and Health Disparities, NIH
6707 Democracy Blvd.
Suite 800, MSC 5465
Bethesda, MD 20892-5465
301-402-2516, Fax: 301-480-4049
Email: vt5e@nih.gov

For administrative and business management questions, contact:

Ms. Priscilla Grant, J.D., C.R.A.
Grants Management Officer
National Institute on Minority Health and Health Disparities, NIH
6707 Democracy Blvd.
Suite 800, MSC 5465
Bethesda, MD 20892-5465
301-594-8412, Fax: 301-480-4049
Email: pg38h@nih.gov
**NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE (NINDS)**

The mission of NINDS is to reduce the burden of neurological disease—a burden borne by every age group, by every segment of society, by people all over the world ([https://www.ninds.nih.gov/About-NINDS/Who-We-Are/Mission](https://www.ninds.nih.gov/About-NINDS/Who-We-Are/Mission)). To this end, the Institute supports and conducts research on the healthy and diseased brain, spinal cord, and peripheral nerves. The NINDS SBIR/STTR ([https://www.ninds.nih.gov/Funding/Small-Business-Grants](https://www.ninds.nih.gov/Funding/Small-Business-Grants)) program funds small business concerns to conduct innovative neuroscience research and/or development (R/R&D) that has both the potential for commercialization and public benefit.

**Limited Amount of Award and Budget Waivers**

NINDS will allow awards to exceed the statutory guideline amounts by up to 50% (up to $225,000 for Phase I and $1,500,000 for Phase II, total funding support) with appropriate justification from the applicant. In addition, NINDS will allow Phase I project periods of up to 2 years and Phase II project periods of up to 3 years with appropriate justification. For budgetary, administrative, or programmatic reasons, NINDS may decrease the length of an award and/or the budget recommended by a review committee, or not fund an application.

NIH has received a waiver from SBA to exceed the hard cap for specific topics that can be found in **APPENDIX A: National Institutes of Health SBA-Approved SBIR/STTR Topics for Awards over Statutory Budget Limitations** and only these specific topics can apply and receive awards over the hard cap. Generally, NINDS does not fund Phase I applications greater than $700,000 total funding support, with no more than $500,000 total cost in any year or project periods greater than 2 years. In addition, the NINDS does not generally fund Phase II applications greater than $3,000,000 total funding support, with no more than $1,500,000 total cost in any year, or project periods greater than 3 years. Information about the NINDS budget guidelines can be found on the NINDS SBIR webpage: [https://www.ninds.nih.gov/Funding/Small-Business-Grants/Budget-Information](https://www.ninds.nih.gov/Funding/Small-Business-Grants/Budget-Information). Applicants considering a requested budget greater than $225,000 for Phase I or $1,500,000 for Phase II are strongly encouraged to contact program staff before submitting an application.

For all other funding opportunities, applications should follow the guidelines in the Award Budget section of those announcements carefully. Additional information can be found on the NINDS SBIR/STTR webpage at: [https://www.ninds.nih.gov/Funding/Small-Business-Grants/Budget-Information](https://www.ninds.nih.gov/Funding/Small-Business-Grants/Budget-Information).

**Phase IIB Competing Renewal Awards**

NINDS only accepts Phase IIB SBIR/STTR Competing Renewal applications through specific opportunities that focus on the commercialization of SBIR and STTR developed technologies. These opportunities can be found on the NINDS Funding Opportunities webpage: [https://www.ninds.nih.gov/Funding/Find-Funding-Opportunities](https://www.ninds.nih.gov/Funding/Find-Funding-Opportunities). Contact Stephanie Fertig at fertigs@ninds.nih.gov for additional information.

**Research Topics of Interest to NINDS**

The specific set of topics that are funded by a particular IC/Office/Agency depends on whether the IC/Office/Agency funds/supports Clinical Trials under SBIR/STTR Awards. Use the following table and explanations to determine which list of topics is applicable.

<table>
<thead>
<tr>
<th>Does IC/Office/Agency Fund/Support Clinical Trials under SBIR/STTR Awards?</th>
<th>No*</th>
<th>Yes**</th>
</tr>
</thead>
<tbody>
<tr>
<td>X</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
If No,
- This IC/Office/Agency funds only those topics listed under the Non-Clinical Trials Topics section below, UNLESS the IC/Office/Agency funds a Small Business Concern for clinical trials under a NON-SBIR/STTR award.

**If Yes or the IC/Office/Agency funds small businesses for clinical trials under a NON-SBIR/STTR funding opportunity,**
- See the table below for which mechanisms the IC/Office/Agency will allow for clinical trials research. Also, see the Clinical Trials Topics section below for a list of funded topics. This IC/Office/Agency also funds research listed under the Non-Clinical Trials Topics section below.

<table>
<thead>
<tr>
<th>Does IC/Office/Agency accept clinical trials applications under this mechanism?</th>
<th>Yes</th>
<th>No</th>
</tr>
</thead>
<tbody>
<tr>
<td>Clinical Trials SBIR/STTR Omnibus/Parent Funding Opportunity Announcement/s</td>
<td>X</td>
<td></td>
</tr>
<tr>
<td>Clinical Trials SBIR/STTR IC/Office/Agency - Specific Funding Opportunity Announcement/s</td>
<td>X</td>
<td>NINDS accepts and supports SBIR and STTR clinical trial applications through specific opportunities, which can be found on the NINDS Funding Opportunities webpage: <a href="https://www.ninds.nih.gov/Funding/Find-Funding-Opportunities">https://www.ninds.nih.gov/Funding/Find-Funding-Opportunities</a>.</td>
</tr>
<tr>
<td>Clinical Trials NON-SBIR/STTR Funding Opportunity Announcement/s where Small Businesses are eligible to apply</td>
<td>X</td>
<td>NINDS accepts and supports non-SBIR/STTR clinical trial applications through specific opportunities, which can be found on the NINDS Funding Opportunities webpage: <a href="https://www.ninds.nih.gov/Funding/Find-Funding-Opportunities">https://www.ninds.nih.gov/Funding/Find-Funding-Opportunities</a>.</td>
</tr>
</tbody>
</table>

**NINDS Non-Clinical Trials Topics:**

**General Areas of Interest**

The NINDS accepts a broad range of small business applications that are significant, innovative, and relevant to its mission. Examples of research topics within the mission of NINDS are shown below. This list is not all inclusive and some research areas fall into multiple categories.

1. Therapeutics and Diagnostics Development for Neurological Disorders, including biomarker and diagnostic assays, therapeutics (drugs, biologics, and/or devices) for treatment of neurological disorders, and technologies/methodologies to deliver therapeutics to the nervous system.

2. Clinical and Rehabilitation Tools, including intraoperative technologies for neurosurgeons, rehabilitation devices and programs for neurological disorders, and brain monitoring systems...
3. Technology and Tools, including technologies to image the nervous system, neural interfaces technologies, and tools for neuroscience research and drug development.

In addition to the research topics listed, NINDS also encourages applications in specific program areas. For additional information about NINDS funding opportunities, please visit the NINDS Funding Opportunities webpage at: https://www.ninds.nih.gov/Funding/Find-Funding-Opportunities.

NINDS Priorities

NINDS priorities are given to meritorious research proposals with the greatest potential to advance the NINDS mission (see https://www.ninds.nih.gov/About-NINDS/Who-We-Are/Mission). NINDS is especially interested in:

1. Novel and innovative technologies that are new to the SBIR or STTR programs.
2. Technologies coming to the SBIR or STTR programs for their first indication or market opportunity.
3. Companies and applicants that are new to the SBIR and STTR programs.
4. NINDS Cooperative Agreement (U44) Translational Programs. NINDS has specific translational programs that utilize the SBIR cooperative agreement mechanism (U44) as noted below. If eligible, companies are encouraged to apply through these programs.

NINDS SBIR and STTR funding decisions are based on a combination of factors:

1. potential for high impact on advancing the NINDS mission and the other programmatic priorities described in NOT-NS-18-002 (https://grants.nih.gov/grants/guide/notice-files/NOT-NS-18-002.html);
2. potential for commercialization;
3. portfolio balance (to determine whether similar projects have already been funded, search NIH Reporter http://projectreporter.nih.gov/reporter.cfm);
4. the quality of the previous performance of the applicant and/or company in the SBIR and/or STTR program, including evidence of Phase III activities;
5. for Phase II applicants, the results of the Phase I;
6. the peer review scores and critiques; and
7. availability of funds.

Translational Research

The NINDS offers a variety of specific funding opportunities and programs to accelerate the preclinical discovery and development of new therapeutic interventions for neurological disorders. These programs have specific funding opportunities and allow for budgets over the hard cap. All three programs utilize the cooperative agreement (U44) mechanism, which is milestone-driven and involves NIH program staff participation in developing the project plan, monitoring research progress, and appropriate go/no-go decision-making. SBIR applicants considering projects involving translational research are strongly encouraged to contact program staff well in advance of submission.

- **Cooperative Research to Enable and Advance Translational Enterprises for Biotechnology Products and Biologics (CREATE Bio)** is dedicated to biotechnology product- and biologics-based therapies, which broadly include modalities such as peptides, proteins, oligonucleotides, gene therapies, and cell therapies. The program supports lead optimization, IND-enabling studies for the candidate, and early-phase clinical trials. Contact: Chris Boshoff (chris.boshoff@nih.gov)

- **Translational Neural Devices Program** provides support for projects that focus on pre-clinical and pilot clinical studies for therapeutic devices. Activities supported in this program include implementation of clinical prototype devices, preclinical safety and efficacy testing, design
verification and validation activities, pursuit of regulatory approval for the clinical study, and a clinical study. Contact: Nick Langhals (nick.langhals@nih.gov)

- **Blueprint Neurotherapeutics Network (BPN)** provides both funding and non-dilutive support for small molecule drug discovery and development, from hit-to-lead chemistry through phase I clinical testing. The program offers funding, access to NIH-funded contract research organizations (CROs), and access to consultants with expertise in various aspects of drug discovery and development. Contact: Charles Cywin (cywincl@mail.nih.gov)

Information about these and other programs can be found at https://www.ninds.nih.gov/Current-Research/Research-Funded-NINDS/Translational-Research.

**Brain Research through Advancing Innovative Neurotechnologies (BRAIN) Initiative**

The Brain Research through Advancing Innovative Neurotechnologies (BRAIN) Initiative is a Presidential project aimed at revolutionizing our understanding of the human brain. NIH is one of several federal agencies involved in the BRAIN Initiative. Planning for the NIH component of the BRAIN Initiative is guided by the long-term scientific plan, “BRAIN 2025: A Scientific Vision,” which details seven high-priority research areas. This report can be found at https://braininitiative.nih.gov/.

NIH has a number of specific funding opportunity announcements through the BRAIN Initiative that are targeted to small business concerns. These funding opportunities can be found at https://www.braininitiative.nih.gov/funding/. Applicants are encouraged to consider if these funding opportunities may be appropriate to their research. Contact Stephanie Fertig at fertigs@ninds.nih.gov for additional information.

**NINDS Clinical Trials Topics:**

NINDS accepts clinical trials in any area listed above in the non-clinical trials section.

NINDS is committed to identifying effective treatments for neurological disorders by supporting well-executed clinical trials. NINDS accepts and supports SBIR and STTR clinical trial applications within the NINDS mission through specific opportunities, which can be found on the NINDS SBIR webpage: https://www.ninds.nih.gov/Funding/Small-Business-Grants/Areas-Interest#CT. Other human subjects research can be submitted through the SBIR and STTR Parent (Clinical Trials Not Allowed) solicitation. However, NINDS may decline funding of any application that includes human subjects for programmatic or administrative reasons. SBIR applicants considering projects involving human subjects research are strongly encouraged to contact program staff in advance of submission.

For additional information on the NINDS SBIR/STTR program, contact:
Stephanie Fertig, M.B.A.
Director, NINDS Small Business Programs
301-496-1779
Email: fertigs@ninds.nih.gov

For financial and grants management questions, contact:
Tijuanna Decoster, Ph.D.
Chief, Grants Management Branch
301-496-9231, Fax: 301-402-4370
Email: decostert@mail.nih.gov
NATIONAL INSTITUTE OF NURSING RESEARCH (NINR)

The National Institute of Nursing Research (NINR) supports research focused on biological and behavioral aspects of critical health problems that confront the Nation. Rapid advances in technology and genomic science, as well as significant changes in demographics and health care policies and practice, have inspired the field of nursing science to identify innovative approaches and interventions that improve health outcomes. Emphasis is on seeking ways to reduce the burden of illness and disability by understanding and easing the effects of acute and chronic illness and associated symptoms, improving health-related quality of life by preventing or delaying the onset of disease or slowing its progression, establishing better approaches to promote health and prevent disease, and improving clinical environments by testing interventions that influence patient health outcomes and reduce costs and demand for care.

For additional information about areas of interest to the NINR, please visit our home page at http://www.ninr.nih.gov/, and also at http://www.ninr.nih.gov/researchandfunding.

Limited Amount of Award

NINR considers $350K applications high budget but generally does not apply this rule to SBIR/STTR. NINR does not accept Phase IIB applications.

Research Topics of Interest to NINR

The specific set of topics that are funded by a particular IC/Office/Agency depends on whether the IC/Office/Agency funds/supports Clinical Trials under SBIR/STTR Awards. Use the following table and explanations to determine which list of topics is applicable.

<table>
<thead>
<tr>
<th>Does IC/Office/Agency Fund/Support Clinical Trials under SBIR/STTR Awards?</th>
<th>No*</th>
<th>Yes**</th>
</tr>
</thead>
</table>

*If No,
- This IC/Office/Agency funds only those topics listed under the Non-Clinical Trials Topics section below, UNLESS the IC/Office/Agency funds a Small Business Concern for clinical trials under a NON-SBIR/STTR award.

**If Yes or the IC/Office/Agency funds small businesses for clinical trials under a NON-SBIR/STTR funding opportunity,
- See the table below for which mechanisms the IC/Office/Agency will allow for clinical trials research. Also, see the Clinical Trials Topics section below for a list of funded topics. This IC/Office/Agency also funds research listed under the Non-Clinical Trials Topics section below.
Does IC/Office/Agency accept clinical trials applications under this mechanism? | Yes | No | Other Information: If funding an SBC for clinical trials under a NON-SBIR/STTR award, please identify activity code(s) and other relevant information.

| Clinical Trials SBIR/STTR Omnibus/Parent Funding Opportunity Announcement/s | X |  |
| Clinical Trials SBIR/STTR IC/Office/Agency - Specific Funding Opportunity Announcement/s | X |  |
| Clinical Trials NON-SBIR/STTR Funding Opportunity Announcement/s where Small Businesses are eligible to apply | X |  |

**NINR Non-Clinical Trials Topics:**

A. Technologies to be used in the hospital, long-term care, hospice, assisted living facility, or home setting that improve symptom identification/assessment, diagnosis, evaluation and management in persons with acute and chronic conditions, particularly in individuals that cannot self-report. Examples of symptoms include (but are not limited to) pain, fatigue, cognitive impairment, nausea, behavioral symptoms.

B. Assistive and monitoring devices that can monitor symptoms and/or improve quality of life for individuals with chronic diseases/conditions.

C. Technology-based, behavioral interventions that lead to improved, personalized strategies to prevent and ameliorate adverse symptoms across the lifespan and in diverse populations and settings.

D. Technologies to assist patients to adhere to behavioral and medical regimens, including medical devices to enable providers and/or research scientists to monitor successful adherence to complex behavioral and medication regimens.

E. Devices that improve delivery of care to allow patients to better self-manage.

F. Technologies that monitor and/or promote short and long term self-management behavior changes.

G. Biological and behavioral monitoring devices for patients in at-risk populations (such as rural, minority or other underserved populations).

H. Develop, test, and compare effective strategies that incorporate mHealth tools that promote patient, caregiver self-management.

I. Technological devices to increase awareness and screening, identify risk and protective factors (socio-demographic, behavioral, lifestyle, environmental), prevent disease, and maintain health across the lifespan.
J. Tailored interventions to help people make healthy lifestyle choices that impact them, their families, and communities, given multiple roles and responsibilities (e.g., work, child birth, caregiving)

K. Technologies to disseminate research information to nurses practicing in clinical settings and in the community.

L. Development and application of new and existing knowledge to the implementation of health information technology, and access to and use of electronic health records and other forms of big data.

M. Telehealth and mHealth technologies to improve patient outcomes through, for instance, increasing quality, type, and speed of health information sharing.

N. Web-based information and communication technologies for data collection on hospice and palliative care symptoms and need of care to improve the effectiveness and efficiency of patient report data and integration into appropriate hospice/palliative care

O. Use of Health Information technology for data collection, management and care integration across the spectrum of hospice and palliative care

P. Technologies (e.g., telecommunications) to provide support mechanisms of caregivers of hospice/palliative patients

Q. IT implementation across the spectrum of palliative and hospice settings that highlight the potential of informatics to improve palliative and hospice care

R. Home-based telehealth applications for individuals and family caregivers in palliative and hospice care

S. Technologies to enable healthcare providers at clinical sites to communicate with hospice and palliative care patients at their home—“virtual visit” technologies.

T. Devices to assist in providing palliative care for patients with serious life-limiting illnesses through the disease trajectory whether in active treatment or at the end of life.

**NINR Clinical Trials Topics:**

A. Technologies to be used in the hospital, long-term care, hospice, assisted living facility, or home setting that improve symptom identification/assessment, diagnosis, evaluation and management in persons with acute and chronic conditions, particularly in individuals that cannot self-report. Examples of symptoms include (but are not limited to) pain, fatigue, cognitive impairment, nausea, behavioral symptoms.

B. Assistive and monitoring devices that can monitor symptoms and/or improve quality of life for individuals with chronic diseases/conditions.

C. Technology-based, behavioral interventions that lead to improved, personalized strategies to prevent and ameliorate adverse symptoms across the lifespan and in diverse populations and settings.

D. Technologies to assist patients to adhere to behavioral and medical regimens, including medical devices to enable providers and/or research scientists to monitor successful adherence to complex behavioral and medication regimens.

E. Devices that improve delivery of care to allow patients to better self-manage.

F. Technologies that monitor and/or promote short and long term self-management behavior changes.

G. Biological and behavioral monitoring devices for patients in at-risk populations (such as rural, minority or other underserved populations).

H. Develop, test, and compare effective strategies that incorporate mHealth tools that promote patient, caregiver self-management.
I. Technological devices to increase awareness and screening, identify risk and protective factors (socio-demographic, behavioral, lifestyle, environmental), prevent disease, and maintain health across the lifespan.

J. Tailored interventions to help people make healthy lifestyle choices that impact them, their families, and communities, given multiple roles and responsibilities (e.g., work, child birth, caregiving)

K. Technologies to disseminate research information to nurses practicing in clinical settings and in the community.

L. Development and application of new and existing knowledge to the implementation of health information technology, and access to and use of electronic health records and other forms of big data.

M. Telehealth and mHealth technologies to improve patient outcomes through, for instance, increasing quality, type, and speed of health information sharing.

N. Web-based information and communication technologies for data collection on hospice and palliative care symptoms and need of care to improve the effectiveness and efficiency of patient report data and integration into appropriate hospice/palliative care

O. Use of Health Information technology for data collection, management and care integration across the spectrum of hospice and palliative care

P. Technologies (e.g., telecommunications) to provide support mechanisms of caregivers of hospice/palliative patients

Q. IT implementation across the spectrum of palliative and hospice settings that highlight the potential of informatics to improve palliative and hospice care

R. Home-based telehealth applications for individuals and family caregivers in palliative and hospice care

S. Technologies to enable healthcare providers at clinical sites to communicate with hospice and palliative care patients at their home---“virtual visit” technologies.

T. Devices to assist in providing palliative care for patients with serious life-limiting illnesses through the disease trajectory whether in active treatment or at the end of life.

For additional information on research topics, contact:

Dr. Augie Diana
Program Director
National Institute of Nursing Research (NINR)
Office of Extramural Programs (OEP)
National Institutes of Health (NIH)
6701 Democracy Blvd, Room 720
Bethesda, MD 20892-4870
Office tel: 301-402-6423
Email: dianaa@mail.nih.gov
NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES (NCATS)

NCATS is transforming translational science to improve human health; it relies on the power of data, new technologies and teamwork to develop, demonstrate and disseminate innovations that reduce, remove or bypass costly and time-consuming bottlenecks in translational research.

NCATS small business funding focuses on what is common across diseases and the translational process, rather than targeting a particular disease or area of fundamental science. The Center conducts and supports research on both the scientific and operational aspects of translation to lead to more predictive and successful development of new medical interventions, such as drugs, diagnostics, and medical devices, for all human diseases. For additional information, please visit http://www.ncats.nih.gov.

NCATS is committed to supporting small business Phase I, Phase II, Fast-track and Phase IIB Competing Renewal awards through the Small Business Innovation Research (SBIR) and Small Business Technology Transfer Programs (STTR). For additional information, please visit http://ncats.nih.gov/smallbusiness.

Limited Amount of Award

For budgetary, administrative or programmatic reasons, NCATS may decide not to fund an application or may decrease the length of an award and/or the budget recommended by a review committee. Generally, NCATS will not fund:

- Phase I applications greater than $225,000 total costs or project periods greater than 2 years
- Phase II applications greater than $1,500,000 total costs or project periods greater than 3 years

For certain topical areas (Appendix A), the Small Business Administration has approved an NIH SBIR/STTR Topic Waiver list for which the NCATS generally will not fund:

- Phase I applications greater than $325,000 total costs or project periods greater than 2 years
- Phase II applications greater than $2,000,000 total costs or project periods greater than 3 years

Applicants considering a requested budget greater than these limits are strongly encouraged to contact program staff before submitting an application.

Phase IIB Competing Renewal Awards

Occasionally, NCATS may accept Phase IIB SBIR Competing Renewal grant applications of NCATS supported Phase II awards to continue research and development of products that have a potential to address bottlenecks in the translational process, and where additional time and effort is needed to reach a stage where interest and investment by third parties would be likely. Such products are expected to have broad applicability and be consistent with the mission of NCATS.

Research Topics of Interest to NCATS

The specific set of topics that are funded by a particular IC/Office/Agency depends on whether the IC/Office/Agency funds/supports Clinical Trials under SBIR/STTR Awards. Use the following table and explanations to determine which list of topics is applicable.

<table>
<thead>
<tr>
<th>Does IC/Office/Agency Fund/Support Clinical Trials under SBIR/STTR Awards?</th>
<th>No*</th>
<th>Yes**</th>
</tr>
</thead>
</table>

* indicates a negative response to the question.

** indicates a positive response to the question.

For additional information, please visit http://www.ncats.nih.gov.
*If No,
- This IC/Office/Agency funds only those topics listed under the Non-Clinical Trials Topics section below, **UNLESS** the IC/Office/Agency funds a Small Business Concern for clinical trials under a NON-SBIR/STTR award.

**If Yes or the IC/Office/Agency funds small businesses for clinical trials under a NON-SBIR/STTR funding opportunity,**
- See the table below for which mechanisms the IC/Office/Agency will allow for clinical trials research. Also, see the Clinical Trials Topics section below for a list of funded topics. This IC/Office/Agency also funds research listed under the Non-Clinical Trials Topics section below.

<table>
<thead>
<tr>
<th>Does IC/Office/Agency accept clinical trials applications under this mechanism?</th>
<th>Yes</th>
<th>No</th>
<th>Other Information: If funding an SBC for clinical trials under a NON-SBIR/STTR award, please identify activity code(s) and other relevant information.</th>
</tr>
</thead>
<tbody>
<tr>
<td>Clinical Trials SBIR/STTR Omnibus/Parent Funding Opportunity Announcement/s</td>
<td></td>
<td>X</td>
<td></td>
</tr>
<tr>
<td>Clinical Trials SBIR/STTR IC/Office/Agency - Specific Funding Opportunity Announcement/s</td>
<td></td>
<td>X</td>
<td></td>
</tr>
<tr>
<td>Clinical Trials NON-SBIR/STTR Funding Opportunity Announcement/s where Small Businesses are eligible to apply</td>
<td>X</td>
<td></td>
<td>U01 – however the SBC can only participate if repurposing an existing drug or biologic (therapeutics) that have already completed at least a Phase I trial for a different indication by the time an award is made. These pharma drugs and biologics are listed in PAR-18-332. <a href="https://grants.nih.gov/grants/guide/pa-files/PAR-18-332.html">https://grants.nih.gov/grants/guide/pa-files/PAR-18-332.html</a></td>
</tr>
</tbody>
</table>

NCATS Non-Clinical Trials Topics:

**Drug Discovery and Development**

- Microphysiological systems (MPS)/Tissue Chips
- Small molecule and biologics analytical characterization
- Accelerated bioengineering approaches to the development and clinical application of biomedical materials, devices, therapeutics and/or diagnostics
- Technologies to determine alternative uses for existing therapeutic interventions
- Protein-protein interaction assays for high-throughput screening of rare-diseases-related projects
- Tools and technologies to enable assaying of compound activity on currently “non-druggable” targets
Innovative platforms for identification and prioritization of targets for therapeutic intervention with clear clinical impact
Fluorescence probes to replace antibodies for determination of cellular protein translocation
Co-crystallization high-throughput screening techniques
Tools and technologies that increase the predictivity or efficiency of medicinal chemistry, biologic or other intervention optimization
Use of continuous flow manufacturing technology to improve therapeutic manufacturing and increase efficiencies
Interventions that target molecular pathways or mechanisms common to multiple diseases
Development of novel delivery systems of therapeutic interventions (e.g., inhalation/transdermal technologies for biologics)
Methodologies and technologies to increase efficiencies of manufacturing therapeutics
Development of novel technologies for enzyme replacement therapies (e.g., new cell culture/expression system) to solve a major bottleneck in rare diseases research
Develop platforms for non-antibody biologics, cell-based therapies and gene therapy discovery
Phenotypic assay development, including stem cell technology platforms for human “disease-in-a-dish” applications and the evaluation of toxicity
Development of high-throughput imaging technologies that focus on making translational research more efficient
GMP production of exosomes/extracellular vesicles
Generation of producer lines for large scale production of exosomes/extracellular vesicles
Extracellular RNA-based biomarkers and therapeutics of human diseases
Targeting the human microbiome for drug development

**Biomedical, Clinical, & Health Research Informatics**

Searchable access to information about research resources, facilities, methods, cells, genetic tests, molecules, biologic reagents, animals, assays, and/or technologies with evidence about their use in research studies
Tools and methods for meaningful sharing, re-use and integration of research data
Novel platforms, technologies and tools for: (1) enabling clinical and translational research, particularly those with mechanisms for inclusion of patient-reported data and (2) integration of patient data collected from multiple devices and multiple/diverse clinical studies
Development of personalized phenotypic profiling (as well as personalized intervention) based on patient-centered integration of data from multiple data sources, including social media
Data visualization for researchers, patients, study participants and decision-makers
Gamification of processes that are challenging in translational and clinical research (e.g., creating positive experiences that improve recruitment and retention of participants, or learning in a multidisciplinary environment)
Collaborative platforms for multidisciplinary teams
Predictive models for translation of science
Virtual or augmented reality tools for diagnostic uses
Novel data-gathering and sharing methods

**Clinical, Dissemination and Implementation Research**

Approaches for populating registries in a scalable and affordable way to serve larger goals (e.g., Natural History Study)
Tools and technologies that increase the efficiency of human subjects research, including development of technologies that facilitate rapid diagnosis and/or clinical trial recruitment and subject tracking, institutional review board evaluation, and/or regulatory processes
• Increased efficiency of clinical research conduct, including but not limited to regulatory decision support, patient eligibility analysis, and recruitment and retention tracking
• Tools and technologies to improve and evaluate the consent process.
• Educational tools for clinical and translational science
• Computational or Web-based health research methods including:
  • Platforms for generally applicable and scalable multi-disease registries and natural history studies
  • Clinical trial designs and analyses (e.g., for pragmatic clinical trials)
• Approaches, tools, platforms and environments for synthesizing the totality of evidence
• Dissemination and implementation research
• Sustainable solutions for effective tools and environments in translational research
• Tools and environments that enable an easy interrogation of publically available data
• Development of predictive models for translational science
• Development and validation of patient reported outcomes, clinician reported outcomes, and biomarkers for conditions that are not already supported by a disease-specific NIH IC

**NCATS Clinical Trials Topics:**

NCATS will not accept SBIR applications that propose clinical trials, and all of the topics listed must be for projects that do not propose clinical trials.

For additional information on research topics, please contact:

Lili M. Portilla, MPA  
NCATS SBIR/STTR Program Director  
National Center for Advancing Translational Sciences, NIH  
Phone: 301-827-7170  
Email: NCATS-SBIRSTTR@mail.nih.gov

For Administrative, business management and grants policy questions, please contact:

Ms. Artisha Eatmon  
Grants Management Specialist, SBIR/STTR Project Liaison  
Phone: 301-435-0845, Fax: 301-480-3777  
Email: Artisha.eatmon@nih.gov
NATIONAL CENTER FOR COMPLEMENTARY AND INTEGRATIVE HEALTH (NCCIH)

The mission of NCCIH is to define, through rigorous scientific investigation, the usefulness and safety of complementary and integrative health interventions and their roles in improving health and health care.

The following narrative indicates the scope of projects suitable for the SBIR/STTR program that fit within the mission of NCCIH. For additional information about areas of interest to NCCIH and a listing of NCCIH’s currently funded applications, please visit http://www.nccih.nih.gov/research. Business concerns interested in exploring SBIR/STTR grant opportunities with NCCIH are encouraged to contact NCCIH Program Officers prior to submitting an application.

Research Topics of Interest to NCCIH

The specific set of topics that are funded by a particular IC/Office/Agency depends on whether the IC/Office/Agency funds/supports Clinical Trials under SBIR/STTR Awards. Use the following table and explanations to determine which list of topics is applicable.

<table>
<thead>
<tr>
<th>Does IC/Office/Agency Fund/Support Clinical Trials under SBIR/STTR Awards?</th>
<th>No*</th>
<th>Yes**</th>
</tr>
</thead>
<tbody>
<tr>
<td>Does IC/Office/Agency accept clinical trials applications under this mechanism?</td>
<td>Yes</td>
<td>No</td>
</tr>
<tr>
<td>Other Information: If funding an SBC for clinical trials under a NON-SBIR/STTR award, please identify activity code(s) and other relevant information.</td>
<td>Yes, NCCIH will accept CT through the Omnibus/Parent FOAs.</td>
<td>Development and/or Validation of Devices or Electronic Systems to Monitor or Enhance Mind and Body Interventions (R43/R44)</td>
</tr>
<tr>
<td>Development and/or Validation of Devices or Electronic Systems to Monitor or Enhance Mind and Body Interventions (R41/R42)</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

*If No,
  - This IC/Office/Agency funds only those topics listed under the Non-Clinical Trials Topics section below, UNLESS the IC/Office/Agency funds a Small Business Concern for clinical trials under a NON-SBIR/STTR award.

**If Yes or the IC/Office/Agency funds small businesses for clinical trials under a NON-SBIR/STTR funding opportunity,
  - See the table below for which mechanisms the IC/Office/Agency will allow for clinical trials research. Also, see the Clinical Trials Topics section below for a list of funded topics. This IC/Office/Agency also funds research listed under the Non-Clinical Trials Topics section below.
<table>
<thead>
<tr>
<th>Does IC/Office/Agency accept clinical trials applications under this mechanism?</th>
<th>Yes</th>
<th>No</th>
<th>Other Information: If funding an SBC for clinical trials under a NON-SBIR/STTR award, please identify activity code(s) and other relevant information.</th>
</tr>
</thead>
<tbody>
<tr>
<td>Clinical Trials NON-SBIR/STTR Funding Opportunity Announcement/s where Small Businesses are eligible to apply</td>
<td>X</td>
<td></td>
<td>Phased Innovation Award for Mechanistic Studies to Optimize Mind and Body Interventions in NCCIH High Priority Research Topics (R61/R33)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Innovation Award for Mechanistic Studies to Optimize Mind and Body Interventions in NCCIH High Priority Research Topics (R33)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>NCCIH Natural Product Phase I-IIa Clinical Trial Award (R33)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>NCCIH Natural Product Phase I-IIa Clinical Trial Phased Innovation Award (R61/R33)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>NCCIH Natural Product Phase II Clinical Trial Cooperative Agreement (U01)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>NCCIH Mind and Body Clinical Trial Cooperative Agreement (U01)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Center of Excellence for Research on Complementary and Integrative Health (P01)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Mind and Body Intervention Multi-Site Clinical Trial Data Coordinating Center (Collaborative U24)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Clinical Coordinating Center for NCCIH Multi-Site Investigator-Initiated Clinical Trials of Mind and Body Interventions (Collaborative UG3/UH3)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Natural Product Multi-Site Clinical Trial Data Coordinating Center (Collaborative U24)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Clinical Coordinating Center for NCCIH Multi-Site Investigator-Initiated Clinical Trials of Natural Products (Collaborative UG3/UH3)</td>
</tr>
</tbody>
</table>

**NCCIH Non-Clinical Trials Topics**

**Natural Products** (including botanicals, herbs, probiotics, prebiotics, dietary supplements, or special medicinal diets):

- Development and validation of technologies for standardization and characterization of biologically active ingredients in natural products
- Development and validation of technologies for taxonomic identification of botanical raw materials or detection of adulterants
• Clinical testing of natural products for the management of hard to treat symptoms such as pain, sleep disorders, or mild to moderate depression to allow development of an evidence base that would lead to FDA approval of a drug indication for the natural product
• Development and validation of technologies for the identification and characterization of bioactive metabolites derived from oral consumption of natural products
• Development and validation of methods for the sustainable production of low yield natural products of commercial interest
• Development of novel analytical tools and technologies to study the microbiome, including its composition, genetics, and bioactivity that can help clarify associations between the human microbiome and the brain
• Development of gut microbiome monitoring assays for validating safety and functional analysis of genomic and microbiota interactions

Mind and Body Approaches (including meditation, mindfulness, hypnosis, yoga, Tai chi, acupuncture, manual therapies, etc.):

• Development, testing, and validation of appropriate measures and instruments to measure concepts such as mindfulness and compassion intrapersonally, interpersonally and in different contexts (e.g., classrooms, families, child welfare, juvenile justice etc.)
• Development, testing, and validation of measures and tools to assess training or fidelity of implementation of mind and body approaches in different settings (e.g., healthcare, community, families, schools, child welfare, juvenile justice)
• Development and testing of technologies for the implementation of mind and body approaches or in conjunction with in-person approaches. Examples include the use of mobile health technologies such as smart phone apps, sensors, on-line delivery, phone based delivery, etc.
• Development and validation of methods for standardization and characterization of the active components of mind and body medicine interventions
• Development and validation of technical imaging tools or instruments for studying manual therapies including but not limited to massage, acupuncture, or spinal manipulation

General Tool/Technology Development:

• Development and validation of biomarkers which correlate with efficacy of complementary and integrative health approaches
• Development and validation of standardized, reliable and economical tools that correlate with brain imaging in response to mind and body interventions
• Development and validation of tools, technology and instruments, including gaming technology, for the accurate assessment of adherence and/or fidelity to the use of mind and body practices, interventions, and natural products
• Development and validation of tools to improve patient-reported outcome measures of importance in clinical studies of complementary and integrative health approaches
• Development, pilot test, and validate wireless technologies for real-time data collection and monitoring of brain activity or other physiological signals for mind and body approaches
• Development or adaption of biochemical or epigenetic monitoring devices for complementary health approaches
• Development and validation of tools to improve biological and physiological outcome measures for use in clinical studies of complementary or integrative health approaches
• Development or adaptation of technologies for objective assessment of pain with relevance to complementary and integrative health approaches
• Development of sleep monitoring technologies or biomarker panels to assess sleep deprivation, sleep deficiency, circadian rhythm dysregulation, and connection of sleep disturbances with health risks
NCCIH Clinical Trials Topics:

Natural Products (including botanicals, herbs, probiotics, prebiotics, dietary supplements, or special medicinal diets):

- Development and validation of technologies for standardization and characterization of biologically active ingredients in natural products
- Clinical testing of natural products for the management of hard to treat symptoms such as pain, sleep disorders, or mild to moderate depression to allow development of an evidence base that would lead to FDA approval of a drug indication for the natural product
- Development and validation of technologies for the identification and characterization of bioactive metabolites derived from oral consumption of natural products
- Development of novel analytical tools and technologies to study the microbiome, including its composition, genetics, and bioactivity that can help clarify associations between the human microbiome and the brain
- Development of gut microbiome monitoring assays for validating safety and functional analysis of genomic and microbiota interactions

Mind and Body Approaches (including meditation, mindfulness, hypnosis, yoga, Tai chi, acupuncture, manual therapies, etc.):

- Development, testing, and validation of appropriate measures and instruments to measure concepts such as mindfulness and compassion intrapersonally, interpersonally and in different contexts (e.g., classrooms, families, child welfare, juvenile justice etc.)
- Development, testing, and validation of measures and tools to assess training or fidelity of implementation of mind and body approaches in different settings (e.g., healthcare, community, families, schools, child welfare, juvenile justice)
- Development and testing of technologies for the implementation of mind and body approaches or in conjunction with in-person approaches. Examples include the use of mobile health technologies such as smart phone apps, sensors, on-line delivery, phone based delivery, etc.
- Development and validation of methods for standardization and characterization of the active components of mind and body medicine interventions
- Development and validation of technical imaging tools or instruments for studying manual therapies including but not limited to massage, acupuncture, or spinal manipulation

General Tool/Technology Development:

- Development and validation of biomarkers which correlate with efficacy of complementary and integrative health approaches
- Development and validation of standardized, reliable and economical tools that correlate with brain imaging in response to mind and body interventions
- Development and validation of tools, technology and instruments, including gaming technology, for the accurate assessment of adherence and/or fidelity to the use of mind and body practices, interventions, and natural products
- Development and validation of tools to improve patient-reported outcome measures of importance in clinical studies of complementary and integrative health approaches
- Development, pilot test, and validate wireless technologies for real-time data collection and monitoring of brain activity or other physiological signals for mind and body approaches
- Development or adaption of biochemical or epigenetic monitoring devices for complementary health approaches
- Development and validation of tools to improve biological and physiological outcome measures for use in clinical studies of complementary or integrative health approaches
- Development or adaptation of technologies for objective assessment of pain with relevance to complementary and integrative health approaches
• Development of sleep monitoring technologies or biomarker panels to assess sleep deprivation, sleep deficiency, circadian rhythm dysregulation, and connection of sleep disturbances with health risks

For additional information on research topics, please contact:

Anastasia Solis
Program Analyst, Division of Extramural Research
6707 Democracy Boulevard, Suite 401
Bethesda, MD 20892-5475
301-594-8018
Email: anastasia.solis@nih.gov
**NATIONAL LIBRARY OF MEDICINE (NLM)**

The National Library of Medicine (NLM) offers support for research and development projects in biomedical informatics and data science. Biomedical informatics and data science research applies computer and information sciences to improve the access, storage, retrieval, management, dissemination and use of biomedical information. Grants are made to U.S. small businesses that seek to undertake informatics research and development leading to commercialization. Critical research areas include: representation of medical knowledge in computers; organization and retrieval issues for image databases; enhancement of human intellectual capacities through virtual reality, dynamic modeling, artificial intelligence, and machine learning; medical decision-making; linguistic analyses of medical languages and nomenclatures; investigations of topics relevant to health information or library science; biotechnology informatics issues; and informatics for disaster management. For additional information about areas of interest to NLM and a listing of NLM funded applications, please visit [http://www.nlm.nih.gov/ep](http://www.nlm.nih.gov/ep). Business concerns interested in exploring SBIR/STTR grant opportunities with NLM are encouraged to contact the NLM representatives prior to submitting an application.

**Research Topics of Interest to NLM**

The specific set of topics that are funded by a particular IC/Office/Agency depends on whether the IC/Office/Agency funds/supports Clinical Trials under SBIR/STTR Awards. Use the following table and explanations to determine which list of topics is applicable.

<table>
<thead>
<tr>
<th>Does IC/Office/Agency Fund/Support Clinical Trials under SBIR/STTR Awards?</th>
<th>No*</th>
<th>Yes**</th>
</tr>
</thead>
</table>

*If No,
- This IC/Office/Agency funds only those topics listed under the Non-Clinical Trials Topics section below, **UNLESS** the IC/Office/Agency funds a Small Business Concern for clinical trials under a NON-SBIR/STTR award.

**If Yes or the IC/Office/Agency funds small businesses for clinical trials under a NON-SBIR/STTR funding opportunity,**
- See the table below for which mechanisms the IC/Office/Agency will allow for clinical trials research. Also, see the Clinical Trials Topics section below for a list of funded topics. This IC/Office/Agency also funds research listed under the Non-Clinical Trials Topics section below.

<table>
<thead>
<tr>
<th>Does IC/Office/Agency accept clinical trials applications under this mechanism?</th>
<th>Yes</th>
<th>No</th>
<th>Other Information: If funding an SBC for clinical trials under a NON-SBIR/STTR award, please identify activity code(s) and other relevant information.</th>
</tr>
</thead>
<tbody>
<tr>
<td>Clinical Trials SBIR/STTR Omnibus/Parent Funding Opportunity Announcement/s</td>
<td>X</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
# NLM's SBIR/STTR Grant Programs

NLM's SBIR/STTR grant programs are focused on areas of particular interest from small business. The following narrative indicates the scope of projects suitable for the SBIR/STTR program that fit within the mission of NLM. They are not listed in priority order.

## NLM Non-Clinical Trials Topics:

- New Technologies that facilitate utilization of electronic health records systems in clinical practice and public health
- Explore the use of social media to track disease outbreaks, pandemics, or assist patients in chronic disease management
- Tools for exploring climate and environmental effects on human health
- Tools and systems for applying research data to clinical problems
- Tools for disaster information management
- Tools and approaches for integrating large heterogeneous data sets
- Human-computer interaction and data visualization of complex biomedical data for use by consumers, patients or clinicians

## NLM Clinical Trials Topics:

NLM will not accept SBIR applications that propose clinical trials, and all of the topics listed must be for projects that do not propose clinical trials.

---

For additional information on research topics, contact:

Dr. Jane Ye  
Program Officer  
Division of Extramural Programs  
National Library of Medicine  
301-594-4882, Fax: 301-402-2952  
Email: yej@mail.nih.gov

---

### Does IC/Office/Agency accept clinical trials applications under this mechanism?

<table>
<thead>
<tr>
<th>Clinical Trials SBIR/STTR IC/Office/Agency - Specific Funding Opportunity Announcement/s</th>
<th>Yes</th>
<th>No</th>
<th>Other Information: If funding an SBC for clinical trials under a NON-SBIR/STTR award, please identify activity code(s) and other relevant information.</th>
</tr>
</thead>
<tbody>
<tr>
<td>Clinical Trials NON-SBIR/STTR Funding Opportunity Announcement/s where Small Businesses are eligible to apply</td>
<td>X</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
For administrative and business management questions, contact:

Mr. Dwight Mowery  
Grants Management Officer  
Extramural Programs Division  
National Library of Medicine  
301-496-4221, Fax: 301-402-0421  
Email: moweryd@mail.nih.gov
DIVISION OF PROGRAM COORDINATION, PLANNING, AND STRATEGIC INITIATIVES (DPCPSI), OFFICE OF RESEARCH INFRASTRUCTURE PROGRAMS (ORIP)

ORIP supports high-quality, disease-free animal models and specialized animal research facilities to help meet the needs of biomedical researchers to understand, detect, treat, and prevent a wide range of human diseases. This support enables discoveries at molecular, cellular, and organ levels that lead to animal-based studies which then are translated to patient-oriented clinical research, aiming to find treatments to cure or ameliorate common and rare diseases. Through the small business Phase I, Phase II, Fast-track, and Phase IIB Competing Renewal awards, ORIP is especially interested in funding research to develop biomedical methods and technologies that improve animal models of human diseases, and the care, use, and management of laboratory animals. ORIP also encourage the development and implementation of technologies to directly benefit the welfare of research animals and to directly improve animal facilities that support biomedical and behavioral research.

A list of some potential ORIP program topics follows the description of our Phase IIB Competing Renewal Awards. For additional information about ORIP, please visit our home page at https://orip.nih.gov/.

Phase IIB Competing Renewal Awards

ORIP will only accept Phase IIB SBIR Competing Renewal grant applications of ORIP-supported Phase II awards to continue research and development of methods, technologies, tools and devices for basic or translational research where extraordinary time and effort is needed for completion of these projects. The Phase IIB Competing Renewal award is intended to allow small businesses the opportunity to reach a stage where interest and investment by third parties would be more likely. Such products are expected to have broad applicability, consistent with the mission of ORIP. Budgets that do not exceed $1 M per year in total costs (for up to 2 years), may be requested for this Phase IIB Competing Renewal opportunity; however it is expected that, in most cases, the requested budget would not exceed the final year budget of the applicant's previous Phase II award. This opportunity is available for the SBIR program only.

Please contact your Program Officer before beginning the process of preparing a Phase IIB Competing Renewal application. In addition, prospective applicants are strongly encouraged to submit to the Program Contact (listed after each section), a letter of intent that includes the following information:

- Descriptive title of the proposed research
- Name, address, and telephone number of the Principal Investigator
- Names of other Key Personnel
- Participating organizations
- Funding Opportunity Announcement Number (e.g., PA-18-XXX)

A letter of intent is not required, is not binding, and does not enter into the review of a subsequent application. It is expected that only a few of ORIP SBIR Phase II awards will be eligible for a Phase IIB Competing Renewal grant.

Research Topics of Interest to ORIP

The specific set of topics that are funded by a particular IC/Office/Agency depends on whether the IC/Office/Agency funds/supports Clinical Trials under SBIR/STTR Awards. Use the following table and explanations to determine which list of topics is applicable.

<table>
<thead>
<tr>
<th>Does IC/Office/Agency Fund/Support Clinical Trials under SBIR/STTR Awards?</th>
<th>No*</th>
<th>Yes**</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>x</td>
<td></td>
</tr>
</tbody>
</table>
*If No,
  • This IC/Office/Agency funds only those topics listed under the Non-Clinical Trials Topics section below, **UNLESS** the IC/Office/Agency funds a Small Business Concern for clinical trials under a NON-SBIR/STTR award.

**If Yes or the IC/Office/Agency funds small businesses for clinical trials under a NON-SBIR/STTR funding opportunity,**
  • See the table below for which mechanisms the IC/Office/Agency will allow for clinical trials research. Also, see the Clinical Trials Topics section below for a list of funded topics. This IC/Office/Agency also funds research listed under the Non-Clinical Trials Topics section below.

<table>
<thead>
<tr>
<th>Does IC/Office/Agency accept clinical trials applications under this mechanism?</th>
<th>Yes</th>
<th>No</th>
<th>Other Information: If funding an SBC for clinical trials under a NON-SBIR/STTR award, please identify activity code(s) and other relevant information.</th>
</tr>
</thead>
<tbody>
<tr>
<td>Clinical Trials SBIR/STTR Omnibus/Parent Funding Opportunity Announcement/s</td>
<td>X</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Clinical Trials SBIR/STTR IC/Office/Agency - Specific Funding Opportunity Announcement/s</td>
<td>X</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Clinical Trials NON-SBIR/STTR Funding Opportunity Announcement/s where Small Businesses are eligible to apply</td>
<td>X</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**ORIP Non-Clinical Trials Topics:**

**Division of Comparative Medicine**

A. Development of improved reagents and cost-effective methods to accurately screen and diagnose selected diseases of laboratory animal, and to perform overall assessments of animal quality and health status. An urgent need currently exists for the development of improved methods for detection of active tuberculosis in nonhuman primates.

B. Development of improved reagents and techniques to isolate and propagate embryonic and somatic stem cells from laboratory animals. Improvement of the in vitro and in vivo methods to efficiently generate induced pluripotent stem cells and to reprogram the differentiated cells to other lineages.

C. Development of technology to identify molecular phenotype of a single stem cell or induced pluripotent stem cell from laboratory animals.
D. Development of improved reagents, techniques, and equipment for genomic and transcriptomic analysis and data-mining from tissue or cells of laboratory animals and animal models of human diseases.

E. Development of new technologies to rapidly phenotype large number of animals.

F. Development of technologies to identify biomarkers for clinical diagnostics in well validated disease models.

G. Development of vaccines and new therapeutic agents to prevent and/or control selected laboratory animal diseases. One high priority need is to develop methods to control and prevent Herpes B virus in nonhuman primates.

H. Identification, development, and characterization of spontaneous and engineered vertebrate animal models for studies of various human diseases, excluding most random mutagenesis projects performed on rodents. Applications primarily focused on cancer should typically be directed to NCI. A need exists for a small animal model of Hepatitis C virus (HCV) infection in humans. Methods to produce genetically engineered mice susceptible to HCV replication, without the requirement for individual colonization with transplanted organs or cells in each experimental subject, are encouraged.

I. Identification, development, and characterization vertebrate animal models for studies of various human diseases.

J. Development of technologies and robust tools for the effective preservation of biomedical models.

K. Development and refinement of high throughput technologies and devices for the cryopreservation, and long-term maintenance and revival of cells, tissues, and laboratory animal embryos, gametes, and their predecessors, especially for Drosophila, zebrafish and other aquatic stocks.

L. Development of technologies and devices for the effective monitoring of frozen and cryopreserved cells, biological materials/tissues and laboratory animal embryos, gametes, and their predecessors.

M. Development of technologies for improved embryo transfer within a single animal species or of intraspecific embryo transfer to allow preservation of rare, or unique, animal species that may have unique value as animal models for human disease.

N. Development of improved reagents, techniques, devices, and high throughput technology to perform, analyze, capture and process data gathered in “omics” studies (genomics, transcriptomics, phenomics, proteomics, glycomics, epigenomics, metabolomics, among others) in normal, disease and intervention conditions in animal/biological models.

O. Development of biological tools and reagents for reconstruction, remodeling, repair and regeneration of tissues damaged by injury or disease. Development of the technologies and procedures to test efficacy and safety of these experiments in animal models. Approaches to detect and track the implanted cells and tissues in vivo.

P. Development of in vitro animal cell culture techniques and computational methods to reduce the number of animals used in studies and replace certain tests conducted in animal models with new complementary methods.

Q. Development of acellular biomaterials, biosensors and reagents to promote, detect and track reconstruction, remodeling, repair and regeneration of tissues damaged by injury or disease.

R. Development of reagents, including antibodies, that will facilitate research using zebrafish or Xenopus as animal models of disease or for understanding basic aspects of development, physiology, or genetics.
S. Development of rapid and sensitive technology for the accurate detection and diagnosis of polymicrobial infections in biomedical laboratory animal models, including those agents involved in vertical transmission of diseases into embryos and larvae.

T. Technologies for improved sex determination of embryos, neonatal, and juvenile stages of animals, with one high priority need being nonmammalian species.

Miguel Contreras, Ph.D.
Division of Comparative Medicine,
Office of Research Infrastructure Programs,
Division of Program Coordination, Planning and Strategic Initiatives,
Office of the Director
Phone: 301-435-0744,
Email: contre1@mail.nih.gov

Division of Construction and Instruments

The Division of Construction and Instruments supports the development and implementation of technologies to directly benefit the welfare of research animals and to directly improve animal facilities that support biomedical and behavioral research. In particular, the areas being supported include research on tools and equipment, their use to improve and ease care, and to facilitate monitoring of healthy animals. Another area of interest encompasses research to improve laboratory equipment to maintain the environmental conditions and to upkeep the infrastructure of animal facilities. Of special importance is the employment of green technologies. Examples of topics of special interest include (but are not limited to) research leading to the development of better, more reliable, and more efficient:

A. Equipment such as vacuum cleaners, air filters, hoods, snorkels, autoclaves for animal research facilities, for barrier facilities, and other facilities with special needs and requirements;
B. Equipment to distribute water and food, and monitor their intake by research animals;
C. Equipment to increase the quality of life and prevent injuries of research animals and research staff and investigators;
D. Equipment to monitor and protect the well-being of animals;
E. Equipment and its use for maintenance of disease-free colonies and healthy animals;
F. Equipment to disinfect devices, furnishings, and other apparatus in animal facilities such as aquaria, cages, tunnels, and racks;
G. Cost-effective husbandry and colony management techniques, equipment, and/or new approaches to improve laboratory animal welfare and assure efficient and appropriate research use;
H. Specialized equipment and caging for laboratory animals to permit optimal environmental control and operational efficiency, including improvements in caging, identification/tagging of animals and remote monitoring in animal facilities.

ORIP Clinical Trials Topics:

ORIP will not accept SBIR applications that propose clinical trials, and all of the topics listed must be for projects that do not propose clinical trials.

Research for the development of equipment and protocols for specific research needs is not within the scope of the ORIP mission.
For additional information on research topics, contact:

Miguel Contreras, Ph.D.
Division of Comparative Medicine,
Office of Research Infrastructure Programs,
Division of Program Coordination, Planning and Strategic Initiatives,
Office of the Director
Phone: 301-435-0744,
Email: contre1@mail.nih.gov

Willie D. McCullough, Ph.D.
Division of Construction and Instruments,
Office of Research Infrastructure Programs,
Division of Program Coordination, Planning, and Strategic Initiatives,
Office of the Director
Phone: 301-435-0783
Email: mccullow@mail.nih.gov
CENTERS FOR DISEASE CONTROL AND PREVENTION (CDC)

CDC will accept SBIR grant applications on April 5, 2018; September 5, 2018; January 5, 2019; and April 5, 2019 submission dates.

**CDC’s Mission:** CDC works 24/7 to protect America from health, safety and security threats, both foreign and in the U.S. Whether diseases start at home or abroad, are chronic or acute, curable or preventable, human error or deliberate attack, CDC fights disease and supports communities and citizens to do the same.

CDC increases the health security of our nation. As the nation’s health protection agency, CDC saves lives and protects people from health threats. To accomplish our mission, CDC conducts critical science and provides health information that protects our nation against expensive and dangerous health threats, and responds when these arise.

**CDC Role:**

- Detecting and responding to new and emerging health threats
- Tackling the biggest health problems causing death and disability for Americans
- Putting science and advanced technology into action to prevent disease
- Promoting healthy and safe behaviors, communities and environment
- Developing leaders and training the public health workforce, including disease detectives
- Taking the health pulse of our nation

Those functions are the backbone of CDC’s mission. Each of CDC’s component organizations undertakes these activities in conducting its specific programs. The steps needed to accomplish this mission are also based on scientific excellence, requiring well-trained public health practitioners and leaders dedicated to high standards of quality and ethical practice.

CDC encourages investigator-initiated applications that focus on support for prevention, detection and response to emerging health threats.

**Research Topics of Interest to CDC**

The specific set of topics that are funded by a particular IC/Office/Agency depends on whether the IC/Office/Agency funds/supports Clinical Trials under SBIR/STTR Awards. Use the following table and explanations to determine which list of topics is applicable.

<table>
<thead>
<tr>
<th>Does IC/Office/Agency Fund/Support Clinical Trials under SBIR/STTR Awards?</th>
<th>No*</th>
<th>Yes**</th>
</tr>
</thead>
</table>

*If No,*

- This IC/Office/Agency funds only those topics listed under the Non-Clinical Trials Topics section below, **UNLESS** the IC/Office/Agency funds a Small Business Concern for clinical trials under a NON-SBIR/STTR award.

**If Yes or the IC/Office/Agency funds small businesses for clinical trials under a NON-SBIR/STTR funding opportunity,**
See the table below for which mechanisms the IC/Office/Agency will allow for clinical trials research. Also, see the Clinical Trials Topics section below for a list of funded topics. This IC/Office/Agency also funds research listed under the Non-Clinical Trials Topics section below.

<table>
<thead>
<tr>
<th>Does IC/Office/Agency accept clinical trials applications under this mechanism?</th>
<th>Yes</th>
<th>No</th>
<th>Other Information: If funding an SBC for clinical trials under a NON-SBIR/STTR award, please identify activity code(s) and other relevant information.</th>
</tr>
</thead>
<tbody>
<tr>
<td>Clinical Trials SBIR/STTR Omnibus/Parent Funding Opportunity Announcement/s</td>
<td></td>
<td>X</td>
<td></td>
</tr>
<tr>
<td>Clinical Trials SBIR/STTR IC/Office/Agency - Specific Funding Opportunity Announcement/s</td>
<td></td>
<td>X</td>
<td></td>
</tr>
<tr>
<td>Clinical Trials NON-SBIR/STTR Funding Opportunity Announcement/s where Small Businesses are eligible to apply</td>
<td></td>
<td>X</td>
<td></td>
</tr>
</tbody>
</table>

CDC will not accept SBIR applications that propose clinical trials, and all of the topics listed below must be for projects that do not propose clinical trials.

For additional information about CDC, please visit our home page at [http://www.cdc.gov](http://www.cdc.gov).

Questions of a general nature about the CDC SBIR program should be directed to:

Sean David Griffiths, MPH  
Small Business Innovation Research Program (SBIR) Manager  
Office of the Associate Director for Science, Office of the Director  
Centers for Disease Control and Prevention (CDC)  
1600 Clifton Road NE, Mailstop D-72  
Atlanta, GA 30329  
Phone: 404-639-4641; Fax: 404-639-4903  
Email: SBIR@cdc.gov

Or

Darlene Forrest, MA  
Small Business Innovation Research (SBIR) Program and Logistics Specialist, (Contractor)  
Office of the Associate Director for Science, Office of the Director  
Centers for Disease Control and Prevention  
1600 Clifton Road NE, Mailstop D-72
Atlanta, GA  30329
Phone: 404-639-1023; Fax: 404-639-4903
Email: SBIR@cdc.gov

CDC Non-Clinical Trials Topics:

CENTER FOR GLOBAL HEALTH (CGH)

The Center for Global Health (CGH) leads the execution of the CDC’s global strategy; works in partnership to assist Ministries of Health to plan, manage effectively, and evaluate health programs; achieves U.S. Government program and international organization goals to improve health, including disease eradication and elimination targets; expands CDC’s global health programs that focus on the leading causes of mortality, morbidity and disability, especially chronic disease and injuries; generates and applies new knowledge to achieve health goals; and strengthens health systems and their impact.

Please visit their web site at: http://www.cdc.gov/globalhealth/index.html

(1) Portable Multi-function System for Assessing NTD Program Impact

**Background:** Neglected tropical diseases (NTDs) are infections that disproportionately affect poor and underserved populations. NTDs cause devastating illness for more than one billion among the world’s poorest people. These disabilities are of a severity that make it difficult to succeed in school, care for family or earn a living.

Five NTDs, including lymphatic filariasis (LF) (1.4 billion people at risk in 73 countries), onchocerciasis (120 M people at risk in 37 countries), schistosomiasis (700 M at risk in 74 countries), trachoma (200 M at risk in 42 countries) and three intestinal helminth infections (4 billion at risk, 1 billion infected, worldwide), are targeted for control or elimination through mass drug administration (MDA) of medicines.

There have been significant increases in the number of countries implementing public health programs to combat NTDs, and in the number of persons being treated for NTDs, as the a result of drug donations from pharmaceutical manufacturers as well as funding from the U.S. government, the UK Department for International Development (DFID), the Bill and Melinda Gates Foundation and others.

Program progress is measured through impact evaluations. These assessments require close training and supervision from external advisors, accurate data collection, and timely reporting. Failure to use standardized methods for program evaluation can lead to errors that limit data reliability and comparability of similar efforts carried out in different locations. Currently, there are applications for handheld electronic devices that assist with survey design, enable uploading of data, read point of care tests, provide geolocation, and reinforce use of correct procedures. However, there is no system that integrates all of these functions into a single application, or a suite of applications, on one device. This proposal promotes the development of such an application.

**Specific Research Areas of Interest:** The goal of this project is the development of a portable and field-compatible system (based on smart phones, tablets or similar devices) to assist and guide impact assessments for NTD programs.

The system should contain training modules with step by step guides for survey and diagnostic methods to reinforce previously received training and prevent deviations from intended methodology. This system should merge epidemiological information from questionnaires and laboratory results obtained in the field from rapid diagnostic tests (RDTs). The ultimate objective is to assist program managers in making programmatic decisions on site at the same time as the impact assessment is being conducted to prevent subsequent “field” trips to implement interventions. As NTD endemic areas are often remote and have limited internet connectivity, the application should be able to convert data into a format and file size that can easily be transmitted securely via wireless internet access or cellular networks. The system should have the potential to be adaptable to more than one NTD.
The functions should include:

a. training modules for survey methods and RDT use;
b. assistance with identifying samples for surveys using uploaded maps or census data;
c. the capacity to be used to administer questionnaires and record data;
d. a barcode reader for sample identification;
e. a reader for point of care (RDTs) that converts images into quantitative results;
f. the ability to use geographic information to link data to location;
g. real time or near real time availability of data to a centralized location (e.g., Ministries of Health); and,
h. flexibility with respect to language of use

The project objective is at least one fully functional prototype system that is ready to be piloted under programmatic field conditions, like impact assessments for lymphatic filariasis or for onchocerciasis.

This system should be appropriate for use in resource-limited settings, should include training modules, and should be able to digitally analyze and collect the results from point of care diagnostic tests. Data should be securely stored and easily shared with partners worldwide (real time or near real time). The system should allow for seamless and reliable updates or upgrades, and compatible with multiple operating systems. The system should allow for customization to adapt to local programmatic needs.

Basic system characteristics: intuitive, simple to use, and reliable with secure data storage while allowing secure data portability. The system should have the potential to be compatible with various operating systems (Android and IOS) and operational on multiple types of devices (for example mobile phone or tablet, from more than one manufacturer).

Field compatibility characteristics: compatible with extreme environmental conditions (including variations in temperature and humidity, environments with substantial dust or insect exposure, during transport on rough roads), able to read in outdoor environments, functional in areas with limited availability of electricity (e.g., solar recharging, long battery life, etc.) and with limited internet connectivity.

**Impact and Commercialization Potential:** Development of a system to facilitate monitoring and evaluation of NTD programs will strengthen CDC’s efforts to eliminate NTDs. These tools would allow for improved data quality. It will also allow synthesis of diagnostic and epidemiological data, to be shared in near real-time with WHO and implementing partners. Availability of data will expedite decision making to implement interventions and improve NTD elimination program performance. The training modules would reduce the need for in-person refresher trainings, thus reducing these program costs. Multifunctional diagnostic and treatment aid with geolocation capacity could be expanded to other health initiatives in rural areas of developing countries that could also include business applications.

(2) Development of Immersive Virtual or Augmented Reality Laboratory (AR/VR) Training Modules

**Background:** Laboratory science plays a vital role in the early detection, monitoring and response to a variety of diseases and health events as well as in surveillance to monitor the impact of vaccination programs. Efficient laboratory systems enables countries to better detect, respond, control and prevent the spread of disease. CDC global health programs support the improvement of global laboratory systems through training programs focused on various aspects of laboratory operations and management. Specific training includes workforce development, core laboratory competencies and management, facility and equipment maintenance, quality management system implementation, biosafety and biosecurity, as well as specific disease diagnostics (e.g. Zika, Ebola). Although the traditional hands-on practical approach is the mainstay of laboratory trainings, new and emerging technology-based approaches, such as electronic and mobile learning (E-Learning and M-learning); virtual learning (virtual classrooms), and immersive virtual reality (tactical and strategic immersions) techniques have been increasingly applied. CDC is actively promoting the development and utilization of cost-effective public health laboratory competency training tools using these innovative technologies.
**Specific Research Areas of Interest:** The goals for the proposed research are to address the limited availability of innovative virtual and augmented reality (VR/AR) training tools to improve public health laboratory capacity globally.

Examples of specific research areas of interest include, but are not limited to:

1. Development and field testing of immersive virtual and/or augmented reality laboratory training tools covering modules on guided instruction of standard operating procedures (SOPs) followed by immersive simulation to perform the SOPs.
2. Development and field testing of immersive virtual reality laboratory training tools covering visualization and interactive operation guides for complex, priority laboratory equipment (e.g. equipment used for molecular techniques, serology, immunology and culture).
3. Development and field testing of immersive virtual reality laboratory training tools covering step-by-step processes to mitigate laboratory biohazards, such as proper use and maintenance of engineering controls (e.g. biosafety cabinet) and personal protective equipment (PPE) (e.g. respirator, gowning & gloving) to optimize performance and maximize safety of laboratory operations.

**Impact and Commercialization Potential:** This research will result in increased availability of innovative and cost-effective immersive VR/AR laboratory training tools for global public health laboratory competency training programs that will complement the resource-intensive, hands-on, “wet” laboratory trainings that utilize live clinical specimens. The commercialization potential of these training products is high, as VR/AR training tools for other highly technical subjects have been successfully commercialized by different companies (e.g. Virtual Surgical Training, Flight Simulators, and Undergraduate Science Training etc.).

Visit the CGH homepage for more information on CGH’s research program areas [http://www.cdc.gov/globalhealth/index.html](http://www.cdc.gov/globalhealth/index.html)

For CGH programmatic information, contact:

Lata Kumar, MBA  
Office of the Director  
Center for Global Health  
Centers for the Disease Control and Prevention  
1600 Clifton Rd Ne, MS D-69  
Atlanta, GA 30329  
Phone: (404) 639-7618  
Email: LKumar@cdc.gov

For grants specific, administrative information, contact:

Pamela Render  
Office of the Director  
Office of Financial Resources  
Centers for Disease Control and Prevention  
2920 Brandywine Rd, MS E09  
Atlanta, GA 30341  
Phone: 770-488-2712  
Fax: 770-488-2778  
Email: PRender@cdc.gov
NATIONAL CENTER ON BIRTH DEFECTS AND DEVELOPMENTAL DISABILITIES (NCBDDD)

The mission of CDC’s National Center on Birth Defects and Developmental Disabilities (NCBDDD) is to promote the health of babies, children and adults and to enhance the potential for full, productive living. To achieve its mission, the Center works to identify the causes of birth defects and developmental disabilities, helps children to develop and reach their full potential, and promotes health and well-being among people of all ages with disabilities, including blood disorders. NCBDDD seeks to accomplish these goals through research, partnerships, and prevention and education programs.

Please visit their web site at: http://www.cdc.gov/ncbddd/index.html

(3) Computer-assisted diagnostic assessment to improve identification of childhood mental disorders

Background: Each year, between 13%–20% of US children experience a mental disorder while the diagnosed prevalence of these conditions has increased over time. Because of their prevalence, early onset, and impact on the child, family, and community (including an estimated total annual cost in the U.S. of $247 billion), childhood mental disorders is an important public health issue. Surveillance is critical for documenting prevalence, identifying changes over time, monitoring health service needs, and for informing policy and program development; standard surveillance case definitions are needed to reliably identify mental disorders.

Prevalence estimates for mental disorders often vary between studies (e.g., methodology used to assess for symptoms of these disorders). Diagnostic criteria for mental disorders are defined by the Diagnostic and Statistical Manual of Mental Disorders (DSM) and criteria for most mental disorders can be assessed through diagnostic interviews.

The Diagnostic Interview Schedule for Children (DISC) is a fully structured diagnostic instrument that assesses the presence of many of the more common psychiatric disorders. The DISC can be administered to both parents and children (aged 10 years and older) by minimally trained staff with no clinical experience, by researchers, and by clinicians. DISC-IV, which assesses disorders according to the Diagnostic and Statistical Manual, 4th edition (DSM-IV), became outdated after the publication of DSM-5 in 2013. The DISC instrument has been updated to align with the new diagnostic criteria for over 30 mental disorders in children.

The computer-assisted DISC-5 could be used for data collection and scoring in community-based epidemiologic studies to determine population-based estimates of mental disorders among children. The computer-assisted DISC could also be incorporated into clinical and other research settings. Because the DISC is lengthy, and has numerous and sometimes complicated skip patterns, a computer-assisted version of the DISC-5 could improve the ease of use and increase standardization in interviewing and scoring. Making the computer-assisted DISC-5 available to researchers and providers in clinical practices could result in wider use of the interview, and could result in (1) better standardization across research sites, and (2) improved identification of mental disorders in clinical settings.

Specific Research Areas of Interest: The goal of this project is to develop a program for computer-assisted administration and scoring of DISC-5 that can be used in research studies or clinical practice for conducting structured parent and child interviews and allow for easily accessible and complete data output. To be maximally useful and valid, the program would need to: adhere to the text, flow, and skip patterns inherent in the DISC-5; be capable of storing data securely; and follow established algorithms for symptom threshold and diagnoses to support the clinical report. It is expected that this project would include the development and testing of a subset of the 30 modules (e.g., particular diagnoses) or administration modes (e.g., parent or child reporter).
**Impact and Commercialization Potential:** A standardized, easy-to-use clinical assessment could lead to earlier and more accurate diagnosis of mental, emotional, and behavioral disorders in children and adolescents. Earlier, accurate diagnosis will facilitate more timely referrals to appropriate treatment. Timely receipt of evidence-based treatments can improve health and well-being. Previous versions of the DISC have also been used for training new professionals as they learn how to ask the right questions to assess for standard diagnostic criteria; a computer-assisted version of DISC-5 will allow this practice to continue using current diagnostic criteria.

The DISC was initially designed for epidemiologic studies in order to provide a consistent case definition, and the DISC-IV has recently been used in numerous research studies on childhood mental disorders over the years (According to PubMed, The DISC-IV methodology report has been cited by 805 publication as of November 2017; [https://www.ncbi.nlm.nih.gov/pubmed/10638065](https://www.ncbi.nlm.nih.gov/pubmed/10638065)). It was used in NIH’s Multimodal Treatment Study of children with ADHD (MTA) study, incorporated into CDC’s National Health Examination and Nutrition Survey (NHANES), and has been used in North America, South America, Europe, Africa, and Asia. Additionally, the DISC can be used in other research studies where a standard case-definition and/or a standardized tool across studies is needed. The DISC is unique from other diagnostic tools in that it does not require clinical training to administer.

Given the current absence of a DSM-5-compliant computer-assisted instrument to support diagnosis of mental disorders, this has potential for private sector commercialization. Epidemiologic and clinical researchers comprise one potential market, as evidenced by the 805 citations received by the initial DISC-IV methodology report ([https://www.ncbi.nlm.nih.gov/pubmed/10638065](https://www.ncbi.nlm.nih.gov/pubmed/10638065)). A second group is health care professionals, who use DISC for training on how to ask questions to assess criteria for mental disorders. Technology has been successfully used in the treatment and management of children’s mental, emotional, and behavioral disorders. There is now also opportunity for leveraging these technologies to facilitate assessment and diagnosis in research and patient care. If the program follows user-centered design principles, primary care offices and community health centers may incorporate these modules to improve patient care.

(4) Improving Newborn Screening of Coarctation of the Aorta

**Background:** There are approximately 6000 infants born each year in the United States with nonsyndromic critical congenital heart disease, a condition that typically requires surgical intervention during infancy in order to survive. Before the advent of newborn screening for critical congenital heart disease, approximately 30% of these children were discharged home after birth without a diagnosis having been made. In 2011, critical congenital heart disease was added to the United States Recommended Uniform Screening Panel, with nearly all states now including this condition as part of their newborn screening panel. Newborn screening for critical congenital heart disease screening has been shown to lead to earlier diagnosis, earlier treatment, and, as a result, improved survival of children with this condition. However, the sensitivity of current screening practices remains poor at only 50%.

The current non-invasive method of newborn screening for critical congenital heart disease includes using pulse oximetry on the right hand and either foot of an infant to determine the oxygen saturation of blood. Low levels of oxygen saturation or notable differences in saturation between the right hand and either foot suggest that a child might have critical congenital heart disease. Subsequent testing is then performed to either confirm or rule out critical congenital heart disease. This method works well for most of the 12 main types of critical congenital heart disease. However, for the most common type, coarctation of the aorta, screening with pulse oximetry has a sensitivity of only 32%.

Coarctation of the aorta is a narrowing of the aorta such that the lower half of a child’s body does not receive adequate blood flow. Left untreated, this condition may lead to cardiogenic shock and death. Sometimes a patent ductus arteriosus, a blood vessel bypassing the narrowing in the aorta, provides blood flow with a lower oxygen saturation to the bottom half of the body. Current screening practices may detect coarctation if a patent ductus arteriosus is present, but this is often not the case. Attempts have
been made to improve detection by studying the perfusion index, a measure of the pulsatility of blood flow in the distal circulation. However, these efforts have not been very successful. Thus, there is an unmet need for a reliable method to screen for coarctation of the aorta in the newborn.

**Specific Research Areas of Interest:** The goal of this project is to design, develop, and test the feasibility of a new method of reliably screening for coarctation of the aorta in a newborn infant at approximately 24 hours of age. This new method may include new equipment, new software that can be added to existing equipment (e.g. pulse oximeters), or a new application of existing technology. This new method must balance the screening ideals of high sensitivity, high specificity, affordability, and ease of use.

**Impact and Commercialization Potential:** Reliable screening of coarctation of the aorta would lead to earlier diagnosis and treatment for up to 560 additional newborns each year in the United States; this, in turn, would lead to improved survival for infants with coarctation of the aorta. Furthermore, the overall sensitivity of newborn screening for critical congenital heart disease would increase from 50% to 82%.

Successful technology can be implemented for screening of all newborns (approximately 4 million newborns in the United States each year) in birthing hospitals, including newborn nurseries and neonatal intensive care units (NICUs). This can be either new stand-alone technology that is added to current newborn screening practices, or adjunct technology that is incorporated into current pulse oximetry practices.

(5) **Innovation in Measurement of Head Circumference at Birth**

**Background:** Accurate measurement of head circumference is a critical step in establishing a diagnosis of microcephaly (small head circumference) associated with Zika virus and other intrauterine infections. In spite of staff training and guidelines for measurement and interpretation of results, current measurement methods remain problematic. Head circumference is an indication of brain growth and development and is usually correlated with later developmental functioning. A small brain is often an indication of poor neurological functioning and is a risk for intellectual disability, cerebral palsy, epilepsy, sensory disorders and perhaps even milder disabilities such as behavioral disorders and learning disabilities later in childhood. The recent reports of congenital Zika virus infection have focused on microcephaly (defined as for live births, head circumference at birth less than the 3rd percentile for gestational age and sex) as the most obvious physical sign of underlying brain abnormality. However, researchers quickly discovered that measurement of head circumference at birth is not standardized and measurements are often inconsistent. It is sometimes difficult to measure a small irregularly shaped head without the usual cranial landmarks, and the measurement tools themselves (e.g., tape measures) are sometimes of poor quality. Identification of infants who are candidates for further work-up for congenital Zika virus infection is hampered by the need to standardize the measurement of head circumference. There exists the need to improve the ability to assess the presence of microcephaly in a population of infants at risk for Zika virus infection, as well as to identify other intrauterine infections that may have a phenotype similar to congenital Zika virus infection.

**Specific Research Areas of Interest:** The goal of the project is to design a prototype of a screening tool for microcephaly among infants in the newborn period and identify mechanisms for soliciting expert opinion on the screening tool. The tool should be inexpensive and easy to use with minimal technical training on the part of the user and it needs to be either disposable or sterilizable. An example is a disposable “cap,” shaped like a typical infant’s head and made out of a non-stretchable plastic material. The opening of the “cap” would be for an infant (sex-specific) with a normal head circumference (e.g., 10th percentile head circumference for a 40-week gestation infant). Smaller openings of the cap or different caps would reflect percentiles for the specific ex and gestational age of the infant’s head being measured. The user would select the infant’s gestational age and sex, select the corresponding cap and if the cap is too large, it would indicate that the infant’s head is below the designated percentile (e.g., head circumference <10th percentile).
Impact and Commercialization Potential: This project would contribute to the ability to reliably identify infants with microcephaly potentially associated with a congenital intrauterine infection, with congenital Zika virus infection being the most recent concern in affected geographic areas. There are other prenatally acquired infections and teratogenic conditions for which the identification of microcephaly is important (e.g., congenital cytomegalovirus infection, fetal alcohol syndrome). There may continue to be a need for training and guidance related to interpretation of results, but accuracy of measurement would be increased and confidence of results enhanced. Early identification of affected infants can lead to timelier referral for more definitive diagnostic evaluation and initiation of developmental services. Early referral and intervention provides the best opportunity for providing family support and lessening the impact of later developmental disorders.

This product has the potential to become the standard for screening for microcephaly in all infants at birth if found to be less expensive and more reliable than current methods for measurement of head circumference.

(6) Technology-Assisted In-Office Screening for Mental, Emotional and Behavioral Disorders in Pediatric Practices

Background: Nationally representative data suggest that 15% of U.S. children aged 2–8 years have a parent-reported mental, behavioral, or developmental disorder diagnosis. Among children and adolescents aged 9 to 17 years, as many as one in five may have a diagnosable psychiatric disorder. Adequate treatment can promote lifelong health and development, while a lack of appropriate treatment may lead to worsening and compounding of the child’s difficulties in home, academic, and community settings. Because of the potential consequences of not receiving treatment, a Healthy People objective set a national target for 76% of all children with mental health problems to receive treatment by 2020. A critical prelude to treatment is timely and accurate diagnosis.

Data from the National Survey of Children’s Health showed that more than 90% of children nationwide had visited a primary care provider at least once in the previous year. Because of this widespread coverage, pediatric primary care is well suited for early identification of developmental and behavioral health problems and assessment of child and family needs. The American Academy of Pediatrics has published guidelines recommending the use of brief and research-tested screening tools, yet pediatric primary care providers (PCPs) continue to encounter barriers to conducting systematic screening. Many pediatric PCPs have begun to request completion of pencil and paper-based screening instruments or web-based assessments from parents/legal guardians at home, before their appointment. That approach requires that parents/legal guardians follow through on completing the instruments. The paper-and-pencil instruments face additional barriers in that they rely on parents/legal guardians returning the documents and in-office time to score them. Other commonly reported barriers include insufficient time with parents/legal guardians, inadequate reimbursement, lack of familiarity with validated instruments, and the challenge of integrating a new intervention into existing clinical workflows.

Thus, an in-office, technology-assisted screening process could overcome these widespread challenges, and provide PCPs with the information they need to best serve patients and their families.

Specific Research Areas of Interest: The goal of this project is to develop a scalable application software (“app”) to be accessed via personal smartphones or tablets provided in a waiting room to achieve the following aims:

- The app would be accessed by parents/legal guardians of children in waiting rooms of pediatric primary care physicians, so they can complete off-the-shelf, validated screening tools for mental, emotional and behavioral disorders as appropriate to the child’s age and parent’s concerns.
- The app would then follow scoring procedures associated with the screening tool to produce an overall report of scores for each screener completed by the parent/legal guardian at that visit.
• The app would then provide the PCP with the overall scores and responses to individual items, to allow the PCP to quickly understand the nature and severity of presenting mental, emotional or behavioral concerns.
• The resulting report should be available to the PCP in the same visit, and also available in a format that can be saved in the patient’s records.
• The app and procedure for getting results to the PCP must follow all appropriate security regulations for protected information (e.g., HIPAA).
• The app must accommodate conventionally used screening tools for child and adolescent mental, emotional and behavioral disorders from a variety of different publishers and platforms.
• The app must accommodate different screener formats, including different response types and skip patterns.
• The app should be functional on a range of common mobile operating systems on smartphones, tablets, and other mobile devices (e.g., Android OS [Google], iPhone OS [Apple], Windows 10 Mobile [Microsoft]).

The proposed activities will require an applicant with capacity to:
• Gather input from pediatric PCPs, office staff, and parents/legal guardians to inform the application’s functionality, usability and appearance.
• Gather information from publishers of conventionally used screening instruments to inform the parameters within which the application will need to function.
• Develop the application in line with the above goals.
• Conduct pilot administration of the full functionality of the application (i.e., from parent completion of the screeners to delivering results in real time to a PCP and providing a version to file in patient records) using freely available screeners such as the Strengths and Difficulties Questionnaire (http://www.sdqinfo.org/a0.html) and the Pediatric Symptom Checklist (http://www.massgeneral.org/psychiatry/services/psc_home.aspx).
• Develop a pilot mobile application with potential for use on multiple platforms, with potential for commercialization and scalability to assist pediatric PCPs identify risk for mental, emotional, and behavioral disorders.

*Impact and Commercialization Potential:* A mobile application that increases the available information relevant to provider decision-making could lead to earlier and/or more accurate diagnosis of mental, emotional and behavioral disorders in children and adolescents. This would also alleviate the burden for the provider in identifying which screening instrument(s) are appropriate for their practice and clinical workflow, as well as subsequent interpretation. Earlier, accurate diagnosis will facilitate more timely referrals to appropriate treatment.

Surveys of pediatric primary care providers regularly reveal concerns that they have inadequate amounts of face-to-face time with their patients. By incorporating the patient assessment into the technology-assisted information gained while they are in the waiting room, more time during the visit can be spent discussing treatment options. Technology has been successfully used in the treatment and management of children’s mental, emotional, and behavioral disorders; there is opportunity for leveraging these technologies to facilitate assessment and diagnosis.

Visit the NCBDDD homepage for more information on NCBDDD’s research program areas http://www.cdc.gov/ncbddd/index.html

For NCBDDD programmatic information, contact:

Brenda Colley Gilbert, PhD
Office of the Director
National Center for Chronic Disease Prevention and Health Promotion
Centers for Disease Control and Prevention
4770 Buford Highway, MS F80
NATIONAL CENTER FOR CHRONIC DISEASE PREVENTION AND HEALTH PROMOTION (NCCDPHP)

The CDC's National Center for Chronic Disease Prevention and Health Promotion (NCCDPHP) carries out a variety of activities that improve the nation's health by preventing a range of chronic diseases such as arthritis, cancer, diabetes, heart disease, obesity and stroke, while promoting health and wellness in the areas of reproductive health, oral health, nutrition and physical activity. The Center's activities include supporting states' implementation of public health programs; public health surveillance; translation research; and developing tools and resources for stakeholders at the national, state, and community levels.

Please visit their web site at: http://www.cdc.gov/chronicdisease/index.htm

(7) Clinical Decision Support for Contraception Practice Guidelines

Background: Almost half of U.S. pregnancies are unintended. Unintended pregnancy is associated with greater risk of adverse outcomes for both mothers and infants as well as increased health care costs. To reduce unintended pregnancy and related adverse health outcomes, and to promote optimal birth spacing for improved maternal and child health, strategies to increase access to and use of effective contraceptive methods are important. Primary healthcare providers, as well as other providers who care for women of reproductive age, play a key role in assisting patients to choose and use contraception successfully. Evidence-based guidelines on contraception (such as CDC's US Medical Eligibility Criteria for Contraceptive Use and US Selected Practice Recommendations for Contraceptive Use) are available to assist providers when they counsel patients about contraceptive method choice and related family planning services. Guidelines can also facilitate voluntary quality improvement activities in healthcare systems that provide services to women of reproductive age. However, implementation of these guidelines can be challenging for busy providers and health systems, resulting in missed opportunities to address patients’ family planning needs.

Clinical decision support (CDS) can provide timely information at the point-of-care to inform decisions about patient care and has the potential to increase quality of care, enhance health outcomes, improve efficiency, and increase provider and patient satisfaction. CDS tools for contraception provision may help primary care providers implement clinical recommendations, facilitating patient-centered care and evidence-based decisions, leading to improved access to and use of contraception and lower rates of unintended pregnancy.

Specific Research Areas of Interest: The goal of the project is to develop and evaluate a CDS framework that will integrate evidence-based guidelines directly into providers’ regular clinical workflow
via the electronic health record (EHR) at relevant points during the patient encounters. This integrated
information will assist healthcare providers to 1) screen female patients for need and desire for
contraceptive services and 2) provide quality family planning services, including patient-centered
contraception counseling and evidence-based contraceptive method provision. Evaluation should include
healthcare system outcomes (e.g., proportion of women screened and standard performance measures
from the National Quality Forum for family planning services), provider-level outcomes (e.g., satisfaction
with the tool), and patient-level outcomes (e.g., satisfaction with their visit).

The applicant should have the capacity to 1) develop/adopt a CDS framework that is compatible with
EHR systems; 2) partner effectively with multiple stakeholders, including primary care clinicians, health
systems, and EHR vendors; 3) evaluate the tool for performance on relevant outcomes; and 4) create a
marketing plan for the tool that will appeal to relevant stakeholders.

The prototype phase should support exploration of the feasibility of a CDS tool to provide evidence-based
recommendations integrated into the regular clinical flow through the EHR.

Activities should include but are not limited to:

- Conduct a review of available EHR data elements across different EHR implementations, to make
  the determination if a patient needs further screening or counselling as described by the literature
  and CDC’s evidence-based guidance for contraceptive provision, and validated performance
  measures.
- Develop CDS alerts that will retrieve context specific information and invoke events based on
  practice guidelines e.g. patient-centered counseling tools, workflow alerts, screening tools,
  information retrievals, etc.
- Implement a prototype using a framework that is proven compatible across EHR system in
  delivering CDS alerts.
- Pilot test the tool with key end-users and refine the tool.

**Impact and Commercialization Potential:** CDC-developed tools currently available to assist providers in
using contraceptive guidelines rely on the individual provider to download a smartphone app or
reports/algorithms from the internet to access the most up-to-date contraceptive guidelines. This CDS tool
will facilitate guideline adoption on a larger scale and integrate the guidelines into a routine, provider-
friendly workflow. The larger impact of this CDS will be to increase opportunities for contraception
provision that may otherwise be missed, thereby improving access to contraception, and to improve and
facilitate contraceptive counseling and decision-making so that a woman is able to choose the best
contraceptive method for her. These factors have been shown to improve correct, consistent, and
continuous use of contraception, and in doing so, decrease unintended pregnancy. For healthcare
systems, this would mean increasing the number of women screened for the need and desire for a
contraceptive visit, increasing contraception provision to those in need, and decreasing unintended
pregnancy among their patient population.

The CDS tool could be marketed to health systems for use in their EHRs. The tool could be implemented
among all systems that provide health care to women of reproductive age, and would likely be most
relevant for primary care and other large health systems.

(8) Electronic transmission of assisted reproductive technology pregnancy outcome data

**Background:** The Fertility Clinic Success Rate and Certification Act (FCSRCA) of 1992 mandates that
clinics performing assisted reproductive technology (ART) in the United States (U.S.) annually provide
pregnancy success rates data to the Centers for Disease Control and Prevention (CDC). ART is any
procedure involving the handling of eggs or embryos for the purpose of establishing pregnancy. Fertility
clinics report ART cycle-level data to the CDC, including details of each ART procedure performed,
outcomes of the ART procedure (e.g. pregnant versus not pregnant), and outcomes of any resultant
pregnancy (e.g. live birth versus no live birth). Fertility clinics provide care to patients undergoing ART treatment; therefore, detailed information about the ART treatment procedure is collected directly by the fertility clinic. However, if a patient achieves pregnancy, the patient receives subsequent prenatal and obstetric care from other healthcare providers such as obstetrician/gynecologists. ART clinics may face obstacles in collecting pregnancy outcome information in an effective and efficient manner from ART patients that have achieved pregnancy. They mostly rely on traditional mechanisms, including telephone, mail, and email, to obtain these data from either the patient or the patient’s obstetric provider, and they often have to make multiple attempts to get the required information. This process can be even more challenging if patients come from outside of the state or outside of the U.S. to receive ART treatment and then return home to care for the pregnancy.

The CDC uses the ART surveillance data, including the pregnancy outcome data, for several purposes, including the publishing of clinic-specific success rates on an annual basis, the publishing of other annual reports which describe the characteristics of ART treatment procedures and outcomes at a national and state level, as well for linkage with vital records data in order to generate more robust surveillance and research datasets. Data linkage allows additional research on short- and long-term maternal and infant outcomes such as complications of labor and delivery, neonatal complications, as well as conditions identified after birth.

Pregnancy outcome information is a vital component of ART surveillance. The accuracy of pregnancy outcome information in the ART surveillance system is critical for reporting ART success rates, understanding maternal and treatment characteristics associated with treatment success, and ensuring the accuracy of data linkages between ART surveillance data and vital records. Some fertility clinics may lack a user-friendly, convenient, secure, and verified information delivery mechanism for patients to either: (1) personally report pregnancy outcomes to the fertility clinic in a safe and secure manner and/or (2) provide information on their obstetric provider and consent to the release of pregnancy outcome information to the fertility clinic. Nationwide, approximately 500 fertility clinics in the US perform ART, are required to report ART surveillance data per the FCSRCA and may face the challenge of obtaining pregnancy outcome information from their patients.

**Specific Research Areas of Interest:** The desired primary goal of this project is an effective technology solution that facilitates electronic transmission of pregnancy outcome data from the patient and/or obstetric provider to the fertility clinic. The technology solution should be user-friendly and convenient for both the ART patient and the fertility clinic, such as a phone application. It should also be secure, as it would involve the transmission of sensitive data.

A possible secondary goal of the project would be to use the technology solution as a platform for fertility patients and fertility treatment providers to communicate during the treatment process via a seamless and secure channel. For example, patients could track the timing of medication administration, report side effects and ask questions, while providers could track adherence to the treatment plan, adjust dosage, and schedule appointments.

**Impact and Commercialization Potential:** The desired primary goal of this project is an effective technology solution that facilitates electronic transmission of pregnancy outcome data from the patient and/or obstetric provider to the fertility clinic. The collection of pregnancy outcome data by fertility clinics may be limited due to patients moving from fertility treatment providers to obstetric providers after the establishment of pregnancy and due to a reliance on traditional mechanisms, including telephone, mail, and email, for collection of the information. The problem described above affects (1) infertility patients undergoing ART, (2) fertility clinics who collect and/or report this information, and (3) organizations performing ART surveillance, such as the CDC. Infertility patients will benefit from having a seamless and secure communication channel with their fertility treatment provider, which can save them time and allow reporting of pregnancy outcome data at their convenience. It may also provide a more sensitive approach for collecting the information in the event that a pregnancy does not result in a live birth. Having a convenient and secure information delivery mechanism will help fertility clinics save resources...
typically spent on sending patient reminders or contacting patients. Finally, organizations performing ART surveillance will benefit in receiving more complete and accurate pregnancy outcome data. The estimated national discrepancy rate for pregnancy outcome data in CDC’s ART data has been relatively low, ranging from 0.7% to 3.5% over the last five years; however, clinic-specific discrepancy rates can be substantially higher. Since the CDC publishes both national and clinic-specific success rates as a part of annual reporting requirements, implementation of an effective technology solution will support compliance with the FCSRCA and potentially improve the accuracy of both national and clinic-specific success rates. In addition, improved completion and accuracy of pregnancy outcome data will ultimately improve ART surveillance and the quality of research aimed at improving perinatal outcomes of fertility treatments. For example, recent efforts to link fetal death records in four states resulted in linkage rates ranging from 64% to 80%, rates substantially lower than linkage rates for birth certificate data, which typically are around 90%. One factor possibly contributing to lower linkage rates is the quality of fetal death reporting in the National ART Surveillance System (NASS). Therefore, improving the accuracy of pregnancy outcome data in the CDC’s ART surveillance database may help to improve these linkage rates, and thus improve the quality of surveillance and research conducted using linked data. Overall, this project has the potential to strengthen collaboration between small technology-promoting businesses, healthcare, and public health in the area of fertility treatments and outcomes.

This project requires an effective technology solution that facilitates secure electronic transmission of pregnancy outcome data from the patient to the fertility clinic. The solution should include a tangible product such as a phone application, which either could be sold to fertility clinics, or could contain paid advertisements and be made freely available to clinics. The approach will need to ensure protection of privacy for patients and for clinic data. As previously mentioned, nearly 500 fertility clinics in the US perform ART and are required to report ART surveillance data per the FCSRCA. Clinics could reduce resources spent if a cost-saving, secure technology solution to facilitate collection of pregnancy outcome data was available. In addition, fertility clinics that do not perform ART may be interested in utilizing the solution. Many clinics track their own success rates to understand the effectiveness of the treatment they are offering and for marketing purposes. Therefore, fertility clinics performing services such as ovulation induction or intrauterine insemination in the absence of ART (i.e. clinics not required to report per the FCSRCA) may still be interested in purchasing the software. In addition, adding another component to the technology solution, such as providing a platform for fertility patients and fertility treatment providers to communicate during the treatment process via a seamless and secure channel, may improve marketability.

(9) Food Service Guidelines Algorithmic Database Processing and ID Tool

Background: As part of the effort to encourage availability of healthier and sustainably produced food and beverage options, numerous business industry standards and practice guidelines have been developed. For example, the US federal government has developed food service guidelines based on nutrition (Dietary Guidelines for Americans), environmental sustainability, industry best practices for facility efficiency, food safety, and local economic development. Food service guidelines, such as the updated 2017 Food Service Guidelines for Federal Facilities, are used widely by institutional purchasers including government facilities, worksites, hospitals, universities and schools. Notably, these guidelines provide desired food standards but do not list specific food products meeting the guidelines. The difficulty in identifying qualifying products is a major obstacle in using food service guidelines, particularly when guideline specifications may differ slightly from one jurisdiction to another. For example, New York City’s (NYC) and Los Angeles (LA) County’s food service operations, which serve 25 million people combined, have reported difficulty meeting their own food service guidelines because their primary suppliers do not have the resources (i.e., time, staff) to determine which of their products meet guidelines.

Access to foods that meet food service guidelines is crucial for vendors or food service operators whose institutional clients have specific food service guidelines for food sold in their venues. Easy identification of foods that meet specific standards is also helpful for retailers who want to market specific products to personal or demographic interests. A food service guidelines algorithmic database processing and food
ID tool (FIDT) will increase the ease of operationalizing food service guidelines by providing lists of specific food products that comply with a desired set of guidelines or other user defined attributes. The FIDT will enable distributors to provide their customers (e.g., food service operators) with a wider range of products that meet specific guidelines and attributes included in food service contracts. The tool will also enable food service operators to quickly identify and select products that align with required nutrition standards or that appeal to specific health conscious market segments. In areas that have difficulty in accessing healthier foods (i.e., rural areas and inner cities), this tool can incentivize broader distribution and easier access of those foods, thereby enabling heathier foods and beverages to flow through the food supply chain.

Lastly, the FIDT will allow the user to choose from a number of different nutrition standards or guidelines that a food service operation may be trying to implement, thereby reducing the labor and time burden placed on staff to do individual product analysis against multiple sets of standards. More specifically, a food or beverage product could be analyzed against several different sets of guidelines or standards simultaneously, demonstrating the additional efficiencies that could be created with the FIDT in the food management sector.

**Specific Research Areas of Interest:** The goal of this project is the development of a food ID tool (FIDT), a computer application, designed to help suppliers (e.g., food service companies providing meals, snacks, or vending) identify food products that align with food and nutrition guideline specifications. The FIDT enables suppliers (i.e., distributors, manufacturers) to process their food databases (e.g., nutrient data for ingredients, packaged products, and recipes) to determine if they meet food service guideline (FSG) requirements.

The FIDT should:

- Be easily utilized by manufacturers and distributors to determine which of their foods align with various guidelines;
- Have a second interface available to operators to: 1) determine if customer-requested or desired foods meet specific guidelines (e.g., does a newly marketed Grab N’ Go snack pack meet guidelines); and 2) to create a list or catalog of products that meet standards to aid product selection and purchase from their food suppliers;
- Process various types of databases containing nutrition and other information to determine the ingredients or foods that meet particular sets of guidelines.
- Allow databases to be easily searched/navigated and have the ability to generate and sort lists of products meeting specific guidelines as requested by customers;
- Include product cost information from the supplier so the user can also choose the most affordable product that also meets given guidelines;
- Be secure so that data is private until users enable sharing downstream to clients, including food service and vending operators;
- Incorporate user-testing and heuristics that can be used over time to improve interface and outcomes.

The proposed activity will require an applicant with capacity to:

- Create the computer application and algorithms that identify foods and beverages meeting food service guidelines for food operators.
- Develop functioning algorithms.
- Create algorithms representing the major public food service guidelines, including: Food Service Guidelines for Federal Facilities, USDA school nutrition standards and Smart Snacks guidelines, NYC’s food procurement guidelines, LA County’s food procurement guidelines, and Department of Defense’s (DoD) food service guidelines. Use programing infrastructure that enables the addition of further sets of guidelines that maybe of interest by the private or public sectors.
• Develop an interface system that can process and translate primary computer database software input (i.e., MS Access, MS Excel) and food management software input (i.e., Computrition Hospitality Suite [DoD’s food management software], Foodservice Suite, etc.). Two different interfaces are required – operator-end and supplier-end.
• Provide ability to transfer individual food items via food database or direct food entry on computer or mobile application.
• Conduct concept and feasibility testing to identify any issues with guidelines and foods output.

**Impact and Commercialization Potential:** Currently, public health departments and other organizations responsible for procurement of food service contracts must use scarce resources to develop lists of products that meet guidelines. This creates an attributable time and cost burden and does not provide a consistent tool for the user. By placing the ability to determine foods that meet guidelines within the hands of suppliers, it eliminates not only the burden, but enables suppliers to use a new type of tool to enhance their business model and advances competition in the marketplace. Commercialization of this tool not only impacts suppliers, but can also impact business opportunities and advance competition for food service operators, food manufacturers, and producers.

(10) Innovative Approaches for Maternal and Infant Safety in Maternity Hospitals

**Background:** The Surgeon General’s [Call to Action to Support Breastfeeding 2011](#) identifies breastfeeding as one of the most effective preventive measures to protect the health of mothers and their infants. Among the key actions identified is for the health care system to ensure that maternity practices are fully supportive of breastfeeding and cites the [Ten Steps to Successful Breastfeeding](#) (Ten Steps) as the evidence-based standard for maternity care.

In the United States (US), nearly all infants are born in hospitals, and although their stay is typically short, experiences during this time have lasting effects. Skin-to-skin contact (SSC) between mothers and healthy infants immediately after birth and rooming in are evidence-based practices that promote breastfeeding and align with Steps Four and Nine of the Ten Steps. However, there are concerns related to infant safety during immediate SSC and rooming-in throughout the hospital stay.

Although rare, adverse events, such as infant falls and/or Sudden Unexpected Postnatal Collapse (SUPC) pose potential risks to the safety of infants and may occur during unobserved SSC and in at-risk situations during rooming-in throughout the hospital stay. A recently published American Academy of Pediatrics clinical report titled, [Safe Sleep and Skin-to-Skin Care in the Neonatal Period for Healthy Term Newborns](#), suggests that the use of standardized methods and procedures may help prevent these adverse events. The authors provide suggestions to support safe implementation of SSC and rooming-in throughout the hospital stay, and these suggestions include environmental enhancements and improvements in assessment, monitoring, care practices, documentation, and staff training.

**Specific Research Areas of Interest:** The project goals are to develop creative, innovative approaches, including but not limited to technological applications to standardize methods and procedures to support safe implementation of SSC for healthy infants and safe rooming-in throughout the hospital stay. Technologic approaches to facilitate safe implementation and documentation of SSC and rooming-in throughout the hospital stay should be compatible with consumer/user (i.e., mothers, families, hospital maternity staff, and medical providers) preferences and integrate seamlessly with electronic medical records.

The proposed activities will require an applicant with capacity to: identify, define, and develop design specifications for one or more innovative approaches, systems, methods, procedures, and/or tools for use by hospital staff to promote safe implementation of SSC for healthy infants and safe rooming-in throughout the hospital stay.

At the conclusion of the period of performance, the awardee will provide the design specifications for the proposed innovative approach and a report/assessment of the feasibility of and commercial potential for
further developing this approach. The approach should take into account consumer and user (i.e., mothers, families, hospital maternity staff, and medical providers) preferences, should be user friendly, promote infant and maternal safety, maximize hospital maternity staff efficiency, and conform to all applicable industry standards. The assessment should address, at a minimum, how the approach addresses consumer/user preferences, as well as cost, challenges and barriers related to development and implementation, issues related to patent and/or licensing agreements; the assessment should also address the viability of the proposed innovation and establish proof of concept.

**Impact and Commercialization Potential:** There are approximately 3,300 maternity facilities in the United States, and nearly 4 million infants born each year in these facilities. Of these facilities, 416 are Baby-Friendly designated and represent approximately 20% of US annual births. These 416 facilities are early adopters of evidence-based breastfeeding supportive maternity care, and may represent a potential commercial market willing to be early adopters of innovative approaches, systems, methods, procedures, and/or tools that improve maternal and infant safety during SSC and rooming-in during the hospital stay.

(11) Population Health Data Using Blockchain Technology

**Background:** Today’s health data exchange between care delivery partners relies on point to point (P2P) sharing or exchange facilitated by an intermediary entity such as a health information exchange (HIE). Effective population health management requires integrated data from all locations where patient engagement happens. An example would be having population metrics on newly diagnosed diabetes patients addressing adherence to referrals, care utilization, care gaps, quality of life and safety. Currently health professionals face a complex ecosystem – they engage with varied systems, uneven data standards, different security and access protocols, and individualized data use policies which constrain current HIE and P2P technologies in their ability to scale for population health management needs. Public health access to population health data is often a multistep process that involves manual effort, resulting in data sharing from health systems in different formats. Public health also competes for resources within the healthcare setting to obtain population health data making it challenging.

Blockchain technology offers a promising new distributed framework to support the integration of healthcare information across a range of stakeholders. Blockchain technology has the potential to simplify the process of creating and sustaining data partnerships in the health exchange ecosystem using special contracts and by implementing comprehensive cryptographic data signature services. It may allow public health to improve efficiency by delivering trusted access to population health data in a timely fashion reducing time to public health action, a critical performance measure in public health.

**Specific Research Areas of Interest:** The goal for this grant is to pilot the population health use case using the blockchain technology. Despite the successful adoption in the financial domain (bitcoin transactions), the technology is still new and nascent in the health domain, leaving a number of unanswered questions (e.g., Can it scale to handle large data transactions? What are the ledger contents for health data? Where does health data reside outside the ledger? & How do you link patient data to ledger?).

In order to address the broader goal, CDC proposes specific topic areas for the grantee to address in Phase I. The applicant is expected to conduct an assessment and report on at least 4 or more topics in the proposed list:

- Data standard for health data in the ledger and the reservoir
- Suitable consensus algorithms for health data (e.g. Byzantine Paxos, Regular Paxos)
- File storage mechanism for efficient data retrieval (File Sharding vs. IPFS)
- API pipeline for EHR and other health systems (FHIR vs. XDS map vs. CCDA map)
- Crypto services for handling PII data
- Population health centered special contracts management and delivery
- Data Replication and Linking Strategies for population health data use
• Best effort delivery algorithms for health data
• Data Replication, Reconciliation and Fault Tolerance requirements for health data

The proposed activity will require an applicant with capacity to:

• Conduct a preliminary assessment to determine the implications for a health data blockchain based on the topic areas identified above and publish a finding report.
• Conduct review of the commercially available Blockchain as a Service platforms (e.g. Microsoft, Ethereum, Eris, IBM Healthledger etc.) and implement a platform of choice.
• Demonstrate the capability of the blockchain technology using a minimal population health data use case for a chronic disease condition e.g. Diabetes, Hypertension or Heart diseases.

**Impact and Commercialization Potential:** The overall goal is to leverage innovative technologies to improve the interoperability of population health data so that it directly improves patient health outcomes. The approach if successful will reduce burden on the data providers and public health in getting access to longitudinal population level data in a timely fashion and in an attractive cost model. The security and trust model allows consistent application to who has access to which data and maintains an immutable audit trail across all trusted parties. The use of special contracts will allow data sources to control and permit data access which was a timely and expensive process. Beyond public health agencies, academic researchers and private entities can now gain access securely to authorized population cohorts in an efficient fashion without burdening the healthcare entities and data sources. All these benefits from this technology can greatly impact the future direction and investments on surveillance and program management at Centers for Disease Control and Prevention (CDC).

The envisioned business offering is a commercial Blockchain platform as a service (PaaS). Potential clientele for the Blockchain platform as a service (PaaS) offering includes health systems, health information exchanges, other care providers, researchers, claims processors, risk adjudicators, ACO and public health. The platform can operate on a subscription based revenue model or a product licensing model in a consortium of health care providers needing to establish health data exchange or serve as a part of the HIE offering for a region.

Visit the NCCDPHP homepage for more information on NCCDPHP’s research program areas [http://www.cdc.gov/chronicdisease/index.htm](http://www.cdc.gov/chronicdisease/index.htm)

For NCCDPHP programmatic information, contact:

Brenda Colley Gilbert, PhD  
Office of the Director  
National Center for Chronic Disease Prevention and Health Promotion  
Centers for Disease Control and Prevention  
4770 Buford Highway, MS F80  
Atlanta, GA 30341  
Phone: 770-488-6295; Fax: 770-488-7863  
Email: BColleyGilbert@cdc.gov

For grants specific, administrative information, contact:

Pamela Render  
Office of the Director  
Office of Financial Resources  
Centers for Disease Control and Prevention  
2920 Brandywine Rd, MS E09  
Atlanta, GA 30341  
Phone: 770-488-2712; Fax: 770-488-2778  
Email: PRender@cdc.gov
NATIONAL CENTER FOR EMERGING AND ZOONOTIC INFECTIOUS DISEASES (NCEZID)

The National Center for Emerging and Zoonotic Infectious Diseases (NCEZID) aims to prevent disease, disability, and death caused by a wide range of infectious diseases. NCEZID focuses on diseases that have been around for many years, emerging diseases (those that are new or just recently identified), and zoonotic diseases (those spread from animals to people). Work is guided in part by a holistic “One Health” strategy, which recognizes the vital interconnectedness of microbes and the environment. Through a comprehensive approach involving many scientific disciplines, better health for humans and animals and an improved environment can be attained.

Please visit their web site at: http://www.cdc.gov/ncezid

(12) Antibiotic Resistant Healthcare-Associate Infections

Background: Healthcare-associated infections (HAI) are a threat to patient safety. CDC provides national leadership in surveillance, outbreak investigations, laboratory research, and prevention of healthcare-associated infections. CDC uses knowledge gained through these activities to detect infections and develop new strategies to prevent healthcare-associated infections. Healthcare-associated infections (HAIs) can be found to effect 1 in 25 hospitalized patients on any given day in the United States, leading to an annual burden of 722,000 infections and 75,000 deaths. Meanwhile, among 18 antibiotic resistant (AR) organisms identified by CDC in 2013 as urgent, serious, and concerning threats, nearly half are primarily healthcare-associated. Whereas 1 in 7 HAIs in hospitals overall are caused by AR-threat bacteria, in some types of hospitals, AR-threat bacteria cause 1 in 4 infections. In all cases, HAIs caused by AR-threats are more difficult to treat and some are now untreatable. There are three broad, current strategies that clinicians and nurses need to employ to prevent these AR HAIs: following recommendations for preventing invasive device and surgical procedure-related infections, preventing cross-transmission of AR HAI pathogens, and practicing optimal antibiotic stewardship. In addition, there is a great need for innovation and commercial development in the following three priority areas.

Specific Research Areas of Interest: The goals for the proposed research are to address antibiotic resistant healthcare- associated infections.

Examples of specific research areas of interest include, but are not limited to:

1) Development of novel diagnostics that either: A) offers a more rapid and definitive diagnosis of whether a patient does or does not require an antibiotic (alternatively whether it is safe to stop an antibiotic), or B) better detect (i.e. earlier, more rapidly, and more accurately) whether a patient is infected or colonized (and thereby may transmit) with an AR HAI pathogen.

2) Novel therapeutics and preventative based upon preservation or restoration of the human microbiome.

3) Preventing biofilms on invasive medical devices.

Impact and Commercialization Potential: This research will lead to the development of practical and innovative solutions to address the matrix of complex problems caused by antibiotic resistant healthcare-associated infections. Successful and novel innovation that will reduce disease, disability, and death will have huge commercial potential across many markets.


Background: Overuse of antimicrobial drugs in agriculture, medicine, and industry has resulted in continual pressure for pathogenic organisms to evolve mechanisms by which to evade these drugs. The National Antimicrobial Resistance Monitoring System (NARMS) is a collaborative effort of state public health departments, FDA, CDC, and USDA to monitor trends in antimicrobial resistance over time using a
‘farm to fork’ approach. Although the advent of advanced molecular detection techniques has increased our ability to detect bacterial resistance patterns, there are knowledge gaps that remain to be addressed. Detection of resistance to clinically-relevant drugs requires a laboratory setting and takes days, if not longer, and more research is needed to link data generated by molecular detection to clinical outcome. Finally, the laboratory community has realized that the exciting potential of culture-independent tests may also have an undesired outcome; the loss of important organic material for future study.

**Specific Research Areas of Interest:** The goals for the proposed research are to detect, transmit, and prevent antimicrobial resistance in enteric bacteria.

Examples of specific research areas of interest include, but are not limited to:

1. Rapid, portable, point of care diagnostic and field assays that simultaneously identify bacterial agents and clinically relevant resistance markers
   - Lateral flow technology to detect biomarkers
   - High throughput molecular tests
2. Development of an in vitro system to simulate myriad physiological conditions (human or ruminant gut, for example) in which enteric bacteria develop drug resistance 3D polymer scaffold or 3D-printed substrate ‘organ’ for growth of bacteria in the presence of secretory immune factors to which antimicrobials may be applied or dosed
3. A matrix for archiving bacterial cultures that does not require a cold-chain or frozen storage
   - Preserves the integrity of the organisms
   - Storage matrix requires a tiny footprint, similar to filter paper.

**Impact and Commercialization Potential:** Using an effective in vitro “microbiome” system to study development, rate of transmission and ecology of antimicrobial resistance would require less time and human capital than the large clinical studies that are required to evaluate current and new antimicrobial pharmaceuticals. A system such as this could help to narrow one of the major knowledge gaps in understanding antimicrobial resistance; the correlation between laboratory-determined antimicrobial breakpoints and clinical outcomes. A simple rapid method of preserving important bacteria and organic material related to bacterial resistance would be embraced by the reference and research community. Existing rapid tests could be modified to add detection of clinically-relevant resistance markers, thereby dramatically decreasing time to treatment decision. Reduction of footprint and ambient storage would reduce operating and shipping costs that are currently associated with these materials.

**Background:** Invasive candidiasis is a serious fungal infection caused by *Candida* species that can affect the heart, brain, bones, eyes, and other parts of the body, including the bloodstream (candidemia). Affecting more than 250,000 people worldwide every year, invasive candidiasis is the most common fungal disease among hospitalized patients in the developing world. For the United States and Europe, candidemia is a leading cause of nosocomial bloodstream infections. Despite antifungal therapy, mortality can be as high as 40%, and with the rise of emerging multidrug-resistant *Candida* species, mortality is projected to increase.

The emerging species *Candida auris* was first reported in 2009, and since then has been identified on five continents. Known to colonize skin, contaminate hospital surfaces and be capable of resistance to all three major classes of antifungals, *C. auris* poses a major public health threat. Importantly, the emergence of multidrug-resistance and newly emerging multidrug-resistant *Candida* species like *C. auris* is inevitable; in addition, the type and level of drug resistance is unknown until a patient’s *Candida* species is tested. Thus, it is crucial to develop point-of-care tests that can not only identify *Candida* species in a patient specimen but also determine antifungal drug susceptibility. A hybrid rapid diagnostic test (RDT) to both identify *Candida* species and detect antifungal drug susceptibility would help provide timely, appropriate treatment and reduce the spread of these resistant organisms.
RDTs, like the lateral flow assay, have revolutionized public health responses; one such success story is the Cryptococcal Antigen Lateral Flow Assay for the diagnosis of meningitis caused by the fungus *Cryptococcus neoformans*. As for *Candida* diagnosis, current methods are time-consuming or expensive. They rely on culture, DNA sequencing and/or matrix-assisted laser desorption/ionization-time of flight (MALDI-TOF) assays. Culture is considered the gold-standard, but estimated sensitivity is as low as 50% and average time of assay is one week. DNA sequencing and MALDI-TOF are much more accurate but are often not feasible for low-resource settings. Regarding drug susceptibility testing, the E-test is a promising culture-dependent tool that allows minimum inhibitory concentration (MIC) drug determination of various antifungals within two days. The ability to combine *Candida* species identification with antifungal drug susceptibility testing into a point-of-care, culture-independent diagnostic test would revolutionize the diagnosis and treatment of invasive candidiasis and provide an innovative proof-of-concept for many other infectious diseases.

**Specific Research Areas of Interest:** The specific research aim is the development of a hybrid RDT that performs both identification of *Candida* species and profiling of antifungal drug susceptibility in a simple, point-of-care manner. Ideally, the RDT would also be able to be used on colonized as well as infected individuals using body fluids and/or skin swabs. Specific examples of research goals include:

1. Develop a lateral flow assay for *Candida* species identification.
2. Determine the type and volume of specimen needed.
3. Determine which, if any, *Candida* species can be identified or differentiated at the species level. For example, an RDT that identifies both the major species, *Candida albicans*, and also other species. There would be an identification band for *C. albicans* and a separate identification band(s) for species other than *C. albicans*, such as *C. auris* and/or other *Candida* species.
4. Demonstrate test sensitivity and specificity using clinical specimens as well as artificially spiked body fluids/swabs.

**Impact and Commercialization Potential:** If the research demonstrates that a hybrid RDT that both identifies *Candida* species and profiles antifungal susceptibility is feasible, the small business concern selected for this research could file an assay-specific patent for appropriate innovative technologies. Given that invasive candidiasis caused by multidrug-resistant *Candida* species is a major problem in hospital settings throughout the world, this diagnostic would be in great demand. Moreover, this would be the first diagnostic of its kind that could both identify a pathogen and assess drug susceptibility without employing DNA sequencing and culture-based methods. As such, innovations stemming from the development of this hybrid RDT could be applied to RDT development for many other diseases where emerging pathogens and antimicrobial resistance are an overwhelming challenge.

(15) Vector Borne Diseases: Detection, Prevention, Diagnosis and Response

**Background:** Bacterial and viral vector borne diseases are transmitted to humans primarily through vectors such as an infected mosquito, tick or flea. Some of these diseases have long been present in the United States while others have recently emerged.

Vector-borne diseases are a major public health concern. Lyme disease causes over 300,000 estimated human illnesses annually in the U.S. Tick-borne rickettsial diseases, such as Rocky Mountain spotted fever, ehrlichiosis, and anaplasmosis, are responsible for over 4,000 U.S. cases each year, including some that result in death. Dengue fever causes millions of cases worldwide, including thousands of cases in Puerto Rico each year. Outbreaks of arboviral diseases such as West Nile encephalitis and Chikungunya fever have been reported in recent years. In May 2015, the Pan American Health Organization (PAHO) issued an alert regarding the first confirmed Zika virus infection in Brazil and on February 1, 2016, the World Health Organization (WHO) declared Zika virus a public health emergency of international concern. Local transmission has been reported in many other countries and territories. Less common, but often deadly threats such as Yersinia pestis causes the ancient disease plague. Local plague outbreaks occur in the southwestern U.S., and it is a significant health threat in Africa and Asia.
Specific Research Areas of Interest: The goal of this project is to encourage research that will enhance prevention, detection, diagnosis and response capabilities to vector borne diseases through funding innovative solutions that address the following:

1. Mitigate the spread and impact of vector borne diseases
2. Improve our ability to prevent, detect and respond to outbreaks of vector borne diseases
3. Develop diagnostic tests to differentiate among vector borne diseases
4. Develop vaccines effective against vector borne diseases

Examples of specific research areas of interest include, but are not limited to:

- Development of improved laboratory tests to diagnose vector borne diseases in the field or in healthcare settings (e.g., new diagnostics to detect and differentiate among vector borne diseases after infection, etc.)
- Development of tools to improve monitoring and reporting cases of vector borne disease infection and sequelae
- Development of tools to improve surveillance for vector borne diseases in the US and elsewhere (e.g., better surveillance applications, improved clinical, laboratory, and epidemiological data linkage, interchange, analysis, and visualization, etc.)
- Development of tools to improve linkage to and monitoring of services for vector borne disease-affected families
- Development of tools to improve mosquito, tick and flea control in and around individual houses and in the exterior environment

Impact and Commercialization Potential: Vector-borne diseases continue to cause morbidity and mortality in endemic areas where the threat from these diseases is recurrent. In addition, these diseases can emerge rapidly and unpredictably causing wide-spread outbreaks. Similar symptoms to other diseases can make diagnosis based on symptoms alone difficult and current diagnostic tests can cross-react among different causative agents (e.g., dengue and Zika virus infections). Effective vaccines are not available and environmental control is in need of improvement. Given the large number of individuals affected by these diseases, and the challenges to public health for their containment, improved detection through better diagnostic tests and improved prevention through vaccination would have a great impact on the health of the nation. The proposed research should lead to the development of practical solutions for the detection, prevention and diagnosis of vector-borne diseases. The products and innovations developed through this process will have significant commercial potential and will improve public health and the healthcare system’s response to vector-borne diseases.

Visit the NCEZID homepage for more information on NCEZID’s research program areas http://www.cdc.gov/ncezid

For NCEZID programmatic information, contact:

Paul Smutz PhD
Extramural Research Program Office
Office of the Associate Director for Science
National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention
Centers for Disease Control and Prevention
1600 Clifton Road, MS E60
Atlanta, GA 30329
Phone: 404-718-8830; Fax: 404-718-8822
Email: WSmutz@cdc.gov

For grants specific, administrative information, contact:

Yolanda Sledge
Office of the Director
Office of Financial Resources
NATIONAL CENTER FOR HIV/AIDS, VIRAL HEPATITIS, STD, AND TB PREVENTION (NCHHSTP)

The National Center is committed to our vision of a future free of HIV/AIDS, viral hepatitis, STDs, and TB. NCHHSTP is responsible for public health surveillance, prevention research, and programs to prevent and control HIV and AIDS, other STDs, viral hepatitis, and TB.CDC's National Center for HIV, Viral Hepatitis, STD, and TB Prevention's (NCHHSTP) Strategic Plan Through 2020 articulates a vision, guiding principle, and overarching goals and strategies through 2020 to influence and enhance our programs. The three overarching goals highlighted in this plan are to decrease:

- Incidence of infection,
- Morbidity and mortality, and
- Health disparities.

Every year, millions of Americans are infected with HIV, viral hepatitis, STDs, or TB and tens of thousands die from their infection. Most of these infections share commonalities, from modes of transmission to demographic, social, and economic conditions that increase risk. As a prevention leader, NCHHSTP focuses on high impact prevention and control efforts to reduce incidence, morbidity, mortality, and health disparities due to these infections.

Please visit their web site at: http://www.cdc.gov/nchhstp/

(16) Improved Diagnostic Tests for HIV, STDs, Hepatitis and TB

**Background:** It is estimated that just over 1.2 million people in the United States are living with HIV infection, and almost 1 in 8 (12.8%) are unaware of their infection. Because there are several treatment and prevention options for HIV, a major goal of CDC, other public health agencies and our public and private partners is to further improve the percentage of people that know their HIV status. For individuals that are at risk and uninfected, it allows them to focus on prevention. For those that are infected, there is growing evidence that the sooner a person knows they are infected and can start treatment, the better their overall health can be maintained. There is also emerging evidence that early diagnosis leads to preventing further spread of the virus due to changes in behavior by those who know their status.

Whereas there are specific benefits for HIV testing and treatment, testing and treatment for comorbid pathogens such as TB, hepatitis (B and C), gonorrhea and syphilis are also of great benefit in populations at risk for HIV. These diseases (STDs, TB and hepatitis) can all lead to worse health outcomes for HIV infected individuals. Furthermore, having diseases such as syphilis and gonorrhea can increase the chances of someone acquiring HIV. Because there is an effective vaccine for hepatitis B and effective therapy for hepatitis C, syphilis, gonorrhea and TB, improving tests and testing for these pathogens can lead to a further decrease in HIV transmission or morbidity.

Whereas there is tremendous value in testing and diagnosis for each of the described diseases, some at risk individuals are never tested or do not receive their tests results and often times are only tested for one of the diseases when testing for a combination of the diseases would be more beneficial both for the individual and for public health.
Prognostic tests (e.g. viral load, drug resistance monitoring) also play an important role in improving health outcomes for individuals infected with HIV and the ability to predict recent or long term HIV infection can be used for public health action.

**Specific Research Areas of Interest:** The major goal of the project is development of diagnostic reagents, tests or testing platforms, that will further improve diagnosis or monitoring of HIV or comorbid pathogens such as hepatitis (B and C), syphilis, gonorrhea or TB. The specific area of interest is innovative approaches or novel technology that would allow for diagnosis of HIV and other comorbid pathogens such as hepatitis (B and C), syphilis, gonorrhea and TB alone or in any combination using a single test device or platform. The preferred reagents, test format or technology would facilitate testing that allows for rapid results (preferably less than one hour), is affordable (comparable to currently available tests) and can be performed at the point of care or in a laboratory capable of performing moderately complex tests.

Consideration will also be given to innovative technology that provides prognostic (monitoring) results such as viral load (HIV, HCV, HBV), drug resistance detection (HIV, syphilis, gonorrhea, TB), or disease staging (i.e., acute/recent, longstanding or latent infection).

**Impact and Commercialization Potential:** It is known that early diagnosis and treatment of HIV infection as well as diagnosis and treatment of comorbid pathogens can improve health outcomes for individuals infected with HIV. Furthermore, such testing has the potential for decreasing transmission of HIV and better health outcomes and optimal treatment for the comorbid pathogens. Estimations show that 1.2 million people living in the United States are living with HIV infections, and out of those, 1 in 8 are unaware of their infection. Faster turnaround times, lower cost, and more efficient detection would be highly impactful for these individuals, their partners and the community. Diagnostic reagents, tests or testing platforms, that will further improve diagnosis or monitoring of HIV or comorbid pathogens such as hepatitis (B and C), syphilis, gonorrhea or TB, would be in great demand by the health-care and public health systems as well as other sectors engaged in using diagnostics to treat this patient population.

Visit the NCHHSTP homepage for more information on NCHHSTP’s research program areas [http://www.cdc.gov/nchhstp/](http://www.cdc.gov/nchhstp/)

For NCHHSTP programmatic information, contact:

Paul Smutz PhD  
Extramural Research Program Office  
Office of the Associate Director for Science  
National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention  
Centers for Disease Control and Prevention  
1600 Clifton Road, MS E60  
Atlanta, GA 30329  
Phone: 404-718-8830; Fax: 404-718-8822  
Email: WSmutz@cdc.gov

For grants specific, administrative information, contact:

Arthur Lusby  
Office of the Director  
Office of Financial Resources  
Centers for Disease Control and Prevention  
2920 Brandywine Rd, MS E15  
Atlanta, GA 30341  
Phone: 770-488-2865; Fax 770-488-2688  
Email: ALusby@cdc.gov
NATIONAL CENTER FOR IMMUNIZATION AND RESPIRATORY DISEASES (NCIRD)

The mission of the National Center for Immunization and Respiratory Diseases (NCIRD) is the prevention of disease, disability, and death through immunization and by control of respiratory and related diseases. NCIRD balances its efforts in the domestic and global arenas as well as accommodates the specific needs of all populations at risk of vaccine preventable diseases from children to older adults.

Please visit their web site at: http://www.cdc.gov/ncird/

(17) Prevention and Diagnosis of Acute Respiratory Infections in the US and Globally

**Background:** Acute respiratory infections kill an estimated 3.9 million people annually and in developing countries are the leading cause of mortality in children under 5 years of age. Specific respiratory virus infections such as influenza and respiratory syncytial virus, are major contributors to this burden of disease, as are other respiratory bacterial and viral pathogens. Respiratory virus infections are frequent events in all age groups and impose a substantial burden on social and healthcare delivery systems.

**Specific Research Areas of Interest:** The goal of this research includes, but is not limited to activities that support the development and evaluation of tools for: 1) the prevention of acute respiratory infections such as pneumonia, influenza, and Legionnaire’s disease; 2) rapid recognition and containment of outbreaks; and 3) advanced diagnostic technologies including point-of-care testing, advanced molecular detection and whole genome sequencing.

**Impact and Commercialization Potential:** This research will lead to the development of practical solutions for the prevention and diagnosis of vaccine preventable diseases that have a substantial impact on the economy, health and wellbeing of society. The goal of the research supported through this mechanism is expected to begin shifting viral and bacterial infections from common occurrences to rare events. The innovative technologies and solutions developed through this process will make it possible to improve the public health and healthcare system’s response in a variety of settings, thus making the commercialization potential unlimited.

Visit the NCIRD homepage for more information on NCIRD’s research program areas http://www.cdc.gov/ncird/

For NCIRD programmatic information, contact:

Paul Smutz, PhD
Extramural Research Program Office
Office of the Associate Director for Science
National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention
Centers for Disease Control and Prevention
1600 Clifton Road, MS E60
Atlanta, GA 30329
Phone: 404-718-8830; Fax: 404-718-8822
Email: WSmutz@cdc.gov

For grants specific, administrative information, contact:

Yolanda Sledge
Office of the Director
Office of Financial Resources
Centers for Disease Control and Prevention
2920 Brandywine Rd, MS E15
Atlanta, GA 30341
Phone: 770-488-2787; Fax 770-488-2777
NATIONAL CENTER FOR INJURY PREVENTION AND CONTROL (NCIPC)

For more than 20 years, CDC’s National Center for Injury Prevention and Control (the Injury Center) has helped protect Americans from injuries and violence. We are the nation’s leading authority on injury and violence. We study violence and injuries and research the best ways to prevent them, applying science and creating real-world solutions to keep people safe, healthy, and productive. NCIPC will prioritize funding meritorious applications that address the NCIPC program topics listed in this program announcement. NCIPC may also consider meritorious applications that address current NCIPC research priorities. To learn more about NCIPC research priorities, please visit our web site at: https://www.cdc.gov/injury/researchpriorities/index.html

Please visit their web site at: http://www.cdc.gov/injury/index.html

(18) Improving Platforms for Data Linkage in Drug Overdose Prevention

Background: Drug overdose is a leading cause of injury and death in the United States, accounting for over 52,000 deaths in 2015. Over 60% of these drug overdose deaths involved prescription or illicit opioids. Administrative data from prescription drug monitoring programs and claims data systems can be used to identify risk factors that increase the likelihood of drug overdose, including an individual's use of multiple providers and multiple pharmacies to secure opioids, and use of high dose (> 90 MME/day) opioid therapy. Electronic health records can provide a wealth of information about risk, including behavioral health history (e.g., history of depression, anxiety, or substance use disorder) and inform the development of drug overdose prevention strategies. Law enforcement data can provide valuable information on drug supply and distribution. Linking data from multiple systems can significantly strengthen prescription drug overdose prevention efforts; however, there are no platforms or algorithms available to easily link these data in the area of prescription drug overdose.

Specific Research Areas of Interest: The goal of this project is the creation of new platforms, algorithms, or software packages to allow for linkage of data in the area of drug overdose prevention. Such technologies will allow public health practitioners to link injury-related health, behavioral health, and law enforcement data to strengthen drug monitoring surveillance by public health departments. The technologies would assist in targeting community-level public health interventions that reduce injury and death from prescription drug overdose by identifying factors that place communities at risk (e.g., by identifying where and how to focus public health and law enforcement collaborations, such as healthcare provider education on prescribing practices, availability and distribution of naloxone, linkage to treatment). Proposals are sought that will link data from prescription drug monitoring programs, electronic health records, administrative claims records, emergency medical services records, and law enforcement records. Software developers must attend to privacy concerns associated with these data systems (e.g., protected health and law enforcement data). Software must be user-friendly, and accompanied by guidance for states and localities to use the platform or algorithm.

The awardee is expected to develop and pilot test a new platform, algorithm, or software package that links drug overdose-related data across sources, such as electronic health records, medical claims, emergency medical services, prescription drug monitoring programs, and law enforcement. The awardee will identify data system inputs available at the state and local level available for linkage, and identify data system structure(s) that would either facilitate or pose barriers to linkage.

Impact and Commercialization Potential: Preventing drug overdose is a priority for CDC. Linked data enhances surveillance and epidemiology, as well as strengthens support for state and local public health practitioners. Research that more clearly identifies risk factors for drug overdose could significantly inform where prevention efforts can be targeted. Without the ability to link data systems, CDC, states, and
localities have limited ability to conduct research that can improve surveillance and target prevention efforts.

Development of platforms, algorithms, or software packages that allow for data linkage has technological viability. In the area of motor vehicle injury prevention preliminary linking technologies have been developed; however, there have been significant limitations associated with cost, usability, and compatibility with existing systems that require improvements for utility. Such platforms, algorithms, and software packages could be further developed and improved with a focus on utility for drug overdose work. In future development, there could be application expansion to other data systems that could enhance utility for addressing other injury prevention topics, such as motor vehicle injury, traumatic brain injury, older adult falls, and violence. The technology would have large market size and visibility, with interest from federal public health agencies, state and local health departments, law enforcement agencies, behavioral health agencies, academic researchers, and other stakeholders invested in preventing morbidity and mortality from drug overdose and other injury outcomes. Any new development of platforms, algorithms, or software packages would have a competitive advantage over existing technologies on the market.

(19) Innovations to Reduce Motor Vehicle-Related Deaths and Injuries

**Background:** Motor vehicle crashes account for half of all unintentional injury deaths, are the leading cause of death for people ages 5 - 34 in the United States, and result in nearly 5 million serious injuries. The cost of medical care and productivity losses associated with motor vehicle-related injuries in the United States can exceed $99 billion annually. Globally, motor vehicle crashes kill 3,000 persons daily. In the U.S., the risk of motor vehicle crashes is highest among teen drivers ages 16 - 19. Alcohol consumption is a contributing factor in ~ 30% of motor vehicle crash fatalities and one in four alcohol-impaired drivers in these crashes have had their driver licenses suspended or revoked in the previous three years. In 63% of fatal crashes in the U.S., the occupant killed was not wearing a seat belt. Excessive speed has been identified as a key risk factor in motor vehicle injuries, increasing the risk of a crash and the severity of the injuries that result.

Motor vehicle crashes can result from a single or combination of environmental, human behavioral, and vehicle-related risk factors including hazardous road conditions and environment, driver perception deficits, non-compliance with vehicle safety devices, substance-induced driver impairment, and sub-optimal vehicle performance. Reducing each of these risk factors can substantially lower the likelihood of a crash and increase the chance of survival and recovery in the event of a crash. Reducing any single risk factor can influence other risk factors resulting in lower motor vehicle crash incidence and severity.

Adaptive technologies can generate feedback loops about the road and environment, driver fitness, and vehicle performance, and applications of these adaptive technologies in both private and commercial vehicles can reduce risks associated with motor vehicle crashes. Currently, there are a limited number of adaptive technologies to warn drivers of potential dangers associated with driving; most of these technologies focus on vehicle related performance (e.g. collision warning, autobrake, lane departure warning, adaptive headlights, etc.). Innovative adaptive technologies that can assist in alerting drivers to risks associated with the road or environment and vehicle performance, and that can facilitate drivers to modify personal risk behavior, including alcohol-impaired or fatigue-related driving, are sought. These adaptive technologies can result in the development of tools or systems that will reduce the likelihood and severity of motor vehicle crashes, and assist drivers in making potentially life-saving decisions more quickly and more intuitively.

**Specific Research Areas of Interest:** The goal of this project is the development of improved adaptive technologies that have the potential to further reduce motor vehicle crashes and resulting injuries. These technologies will address risks including driver distraction and impaired driving, non-compliance with use of vehicle safety equipment, environmental conditions (including road quality), and vehicle performance. Projects might include the development of real-time adaptive technologies including distraction and...
vehicle performance warning systems, sensors that detect alcohol or other drugs, and sensors that detect unsafe driving motions, activities, and environmental conditions. Adaptive technologies that can be applied in both occupational and private vehicle use in domestic rural settings are of high interest, along with adaptive technologies that can be applied to assist persons with cognitive or psychomotor limitations (e.g., persons who become distracted while driving, drowsy driving and fatigue, alcohol impaired or drug impaired driving, age-related changes, and physical and/or mental disabilities). Innovations that would be suitable for overseas applications in low and middle-income countries are highly desirable.

**Impact and Commercialization Potential:** Development of technology systems to reduce the risk of motor vehicle crashes have significant commercial viability. These adaptive technologies will have the potential to have high visibility and reach a large market share. There will likely be significant interest from automobile/commercial vehicle industry who historically develop and implement new technologies that reduce the potential for motor vehicle crashes.

(20) Innovative Technology or Media to Prevent Violence

**Background:** Violence is a significant public health problem in the United States. In 2015, more than 62,000 people in the United States died as a result of violence and more than 2.1 million people were treated in emergency departments for a violence-related injury. In 2014, nearly 16,000 people died from homicide and nearly 43,000 died from suicide. Far more people experienced nonfatal violence. For example, over 1.6 million people were treated for nonfatal injuries from assaults and nearly 500,000 people were treated for self-harm injuries in U.S. emergency departments in 2013. In 2014, there were 3.6 million referrals to child protective services for child abuse and neglect. The different forms of violence, including child abuse and neglect, youth violence, intimate partner violence, sexual violence, and self-directed violence, often share common risk and protective factors. These factors can start in early childhood and continue throughout the lifespan. They go beyond individual-level factors to include family and peer relationships and other influences from schools, the community, and society. Prevention strategies are often delivered with families or in school classrooms. Many effective violence prevention strategies have been developed, and broader benefits could be achieved from wider dissemination through innovative media and communication technology (e.g., mobile applications, social media, games, Internet-based interventions). Media and communication technology also create the opportunity for the development of new prevention approaches based on what is known about violence risk and protective factors and strategies that work in traditional settings.

A goal of CDC’s research is to maximize the impact of violence prevention activities by taking fuller advantage of the interconnections across the different forms of violence. By focusing on activities that prevent multiple forms of violence, communities can achieve the greatest impact and increase scalability of their prevention strategies. Additionally, prevention efforts are ideally designed to use resources more effectively and to better address disparities by focusing on the populations at greatest risk. Innovative media and communication technology can play an important role in effectively reaching populations at greatest risk for multiple forms of violence. Research is needed to guide the development of technological applications for prevention strategies that can effectively protect those who are most at risk for experiencing multiple forms of violence as a victim and/or perpetrator.

**Specific Research Areas of Interest:** The goals of this project include developing innovative technology or media, such as applications for mobile devices, social media, games, or Internet-based interventions to prevent violence. Specific prevention strategies could be designed to work across multiple forms of violence. For example, a project could develop innovative media or communication technology to enhance young people’s skills and relationships to reduce risk for multiple forms of violence, such as youth violence, teen dating violence, and suicide. A project could also use social media strategies to increase the accessibility of evidence-based prevention strategies or to modify attitudes and norms about violence and help-seeking behavior. Other projects might be more relevant to a specific form of violence. For example, there is potential for innovative prevention strategies, such as the creative use of social media or technology, to help those at greatest risk for suicide by reducing stigma and other barriers to accessing services. Another example of a focused project could be the development of social media...
approaches and other technologies, such as applications for mobile devices and text support services, to prevent sexual violence in specific settings. The widespread use of smartphone applications, social media, and wearable technology provides unique opportunities for novel approaches and broad dissemination of prevention strategies to significantly reduce violence.

The prototype (e.g., developing innovative technology or media) should be informed by prior research about violence risk and protective factors and/or evidence-based prevention strategies and through consultation with subject matter experts in the form(s) of violence and the technology or media selected. The awardee should describe the target audience, the type(s) of violence addressed, the process through which the technology or media is expected to work, goals for the product, the functionality and actions for users to take, the measurements and key performance indicators for tracking progress toward the goals, the estimated costs and logistics of scalability, a description of potential barriers to implementation, and any evidence for the potential benefits from prior research.

For resources on evidence-based approaches please see Prevention Strategies pages for specific types of violence at http://www.cdc.gov/violenceprevention/index.html.

**Impact and Commercialization Potential**: Technological or media innovations that show effectiveness in preventing violence could have a range of commercial potential. Depending on the nature of the strategy, the target audience, and the costs/logistics of scalability, the product could be in demand by school systems, colleges and universities, youth serving organizations, law enforcement, public health agencies, community groups, parents, and their children.

**(21) Technological Tools for Monitoring Children’s Symptoms after Traumatic Brain Injury**

**Background**: As a result of Traumatic Brain Injury (TBI), children can experience changes in their health, thinking, and behavior that affect learning, self-regulation, and social participation. TBI of any severity experienced by a child can result in changes that affect a child’s daily life. Symptoms of mild TBI (mTBI) are typically headaches, dizziness, and problems with thinking/memory, physical activities, emotions and moods, and sleep. Longitudinal studies suggest that most children with mTBI recover from the initial symptoms within 1–6 weeks after injury, with approximately 60% having persistent symptoms at one month post injury, 10% at three months post injury, and less than 5% at one year post-injury. Although most children recover well physically, they often experience changes in behavior and cognition that are not immediately obvious. Relatively little is known about what factors lead to prolonged post-concussive symptoms in children. This lack of prognostic data has led to significant uncertainty among patients, families, caregivers and health care providers as to which patients would benefit from specialist follow-up, extended academic accommodations, prolonged abstinence from athletic participation, and even permanent cessation of high-risk activity. Parents or primary caregivers who are with children on a daily basis have been shown to be reliable in reporting behaviors when structured systems are devised for their responses.

**Specific Research Areas of Interest**: The goal of this project is the development of innovative assistive technology (e.g., smart-device apps) that can facilitate parental or primary caregiver reporting of children’s symptoms after the diagnosis of TBI to healthcare providers. Funds are available to support the development of a technological tool that will assist parents or primary caregivers to more easily monitor and record symptoms during “return-to-activity” (i.e. school, recreation, social interaction, driving) after a TBI. This technology must use well-validated symptom inventories and provide an easy-to-use interface that can be integrated into devices used routinely by parents or caregivers (e.g., smartphones). It is important to include functionality that allows for the ability to easily convey this information to others involved with the management of TBI, including physicians, teachers, school nurses, athletic trainers, and coaches. In addition, the technological tool should prompt parents or primary caregivers to regularly record the child’s symptoms and provide guidance on seeking a physician for medical follow-up and seeking increased support services from a school or athletic institution.
**Impact and Commercialization Potential:** The availability of a technological tool to assist parents and primary caregivers in recording and reporting children’s symptoms after a TBI can better ensure that needed follow-up care, referrals, services, and accommodations are received. By improving the management of TBI and post-concussive care in children, the expected public health benefit is reduced recovery time and reduced negative behavioral and cognitive impacts following a TBI.

Development of a technological tool that allows for reporting and monitoring of children's injury symptoms over time as they return to activities has commercial viability. Commercial applications of this technology may be of interest to parents and primary caregivers, healthcare providers, educational staff, athletic and training staff, state and local health departments, academic researchers, and other stakeholders invested in preventing morbidity from traumatic brain injury in children.

Visit the NCIPC homepage for more information on NCIPC’s research program areas [http://www.cdc.gov/injury/index.html](http://www.cdc.gov/injury/index.html)

For NCIPC programmatic information, contact:

Marcienne Wright, PhD, LT USPHS  
Office of the Director  
National Center for Injury Prevention and Control  
Centers for Disease Control and Prevention  
4770 Buford Hwy, MS F-63  
Atlanta, GA 30341  
Phone: 770-488-4850; Fax: 770-488-3560  
Email: MWright3@cdc.gov

For grants specific, administrative information, contact:

Barbara R. Benyard Office of the Director Office of Financial Resources  
Centers for Disease Control and Prevention  
2960 Brandywine Rd, MS E -14  
Atlanta, GA 30341  
Phone: 770-488-2757; Fax: 770-488-2868  
Email: BBenyard@cdc.gov

**NATIONAL INSTITUTE FOR OCCUPATIONAL SAFETY AND HEALTH (NIOSH)**

The National Institute for Occupational Safety and Health (NIOSH) is part of the U.S. Centers for Disease Control and Prevention. It has the mandate to assure “every man and woman in the Nation safe and healthful working conditions and to preserve our human resources.” NIOSH has more than 1,300 employees from a diverse set of fields including epidemiology, medicine, nursing, industrial hygiene, safety, psychology, chemistry, statistics, economics, and many branches of engineering. NIOSH works closely with the Occupational Safety and Health Administration (OSHA) and the Mine Safety and Health Administration in the U.S. Department of Labor to protect American workers.

For additional information about NIOSH, please visit their web site at: [http://www.cdc.gov/niosh/programs](http://www.cdc.gov/niosh/programs).

**Control Technology and Personal Protective Equipment for High Risk Occupations**

**Background:** Personal protective equipment (PPE) protects workers from death and disabling injuries and illnesses as well as from the specific threats of exposures to certain airborne biological particles, chemical agents, nanomaterials, splashes, noise exposures, fall hazards, head hazards, and fires. It is estimated that 20 million workers use PPE on a regular basis to protect them from job hazards and a total
of 135,000 workers potentially could benefit from the use of PPE (Worker Health Chartbook 2004). Engineering controls include substitution of a safe material for a hazardous one, design changes to equipment, or modification of work methods to eliminate or reduce hazards. Research is needed to develop and evaluate control strategies and personal protective equipment for specific hazards and to assure their practicality and usability in workplaces in all of the high risk industrial sectors.

For additional information about NIOSH PPE and Engineering control programs, please visit their web site at:  http://www.cdc.gov/niosh/programs/ppt/ and http://www.cdc.gov/niosh/programs/eng/.

Examples of specific research areas of interest include, but are not limited to:

- Conduct research on the ability of existing containment and control strategies to prevent releases and potential human exposures to engineered nanomaterials.

- Conduct research to evaluate the effectiveness of personal protective equipment in protecting workers against exposure to engineered nanomaterials. Provide data to fill knowledge gaps and support guidance for the selection and use of gloves and protective garments to prevent exposures. Respiratory protection research needs to be extended to a broad range of engineered nanomaterials.

- Develop a heads-up display coupled with a personal noise exposure monitoring system. Personal noise alert “badges” and personal noise dosimeters exist, but do not have an effective way to alert the user immediately when a noise hazard occurs. A system that displays a warning within the user’s visual field (via lights on protective eyewear, hardhat, etc.) would facilitate hazard recognition.

- Develop an inexpensive hand-held earplug test device based on the NIOSH QuickFit concept. Studies of hearing protector users have shown repeatedly that average protection values are much lower than the labeled Noise Reduction Ratings (NRR) determined in laboratories. A QuickFit test system would help workers determine if their hearing protection is giving them at least 15 decibels of attenuation.

- Develop innovative engineering control approaches and technologies for reducing asphalt exposures in roofing, and skin exposures and disease in construction workers.

- Conduct research to understand PPE integration and interoperability issues. In most cases, individual PPE are currently used without consideration for their ability to function together. Research is needed to test interfaces among different PPE and components. Current interfaces do not provide seamless integration of PPE components resulting in reduced comfort, fit, usability, and protection for the wearer as well as logistical challenges for safety managers and employers.

- Develop innovative educational and professional training materials suitable for today’s diverse workplace on the role of PPE in occupational safety and health. This is especially critical for high risk occupations. Innovative methodologies, including social media, should be explored and evaluated to demonstrate their effectiveness at improving workplace safety and health. For example, to what extent can mobile application media be focused on worker safety and health to provide up-to-date PPE information to a diverse range of employers and employees through portable communication devices?

Impact and Commercialization Potential: The impact of the proposed research will prevent work-related injury, illness, and death by advancing the state of knowledge and application of personal protective equipment. Potential products include technical methods, processes, techniques, tools, and materials that support the development and use of personal protective equipment worn by individuals to reduce the effects of their exposure to a hazard.
(23) Exposure Assessment Methods for High Risk Occupations

**Background:** Exposure assessment provides multi-disciplinary strategies and methods to anticipate, recognize, evaluate, control, and confirm effective management of occupational health stressors, exposures to those stressors, and resulting health risks. Major gaps in current approaches include: (1) the lack of practical methods for hazard identification and measurement that can be applied at reasonable cost in many workplaces where health stressors may exist, (2) the lack of validated, noninvasive biological methods for monitoring relevant exposure and resulting dose, and (3) the lack of strategies and methods for epidemiologic studies to demonstrate either a dose-response effect or a conclusion of no association between the agent and disease in the complex environments of today's workplaces.

For additional information about NIOSH Exposure Assessment programs, please visit their web site at: [http://www.cdc.gov/niosh/programs/expa/](http://www.cdc.gov/niosh/programs/expa/).

**Examples of specific research areas of interest include, but are not limited to:**

- Two areas of research are needed to support effective assessment of worker exposure to engineered nanomaterials. 1) Real-time sensors capable of reliably detecting nanoparticles and providing information on size distribution and count, that can be used for personal monitoring; and 2) Development of methods that can detect and quantify the presence of engineered nanomaterials in samples collected for the purpose of characterizing exposures. These methods need to be cost-effective and available to the OS&H practitioner community. Broader application to general public health assessments should be factored into the research.

- Develop new or improved methods to measure occupational health stressors such as psychological and ergonomic factors, noise, chemicals, particles and fibers, physical agents, non-ionizing radiation, or mixtures of stressors in the work environment. Enhanced measurement performance and functionality can include sensitivity, selectivity, size and weight considerations, ease of use, and capabilities to measure multiple analyses simultaneously.

- Develop or adapt easy-to-use, direct-reading instruments and test kits to rapidly and inexpensively measure exposures in a variety of workplaces. Critical applications include routine monitoring, evaluating the success of control technologies, and supporting epidemiological studies. For example, developing a sound level meter to monitor worker noise exposure that can be used in underground coal mines.

- Improve the measurement of low concentrations of chemicals and biomarkers in biological specimens such as blood, urine, saliva and sweat so that such concentrations can be linked to internal dose at the target organs, work tasks and workers can be categorized according to hazard bands and exposure bands, and at-risk workers can be identified and protected.

- Develop a computerized system that can be used to predict worker noise exposure from mining machine noise emissions. The system would include an acoustic model of mining environments and algorithms to characterize exposure based on noise source characteristics. The main application for this technology would be for mining machine manufacturers to evaluate the potential effects of noise controls during the design process. If the impact of design changes on exposure reduction can be accurately predicted without the need for extensive field measurements, innovative noise controls can reach implementation much more quickly.

**Impact and Commercialization Potential:** This research will lead to the development of practical solutions and prevention activities to address complex problems that cause occupational diseases, injuries, and fatalities and that will lead to reductions in occupational injuries and illnesses among all workers. This research will lead to the development and translation of exposure assessment methods and research findings into prevention practices and products that will be adopted in occupational settings.
Potential products include technical methods, processes, techniques, tools, and materials that support the assessment of exposure to physical, chemical and biological hazards in the work environment.

(24) Work-related Injuries from Motor Vehicle Crashes

**Background:** The risk of injury associated with on-the-job operation of motor vehicles affects millions of U.S. workers. Motor vehicle-related incidents are consistently the leading cause of work-related fatalities in the United States. Of over 43,000 work-related fatalities reported by the Bureau of Labor Statistics between 2003 and 2010, 15,396 (36%) were associated with motor vehicles. The public health toll for 2003-2010 included:

- 10,202 deaths in single- or multiple-vehicle crashes on public roadways
- 2,487 deaths in crashes that occurred off the highway or on industrial premises
- 2,707 pedestrian worker deaths as a result of being struck by a motor vehicle

Over the same period, workers incurred nearly 400,000 lost-workday injuries due to these incidents. Crash-related fatalities and serious injuries have a devastating impact on workers and their families, and on the economic health and productivity of American businesses. In some instances, e.g., the operation of heavy trucks, work vehicles also have an impact of the safety of the motoring public.

The virtual NIOSH Center for Motor Vehicle Safety coordinates the CDC/NIOSH response to this pressing worker safety issue. Many NIOSH programs include motor vehicle crashes among their top injury prevention priorities: Traumatic Injury; Transportation, Warehousing, and Utilities; Wholesale and Retail Trade; Oil and Gas Extraction; Public Safety; and Global Collaborations.

**Examples of specific research areas of interest include, but are not limited to:**

The highest priority is to develop, implement, and evaluate interventions in an effort to build the scientific evidence base to guide prevention of work-related motor vehicle crashes and resulting injuries. This may be achieved by developing new design concepts and standards for use by national standard-setting organizations in updating or developing design standards for specialized work vehicles, enhancing effective interventions for driver training and assessment to reduce work-related motor vehicle crashes, evaluating the effectiveness of technology- or management-based intervention strategies to reduce the incidence or severity of work-related motor vehicle crashes, and enhancing engineering controls for preventing work-related crashes and injuries.

**Impact and Commercialization Potential:** Application of evidence-based interventions is expected to have a large impact on reducing the incidence and severity of work-related motor vehicle crashes. This will yield substantial public health benefits, and will positively affect workers’ compensation and health insurance premiums and costs. CDC/NIOSH has well-established working relationships with employers, their trade associations, and standards-setting organizations, and is therefore strongly positioned to communicate findings and guidance to potential users. CDC/NIOSH also has strong infrastructure to facilitate the transfer of technology-based interventions to the marketplace. Given the extremely short induction period between exposure and injury occurrence, CDC can make a measurable difference in a very short period of time (< 4 years).

Visit the NIOSH homepage for more information on NIOSH's research program areas [http://www.cdc.gov/niosh/homepage.html](http://www.cdc.gov/niosh/homepage.html).

For NIOSH programmatic information, contact:

Steve Dearwent, Ph.D., M.P.H.
Centers for Disease Control and Prevention
National Institute for Occupational Safety and Health
Mail Stop E-74
1600 Clifton Road, N.E.
Atlanta, Georgia 30333
Phone: 404-498-6382, Fax: 404-498-0751
Email: SDearwent@cdc.gov

For grants specific, administrative information, contact:

Ms. Mary Pat Shanahan
Centers for Disease Control and Prevention
Procurement and Grants Office, Field Branch V
PO Box 18070
626 Cochrans Mill Road
Pittsburgh, PA 15236-0070
Phone: 412-386-4453, Fax: 412-386-6429
Email: MShanahan@cdc.gov
FOOD AND DRUG ADMINISTRATION (FDA)

FDA will accept SBIR grant applications on April 5, 2018; the September 5, 2018; January 7, 2019; and April 5, 2019 submission dates.

The FDA is responsible for protecting the public health by assuring the safety, efficacy, and security of human and veterinary drugs, biological products, medical devices, our nation’s food supply, cosmetics, and products that emit radiation. The FDA is also responsible for advancing the public health by helping to speed innovations that make medicines and foods more effective, safer, and more affordable; and helping the public get accurate, science-based information they need to use medicines and foods to improve their health.

For additional information about areas of interest to the FDA, please visit our home page at http://www.fda.gov.

Research Topics of Interest to FDA

The specific set of topics that are funded by a particular IC/Office/Agency depends on whether the IC/Office/Agency funds/supports Clinical Trials under SBIR/STTR Awards. Use the following table and explanations to determine which list of topics is applicable.

<table>
<thead>
<tr>
<th>Does IC/Office/Agency Fund/Support Clinical Trials under SBIR/STTR Awards?</th>
<th>No*</th>
<th>Yes**</th>
</tr>
</thead>
</table>

*If No,
- This IC/Office/Agency funds only those topics listed under the Non-Clinical Trials Topics section below, UNLESS the IC/Office/Agency funds a Small Business Concern for clinical trials under a NON-SBIR/STTR award.

**If Yes or the IC/Office/Agency funds small businesses for clinical trials under a NON-SBIR/STTR funding opportunity,
- See the table below for which mechanisms the IC/Office/Agency will allow for clinical trials research. Also, see the Clinical Trials Topics section below for a list of funded topics. This IC/Office/Agency also funds research listed under the Non-Clinical Trials Topics section below.

<table>
<thead>
<tr>
<th>Does IC/Office/Agency accept clinical trials applications under this mechanism?</th>
<th>Yes</th>
<th>No</th>
<th>Other Information: If funding an SBC for clinical trials under a NON-SBIR/STTR award, please identify activity code(s) and other relevant information.</th>
</tr>
</thead>
<tbody>
<tr>
<td>Clinical Trials SBIR/STTR Omnibus/Parent Funding Opportunity Announcement/s</td>
<td>X</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
FDA will not accept SBIR applications that propose clinical trials, and all of the topics listed below must be for projects that do not propose clinical trials.

**FDA Non-Clinical Trials Topics:**

**CENTER FOR BIOLOGICS EVALUATION AND RESEARCH (CBER)**

CBER is responsible for ensuring the safety, efficacy, potency and purity of biological and related products intended for use in the treatment, prevention or cure of diseases in humans as well as the safety of the nation's supply of blood and blood products. The primary responsibility of CBER is to review the quality, safety and efficacy of vaccines, blood products, certain diagnostic products and other biological and biotechnology-derived human products.

CBER's activities include: evaluating the quality, safety and effectiveness of biological products before marketing, and monitoring the pre-clinical and clinical testing of new biological products; licensing biological products and manufacturing establishments, including plasmapheresis centers, blood banks, vaccine and biotechnology manufacturers; AIDS program and policy activities, including research on AIDS therapeutic products, diagnostic tests and vaccines; research to establish product standards, develop improved testing methods and assess the safety of biological products; compliance, lot release program and post market surveillance; meeting PDUFA goals, new research programs, and new regulatory initiatives (managed review process for all products).

**CENTER FOR DRUG EVALUATION AND RESEARCH (CDER)**

CDER develops FDA policy with regard to the safety, effectiveness, and labeling of all drugs for human use; evaluates new drug applications and investigational new drug applications; develops standards for the safety and effectiveness of all over-the-counter drugs; monitors the quality of marketed drugs through product testing (bioavailability/bioequivalence testing), post marketing surveillance, and compliance programs; develops guidelines on good manufacturing practices; conducts research and develops scientific standards on composition, quality, safety, and efficacy of human drugs.
Drug regulatory research as conducted in CDER is directed at the discovery of new knowledge relevant to drug development, post marketing drug experience (patterns of drug use and safety), and drug regulation to enhance FDA regulatory decisions. These drug regulatory decisions impact on the development of regulations, guidelines and guidance for the regulated industry and provide clarity and consistency in application of CDER regulatory requirements. These drug regulatory decisions also impact public health by ensuring that marketing drugs are safe and efficacious and that their risk: benefit profile remains acceptable during the market life of a drug. Specific areas of research conducted by the Center include: Pharmacology/toxicology, microbiology/virology, clinical pharmacology, pediatric issues in drug therapy, post marketing drug safety, evaluation of effectiveness of regulatory actions, patterns of drug use, including off-label, signal detection methodologies (e.g., data mining techniques), epidemiologic studies of therapeutics using population-based data, regulatory compliance, product quality, and active surveillance methods.

Research and development opportunities within the FDA that lend themselves to performance by small businesses include, but are not limited to, the following:

A. Develop a system for gathering real-time data on physician prescribing behavior, understanding and compliance with drug product labeling and frequency of off-label prescribing.

B. Develop and evaluate the effectiveness of new methods and tools for managing the known risks of marketed drug products (e.g., communicating newly identified risks to health care practitioners and patients).

C. Develop methods for timely active surveillance of newly approved drug products in large populations to identify both expected and unexpected outcomes.

D. Develop methods for actively collecting information on all cases of classically drug-associated events (e.g., acute liver failure, blood dyscrasias, severe desquamating skin disorders) to augment the FDA’s current passive surveillance system.

E. Develop improved clinical markers and methods with potential for bed-side application for detection of the early onset of adverse drug events.

F. Develop surrogate potency methods for biotech drug products to replace traditional animal testing.

G. Development of psychochemical and in-vitro biological tests to evaluate pharmaceutical equivalence of complex drug substances and drug products.

H. Research into approaches to handle informative missing patient data in clinical trials, including innovations in study designs and statistical methods of analysis.

I. Statistical and computational methods and strategies for the design, analysis and interpretation of microarray, genomic and proteonomic data.

**CENTER FOR FOOD SAFETY AND APPLIED NUTRITION (CFSAN)**

The FDA is responsible for the safety of the vast range of food Americans eat; about 80 percent of all food sold in the United States. This includes everything except for the meat, poultry, and processed egg products that are regulated by the USDA. Consequently, CFSAN seeks research designed to complement and accelerate efforts aimed at the detection, prevention, and control of contamination that may be responsible for illness or injury conveyed by foods, colors, and cosmetics. CFSAN conducts research, and develops regulations, guidance and standards related to the composition, quality, nutrition, and safety of food, food additives, colors, and cosmetics. The Center evaluates FDA’s surveillance and compliance programs relating to foods, colors, and cosmetics; reviews industry petitions, and develops regulations for food standards to permit the safe use of color and food additives.
CFSAN maintains an active research program that is focused on the following priorities; ensuring the safety of food, dietary supplements and cosmetics; improving nutrition; and promoting the security and integrity of the food supply. The Center’s research activities are intended to; support the FDA’s regulatory activities; reduce the incidence of foodborne illness by improving our ability to detect and quantify foodborne pathogens, toxins, and chemicals that could jeopardize the safety and security of the food supply; find new and improved ways to control these agents; and safely produce, process, and handle food and food products. FDA is committed to reducing the incidence of foodborne illness to the greatest extent feasible while at the same time protecting the nation’s food supply. Mission-critical knowledge gaps are addressed through translation research focused on the risks associated with FDA regulated products throughout their life cycles, from production to consumption. Ideally extramural research is sought that complements the Center’s intramural research efforts, and which will enhance the Agency’s and the Nation’s ability to reduce the incidence of foodborne illness and protect the integrity of the nation’s food supply. FDA’s mission-critical needs require that the research not simply end with the generation of new knowledge and technologies, but extend to the validation of new approaches by using realistic conditions that accurately reflect the diversity of the food industry and offer potential solutions that can be accept by appropriate sectors of the food industry.

**CENTER FOR DEVICES AND RADIOLOGICAL HEALTH (CDRH)**

CDRH develops FDA policy and solves problems related to public health and safety of medical devices and radiation-emitting electronic products. It evaluates applications for premarket approval of medical devices, approves products development protocols and exemption requests for investigational devices. It classifies devices into regulatory categories, develops safety effectiveness standards and good manufacturing practices regulations, operates post market surveillance and compliance programs, and provides technical, non-financial assistance to small manufacturers. The Center also conducts programs to reduce human exposure to hazardous ionizing and nonionizing radiation, through an electronic product radiation control program and other programs designed to control and limit radiation exposure. The Center develops and conducts research and testing programs in the areas of physical, life, and engineering sciences related to the human health effects of radiation and medical device technologies, provides expertise and analyses for health-risk assessments, and also develops new or improved measurement methods, techniques, instruments and analytical procedures for evaluating product performance and reliability.

Research and development opportunities within the FDA that lend themselves to performance by small businesses include, but are not limited to, the following:

A. Examine the setup, documentation and optimization of our Sun Grid Engine (SGE). The architecture of this networking application is particularly suited to managing surge capacity in high performance computing. The modeling of many physiologic functions and bioinformatic analyses can take months or even years to run on a standard desktop computer. The SGE takes the overall problem and distributes it to a cloud of computers on a network so that no user knows, or cares, if a computation is performing in the background on their machine. As FDA rolls out laptops with multi-core CPU's and which are equipped with prodigious amounts memory this experiment in "cloud computing" could become a reality on the Whiteoak Campus. The scope of work would be to develop, document, and provide training systems for developers, network architects, and users on working methodologies for the integration of cloud computing with the existing FISMA compliant conventional networking.

B. Develop a high-speed, low light spectral CMOS linear imaging system to measure complete spectra of multiple variables from living tissue. Complete spectra of fluorescence signals (including auto-fluorescence and FRET) could be measured along a line at high speeds (10 kHz) with a rectangular CMOS grid (e.g. 10 x 1,000 pixels -> 10 sites 1000 wavelengths).
C. Develop bioassays/biosensors to identify injurious levels of nerve stimulation utilizing bioluminescence and neurotransmitter detection technologies. Research capabilities needed include voltage clamp, current clamp and extracellular techniques in peripheral nerves and brain slices to explore stimulation protocols that release neuroactive substances released in injury and inflammation which are not normally evoked under normal physiological conditions.

D. Design, build, and validate a phantom that is traceable to a national metrology institute (NMI) such as NIST (or any other NMI) to improve the accuracy and clinical utility of bone mineral density measurements made using dual energy X-ray absorptiometry (DXA). The calibration phantom should be constructed using biosurrogate materials with known/tabulated data for body tissue and tissue substitutes.

**CENTER FOR VETERINARY MEDICINE (CVM)**

CVM is a public health organization that enables the marketing of effective drugs, food additives, feed ingredients, and animal devices that are safe to animals, humans, and the environment. The Center, in partnership with Federal and state agencies and other customers, ensures animal health and the safety of food derived from animals. The Center makes timely, quality decisions and takes regulatory actions to ensure that these products provide for quality health care of animals, minimize the transmission of zoonotic diseases, and increase the efficiency of production of animal-derived food and fiber. Regulatory decisions are supported by research, the monitoring of product safety, and efficacy, and the continual improvement of processes.

Research and development opportunities within the Center for Veterinary Medicine that lend themselves to performance by small businesses include, but are not limited to, the following areas of interest:

A. Development, for the specific purpose of obtaining approval or conditional approval, of products for the treatment, control or prevention of diseases or conditions occurring in minor species or small numbers of major species.

B. Development and validation of high throughput/screening quantitative and qualitative analytical methods for analyzing drugs, additives, and contaminants in animal tissues and feeds.

C. Development of methods to determine absorption, distribution, metabolism, and excretion of drugs, feed additives and contaminants (microbial and chemical) in food animals, including minor species.

D. Development of new biomarkers and models for determining the safety and effectiveness of veterinary drugs and food additives in domestic animals, including minor species.

E. Development of methods to determine the effects of drugs, food additives, and contaminants (microbial and chemical) on immunological and physiological functions of domestic animals, including minor species.

**OFFICE OF CRITICAL PATH PROGRAMS**

The Office of Critical Path Programs, in FDA’s Office of the Chief Scientist, coordinates the cross-agency Critical Path Initiative (CPI), FDA's strategy for transforming the way medical products are developed, evaluated, and manufactured. CPI activities are under way throughout the Agency, from the product centers to the Office of the Commissioner. For details, see [http://www.fda.gov/ScienceResearch/SpecialTopics/CriticalPathInitiative/default.htm](http://www.fda.gov/ScienceResearch/SpecialTopics/CriticalPathInitiative/default.htm). Collaboration is key to the CPI initiative because bringing safe, effective, and innovative therapies to the American public requires FDA to leverage the resources and expertise of all stakeholders, including other Federal agencies, academia, healthcare professionals, patient and consumer groups, regulated industry, and health-related organizations. In 2008, CPI collaborations involved 84 government agencies, universities,
industry leaders, and patient groups from 28 states and 5 countries on a raft of groundbreaking research projects.

Research and development opportunities within FDA that lend themselves to performance by grantees include, but are not limited to, the following:

A. Studying the immunological correlates of TB immunity and developing tools to evaluate TB vaccine efficacy.
B. Developing study models for testing combination-antimicrobials as a strategy to prevent the development of drug resistance.
C. Developing new approaches to preclinical safety testing.
D. Identifying biomarkers for safety and efficacy evaluation of medical products.

OFFICE OF ORPHAN PRODUCTS DEVELOPMENT

The Office of Orphan Products Development was established to identify and facilitate the development of orphan products. Orphan products are drugs, biologics, medical devices and foods for medical purposes, which are indicated for a rare disease or condition (i.e., one affecting fewer than 200,000 people in the United States). These products may be useful in a rare disease/disorder but lack commercial sponsorship because they are not considered commercially attractive for marketing. A subcategory of orphan products are those marketed products in which there is evidence suggesting usefulness in a rare disease/disorder but which are not labeled for that disease/disorder because substantial evidence of safety and effectiveness for that use is lacking.

Research and development opportunities within the FDA that lend themselves to performance by small businesses include, but are not limited to, the following:

A. Development of products for the treatment of rare diseases or disorders including but not limited to neurological, metabolic, genetic, ophthalmologic, hematologic, and dermatological diseases or disorders for the specific purpose of obtaining marketing licensure.
B. Development of products for use in diagnosis of rare diseases for which the diagnostic tool would be used in fewer than 200,000 persons annually in the United States.
C. Development of vaccines for the prevention of rare diseases to be used in fewer than 200,000 persons annually in the United States.

For additional information on research topics and administrative and business information, contact:

Kiara Fowler
Grants Management Specialist
Grants and Assistance Agreements Team
240-402-3099, Fax: 301-827-0505
Email: Kiara.Fowler@fda.hhs.gov

Food and Drug Administration
Division of Acquisition Support and Grants
5630 Fishers Lane - HFA 500
Rockville, MD 20857
APPENDIX A: NATIONAL INSTITUTES OF HEALTH SBA-APPROVED SBIR/STTR TOPICS FOR AWARDS OVER STATUTORY BUDGET LIMITATIONS

National Institutes of Health SBA-Approved SBIR/STTR Topics for Awards over Statutory Budget Limitations

1/1/2018

NIH has received approval from SBA for the topics listed within for budgets greater than $225,000 for Phase I SBIR/STTR awards and greater than $1,500,000 for Phase II SBIR/STTR awards for 2018-2019. Applicants are strongly encouraged to contact NIH program officials prior to submitting any award budget in excess of these amounts. Applicants are also required to follow NIH Institute- and Center-specific budget guidance found in all SBIR and STTR funding opportunity announcements.
Table of Contents

National Cancer Institute (NCI) ......................................................................................... 244
National Center For Advancing Translational Sciences (NCATS) .................................. 245
National Center for Complementary and Integrative Health (NCCIH) ............................ 246
National Eye Institute (NEI) .............................................................................................. 247
National Heart, Lung, and Blood Institute (NHLBI) ......................................................... 248
National Human Genome Research Institute (NHGRI) .................................................. 249
National Institute on Aging (NIA) ..................................................................................... 250
National Institute on Alcohol Abuse and Alcoholism (NIAAA) ......................................... 257
National Institute of Allergy and Infectious Diseases (NIAID) ......................................... 258
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) ............. 261
National Institute of Biomedical Imaging and Bioengineering (NIBIB) ............................ 262
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) .......................................................... 264
National Institute on Deafness and Other Communication Disorders (NIDCD) .............. 266
National Institute of Dental and Craniofacial Research (NIDCR) .................................... 267
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) ................... 269
National Institute on Drug Abuse (NIDA) ........................................................................ 270
National Institute of Environmental Health Sciences (NIEHS) ....................................... 271
National Institute of General Medical Sciences (NIGMS) .............................................. 272
National Institute of Mental Health (NIMH) .................................................................... 274
National Institute on Minority Health and Health Disparities (NIMHD) ......................... 278
National Institute of Neurological Disorders and Stroke (NINDS) ................................. 279
National Institute of Nursing Research (NINR) ............................................................... 281
National Library of Medicine (NLM) ............................................................................... 282
Division of Program Coordination, Planning, and Strategic Initiatives (DPCPSI), Office of Research Infrastructure Programs (ORIP) .......................................................... 283
NATIONAL CANCER INSTITUTE (NCI)

A. Therapeutics (e.g. Small Molecules, Biologics, Radiomodulators, and Cell-based Therapies)

B. *In Vitro* and *In Vivo* Diagnostics (e.g. Companion Diagnostics and Prognostic Technologies)

C. Imaging Technologies (e.g. Agents, Devices, and Image-Guided Interventions)

D. Devices for Cancer Therapy (e.g. Interventional Devices, Surgical, Radiation and Ablative Therapies)

E. Agents for Cancer Prevention (e.g., Vaccines, but not “Technologies for Cancer Prevention”)

F. Development of Low Cost Technologies for Global Health

G. Development of Digital Health Tools
**NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES (NCATS)**

A. Innovative platforms for identification and prioritization of targets for therapeutic intervention with clear clinical impact.

B. Technologies to determine alternative uses for existing therapeutic interventions.

C. Tools and technologies to allow assaying of activities of compounds on currently "non-druggable" targets.

D. Phenotypic assay development, including stem cell technology platforms for human "disease in a dish" applications and the evaluation of toxicity.

E. Co-crystallization high-throughput screening techniques.

F. Small molecule and biologics analytical characterization.

G. Tools and technologies that increase the predictivity or efficiency of medicinal chemistry, biologic, or other intervention optimization.

H. Accelerate bioengineering approaches to the development and clinical application of biomedical materials, devices, therapeutics, and/or diagnostics.

I. Tools and technologies that increase the efficiency of human subjects research, including development of technologies that facilitate rapid diagnosis and/or clinical trial recruitment and subject tracking, IRB evaluation, and/or regulatory processes.

J. Novel platforms, technologies and tools for: (1) enabling clinical and translational research, particularly those with mechanisms for inclusion of patient reported data and (2) integration of patient data collected from multiple devices and multiple/diverse clinical studies.

K. Searchable access to information about researchers and their expertise, including but not limited to their publications, published data sets, methods, patents, clinical trials, partnerships, collaborators, and clinical specialty/expertise (if applicable).

L. Tools for meaningful sharing of research data with low barrier for provision and user friendly access.

M. Microphysiological Systems (MPS)/Tissue Chips.
NATIONAL CENTER FOR COMPLEMENTARY AND INTEGRATIVE HEALTH (NCCIH)

A. Development and validation of biomarkers which correlate with efficacy of complementary health approaches.

B. Formulation, development, and clinical testing of complementary health approaches and natural products that would permit FDA approval of a natural product for a specific indication.

C. Identification and validation of biological targets associated with complementary health approaches.

D. Development of innovated technologies and methods to assess natural product-drug interactions in humans.

E. Studies of the mechanistic effects of mind and body interventions that will allow for optimization of the efficacy and safety of the mind and body approach for commercialization.

F. Non-traditional phenotypic assay development for complex natural product mixtures.

G. Integrated *in silico* tools for exploiting natural product bioactivity.
NATIONAL EYE INSTITUTE (NEI)

General Research and Development Topics

A. New or improved ophthalmic or surgical instruments for diagnosis and treatment of eye disorders.
B. Drug delivery systems; gene therapy, cell-based therapy or regenerative medicine.

Retinal Diseases

A. New therapeutic approaches for inflammatory and degenerative diseases and for inhibition of abnormal angiogenesis in the retina and choroid.

Corneal Diseases

A. New therapeutic approaches, artificial corneas, and drug delivery methods for the treatment of corneal injury, infection, dry eye, ocular pain, and other ocular surface disorders.

Lens and Cataract

A. New approaches in the management of cataracts.

Glaucoma and Optic Neuropathies

A. New therapeutic agents for treatment of glaucoma.

Visual Impairment and Blindness

A. New or improved devices, systems, or programs that meet the rehabilitative and everyday living needs of blind or visually-impaired persons.
NATIONAL HEART, LUNG, AND BLOOD INSTITUTE (NHLBI)

A. Biomedical technologies (medical devices, instruments, pharmaceuticals, drugs, therapeutics, vaccines, diagnostics and biologics) for heart, lung, blood, and sleep related diseases and disorders requiring Federal regulatory approval (FDA) or clearance to be commercialized.

B. Small and large animal testing of products of tissue engineering and regenerative medicine, drugs, medical devices, therapeutics, and biologics and studies involving in vivo animal experiments for heart, lung, blood, and sleep related diseases and disorders.

C. Clinical trials and other experiments involving human subjects for heart, lung, blood, and sleep related diseases and disorders.

D. Therapeutics (drugs, devices, or biologics) development for heart, lung, blood, and sleep related diseases and disorders.

E. Device development for heart, lung, blood, and sleep related diseases and disorders

F. Diagnostics development for heart, lung, blood, and sleep related diseases and disorders.

G. Investigation of biomarkers and biosignatures of heart, lung, blood, and sleep related diseases and disorders.

H. Technologies to enhance clinical research for heart, lung, blood, and sleep related diseases and disorders.

I. Advanced instrumentation and high throughput tools for biomedical research in heart, lung, blood, and sleep related diseases and disorders.

J. Tools and platforms to improve the dissemination and implementation of evidence-based interventions for heart, lung, blood, and sleep related diseases and disorders.
NATIONAL HUMAN GENOME RESEARCH INSTITUTE (NHGRI)

A. Development of novel or significant improvements for nucleic acid sequencing technology.

B. Development of novel or significant improvements for functional genomics technology.

C. Genomics tools ranging from new instruments to sophisticated molecular biology kits.

D. Bioinformatics software for genomic, genetic and sequence data analysis, functional genomics, associations between genomic data and diseases or phenotypes, interpretation of variants, and genomic data integration.

E. Databases and data management for genomics research and application including sequences, functional data, annotation of variants, and phenotypes.

F. Incorporating genomic results into electronic medical records.

G. Informatics tools that assist in delivering genomic medicine to patients.

H. Development and application of methods for machine learning, pattern detection, and knowledge networks for genomics and translation to genomic medicine.

I. Informatics methods and platforms to enhance privacy, data standards, and data exchange in genomics and translation to genomic medicine.

J. Use of cloud and other computing models to improve scale, reproducibility, interoperability, cost-effectiveness, and utility of genomic and clinical data in genomics and translation to genomic medicine.

K. Single cell genomic analysis.
NATIONAL INSTITUTE ON AGING (NIA)
Division of Behavioral and Social Science (DBSR)

A. Development and translation of behavioral-economics approaches (incentives or disincentives) to motivate sustainable behavior change to improve health and well-being:
   1. Increase levels of physical activity or promote treatment adherence or social connectedness;
   2. Address biases such as loss aversion, errors in affective forecasting, present bias, ambiguity effect, base-rate neglect, and susceptibility to framing effects in health and financial decision making;
   3. Use information, or the mode of data presentation, to improve decision-making (e.g., through “nudges,” policies, or practices that constrain choices);
   4. Integrate behavioral economics techniques with retail Electronic Health Records (EHRs) to produce low cost interventions designed to improve physician adherence to recommended treatment guidelines without overruling physician autonomy.

B. Development of robotics applications to aid elderly:
   1. Develop socially-assistive robots to enhance the capabilities of older Americans to preserve their independence and remain in their homes. NIA envisions these robotics applications supporting machine cognition, language understanding and production, human-robot interaction (cognition, perception, action control, linguistics, and developmental science), and perception;
   2. Use of robots to promote social interaction and engagement and reduce loneliness among the elderly;
   3. Use of robots to motivate elderly to exercise.

C. Development of cognitive training applications/intervention to improve cognitive function in elderly:
   1. Rapidly develop novel, engaging computer-based cognitive training programs that are based on efficacious approaches and that use cognitive training to target a specific neural system/functional domain;
   2. Augment existing computerized cognitive interventions to be personalized, engaging, adaptive, sufficiently challenging, and optimal for maximizing real world functional improvements;

D. Development of blood-spot technology for biological data collection:
   1. Develop multiple and reliable assays for limited blood-spot specimens for large surveys.

E. Development of social, behavioral, environmental and or/technical interventions on the individual, institutional, family, community or national level intended to maintain older adult independence or functioning, increase well-being and prevent disease and/or disability:
   1. Devise interventions that promote a safe home environment, including technological innovations to improve monitoring and communication;
   2. Devise interventions addressing self-management of chronic diseases among the elderly, including behavioral change and compliance;
   3. Devise interventions to promote self-awareness and attention to health and well-being in caregivers; including interventions focusing on stress management, maintaining a healthy
diet, creating and maintaining contact with a supportive social network, and attending to one’s own physical health;

4. Devise interventions to promote productive and effective communication with health-care providers, interventions that enhance understanding and communication of changes in symptomology, promote transparency of care needs, increase receipt of family-centered optimal care, make informed health-care decisions, and for informed advance-care planning and directives;

5. Devise interventions and/or assistive devices to promote independence outside of the home, including but not limited to such activities as driving, wayfinding, and navigation;

6. Develop evidence-based methods, technologies, and behavioral interventions to reduce the burden of caregiving for AD caregivers. In addition, development should yield training materials/resources appropriate for use by either health-care organizations or community-based organizations.

F. Development of genetics and Genome Wide Association Approaches (GWAS):

1. Develop online genetic counseling for users to interface with professionals regarding issues that may have arisen after learning about genetic risk for disease;

2. Create smartphone applications that are capable of crowd sourcing new phenotype information from participants who have been genotyped.

G. Development of new sampling and data-collection methodologies for use in large population-based household surveys and behavioral interventions of relevance to aging. These include:

1. Develop methods and/or devices to conduct experience-sampling and other real-time collection of data, particularly for recording and analyzing social interactions;

2. Develop, test, and market assays to analyze bio-specimens collected as part of large longitudinal studies of aging.

H. Development of survey and archiving/database-support technology and resources:

1. Develop new databases and database-support infrastructure to satisfy data and research needs in aging;

2. Develop innovative data archives to make current statistical and epidemiological data more accessible per NIH rigor/reproducibility policy;

2. Develop data-extraction web and archiving tools for public-use databases;

3. Develop innovative methods and software to provide improved access to complex longitudinal studies or surveys that preserve confidentiality;

4. Develop innovative methods and software to facilitate analysis of personal data linked to geocoded data, biological, cognitive or genetic measures, with improved protection for confidentiality of respondents;

5. Develop data infrastructure and tools for assessing the economic impact of federally-funded research;

6. Develop and enhance existing NIA-supported longitudinal surveys/studies by creating longitudinal data files and corresponding codebooks (similar to the Rand Health Retirement Survey files and codebook);

7. Test, validate, process, and analyze biospecimens collected as part of large longitudinal studies of aging;
8. Develop remote data-enclave infrastructure to enable researchers to share and analyze restricted data (e.g. CMS claims records and other sensitive data).

I. Develop risk-reduction programs (also referred to as health-promotion, health-management, demand-management, and disease-prevention programs) among those aged 45-64 years. The goal of these interventions would be to improve the health of older workers, lower the rate of health-care utilization, and improve the cost effectiveness of employer-based insurance plans.

J. Integrate technology, big data, artificial intelligence (AI) and machine learning for early diagnosis of aging-related illnesses;

K. Develop technology and innovative statistical methods (e.g., machine learning, development of artificial intelligence algorithms) to analyze Big Data (including, for example, time-intensive, multi-source data) to provide a better understanding of mechanisms underlying aging in formal or institutional treatment settings (e.g. early diagnosis of aging related disease such as dementia, and multiple co-morbidities in using EHR data) and in naturalistic settings (e.g. home assessment using technology to mine and integrate Big Data to predict early diagnosis of aging-related diseases).

L. Develop new and/or validate existing sensitive, specific, and standardized tests for diagnostic screening of Mild Cognitive Impairment (MCI) to distinguish it from normative age-related cognitive change. Such development could include the creation of novel technology and/or methods or the validation of existing measures/methods/technology for the early detection of cognitive impairment and MCI. Examples of such technology include biosensors, prosthetic devices, and software development targeting the assessment, diagnosis, and remediation of age-related cognitive decline.

M. Discover, develop, and evaluate behavioral methods to remediate age-related cognitive decline, and to treat the cognitive impairment and/or behavioral symptoms associated with MCI, as well as to slow and/or reverse the course of cognitive decline or to prevent it entirely.

**Division of Aging Biology**

A. Development of anti-oxidants or other interventions to reduce oxidative or other stresses and aging-related diseases, including interventions that address how metabolic regulation influences longevity.

B. Development of minimally-perturbing techniques for collecting blood from mice, rats, and other animals several times a day in sufficient quantities for measurement of hormone levels and other circulating factors in young and old non-human animals, or development of non-invasive research and test methods for use in non-human animals.

C. Development of interventions that improve the immune response to foreign molecules or reduce the response to self or suppress age-induced inflammation.

D. Validation and further development of candidate interventions which have been found to enhance longevity or slow aging and may affect other age-related conditions or diseases.

E. Development of novel strategies for treating age-related renal, pulmonary, urology, reproductive disorders, and age-related changes in hormone production and function, including devices, pharmacological targets and their validation, small molecules and other approaches to treat these disorders in the elderly; early-stage pharmacological validation of novel targets and accompanying pre-therapeutic leads for these age-related diseases are encouraged.
F. Development of novel methodology for treating osteoarthritis, including devices, processes and pharmacological agents with the potential to: (1) slow the rate of joint deterioration, (2) promote the remodeling of damaged joints, (3) reduce the likelihood of progression to osteoarthritis, and/or (4) improve outcomes for patients with active osteoarthritis.

G. Development of interventions that reduce the level of damage to nucleic acids, proteins and lipids and the macromolecular complexes formed from these molecules, and improve the damage surveillance and repair potential of cells.

H. Development of tools and resources in genetics and genomics to study molecular mechanisms of normal aging or aging-related diseases.

I. Development of novel methodology for treating chronic wound healing, including devices, processes and pharmacological agents with the potential to: (1) improve the rate and or quality of wound healing, and/or (2) improve outcomes for patients with chronic wounds.

J. Development of biomarkers for prognosis, diagnosis, or treatment monitoring of aging or aging-related diseases.

K. Analysis and integration of large data sets for developing biomarkers or biomarker signatures of aging or age-related diseases.

Division of Geriatrics and Clinical Gerontology

A. Development of clinical decision-support tools able to broadly integrate into the electronic health record to help physicians/providers caring for patients with multiple (3 or more) chronic conditions prioritize, coordinate, and deliver the interventions that are most beneficial and relevant within the context of these patients’ lives and the health-care-delivery system.

B. Development of assistive technologies/robotics to enable and support older persons to live independently and safely at home; socially-assistive robots; robots for caregiver and mobility assistance; robots for exercise and rehabilitation assistance.

C. Development of technologies/robotics/sensors to assist in the improvement of physical function and mobility in older persons prior to (pre-habilitation) or following (rehabilitation) elective/planned surgery.

D. Development and validation of improved approaches for evaluation, monitoring or treatment of diastolic dysfunction in older adults.

E. Development of improved instrumentation/ imaging and sensor technology for measuring ambulation and biomechanics of movement including balance, sway, gait, and postural control to identify stable and unstable patterns of movement during activities of daily living.

F. Development of methods and technology to accurately determine the renal glomerular filtration rate (GFR) in older persons and patients with chronic kidney disease; new methods and technology should accommodate the effects of age-related changes in muscle mass, levels of serum creatinine, renal blood flow and renal concentrating ability.

G. Development and validation of non-invasive methods of examining bone quality (density, architecture, and strength of bone).

H. Development and validation of instruments and/or methods to evaluate fatigability—the level of fatigue related to the intensity, duration, and/or frequency of activity (in contrast to measures of fatigue), particularly in adults with or at-risk of developing age-related conditions or diseases leading to physical disability.
I. Development and validation of innovative approaches to pain control that considers age-related physiologic changes such as gastrointestinal absorption, cutaneous integrity, and musculoskeletal structure and function.

J. Development and validation of new technology such as non-invasive methods to examine blood-flow velocity in arteries, individual coronary arteries, renal arteries, and cerebral arteries.

K. Development of clinical decision support tools that help physicians caring for patients with multiple chronic conditions to prioritize the interventions that are most beneficial and relevant within the context of these patients’ lives; or tools for patient self-management of multiple chronic conditions. Development of patient-focused tools for prioritizing and making decisions about the most significant health concerns to help select and order their self-management behaviors related to 3 or more chronic conditions.

L. Development of new therapeutic interventions to promote wound healing, including improved post-surgical treatments/technologies promoting wound healing, prevention of chronic wounds, or reduced scar formation.

M. Development of vaccines and other agents for preventing and treating infections in older persons, including development of new vaccines or preventive interventions, and new methods using currently available vaccines or preventive medications. Improve vaccine response/immune function, and for physical functional problems in old age.

N. Development of devices and/or techniques for preventing or treating urinary incontinence.

O. Development and effectiveness testing of innovative, practical, cost-effective technologies, data collection and extraction systems and devices that could enhance the participation in clinical trials of older vulnerable people who are typically under-represented in clinical trials.

P. Development and validation of novel, practical, cost-effective and reliable assays of multiple markers of age-related chronic inflammation, designed for use in comprehensive geriatric assessment and for research purposes.

Q. Development of new diagnostic tests to predict adverse and/or costly, or favorable, health outcomes with aging or in the setting of chronic diseases, injuries, surgery, hospitalization, or other health-related conditions.

R. Development of new therapeutic interventions targeting putative aging mechanisms that influence the risk or progression of multiple age-related conditions.

Division of Neuroscience (DN)

A. Development of new and/or validation of existing sensitive, specific, and standardized tests for diagnostic screening of Mild Cognitive Impairment (MCI), Alzheimer’s disease (AD), and Alzheimer’s disease related dementias (ADRD), which includes but is not limited to the development of minimally-invasive biomarkers that can be used for screening in the general populations and in a community setting, biomarkers that could serve as surrogate measures for disease progression in MCI, AD and ADRD, novel neuropsychological, biochemical, and neuroimaging technology and/or methods or the validation of existing measures/methods/technology for the early detection of cognitive impairment and MCI and the early diagnosis of AD and ADRD and development of new technology and tests for detection of pre-clinical AD and other dementias of aging.
B. Discovery, development, and/or evaluation of compounds, drugs, biological or natural products, including central-nervous-system delivery systems to remediate age-related cognitive decline, and to treat the cognitive impairment and/or behavioral symptoms associated with MCI, AD, and ADRD as well as to slow and/or reverse the course of the disease or to prevent it entirely. Development of therapies that might prevent, slow or reverse the course of AD and ADRD, through the application of system biology and systems pharmacology approaches.

C. Development of new technologies for in-home use or for coordination or delivery of services to sustain in-home living for individuals with MCI, AD, ADRD or other dementias. Examples include systems and devices to: evaluate, monitor and improve or adapt to changes in cognition; to improve health-service delivery; to prolong functional independence; to support independent living and performance of tasks of everyday life; to provide information to healthcare providers and family members to enable them to evaluate the need for intervention; and to promote communication and interaction between individuals living in the community or in institutional settings and their health-care providers, friends, and family members.

D. Testing in clinical trials of drug, nutritional, behavioral, cognitive or other types of interventions to remediate age-related cognitive decline, and to treat cognitive impairment and/or behavioral symptoms associated with MCI, AD, ADRD, and other dementias of aging as well as to prevent the onset of disease or to slow and/or reverse the course of disease.

E. Development of manuals for existing evidence-based interventions that reduce the burden of caregiving for AD caregivers so that the manuals and training materials can be used by community-based agencies or health care organizations.

F. Development of a predictive platform or tool that would enable Medicare Advantage managed care providers to estimate future costs for care of patients with AD, ADRD, and other forms of dementia. The predictive tool would use Medicare claims data, particularly incidence and cost data. In addition, the predictive tool would allow for adjustments to reflect variable plans and kinds and levels of coverage associated with diverse patient demographics and risk profiles.

G. Development of behavioral, environmental, pharmacological, & nutritional interventions to prevent and/or remediate brain biochemical and/or neurophysiological changes caused by neurodegenerative diseases, including age-related sensory dysfunction, motor dysfunction or age-related decrements in balance & postural control, gait performance, and mobility.

H. Development of biosensors and prosthetic devices, technologies, and related software development to aid in the assessment, diagnosis, and remediation of age-related cognitive decline or sensory dysfunction (including pain, age-related vision loss, and age-related hearing loss), motor dysfunction (including Parkinson’s disease and other motor disorders of aging), or age-related changes in balance, postural control, and gait.

I. Development of novel markers of normal age-dependent cognitive decline or sensory and/or motor system changes at the molecular cellular, circuitry, physiological or behavioral level in humans or relevant animal models.

J. Development of technology and analysis tools to examine genetic, epigenetic, transcriptomic, proteomic, metabolomic, and cell stress pathways in neurons and glia of the aging and AD brain. Development of molecular imaging technology and/or chip-based technology for the in-vitro and in-vivo analysis of gene, epigenome, proteostasis, lipidomics and metabolomics and metabolic function in the normal aging brain and in AD.

K. Improvement of technology to analyze structural and functional brain connectivity at the cell, neural circuitry and global-network levels to define the normal trajectory of brain structure and function over the adult lifespan.

L. Development of technology, including non-invasive methods and novel probes, to monitor and manipulate the plasticity of neural circuits in the adult and aged nervous system.
M. Development of novel markers of neural stem cell function (proliferation, migration, and differentiation) as well as methods to assess the integration and function of stem cells in the nervous system.

N. Development of novel approaches for analysis of next-generation sequence data.
NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM (NIAAA)

A. Treatment of alcoholism.
   - Pharmacological discovery, strategies, and development
   - Innovative therapeutic approaches
   - Prevention strategies
   - Therapies for co-morbid conditions, including organ damage

B. Technology development to support screening, brief intervention, and referral to treatment for alcohol-involved patients in medical settings.

C. Development of novel technologies or methods.
   - To detect the effects of alcohol on CNS structure and activities
   - To prevent harmful drinking during pregnancy, to identify prenatal alcohol exposure, and to enhance outcomes of individuals with Fetal Alcohol Spectrum Disorder
   - Tools for alcohol-related laboratory studies, such as animal strains, cell lines, stem cells, in vitro techniques, neuroimaging, ligands, in vivo detection of neuromodulators, or computational tools
   - Stem cell generation, dissemination, and model development
   - Voice technology, cell phones, and other

D. Development of Biomolecular Signatures of Alcohol Exposure and Alcohol-induced Tissue Injury.

E. Development, Optimization, and Validation of Novel Tools and Technologies for Neuroscience Research.

F. Design, Development, and Improvement of Alcohol Biosensors.

G. Investigational New Drug (IND)-enabling Development of Medications or Devices to Treat Alcohol Use Disorder and Alcohol-related Disorders.

H. Genotyping of DNA samples from subjects with addiction and substance use disorders.
NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES (NIAID)

Division of Allergy, Immunology, and Transplantation (DAIT)

A. Allergy, Asthma and Airway Biology Branch will consider preclinical and clinical research for conditions of interest: asthma, food allergy, eosinophilic esophagitis and gastroenteritis in relation to food allergy, atopic dermatitis, urticaria, rhinitis, rhinosinusitis, drug allergy, and sepsis. This includes but is not limited to the development of methodologies to manage, and analyze clinical and epidemiologic research in the above conditions and the development of biomarkers as diagnostic markers, markers of disease severity, predictive markers for treatment effectiveness, particularly of immunologic interventions such as allergen immunotherapy for food and respiratory allergy; novel approaches for detecting infants at risk for developing asthma and other allergic diseases; immune targets for asthma and allergic disease interventions; development of immunotherapies to prevent or treat allergic diseases.

B. Basic Immunology Branch will consider preclinical and clinical research to study the origin, maturation, and interactions of immune cells, immune cell receptors, ligands, cytokine biology, molecular basis of activation, antigen recognition, immune tolerance, immune response regulation, hematopoiesis and stem cell biology, enhancement of vaccine effectiveness in neonates and adults, and basic immunology of vaccines and immunotherapeutics as medical countermeasures for biodefense. This research includes but is not limited to development of novel vaccine adjuvants; single cell assays to isolate and study antigen-specific lymphocytes; immunotherapeutic antibodies; biomarkers of host immune defense; single cell and other sample-sparing assays for study of human immunology.

C. Autoimmunity and Mucosal Immunology Branch will consider preclinical and clinical research to develop and improve therapies for the treatment of autoimmune diseases and primary immune deficiencies (not HIV), basic research of autoimmune disease mechanisms, and biomarkers, immunotherapy of disease processes, disorders mediated by lymphocyte products, and mucosal immunity. This includes but is not limited to innovative treatments for autoimmune diseases; standardized validated diagnostic criteria and outcome measures for autoimmune diseases correlated with disease activity; high throughput assay of T-cell activity in autoimmune diseases; biomarkers to measure risk, disease activity, and therapeutic response in autoimmune diseases; innovative treatments for autoimmune diseases; mucosal immunity.

D. Transplantation Branch will consider preclinical and clinical research in organ, vascularized composite tissue and cellular transplantation: acute and chronic graft rejection, allogeneic and xenogeneic transplantation, development of immunomodulatory agents to prevent and treat graft rejection and to promote acute and long term graft acceptance and immunologic tolerance, genomics of the alloimmune response, graft versus host disease and engraftment for hematopoietic stem cell transplantation, minor histocompatibility antigens, complications of immunosuppression in transplantation, and major histocompatibility complex (MHC) region genomics and technologies for MHC typing. This includes but is not limited to methods and analysis tools to facilitate high throughput, high resolution MHC typing in humans and non-human primates.

E. Radiation Countermeasures Program will consider preclinical research on the identification and evaluation of medical countermeasures (MCMs) for public health emergencies involving ionizing radiation, through: 1) development of mitigators and therapeutics for acute radiation syndrome, delayed effects of acute radiation exposure, and/or radiation combined injury; 2) advancement of radionuclide-specific therapies, including chelating, blocking, or other novel decorporation agents; 3) improved methods of accurate, high-throughput radiation biodosimetry; 4) identification of biomarkers of organ-specific radiation injury; and 5) assessment of biomarkers of radiation injury in special populations and formulation of MCMs for administration to these affected groups.

Division of Microbiology and Infectious Diseases (DMID)
A. Identify and qualify infectious disease-related biomarkers, including:
   1. Biomarkers to predict susceptibility to infection and/or diagnose an infectious disease.
   2. Biomarkers to predict or monitor a subject’s response to therapeutics or vaccinations.
   3. Biomarkers from natural history studies that could be used to assess disease progression in acute and chronic diseases.

B. Development of rapid, highly sensitive and specific clinical diagnostics that are easy to use, cost-effective and can diagnose individuals infected with pathogens or individuals that have been exposed to toxins.

C. Development of vaccines for infectious diseases.

D. Development of vaccine enhancement and formulation technologies with the goal of providing protection against infectious disease agents, providing accelerated immune responses (more rapid schedules or reduced number of immunizations), increase ease of administration (i.e., self-administration), and increase product stability to minimize cold chain requirements.

E. Discovery and development of therapeutics for infectious diseases.

F. Development of technologies or approaches that address arthropod vector monitoring, management, and control to prevent transmission of vector-borne pathogens to humans.

Division of AIDS (DAIDS)

A. Development of anti-HIV agents directed at new viral or cellular targets, including development and in vivo evaluation of sustained release formulations for treatment and prevention of HIV infection.

B. Development and evaluation of therapeutic vaccines and other immune-based therapies to attenuate HIV disease progression or reduce HIV infectiousness.

C. Development of therapeutic strategies for curing HIV infection or effecting a sustained remission in the absence of daily antiretroviral drug therapy.

D. Development of methods for detecting and quantifying persistent reservoirs of replication competent latent HIV in blood and tissues, including bio-imaging.

E. Development and evaluation of practical and affordable tests (e.g. viral load, drug toxicities, drug resistance) to monitor populations infected with HIV and associated infectious agents. Development of tests to detect early infection in seropositive HIV-infected individuals and to determine HIV incidence (HIV infection before seroconversion).

F. Discovery and development of agents or strategies for sustained release protection (>30 days) from HIV infection in the genital and gastrointestinal tracts of men and women for Pre-exposure prophylaxis (PrEP) and Multipurpose Prevention Technologies (MPT).

G. Development of rapid tests for the detection of ARTs in various human matrices (e.g. blood, urine, hair).
H. Characterization, process development, formulation and manufacturing of HIV Env immunogens and novel HIV vaccines including RNA vaccines.

I. Research on HIV vaccine adjuvants, analytics, formulations and immune responses.

J. Development of formulation technologies to prevent or treat HIV and HIV-associated co-infections.
NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES (NIAMS)

A. Research and development of new therapies using small molecules or biologics for arthritis, musculoskeletal and skin diseases.

B. Research and development of novel biomedical devices or tissue engineered products for arthritis, musculoskeletal and skin diseases.

C. Research and development of new biomarkers or novel imaging technologies for arthritis, musculoskeletal and skin diseases.

D. Research and development of innovative internet-based technologies to manage arthritis, musculoskeletal and skin diseases.
NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERING (NIBIB)

A. **Image-Guided Interventions.** Research on use of images for guidance, navigation and orientation in minimally invasive procedures to reach specified targets. Examples include image-guided interventions for minimally invasive therapies such as surgery and radiation treatment, for biopsies, and for the delivery of drugs, genes and therapeutic devices.

B. **Magnetic Resonance Imaging and Spectroscopy.** Development of MR imaging and MR spectroscopic imaging, for both animal and human research, and potential clinical applications. Examples include (but are not restricted to) fast imaging, high field imaging, design of novel RF and gradient coils, novel pulse sequences, design of novel contrast mechanisms, imaging informatics, *in vivo* EPR imaging, molecular imaging, etc. The emphasis should be on technological development rather than detailed applications to specific diseases or organs.

C. **Medical Devices and Implant Science.** Design, development, evaluation and validation of medical devices and implants. This includes exploratory research on next generation concepts for diagnostic and therapeutic devices; development of tools for assessing host-implant interactions; studies to prevent adverse events; development of predictive models and methods to assess the useful life of devices; explant analysis; improved *in vitro* and animal models for device testing and validation.

D. **Micro- and Nano-Systems, Platform Technologies.** Development of BioMEMS, microfluidics and nanoscale technologies, including micro-total analysis systems, arrays, and biochips, for detection and quantitation of clinically relevant analytes in complex matrices. Application areas include biomedical research, clinical laboratory diagnostics, biodefense, high-throughput screening, drug delivery, tissue engineering, and implantable devices, among others.

E. **Optical Imaging and Spectroscopy.** Development and application of optical imaging, microscopy, and spectroscopy techniques; and development and application of optical imaging contrasts. Examples of research areas include fluorescence imaging, bioluminescence imaging, OCT, SHG, IR imaging, diffuse optical tomography, optical microscopy and spectroscopy, confocal microscopy, multiphoton microscopy, flow cytometry, development of innovative light sources and fiber optic imaging devices.

F. **Telehealth.** Development of software and hardware for telehealth studies that have broad applications as well as early stage development of telehealth technologies that may have specific focus areas. Research that is supported includes methods to address usability and implementation issues in remote settings, and methods to develop technology for standardizing and incorporating state of the art security protocols for verifying user identities and preserving patient confidentiality across remote access.

G. **Tissue Engineering and Regenerative Medicine.** Development of enabling technologies including real-time, non-invasive tools for assessing the function of engineered tissues; real-time assays that monitor the interaction of cells and their environment at the molecular and organelle level; predictive computational models for engineering function 3D tissues; high-throughput assays and instruments to reduce the cost, time, and complexity of tissue engineering; novel bioreactor techniques for expanding stem cells and growing tissues and organs on a large scale; and strategies for preserving, sterilizing, packaging, and transporting living-tissue products. The program also supports applications of rational engineering design principles to functional engineered tissues; the development of novel biomaterials for use as tissue scaffolds that mimic the extracellular matrix and support multiple cell types in defined spatial orientation; and engineering approaches to study how biomaterials interact with cells and guide cell growth, differentiation, and migration.

H. **Ultrasound.** Improvement of technologies for diagnostic, interventional and therapeutic uses of ultrasound. The diagnostic ultrasound program includes, but is not limited to the design, development and construction of transducers, transducer arrays, and transducer materials,
innovative image acquisition and display methods, innovative signal processing methods and devices, and optoacoustic and thermoacoustic technology. It also includes the development of image-enhancement devices and methods, such as contrast agents, image and data presentation and mapping methods, such as functional imaging and image fusion. The interventional ultrasound program includes the use of ultrasound for therapeutic use, or as an adjunct for enhancement of non-ultrasound therapy applications. Examples include, but are not limited to, high-intensity focused ultrasound (HIFU) as a non-invasive or minimally invasive interventional surgical or therapy tool, and as an adjunct interventional tool. It also includes the use of ultrasound contrast agents for therapy and for targeted drug delivery, and the use of ultrasound for image-guided surgery, biopsy, and other interventions.
EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH AND HUMAN DEVELOPMENT (NICHD)

Child Development and Behavior Branch

A. Real time Human Interactive Data Acquisition and Analysis Technologies: Development and research testing of new or adaptation of existing devices and innovative technologies to improve the collection, analysis, and automated coding of audio and video recordings in real world settings (e.g., homes, childcare centers, schools, and primary care offices) over prolonged periods of time (i.e., days, weeks, or longer) to allow for (1) rapid analysis of interactions, including those involving one or more languages, and (2) simultaneous analysis of nonverbal and verbal behaviors during interactions. Incorporation of data from sensors capable of simultaneously recording real time physiological signals (e.g., pulse, heart rate, skin conductance response, temperature, accelerometer, etc.) time-locked to audio and video data and analyses is also highly desired.

Contraception Research Branch

A. Development of innovative contraceptive approaches for both males and females.

Developmental Biology and Structural Variation Branch

A. Innovative technologies for imaging developmental processes and gene expression; technologies for gene manipulations and perturbations; and in vivo tools for quantitative measurement of physical properties of cells and tissues contributing to embryonic morphogenesis.

Fertility and Infertility Branch

A. Development of novel techniques for assessment of gamete quality.

Gynecologic Health and Disease Branch

A. Development of innovative technologies for the treatment of endometriosis, uterine fibroids, or pelvic floor dysfunction, the latter including pelvic organ prolapse, urinary incontinence or fecal incontinence.

Intellectual and Developmental Disabilities Branch

A. Technology development to improve screening, diagnosis and treatment of intellectual and developmental disabilities.

Maternal and Pediatric Infectious Disease Branch

A. New technologies relevant to resource-limited countries for screening, diagnosis, and management of HIV and other infectious diseases, including tuberculosis, viral hepatitis, other congenital infections such as cytomegalovirus, respiratory infections, etc., in infants, children and pregnant/breastfeeding women.

B. Development and evaluation of vaccines relevant to HIV and other infectious diseases for infants, children, and pregnant/breastfeeding women.

Obstetric and Pediatric Pharmacology and Therapeutics Branch
A. Development of devices to help diagnose or treat pediatric and pregnancy associated disorders.

**Pediatric Growth and Nutrition Branch**

A. Isolation, purification and synthesis of human milk oligosaccharides and peptides with antimicrobial activity.

B. Develop rapid and reliable methods to test human milk components for antimicrobial activity.

**Pediatric Trauma and Critical Illness Branch**

A. The development of devices, innovative therapeutic technologies and behavioral interventions to improve pediatric patient outcomes and minimize the negative sequelae of trauma, injury or critical illness.

**Population Dynamics Branch**

A. Developing tools and methods to accurately and reliably measure head circumference in infants and children

**Pregnancy and Perinatology Branch**

A. Devices, instruments, and tools to minimize bacterial colonization, reduce proclivity for thrombus formation; reduce health-care associated infection risks.

B. Methods to reduce pain in all of perinatal care (in newborn infants, in mothers in labor, during postpartum after spontaneous delivery and cesarean section

C. Novel Methods to predict, assess, monitor or treat (when feasible) fetal health, fetal growth, preterm birth, preeclampsia.

**National Center for Medical Rehabilitation Research**

A. Development of medical rehabilitation interventions and biomedical technologies to improve rehabilitation treatment for restoration of function.
NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS (NIDCD)

A. Research and development for biomedical technologies (medical devices, diagnostic instruments, pharmaceuticals, drugs, therapeutics, vaccines, and biologics) that require clearance by the FDA as a regulated product before commercial distribution.
NATIONAL INSTITUTE OF DENTAL AND CRANIOFACIAL RESEARCH (NIDCR)

Infectious Diseases and Immunity

A. Develop oral topical formulations with combined microbicidal, analgesic, and anti-inflammatory activities to enhance oral mucosal defenses and prevent and/or control oral infections and lesions in HIV-infected and/or immunosuppressed subjects.

Preclinical Research

A. Preclinical research and development activities for dental and craniofacial technologies (including devices, diagnostic instruments, reconstructive materials, pharmaceuticals, therapeutics, vaccines and biologics) that require review and approval by the FDA as a regulated product before commercial distribution.

Clinical Research

A. Develop improved methods to detect and predict progression of dental caries, periodontal disease, reversible and irreversible pulpitis.

B. Develop new or improve methods or materials to enhance oral and craniofacial surgery. This would include both intraoral and extraoral surgery.

C. Develop improved methods or materials to mechanically and/or biologically repair or treat tooth structure damaged by dental caries or periodontal disease.

D. Develop safe and efficacious methods to diagnose caries, pulp vitality and/or periodontal diseases utilizing non-ionizing radiation.

E. Develop technologies for local delivery of drugs to treat oral and craniofacial diseases or disorders.

F. Develop novel non-opioid pharmacological medications for management of acute dental pain.

Oral, Oropharyngeal and Salivary Gland Cancers

A. Develop imaging techniques for the early detection, diagnosis and prognosis of pre-malignant lesions.

B. Develop genetic animal models of oral cancer premalignancy and oral cancer progression that mimic human oral cancers, including HPV associated oropharyngeal cancers.

Temporomandibular Disorder and Orofacial Pain

A. Identify and develop novel pharmacologic or biologic agents, including but not limited to small molecules, peptides, recombinant proteins and nucleic acids to prevent, control, and/or treat orofacial pain.

Saliva, Salivary Diagnostics, and Salivary Gland Diseases

A. Develop viral, non-viral and gene therapy-based approaches to address compromised salivary gland function. Develop cell and tissue-based strategies and technologies for restoration of damaged or destroyed salivary gland function.

B. Develop novel compounds or materials that protect and preserve salivary glands from head and neck cancer irradiation therapy.
C. Development of non-invasive methods for the determination of efficacy and safety of artificial saliva, sialogogues, and of their delivery vehicles used in addressing the diminution or lack of saliva (xerostomia) due to Sjögren’s Syndrome or head and neck cancer irradiation therapy.

D. Develop biomarker-based technologies for the identification of Sjögren’s Syndrome using blood or saliva as body fluids.

Biotechnology, Biomaterials, and Applications for Regeneration and Restoration of Oral, Dental and Craniofacial Tissues

A. Develop methods, materials, and devices for orthodontic, prosthetic, periodontic, endodontic and craniofacial applications including those that can be used for craniofacial bone distraction, reconstruction, hard and soft craniofacial tissue healing and regeneration, and scarless craniofacial tissue repair.

B. Develop imagining diagnostics to accelerate clinical implementation of reliable, reproducible, highly specific and sensitive diagnostic instruments for various applications, including but not limited to dental caries, cracked teeth, pulp vitality, bone quality, and periodontal disease.

Clinical and Behavioral Research

A. Develop and test for safety, efficacy, and/or effectiveness of measures or materials for diagnosing, preventing, or treating oral, dental, and craniofacial conditions and disorders.
NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES (NIDDK)

NIDDK supports the topics below as they pertain to Diabetes (Type 1 and Type 2 Diabetes, Metabolic Disorders, Cystic Fibrosis, and Endocrine Disorders), Digestive Diseases (Gastrointestinal Diseases, Liver and Pancreatic Diseases, Obesity, Nutrition, and related diseases), and Kidney Diseases (Kidney Diseases, Urologic Diseases, and Hematologic Diseases).

A. Development or evaluation of pharmacological agents (i.e., drugs, therapeutics), gene therapies, novel formulations, cell-based or other biological technologies for intervention in or prevention of Diabetes and Digestive and Kidney Diseases.

B. Development or evaluation of biomedical devices, tools, techniques, or instrumentation for intervention in or prevention of Diabetes and Digestive and Kidney Diseases.

C. Development of biomarkers, assays, techniques, diagnostic technologies or associated reagents for assessing state or function in normal, developing, or diseased cells or tissues affected by Diabetes and Digestive and Kidney Diseases.

D. Development or evaluation of imaging, screening, or evaluation techniques or technologies for assessing state or function in normal, developing, or diseased cells or tissues affected by Diabetes and Digestive and Kidney Diseases.

E. Development or evaluation of animal or cell models for studying Diabetes and Digestive and Kidney Diseases.

F. Development or evaluation of novel materials or material treatments (e.g., sterilization, coating, etc.) for use in devices or other tools or methods used to prevent, diagnose, or treat Diabetes and Digestive and Kidney Diseases.

G. Development of cell- or data-banks for the biomedical research community.

H. Development or evaluation of technologies, including software applications, for improving patient adherence in Diabetes and Digestive and Kidney Diseases.

I. Development or evaluation of technologies for improving clinical research in Diabetes and Digestive and Kidney Diseases, including technologies for improving data collection and reporting of patient outcomes.

J. Development or evaluation of –omics, informatics, or internet-based technologies for biomedical research or clinical applications in diagnosing or managing Diabetes and Digestive and Kidney Diseases.

K. Development or evaluation of technologies to prevent or avert cell or tissue injury during other disease states or surgical procedures.
**NATIONAL INSTITUTE ON DRUG ABUSE (NIDA)**

1. Drug (Medication) discovery and development-enabling activities for Substance Use Disorders (SUDs).

   A. Innovative in vitro, in situ, or in vivo tools for the analysis of the central nervous system, normal and/or diseased.
   B. Technologies, including molecular imaging, gene expression profiling, and genotyping and sequencing approaches designed to better inform SUD diagnosis and treatment.
   C. Assay development (e.g., biochemical, functional) and validation, especially, hiPSC-based assays, human organoid, or 3-D culture systems with the intention of developing medium to high-throughput assays.
   D. Tools to simplify the design and preclinical development of medications for SUDs.
   E. Discovery of SUD-related biomarkers (BM, e.g., BMs of chronic drug exposure, pharmacodynamic, toxicological/safety; BM assay development and validation), and BM-associated device development.
   F. Development of BM known to be associated with a health (salutary) outcome, which are quantitatively affected by reduction in drug use are particularly welcome.
   G. Predictors of clinical outcomes in SUDs, e.g. physiological, electroencephalographic, cognitive tests, and biochemical, epigenetic, and genetic assays.
   H. Point of care monitoring systems to improve quantitative assessment of subject adherence to clinical trial protocols.
   I. Tools that could be used as quantitative direct (e.g. plasma, saliva, or urine) measures or indirect (e.g. physiological, facial, motor, pupillometry) BMs of drug intoxication.

2. Drug (Medication) discovery and development activities.

   Application of emerging and existing technologies and platforms for SUD medication development with the focus on products with the potential to minimize drug seeking, compulsive behavior:

   A. Early therapeutic discovery activities ranging from Target ID and validation through lead development
   B. Preclinical and/or clinical drug development
   C. Technologies or formulations to improve medication delivery
NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES (NIEHS)

A. Development and validation of alternative test methods to protect human and animal health while reducing, refining, or replacing animal tests.
NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES (NIGMS)

Division of Cell Biology and Biophysics

A. Development of reagents and methods for detecting in real time, analyzing, and separating biologically important compounds, macromolecules, and their interactions.

B. Development of new methods and materials directed toward the solution of biological macromolecule structures, including membrane proteins, assemblies and complexes by, but not limited to, x-ray diffraction, electron diffraction, NMR and mass spectroscopy.

C. Imaging probes and sensors, other reagents and methods, instrumentation, software for microscopy, spectroscopy, and single molecule analysis of molecules, cells, tissues, embryos and small model organisms. Technologies for applications of microscopy, spectroscopy and single molecule analysis in basic biomedical research, including but not limited to light, electron, X-ray, cryo-electron, and scanning probe microscopy and fluorescence, magnetic and electron paramagnetic spectroscopy. NOT included are small animal and preclinical imaging and high throughput platforms for diagnostic and clinical applications.

D. Development of high-throughput and/or computational methods and strategies to define/characterize the function, inhibition, and/or interactions of biological macromolecules and cells.

Division of Genetics and Developmental Biology

A. Development of probes for detection of genetic polymorphisms, including disease genes.

B. Development of valid animal models for genetic diseases and birth defects.

C. Improvement of methodology (technology) for genetic analysis (e.g., gene expression, probes).

D. Development of tools and technologies to detect and monitor complex phenotypes or traits.

E. Development or improvement of methods for high throughput detection of epigenomic changes.

F. Development of improved technology, reagents and tools to derive, grow, isolate, differentiate and characterize cells.

G. Development or improvement of methods for characterizing and studying complex communities of microorganisms, including interactions with host organisms.

H. Development of non-mammalian model systems.

Division of Pharmacology, Physiology, and Biological Chemistry

A. Methods for isolation, characterization, and production of natural and bio-engineered products.

B. Development of methodology to improve the efficiency of discovery, development, and production of bio-medically relevant compounds.

C. Isolation, characterization, and development of factors and strategies, methods, or treatments involved in tissue repair, wound healing, sepsis, and traumatic injury, emergency, peri-operative, or critical care conditions, and associated pain management.

D. Research to improve drug design and delivery.

E. Development of technologies, including instrumentation, reagents, and methods for -omics, including but not limited to robotics, sample preparation and pre-fractionation, analytical separations, mass spectrometry, intelligent automated data acquisition, and improved informatics technologies.
F. Development of technologies, including instrumentation, software, reagents, and methods for the study of carbohydrates, including but not limited to development of: specific glycan structural databases, methodologies for synthesis of robust glycan libraries, glycan labeling reagents and glyco-enzyme inhibitors, and analytical tools for determining carbohydrate structure and biological function.

G. Development of tools to study oxidative stress and/or mitochondrial function.

**Division of Biomedical Technology, Bioinformatics, and Computational Biology**

A. Development of instrumentation and devices for detection, analysis, separation and/or manipulation of biologically important molecules, cellular components or cells.

B. Development of instrumentation and devices for elucidating interactions of biologically important molecules *in vitro, in vivo*, within cells, or in fluid or solid-state conditions.

C. Development of tools and methods for the modeling, simulation, and/or analysis of complex biological systems.

D. Development and/or enhancement of computational tools and methods to collect, store, interpret, analyze and/or visualize biomedical data.

E. Development of software and hardware for improving the effectiveness of computational approaches in biomedical research.

**Division of Training, Workforce Development, and Diversity**

A. Development of products or services to enhance diversity of the scientific workforce.

**Center for Research Capacity Building**

A. Development of efficient, user-friendly, and culturally appropriate resources to enhance health science literacy
NATIONAL INSTITUTE OF MENTAL HEALTH (NIMH)

All Divisions:

A. Preclinical drug/device development studies, including pharmacology, efficacy and toxicology.

B. Completion of studies as required by the Food and Drug Administration (FDA) for Investigational New Drug (IND) or Radioactive Drug Research Committee (RDRC) application.

C. Studies in normal healthy volunteers to determine a drug's safety profile, metabolism, etc.

D. Clinical studies in patient/disease population to assess the drug's effectiveness.

E. Assessment of devices with regard to performance standards related to the FDA approval process.

F. Safety and effectiveness studies of novel medical devices.

G. Evaluation of novel imaging approaches for diagnostic purposes.

H. Clinical studies in support of Pre-Market Approval for biomarkers/medical devices by the FDA.

I. Rapidly develop novel, engaging computer-based cognitive training programs that are based on efficacious neurotherapeutic approaches and which use cognitive training to target a specific neural system/functional domain.

J. Augment existing computerized cognitive interventions to be personalized, engaging, adaptive, sufficiently challenging, and optimal for maximizing real world functional improvements.

K. Test the feasibility, efficacy and potential adverse effects of these programs utilizing measures of functional outcomes in an identified clinical population, particularly those with neuropsychiatric disorders, ASD, and/or HAND, at a specified developmental stage, including measurement of the duration of treatment effects.

L. Rapid development and evaluation of mobile based platforms and applications.

Division of Neuroscience and Basic Behavioral Science (DNBBS)

A. Novel imaging probes to study brain structure and function at all levels, from the molecular to the whole organ, using any imaging modality (PET, fMRI, optical, etc.).

B. Drug discovery/drug development of novel compounds which act on molecular pathways (receptors, enzymes, second messengers, etc.) that are not typically targeted with currently available psychiatric drugs, and that have a strong biological justification as a novel mechanism for treatment of psychiatric disorders.

C. Novel screening assays for high throughput acquisition and analysis of data about behavior and the brain, from the level of genes to the level of behavior.

D. Novel technologies that would enable researchers to study how populations of neural cells work together within and between brain regions, in order to understand how changes in neural activity contributes to mental disorders.

E. Complex instrumentation for neuroscience research
F. Complex brain or cellular imaging or analysis.

G. Tools to facilitate the detailed analysis of complex circuits and provide insights into cellular interactions that underlie brain function.

H. Proof-of-concept testing and development of new technologies and novel approaches for large scale recording and manipulation of neural activity, at or near cellular resolution, at multiple spatial and/or temporal scales, in any region and throughout the entire depth of the brain.

I. Iterative refinement of such tools and technologies with the end-user community with an end-goal of scaling manufacture towards reliable, broad, sustainable dissemination and incorporation into regular neuroscience practice.

J. Novel informatics tools to facilitate the sharing of complex data sets between laboratories.

K. Novel tools for investigating brain-derived GPCRs in mental health research.

L. Educational tools/technologies for neuroscience and mental health.

M. Technologies to support the goals of the BRAIN Initiative: [http://www.braininitiative.nih.gov](http://www.braininitiative.nih.gov)

### Division of Translational Research (DTR)

A. Develop, test and validate reliable and stable biomarkers that can identify at-risk individuals prior to disease onset, improve diagnosis, predict treatment response, or measure disease progression. Biomarkers are also needed in clinical trials to identify dose ranges, to identify a specific subpopulation of subjects to enroll in a treatment trial, or to measure efficacy or toxicity/side effects.

B. Develop novel and targeted interventions (pharmacological, cognitive, behavioral, computer, or device-based) that affect particular neural circuits and signaling pathways relevant to the developmental trajectory of the disease.

C. Conduct early stage, proof of concept clinical trials to advance the development of novel therapeutics. The clinical trials are expected to include biological/behavioral data to assess target engagement and to help determine potential success or failure of the compound before moving on to larger clinical trials (see NOT-MH-11-015 [http://grants.nih.gov/grants/guide/notice-files/NOT-MH-11-015.html](http://grants.nih.gov/grants/guide/notice-files/NOT-MH-11-015.html)).

D. Based on expanded knowledge of neurobehavioral trajectories, develop novel objective assessment tools that can identify early signs of risk or onset of recurrence of particular mental disorders or in domains of functioning (see MH’s RDoC project: [http://www.nimh.nih.gov/research-funding/rdoc/index.shtml](http://www.nimh.nih.gov/research-funding/rdoc/index.shtml)) for pediatric populations.

E. Develop computational biological/behavioral assessment tools that can be used across ages, species, and cultures to evaluate dysfunction in domains relevant to mental disorders (e.g., mood dysregulation, deficits in executive function).

F. Develop computational platforms to enable the integration and sharing of data characterizing typical and atypical developmental trajectories in humans and non-human animals.

G. Clinical research tools.
H. Develop valid measures of the various constructs in the Research Domain Criteria (RDoC) matrix (see http://www.nimh.nih.gov/research-funding/rdoc/index.shtml), e.g., neurocognitive tasks, psychometrically sophisticated questionnaires, measures of behavior, and biomarkers, into a commercial product.

I. Develop clinical risk assessment instruments that encompass multiple domains (e.g., genetic, neurobiological, and environmental), are sensitive to developmental stage, and have high predictive power for the onset or recurrence of mental illness.

J. Developing clinical risk assessment instruments for developing particular benefits or harms during treatment for mental disorders, and communicating such probabilistic information to patients and their families in a readily understandable manner.

K. Develop electronic sensors, monitoring devices and systems, and data analysis software for automated detection and diagnosis of mental disorders and key transdiagnostic dimensions of psychopathology.

Division of AIDS Research (DAR)

A. Develop and test novel, non-invasive diagnostic approaches (instrumentation, imaging, biomarkers, central nervous system [CNS] cell-based \textit{in vitro} models) to detect neurocognitive dysfunction associated with HIV-1 infection and innovative technologies to study the mechanisms involved in HIV-1 associated neuropathogenesis and persistence of HIV-1 in the CNS or strategies to prevent viral resurgence in the CNS upon cessation of anti-retroviral therapy.

B. Design and test novel therapeutic strategies aimed at amelioration of HIV-1 induced CNS dysfunction and/or eradication of HIV-1 from CNS reservoirs or strategies to prevent viral resurgence in the CNS upon cessation of anti-retroviral therapy.

C. Discover and develop innovative technologies for targeting therapies to the brain, including antiretroviral drugs, nanotechnology, imaging tools to study HIV-aging interactions or HIV-related neurodegeneration and neuroprotective strategies with improved capability to cross the blood-brain barrier for amelioration of HAND.

D. Develop evidence-based interventions to reduce risk for HIV among at-risk individuals or improve outcomes along the HIV care continuum for individuals living with HIV which are delivered through mobile devices or other technologies.

Division of Services and Intervention Research (DSIR)

A. Randomized clinical trials evaluating the effectiveness of known efficacious interventions.

B. Analyses of naturalistic databases to evaluate the effectiveness of known efficacious interventions.

C. Identifying moderators and mediators of intervention effects as a step to design and test personalized interventions.

D. Evaluating the combined or sequential use of interventions.

E. Determining the optimal length of intervention, establishing the utility of continuation or maintenance treatment (that is, for prevention of relapse or recurrence).
F. Evaluating the long-term impact of efficacious interventions on symptoms, functioning, and quality of life.

G. Developing novel information technology tools designed to improve the delivery and dissemination of evidence-based interventions and assist healthcare providers in identifying, adopting, and implementing proven prevention and treatment interventions.

Services research covers all mental health services research issues across the lifespan and disorders, including but not limited to:

A. Services organization, delivery (process and receipt of care), and related health economics at the individual, clinical, program, community and systems levels in specialty mental health, general health, and other delivery settings (such as the workplace).

B. Interventions to improve the quality and outcomes of care.

C. Enhanced capacity for conducting services research.

D. The clinical epidemiology of mental disorders across all clinical and service settings.

E. The dissemination and implementation of evidence-based interventions into service settings.
NATIONAL INSTITUTE ON MINORITY HEALTH AND HEALTH DISPARITIES (NIMHD)

A. Telehealth, telemedicine, and mobile health technologies (e.g., smart phone apps, web-enabled wearable sensors) to improve remote access to prompt diagnosis, early treatment, and clinical management for adult and pediatric patients in minority and health disparity populations, and to improve access to specialty care that would otherwise be inaccessible due to high cost or transportation barriers (e.g., by linking academic tertiary care-oriented health centers with community-based primary care settings).

B. Products, technologies or services designed to improve accessibility or uptake of existing technologies (e.g., mobile phones, tablets, free WiFi, diabetic glucometers, blood pressure monitors, etc.) within disadvantaged communities and medically underserved areas (including urban, rural, remote, or island regions) to promote healthy lifestyles, enhance patient-clinician communication, provide patient education for self-management of chronic diseases/conditions, or enhance surveillance of communicable and non-communicable diseases in minority and health disparity populations.

C. Products, technologies or services that take advantage of existing or emerging technologies (e.g., electronic health record systems, biomedical informatics platforms, big data resources and analytics, precision medicine) to improve health services delivery and quality of care, including but not limited to coordination of primary and specialty care, integration of behavioral health services into primary care settings, enhancement of provider-patient communication, and reduction of health literacy barriers in minority and health disparity populations.

D. Products, technologies or services to enhance early detection of diseases, pre-disease states, or adverse health conditions in minority and health disparity populations through analysis of novel or validated biomarkers in saliva, breath, blood, and other tissues or specimens, including microbiota.

E. Groundbreaking products or technologies to monitor real-time or cumulative exposures to physical, social and environmental risk factors acting at multiple levels across the life course ("exposome") to improve understanding and situational awareness of factors that may significantly contribute to population health disparities, and/or to empower individuals or communities to take steps to avoid or mitigate the effects of such exposures.
NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE (NINDS)

The NINDS accepts a broad range of small business applications that are significant, innovative, and relevant to its mission. Examples of research topics within the mission of NINDS are shown below. This list is not all inclusive and some research areas fall into multiple categories.

A. Therapeutics and Diagnostics Development for Neurological Disorders, including biomarker and diagnostic assays, therapeutics (drugs, biologics, and/or devices) for treatment of neurological disorders, and technologies/methodologies to deliver therapeutics to the nervous system.

B. Clinical and Rehabilitation Tools, including intraoperative technologies for neurosurgeons, rehabilitation devices and programs for neurological disorders, and brain monitoring systems.

C. Technology and Tools, including technologies to image the nervous system, neural interfaces technologies, and tools for neuroscience research and drug development.

Within these research topics, the following research may require additional funds above the hard budget caps:

A. *In vivo* animal testing required for therapeutics and diagnostics development.

B. Drug and biologics preclinical discovery and development activities for regulatory submission, such as lead identification/optimization, preclinical efficacy testing, IND-enabling studies, and manufacturing for clinical trials.

C. Device preclinical discovery and development activities for regulatory submission, such as hardware prototyping, device/software verification, biocompatibility/sterilization testing, pre-clinical efficacy testing, large animal GLP safety testing, and preparing material/devices for human testing.

D. Clinical testing of therapeutics (drugs, devices, or biologics), diagnostics, clinical and rehabilitation tools (i.e. intraoperative technologies, rehabilitation devices and programs, and brain monitoring systems), and technologies for clinical research. This would include clinical research studies to test scientific hypothesis that are not feasible or practical to conduct in animal models but would inform a final device design.

E. *In vivo* animal testing of technologies for animal research and development of animal models for drug development and neuroscience research.

F. Research that requires special facilities to contain hazardous or infectious materials.

Brain Research through Advancing Innovative Neurotechnologies (BRAIN) Initiative

The Brain Research through Advancing Innovative Neurotechnologies (BRAIN) Initiative is a Presidential project aimed at revolutionizing our understanding of the human brain. NIH is one of several federal agencies involved in the BRAIN Initiative. Planning for the NIH component of the BRAIN Initiative is guided by the long-term scientific plan, "BRAIN 2025: A Scientific Vision," which details seven high-priority research areas. This report, as well as a list of the specific BRAIN Initiative funding opportunities, can be found at [http://braininitiative.nih.gov/](http://braininitiative.nih.gov/).

Based on priority areas identified by the BRAIN 2025, technology areas were identified to be appropriate for commercial development and may require additional funds above the hard budget caps:

A. Development of research tools and technologies to understand the dynamic activity of neural circuits.

B. Development of novel tools and technologies to facilitate the detailed analysis of complex circuits to provide insights into cellular interactions that underlie brain function.
C. Development of invasive and non-invasive devices for recording and modulation in the human central nervous system.
NATIONAL INSTITUTE OF NURSING RESEARCH (NINR)

A. Development of technologies or devices requiring extensive engineering. Some examples include mobility assistive devices, POC monitors, or monitors of gait or other physiological measures. This does not include projects utilizing only mHealth technology.

B. Projects proposing large (hundreds of participants) clinical trials.

C. Technologies to facilitate delivery of prevention interventions across the lifespan.

D. Innovative web-based information and communication technologies for addressing clinical care and advance care planning specific to hospice and palliative care symptoms, and for those in need of care to improve the effectiveness and efficiency of patient report data and integration into appropriate hospice/palliative health care systems.

E. Use and integration of Health Information technology within/across “big data” systems, e.g., electronic health records for data collection, management and care integration. Of particular interest is technology that can be used across the spectrum of hospice and palliative care services/health systems.

F. IT implementation across the spectrum of palliative and hospice settings that highlight the potential of informatics to improve the metrics and standards of palliative and hospice care.
NATIONAL LIBRARY OF MEDICINE (NLM)

A. Technology development and applications to improve storage, retrieval, access, management and use of biomedical knowledge

B. Computational representation of biomedical knowledge

C. Enhancement of human intellectual capacities through virtual reality, artificial intelligence, and machine learning

D. In silico science

E. Natural language understanding

F. Support for health decisions

G. Integration, organization and retrieval in very large databases, disparate forms of knowledge, and multiple datasets

H. Investigations of topics relevant to health information science, computational modeling, and management of information during disasters
DIVISION OF PROGRAM COORDINATION, PLANNING, AND STRATEGIC INITIATIVES (DPCPSI), OFFICE OF RESEARCH INFRASTRUCTURE PROGRAMS (ORIP)

RESEARCH AND DEVELOPMENT IN THE DIVISIONS OF COMPARATIVE MEDICINE AND OF CONSTRUCTION AND INSTRUMENTS

A. Development of new technologies to rapidly phenotype large number of animals.
B. Development of technologies to identify biomarkers for clinical diagnostics in well validated disease models.
C. Development of vaccines and new therapeutic agents to prevent and/or control selected laboratory animal diseases. One high priority need is to develop methods to control and prevent Herpes virus B in nonhuman primates.
D. Design of specialized equipment and caging for laboratory animals to permit optimal environmental control and operational efficiency, including improvements in caging, identification/tagging of animals and remote monitoring in animal facilities.
E. Identification, development, and characterization of spontaneous and engineered vertebrate animal models for studies of various human diseases, excluding most random mutagenesis projects performed on rodents.
F. Development and refinement of high throughput technologies and devices for the effective cryopreservation, long-term maintenance of cells, tissues, and laboratory animal embryos, gametes, and their predecessors.
G. Development of technologies and devices for the effective monitoring of frozen and cryopreserved cells, biological materials/tissues and laboratory animal embryos, gametes, and their predecessors.
H. Development of improved reagents, techniques, devices and high throughput technology to perform, analyze, capture and process data gathered in "omics" studies (genomics, transcriptomics, phenomics, proteomics, glycomics, epigenomics, metabolomics, among others) in normal disease and intervention conditions in animal/biological models.
I. Development of biological tools and reagents for reconstruction, remodeling, repair and regeneration of tissues damaged by injury or disease. Development of the technologies and procedures to test efficacy and safety of these experiments in animal models. Approaches to detect and track the implanted cells and tissues in vivo.
J. Development of acellular biomaterials, biosensors and reagents to promote, detect and track reconstruction, remodeling, repair and regeneration of tissues damaged by injury or disease.